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ABSTRACT OF THE DISSERTATION 
A CASE-ONLY GENOME-WIDE ASSOCIATION STUDY OF GENDER- AND 
AGE-SPECIFIC RISK MARKERS FOR CHILDHOOD LEUKEMIA 
by 
Sandeep Kumar Singh 
Florida International University, 2015 
Miami, Florida 
Professor Stanislaw F. Wnuk, Co-Major Professor 
Professor Mehmet T. Dorak, Co-Major Professor 
Males and age group 1 to 5 years show a much higher risk for childhood acute 
lymphoblastic leukemia (ALL). We performed a case-only genome-wide association 
study (GWAS), using the Illumina Infinium HumanCoreExome Chip, to unmask gender- 
and age-specific risk variants in 240 non-Hispanic white children with ALL recruited at 
Texas Children’s Cancer Center, Houston, Texas. Besides statistically most significant 
results, we also considered results that yielded the highest effect sizes. Existing 
experimental data and bioinformatic predictions were used to complement results, and to 
examine the biological significance of statistical results.  
Our study identified novel risk variants for childhood ALL. The SNP, rs4813720 
(RASSF2), showed the statistically most significant gender-specific associations (P < 2 x 
10-6). Likewise, rs10505918 (SOX5) yielded the lowest P value (P < 1 x 10-5) for age-
specific associations, and also showed the statistically most significant association with 
age-at-onset (P < 1 x 10-4). Two SNPs, rs12722042 and 12722039, from the HLA-DQA1 
region yielded the highest effect sizes (odds ratio (OR) = 15.7; P = 0.002) for gender-
vii 
 
specific results, and the SNP, rs17109582 (OR = 12.5; P = 0.006), showed the highest 
effect size for age-specific results. Sex chromosome variants did not appear to be 
involved in gender-specific associations. 
The HLA-DQA1 SNPs belong to DQA1*01:07and confirmed previously reported 
male-specific association with DQA1*01:07. Twenty one of the SNPs identified as risk 
markers for gender- or age-specific associations were located in the transcription factor 
binding sites and 56 SNPs were non-synonymous variants, likely to alter protein function. 
Although bioinformatic analysis did not implicate a particular mechanism for gender- and 
age-specific associations, RASSF2 has an estrogen receptor-alpha binding site in its 
promoter. The unknown mechanisms may be due to lack of interest in gender- and age-
specificity in associations. These results provide a foundation for further studies to 
examine the gender- and age-differential in childhood ALL risk. Following replication 
and mechanistic studies, risk factors for one gender or age group may have a potential to 
be used as biomarkers for targeted intervention for prevention and maybe also for 
treatment. 
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1.  INTRODUCTION 
Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells1. ALL is the 
most common form of childhood cancer in most parts of the world, except in Africa2. 
Although ALL is relatively rare, its incidence rate has significantly increased (0.8% per 
year) since 1975 in the United States3-5. The reasons for the increasing incidence rate are 
still unknown. Change in environmental factors may be responsible for some increase2. 
Unfortunately, childhood cancers are not public health priorities in most part of the world 
despite being a major cause of childhood death2-4. Unlike adult cancers, preventable risk 
factors for childhood cancers are mostly unknown3. Incomplete knowledge of childhood 
ALL etiology, unknown environmental risk factors, and known but understudied gender, 
age, and race/ethnicity differences signify the need for more research. For more than 95% 
of cases, childhood ALL etiology is still unknown1-4, which makes formulating policies 
to reduce childhood ALL incidence impossible.  Therefore, focused research to unmask 
the causes of childhood ALL is crucial. 
1.1. Descriptive epidemiology of childhood acute lymphoblastic leukemia 
Cancers are one of the major causes of death among children in the United States 
of America2-4. Leukemia alone represents one-third of all childhood cancers of which 
80% are ALL, with an annual incidence rate of 38 cases per 106 children per year under 
age 14, or 31 cases per 106 children per year under age 19 in the United States2-5. 
Although treatment is now more successful, there is an increase in annual incidence rate 
by 0.6 % per year from 2006 to 2010 in children aged 14 years and younger2-4. This trend 
has been consistent since 1975 (Figure 1).  
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Figure 1. Childhood acute lymphoblastic leukemia incidence rates from 1975 to 2010  
Age-adjusted Surveillance, Epidemiology, and End Results cancer-incidence rates, in childhood ALL, 
age 0-14 years. Incidence rates are per 1,000,000 per year and are age-adjusted to the United States 
standard population. X-axis represents years and Y-axis represents incidence rate per 1,000,000 per 
year.  
 
Source: National Cancer Institute, Surveillance, Epidemiology, and End Results5 
 
 
Furthermore, survivors of childhood ALL still suffer from late effects like relapse, 
social and behavioral issues, and secondary malignancies6-16. Thus, prevention is of 
paramount importance. 
1.2. Gender difference in childhood acute lymphoblastic leukemia 
 
Gender difference in cancers, whether it is childhood17-23 or adult4, 24-26, 
specifically in hematological cancers27, is well known. Descriptive epidemiology 
consistently shows male predominance in childhood ALL (Figure 2)2-4, 19, 21, 22, 26-30 . 
Males experience around 20% higher incidence and worse prognosis than females in all 
ethnicities2-4, 28. Moreover, the 5-year and 30-year survival rates are worse in male 
children with ALL, even after adjusting for age-at-diagnosis, race, year of diagnosis, and 
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cell type31. Furthermore, relapse and secondary malignancies have been consistently 
reported more frequently in males31. Males are subject to more intense treatment 
protocols in childhood ALL as a result of having more severe disease23.  
 
 
Figure 2. Gender differences in the incidence rate of childhood acute lymphoblastic leukemia 
Age-adjusted Surveillance, Epidemiology, and End Results cancer-incidence rates, 2006-2010, in 
childhood ALL, age 0-14 years. Incidence rates are per 1,000,000 per year and are age-adjusted to 
the United States standard population. Males show higher incidence rates. X-axis represents 
incidence rate per 1,000,000 per year and Y-axis represents both genders and overall incidence 
rates.  
 
Source: National Cancer Institute, Surveillance, Epidemiology, and End Results5 
 
 
1.3. Age peak in childhood acute lymphoblastic leukemia 
Childhood ALL risk is highest among age group 1-5 years 2, 3, 5 (Figure 3) with an 
annual incidence rate of 72 cases per 106 children per year. Precursor B-cell leukemia is 
the most common type of childhood ALL in the age group 1-5 years. In contrast, infants 
< 1 year of age suffer from a morphologically different type of leukemia that is more 
aggressive and shows a less favorable outcome1.  
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Figure 3. Age-specific incidence rates in childhood acute lymphoblastic leukemia by 
single year of age-at-diagnosis  
Age-adjusted Surveillance, Epidemiology, and End Results cancer-incidence rates, 2006-2010, in 
childhood ALL, age 0-14 years. Incidence rates are per 1,000,000 per year and are age-adjusted to 
the United States standard population. Y-axis represents incidence rate per 1,000,000 per year and 
X-axis represents age in years.  
 
Source: National Cancer Institute, Surveillance, Epidemiology, and End Results5 
 
1.4. Ethnic differences in childhood acute lymphoblastic leukemia 
 
ALL risk is higher in Hispanics and Non-Hispanic White children than in any 
other ethnicity30, 32. African-Americans have the lowest risk although the mortality rate is 
higher in African American and Hispanic children3, 33-35.  
1.5. Risk factors contributing to childhood acute lymphoblastic leukemia 
Although the pathogenic events behind the development of childhood ALL risk 
are still ambiguous, several congenital syndromes, such as Down syndrome, show 
significant associations with childhood ALL risk1, 36. The only known environmental risk 
factor is ionizing radiation1. Descriptive epidemiology consistently showed male gender 
(M:F = 1.2), age peak (1-5 years), White race (White: African American = 2.0) and to a  
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Table 1. Risk factors (known, suggestive or with limited evidence) associated with childhood acute  
lymphoblastic 
 
 
 
 
 
 
               
 
 
 
 
 
 
 
 
 M:F indicates male-to-female ratio of incidence 
  
 Source: Linet MS et al. Interpreting epidemiological research: lessons from studies of childhood cancer. Pediatrics 2003; 112:218-232 22. 
Known Suggestive Limited evidence 
Gender (M:F = 1.2) 
 
Maternal fetal loss
 
Paternal smoking before 
conception 
Congenital disorders, ataxia-telangiectasia, 
neurofibromatosis, Fanconi anemia and 
Nijmegen breakage syndrome 
Mother older than 35 years at 
pregnancy 
 
 
Parental occupational exposure      
Hydrocarbon                               
Paint                                                
Motor vehicle exhaust 
White: African American = 2.0 60-Hz magnetic fields > 0.4 uT 
Age peak ( 1-5 y) Postnatal chloramphenicol use 
Down syndrome Family history 
Ionizing radiation                                             
(diagnostic, in utero                                   
therapeutic, postnatal)  
Decreased risk associated with 
breastfeeding 
 
Birth weight > 4000 g 
Higher  socioeconomic  status 
6 
 
degree, birth weight (> 4000 g) as risk factors for childhood ALL22. Several other 
epidemiological studies have found environmental exposure such as parental 
occupation37, 38, smoking, tobacco & alcohol use38, 39, maternal reproductive history40, 
maternal diet41, exposure to pesticides or solvents42, 43, and exposure to residential power-
frequency magnetic fields 44 to be associated with childhood ALL risk with inconsistent 
results22. Most of these exposures are either maternal, during pregnancy, or early 
childhood. Studies suggest that the incidence of ALL is higher in developed countries 
than developing and under developed countries45. A list of risk factors that are known, 
suggestive or with limited evidence is provided in Table 1.  
The types of cancers that most frequently develop in children are different from 
the most common adult cancers3, 4. For example, although leukemia, lymphoma, and 
brain/other nervous system cancers account for more than half of all childhood cancers, 
they account for less than 10% of cancer cases in adults.  In addition, etiologic 
differences and genomic variations within the same cancer type suggest that the 
childhood and adult cancers may be discrete diseases46. Because more than 95% of causal 
risk factors, including environmental risk factors, for childhood ALL are still unknown1, 
36, the current focus is on unraveling genetic risk markers36 to develop a predictive model 
and learn more about disease causation for preventive and therapeutic purposes.  
1.6. Statement of the problem and public health significance 
Among all childhood cancers, ALL alone accounts for more than 30% of cases in 
children up to 19 years of age, with approximately 3000 to 3500 cases diagnosed 
annually in the U.S.2-4. Over the past few decades there has been tremendous progress in 
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early diagnosis and treatment of childhood cancers in the U.S.6, 19 yet childhood cancers 
are still the leading cause of disease-related mortality3, 4 Childhood leukemia is the most 
costly pediatric cancer to treat and average annual hospitalization cost is around $385.8 
million47.  The survival rate of childhood ALL has improved with new treatments, and 
current 5 year survival rate is around 90%5. According to Surveillance, Epidemiology, 
and End, Result (SEER) data (Figure 4), as of 2010, there were around 379,112 
childhood and adolescent cancer survivors (diagnosed at age 0-19 years) and around 
60,489 of them were ALL survivors2, 3.  
  
 
        Figure 4. United States childhood cancer survivors 
 Number of people previously diagnosed with cancer as children in the United States and alive 
 January 1, 2010. Y-axis represents complete prevalence count by age-at-prevalence and X-axis     
represents age group in years.  
 
        Source: National Cancer Institute, Surveillance, Epidemiology, and End Results5 
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As of January 1st 2010, more than 70% of childhood cancer survivors are 20 years 
of age and older and the majority of them are childhood ALL survivors. It has been 
estimated that, approximately 1 out of every 530 young adults between the ages of 20 
years and 39 years is a childhood cancer survivor2, 3. Childhood ALL survivors will soon 
be a significant proportion of young adults in the U.S., this suggests an immediate step 
towards prevention to reduce the increasing burden on public health is necessary.  
Family burden, in the form of grief and financial burden starts at the time of 
diagnosis, when parents learn that their child has cancer and will go through necessary 
harm in order to survive7. It is important to recognize that “children are not little adults”. 
Their bodies are still developing during illness and treatment. Therefore, cancer treatment 
affects them unequally over their life compared with adults. Although survival statistics 
have  improved dramatically, the literature suggests that preventable suffering is a part of 
a childhood  survivors’ life8. It significantly affects the quality of life of these children 
and their families. The extreme cost of survival for some treatable cancers is one of gross 
mental impairment. Even after treatment, these children suffer from poor motor 
functioning and compromised social well-being for decades of life7.  
For cancers, which show higher survival probabilities, such as childhood ALL, a 
significant proportion of survivors will have chronic and life altering side effects as a 
result of treatment7, 8.  Childhood cancer survivors continue to have social and behavioral 
difficulties9. Two-thirds of childhood ALL survivors also experience one or more 
permanent side effects of treatment such as heart dysfunction, neurocognitive 
impairment, osteonecrosis, osteoporosis, reproductive issues, severe growth retardation, 
permanent hearing loss, obesity or second malignant neoplasm6, 8, 10-16.  
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Every year, more than 200,000 children under the age of 15 years are diagnosed 
with cancer all over the world8. Low-income countries represent four-fifths of all 
childhood cancers, and in the absence of best therapies and/or a very high cost, the 
mortality rate is significantly high (> 80%) in comparison with that of developed 
countries (< 20%)21, 48. Therefore, an urgent action toward prevention is highly 
recommended by the International Society of Pediatric Oncology to reduce the mortality, 
life-long burden of survivors, burden on the health care system and society17. 
A few genome-wide association studies (GWAS) have been completed in 
childhood ALL49-54. These studies yielded somewhat consistent associations, but with 
small effect sizes. Thus, the explained proportion of genetic susceptibility is very low. A 
recent re-analysis, however, showed that by considering all genotyped single nucleotide 
polymorphisms (SNPs) simultaneously, 24% of the total variation in precursor B-cell 
ALL risk is accounted by common genetic variation55. This result provides support for 
the involvement of many more SNPs than already identified in susceptibility to precursor 
B-cell ALL. The reasons for failure to obtain individual significant results are much 
debated56. One of the reasons that is most relevant to the current work is the possibility of 
associations masked by effect modification  (interactions with other genes or 
environmental factors, gender or age)57.  
1.7. Consideration of study design  
We used a case-only design to see associations differing by gender and age 
groups. This study design is more efficient than other traditional epidemiological studies 
at detecting such effect modifications, which were the main focus of this study58.  
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Recruitment of cases in a rare disease like childhood ALL is a challenge59, and hence, 
preferring a statistically powerful research design is more practical.   
The case-only design is a transformation of the conventional case-control design 
to detect statistical interactions. An assumption of the case-only design, requires 
genotype and gender/age to be independent in the population i.e., genotype frequencies 
should not differ between genders or age groups in a healthy population.  When this 
assumption is met, it is easy why a case-only study can be used instead of a case-control 
study59.  
Table 2. Odds ratio calculation for association of disease with gender, by genotype 
Gender 
Risk genotype positive Risk genotype negative 
Cases Controls Cases Controls 
Male a b e f 
Female c d g h 
Odds ratio ad/bc eh/fg 
 
 
Table 3. Odds ratio calculation for association of disease with gender and genotype, 
in cases and controls separately 
Gender 
 
Cases Controls 
Risk 
genotype 
positive
Risk 
genotype 
negative
Risk 
genotype 
positive
Risk 
genotype 
negative 
Male a e b f 
Female c g d h 
Odds ratio ag/ce bh/df 
 
In a traditional case-control study, interaction will be measured by their ratio 
adfg/bceh (Table 2), which is basically the ratio of two odds ratios (ORs) (ad/bc and 
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eh/fg). Now, the same data is rearranged in Table 3. Again, interaction will be measured 
by the ratio agdf/cebh, which is the ratio of two ORs (ag/ce and bh/df) and equivalent to 
the OR derived in Table 2. According to the main assumption, genotype and gender/age 
should not be correlated60. In case of a rare disease, such as childhood ALL, disease-free 
controls would be representative of the normal population and second OR bh/df should 
be one, meaning genotype frequencies between two genders and age groups will be 
similar. This is the simplest rationale to explain the case-only design. It suggests that 
under the required assumption of test of independence, it is possible to estimate 
interactions from the cases-only design60.  
In this scenario, we can estimate a statistical interaction from the association 
between genotypes and gender or age in the case-only study design, under the assumption 
that exposures and genotypes are independent60, 61. There is no reason to believe that 
healthy males and female controls62, and healthy controls in two age groups (1-5 years 
and 6-10 years) have different genotype frequencies. The preference of the case-only 
design over the case-control is also due to its greater precision in estimating interaction 
(i.e., smaller standard errors)60 and smaller variance based on four cells of individuals 
(Table 4) instead of eight cells of individuals in the case-control design (Table 2)63.   
Table 4. Odds ratio for association of disease with gender and genotype, 
 in case-only studies 
Gender 
 
Cases 
Risk genotype 
positive
Risk genotype 
negative
Male a e 
Female c g 
Odds ratio ag/ce 
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This study design is only good to calculate OR for interactions61, 64. It cannot 
calculate OR for the main effects of genotype (ORg) or gender/age (ORe) individually. 
Our main interest is in gender- and age-specific risk markers, and we were not interested 
in the main effects.  
The statistical power of the case-control design and the case-only design was 
compared in a study by hypothetical (200 cases and 400 controls vs 200 cases) and 
empirical data (four case-control studies)65. Although results showed similar ORs for 
interaction in both study designs, the case-only design had a much narrower 95% 
confidence interval. Similarly, the four case-control studies also showed no substantial 
difference in OR for interaction, but confidence intervals were narrower in the case-only 
analysis. It suggests that the case-only study design has greater statistical power for 
detecting gender-genotype or age-genotype interactions with smaller sample size in 
comparison to a case-control study design65. 
Table 5. Odds ratio for association of disease with age and genotype, in case-only studies 
Age 
 
Cases 
Risk genotype 
positive
Risk genotype 
negative
Age (1 to 5 years) a e 
Age (6 to 10 years) c g 
Odds ratio ag/ce 
 
A case-only study was also used to examine the age-specific associations with 
childhood ALL.  In this scenario, we used the same approach as it has been explained 
earlier for gender (Table 5). Again, in the case of effect modification by age, the case-
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only approach provides more statistical power than traditional case-control design when 
the case group is split into two age groups.  
1.8. Structure of the dissertation 
This dissertation is written in a traditional style which contains eight chapters 
including this chapter. Following this chapter, Chapter 2 comprehensively reviews 
literature relating to gender- and age-specific associations in general, including childhood 
ALL. The purpose of the literature review is to provide insight that genetic architecture 
can significantly contribute to gender- and age-specific risk associations in childhood 
ALL.  Chapter 3 explains hypothesis and specific aims of the study.  
Chapter 4 provides an overview of the methods used for the gender- and age-
specific associations in childhood ALL. It mainly addresses: rationale for quality controls 
(QCs) to assess the sample, genotyping method, and generated results, statistical analyses 
used to identify gender- and age-specific associations. Bioinformatic and empirical 
analyses were also performed for all identified markers to assess their functionality as 
explained in Chapter 4. 
All gender- and age-specific association results and bioinformatic analyses of 
identified markers are provided in Chapter 5. Relevant tables with interaction ORs and 
interaction P values are provided at the end of Chapter 5. Chapter 6 provides a detailed 
discussion of identified genetic markers or genes and their possible relevance to gender- 
or age-specific associations. Limitations and strengths of the present study are provided 
in Chapter 7. Conclusion is explained in Chapter 8. 
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All tables and figures are provided in the relevant section of the chapters or in the 
appendix. All references are provided at the end of the dissertation.  
1.9. Significance of the dissertation 
This dissertation mainly focused on gender- and age-specific risk markers. This 
was the first GWAS of childhood ALL specifically addressing these issues. Gender 
difference is an underappreciated and understudied research area in cancer research26. 
Findings from this dissertation may inform future studies of childhood ALL as well as 
other diseases, which show significant gender and age differences.  
In majority of developing and underdeveloped countries, childhood cancers are 
not considered a major public health issue because of the high numbers of deaths from 
infectious diseases66. Most importantly these countries also represent a higher percentage 
of younger population. Recent studies suggest that childhood cancers are among top five 
leading cause of death in children in developing and underdeveloped countries2. Even 
countries like U.S. invest little on childhood cancer prevention67. Childhood cancers, 
gender and age difference in cancers are major public health issues and medical concern. 
Therefore, this research and the results from this project addressed a major public health 
issue aiming to elucidate currently unknown risk factors for childhood ALL.   
1.9.1. Better understanding of gender- and age-disparities in childhood acute 
lymphoblastic leukemia 
Although descriptive epidemiological data have shown a significant role of 
gender and age specificity in childhood ALL, to date there have been few examples of 
gender- and age-specific associations. Our main interest was, therefore, the detection of 
15 
 
association differing in directions between males and females (risk vs protection), means 
risk association for one gender and protective association for another. Interaction with 
gender implies statistically significant differences in male- and female-specific ORs 
which is basically a difference in magnitude (for example, an OR = 1.5 in females and 
3.5 in males and Pinteraction < 0.05). This type of quantitative interaction in the overall 
analysis would yield an OR that is approximately the average of the two gender-specific 
ORs. We were interested in qualitative interactions that would be missed in the overall 
analysis (like in previous GWASs)50-53, 68. A qualitative interaction is a result of two ORs 
differs in their directions (risk vs protection) rather than being in the same direction 
(differ in magnitude). Cross-over effect (association differing in direction) usually results 
in an OR close to the unity (OR = 1.0) with no statistical significance in the overall 
analysis. Such SNPs are typically dismissed for any further consideration. Gender-
specific associations, differing in direction, are difficult to identify, even in secondary 
analysis, unless all of the raw data are re-analyzed. Associations differing in direction are 
simple examples of an effect modification where a polymorphism shows a risk 
association in one gender and a protective association in the other. Our main objective 
was to unravel associations differing in direction that would have remained undetected in 
the overall analysis.  
A list of previously identified childhood ALL risk markers in GWAS are reported 
in the appendix Table 1. Our long-term aspirations are to learn more about the gender and 
age disparity and exploit this information to implement preventive and therapeutic 
measures. Because males are more prone to develop ALL and more likely to have 
unfavorable clinical outcome, it may appear that only males will benefit from the results. 
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This is not our thinking, and we believe that any information on disease pathogenesis will 
have multiple beneficiaries including other people with other childhood and adult cancers 
that show differential distribution between genders and among age groups. 
1.9.2. Guidance for new strategies for studying other complex diseases 
The case-only design circumvents several limitations of the traditional case-
control design in interaction analysis. Successful application of this approach may be 
conducive, not only for childhood ALL, but also for research on other rare, gender-and 
age-specific disorders. It is well known that the time course and cost of recruiting 
subjects is hard for a prospective cohort study in case of rare diseases. Therefore, this 
project could provide guidance for new strategies to investigate an unidentified 
component of genetic susceptibility and effect modification in more common complex 
diseases.
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2. REVIEW OF LITERATURE 
Descriptive epidemiological data have consistently provided evidence for gender 
and age differences in distribution of nearly all cancers18, 24, 69. Males generally show 
higher susceptibility, mortality and worst survival in most cancers. Studies that exploited 
gender differential for etiological clues identified several gender-specific risk markers68, 
70-74. Similarly, studies that used age differential for clues also unmasked risk markers for 
early or late-onset of diseases75-78. Prior to the present study, there was no GWAS in 
childhood ALL that has used a gender- and age-specific approach to identify markers for 
childhood ALL susceptibility. Furthermore, a time-to-event analysis approach was used 
to unravel risk markers that might be associated with early-onset of childhood ALL risk.  
2.1. Genome-wide association studies  
 The National Institute of Health (NIH) defines GWAS as a study of common 
genetic variations across the entire genome designed to identify genetic associations with 
observable traits79, 80. A GWAS uses high-throughput genotyping technology. It examines 
thousands of polymorphisms to relate them to a clinical condition or  measurable traits80. 
It is a hypothesis-free approach to scan markers across the whole genome. There are 
millions of genetic variants in the human genome. A traditional case-control study design 
is the most common approach in GWASs. GWASs also use stringent QC protocols to 
reduce the error in the study81. These QC protocols assess the sample, genotyping 
methods and generate results for potential causes of systematic error82. All QCs measured 
in this case-only GWAS are explained in Chapter 4. 
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 The human genome contains around 19,881 genes83, 84. These genes are discrete 
segments of deoxyribonucleic acid (DNA) that convey information to protein via 
ribonucleic acid (RNA).  Genetic variation refers to DNA sequence polymorphism83. An 
allele is one of the several forms of a DNA segment (e.g. a gene or locus).   
  There are many forms and levels of genetic variations83. The most common 
genetic variation that has been examined in this study is called a SNP. For example, the 
same nucleotide position may be occupied by a guanine (G) in one individual and a 
cytosine (C) in another. An allele, which occurs less frequent in a population is called a 
minor allele. In the example given below, C is the minor allele, and polymorphism will 
be represented as G>C polymorphism.   
   Subject 1: ACTGACTCAT 
   Subject 2: ACTCACTCAT 
In this instance, the two nucleotides represent two different alleles. These SNPs 
occur in every 100 to 300 nucleotides on average in human genome. It has been estimated 
that number of SNPs in the human genome is up to 40 million. The most common 
variation of a SNP has two alleles. There are three possible genotypes from a SNP with 
two alleles. Genotype is the genetic constitution of an organism specifying the particular 
alleles at a defined locus in the genome. It is basically two alleles inherited at a specific 
locus. Human genome contains 22 pairs of autosomal chromosomes and a pair of sex 
chromosomes. Males have one X and one Y chromosome, and females have one pair of 
X chromosomes. So, the genotype is the combination of two alleles, one from each 
chromosome. For example, the three genotypes in a population are: 
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Subject 1 = GG (wild-type), both chromosomes have G allele and G allele is commonly 
present in the population 
 ACTGACTCAT 
    ACTGACTCAT 
Subject 2 = GC (heterozygote), one chromosome has G allele and another chromosome 
has C allele. 
ACTGACTCAT 
    ACTCACTCAT 
Subject 3 = CC (homozygous variant), both chromosomes have C alleles, and C allele is 
less frequently present in the population.    
ACTCACTCAT 
   ACTCACTCAT 
   The wild-type genotype is the referent group in a statistical analysis. The other 
two genotypes may be included in the analysis as they are (gene dosage analysis) or may 
be pooled depending on the genetic model. Genetic models are explained in Chapter 4. 
Most genetic associations are mediated by gene expression changes due to genetic 
variation and their effect may be opposite in males and female83, 85, 86.  
2.2. Gender disparity in cancer incidence 
 Gender is an important risk factor in disease pathogenesis24, 32, 68, 87, 88. Studies 
clearly suggest biological, physiological and behavioral differences between males and 
females, including differences in the incidence, progression, mortality and survival of 
many diseases24, 26, 32, 86. Males  have a higher life time probability of developing cancer 
than females (43.9% vs 38.0%)4. The National Cancer Institute (NCI) SEER database 
shows that males consistently have a higher incidence (males: 542.3 vs females 418.8 per 
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100,000) and mortality rates (males: 215.3 vs females: 149.7 per 100,000)4, 24.  Incidence 
rates were age-standardized to the 2000 US standard population and are for all cancers 
for 2006-2010. Males also show worse survival than females. Cook et al24 in a recent 
study used SEER data to calculate gender-specific incidence rates and male-to-female 
incidence rate-ratios (IRR) for specific cancer sites for the period 1975 to 2004. Only five 
cancers (breast, gall bladder, thyroid, pertitoneum/omentum/mesentry, and anus/anal 
canal/anorectum) were significantly higher in females when compared with males4. The 
leading cancers also show a higher male-to-female (M:F) ratio: lung and bronchus: 1.45; 
colorectal cancers: 1.32; urinary bladder: 4.05; non-Hodgkin lymphoma (NHL): 1.43 4. 
Males consistently show higher cancer risk in 32 of 35 cancer sites, excluding sex-
specific cancers, across geographical regions25.  
Likewise, for all childhood cancers, males show a higher incidence rate  than 
females (178.0 vs 160.1 per 1,000,000)3. Incidence rates were age-standardized to the 
2000 US standard population and are for all cancers for 2006-2010. These observations 
suggest the importance of analyzing results by gender, and how it may provide a 
fundamental understanding of human physiology, pathology and pharmacology that will 
ultimately benefit both genders88. Cancer epidemiology has been more concerned with 
disease etiology than disease heterogeneity and failed to examine gender as a major risk 
factor24. Adjusting the results for gender does not explain gender difference in 
susceptibility of a disease, it rules out confounding by gender26. Stratified analysis by 
gender is one approach to unravel a gender-specific association, which can be confirmed 
by a statistical interaction analysis. Thus, gender-specific approach may provide 
important etiological clues in disease pathogenesis, progression, and treatment. Examples 
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include liver, colon and thyroid cancer. Higher interleukin-6 (IL6) levels may be one 
reason for higher incidence of hepatocellular carcinoma (HCC) in males89, 90. A study on 
endogenous hormones suggests the protective role of estrogen in women through 
suppressing IL6 mediated inflammation of the liver. On the contrary, testosterone can 
increase liver cell proliferation in men. Likewise, males again show higher incidence rate 
than females to develop colon cancer4. Estrogen plays a protective role in women for the 
development of colon cancer, and estrogen replacement therapy further reduces the 
incidence of colorectal cancer in postmenopausal women91, 92. The androgen receptor 
expression in thyroid follicular cells may be responsible for higher incidence of thyroid 
follicular cancer in females93, 94. These physiological differences elucidate the importance 
of gender difference in cancer. Thus, it would be difficult to predict a disease risk with 
the same accuracy in both genders, if results are not analyzed by gender68.  
2.3. Gender disparity in other diseases 
 Gender differences are also common in other diseases. Like cancers, susceptibility 
to infections is greater in males from birth95, 96. For example, incidence of septicemia, 
meningitis and tuberculosis is higher in males from infancy to childhood. Moreover, 
males have a poorer immune response than females to several bacterial and viral 
infections87, 97-101. Gender differences in infections are similar to cancer. Immune 
surveillance mechanisms are similar against cancers and infections. This suggests that the 
difference in immune system activity between males and females may play a significant 
role in gender differences.  As in cancers, only few infections show higher morbidity and 
mortality rates in females, such as pertussis and mycoplasma pneumonia102, 103. Nearly all 
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human diseases show gender-specific differences in prevalence, age of onset and/or 
severity. In utero loss is also more prominent with the male fetus104. In comparison to 
males, average life span of females is longer105, and not only they are healthier, but the 
survival rates from infectious diseases, sepsis, trauma or injury are also higher106, 107.   
The immunological disadvantage of being males in comparison to females is well 
known96, 108. Lower production of antibodies has been noted in males in comparison to 
females. In general, females have a better innate and adaptive immune system109. These 
also contribute to higher incidence of autoimmune and inflammatory diseases in females.  
For example, autoimmune thyroid diseases (Hashimoto thyroiditis and Graves’ disease), 
systemic lupus erythrmatosus, Sjogren syndrome, multiple sclerosis, primary biliary 
cirrohsis and celiac disease are more common in females110.    
The X chromosome contains the largest number of immune-related genes in the whole 
human genome96. The difference in X chromosome numbers results in immunological 
differences in males and females despite the presence of dosage compensation 
mechanisms in females96, 111. X-linked primary immunodeficiencies are typical examples 
of gender difference and the disadvantage of being male96. Mutations or polymorphisms 
of an X chromosome-linked gene phenotypically expressed in males, who then show 
functional impairment of the respective proteins leading to diseases such as primary 
immunodeficiencies96, 111.    
Environmental and occupational exposures are commonly believed to play a 
significant role in gender differences in diseases. The male excess in cancers may be due 
to some environmental factors, including smoking, diet and life style, but environmental 
variations alone cannot explain gender difference in cancer risk26. Thus, genetic factors 
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may shed some light on male excess in cancers. The examples given above suggest that 
physiological differences, immune system, X chromosome number, environmental risk 
factors and genetics may affect the disease susceptibility with gender specificity. Most of 
the endogenous causes of gender differences in disease are still unknown. In comparison 
to most of these endogenous causes, such as sex hormones and immune functions, the 
genetic contribution to gender difference, until recently, is an understudied research area. 
A stratified result by gender would produce more meaningful results, if one gender has a 
higher risk. 
To understand the biology of sex and gender difference, the Institute of Medicine 
(IOM) formed a committee in November 1999112. The committee issued three common 
messages: 
1- Sex matters. 
2- The study of sex difference is evolving into a mature science.  
3- Barriers to the advancement of knowledge about sex differences in health and 
illness exist and must be eliminated.      
It is important to understand that gender differences in health and disease need 
scientific inquiry in all aspects of biomedical, health-related and epidemiological 
research. The committee made several recommendations including112: 
1- Promote research on sex at the cellular level. Determine how genetic sex 
differences influence other level of biological information, including 
susceptibility to disease, and develop systems that can identify and distinguish 
between the effects of genes and the effects of hormones.  
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2- Study sex differences from womb to tomb. Inclusion of sex as a variable in basic 
research design. 
3- Investigate natural variations. Examine genetic variability, disorders of sex 
differentiation, reproductive status, and environmental influences to better 
understand human health.   
4- Monitor sex differences and similarities for all human diseases that affect both 
sexes. 
Therefore, further studies designed to look for possible gender differences in all 
clinical and epidemiological research has been encouraged.  
2.4. Genetic basis of gender disparity 
The role of sex hormones, oxidative stress, chromosomal telomere length, iron 
level, and immune function are thought to be the reasons for gender differential in human 
diseases113. Genetic contribution to gender differences, however, has rarely been 
explored. Although the role of X chromosome is mainly hypothesized for gender-specific 
gene expressions, autosomal chromosomes show gender-specific gene expression 
patterns86, 96, 114. It has been assumed that autosomal genome is similar between males 
and females. However, studies suggest that genetic variations within autosomal genomes 
affect anatomical, behavioral and physiological traits differently in males and females86, 
114-117. Thus, potential of a polymorphism to show a gender-specific association does not 
depend on its genomic location26.  
Recent evidence suggests that the regulatory genome is sexually dimorphic118 i.e., 
there is a phenotypic difference between the two genders. Most phenotypic sexual 
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dimorphisms, including gender-specific effects on diseases, are a result of gender-specific 
differences in gene expression regulation. Sexually dimorphic gene expression at 
messenger RNA level has been observed in a wide range of organisms, including 
primates, rodents, fish, worms and flies114, 118-121. A mouse study on gender-specific gene 
expression identified thousands of gender-biased genes in autosomes119. Thus, 
mammalian genomes are enriched with gender-biased genes that show gender-specific 
expression. These animal models also suggest that genotype gender-interactions are 
prevalent and that genetic contribution to disease etiology will be masked if gender-
specific analysis is overlooked.  
There are, however, very few examples of documented genetic basis behind a 
gender differential in humans, presumably due to lack of analysis by gender. Studies that 
have used gender-specific approaches have so far successfully unmasked a number of 
gender-specific risk markers in childhood ALL (Table 6)122-131 and in other diseases132-
138. For example, two ARID5B (AT rich interactive domain 5B (MRF-1 like)) 
polymorphisms (rs10994982 and rs10740055), previously identified as a risk marker in 
childhood ALL in GWAS51, 52 (Table 6), yielded significant gender-specific associations 
(Pinteraction = 0.01 and Pinteraction = 0.03, respectively)139 (Table 7). These SNPs were 
significantly associated with risk only in males (OR = 3.79 and OR = 4.35, respectively; 
ORs for females were: 1.03 and 1.37). Other ARID5B polymorphisms did not show any 
statistically significant interactions, but males had a higher risk (Table 7). However, one 
major limitation of this study is selection of controls, as controls are mainly adults 
(median age 30.1 years vs 4.2 years in cases) and recruited at locations different from 
childhood ALL cases. Thus, gender-specific results might be affected by selection bias, 
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Table 6. SNPs associated with gender-specificity in childhood acute lymphoblastic leukemia risk 
SNP Overall  
(OR; 95% CI) 
Males 
 (OR; 95%CI) 
Females 
 (OR; 95%CI) 
Pint References  
HLA-DRB9 rs2395185 2.49 (1.43-4.34) 6.07 (2.85-12.9) 0.62 (0.21-1.86) 0.001 125 
HLA-DRA rs7192 1.05 (0.68-1.63) 0.66 (0.37-1.20) 1.84 (0.92-3.68) 0.03 130 
TNXB rs3130342 1.35 (0.85-2.15) 0.85 (0.44-1.65) 2.22 (1.15-4.29) 0.04 130 
SKIV2L rs419788 1.25 (0.80-1.94) 0.82 (0.45-1.50) 2.11 (1.07-4.15) 0.04 130 
SLC11A2 rs224589 0.89 (0.55-1.43) 1.44 (0.78-2.67) 0.43 (0.19-0.98) 0.02 Unpublished (Dorak et al) 
NRAMP2 rs422982 0.74 (0.53-1.04) 1.15 (0.73-1.82) 0.44 (0.26-0.74) 0.007 Unpublished (Dorak et al) 
HFE rs807212 0.77 (0.35-1.70) 0.28 (0.06-1.21) 1.69 (0.63-4.56) 0.05 128 
HLA-DRA rs313588 1.39 (0.95-2.04) 0.95 (0.54-1.66) 2.05 (1.21-3.49) 0.05 130 
ARID5B rs10994982 2.29 (1.42-3.69) 3.79 (1.94-7.45) 1.03 (0.45-2.39) 0.01† 139 
ARID5B rs10740055 2.76 (1.68-4.53) 4.35 (2.16-8.84) 1.37 (0.58-3.23) 0.03† 139 
            SNP = single nucleotide polymorphism; OR = odds ratio; CI = confidence interval; Pint = P value for interaction  
             †P values denotes the Mantel-Haenszel χ2 test of homogeneity for risk differences between males and females 
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Table 7. SNPs associated with childhood acute lymphoblastic leukemia risk in previous genome-wide association studies with 
gender- and age-specificity 
        Gender-specific Age-specific     
SNP Gene OR (95% CI) P value Male Female P value (interaction) P value 
Ref 
GWAS
Other 
Ref** 
rs10821936 ARID5B 
1.91 (1.60-2.20) 1.4 x 10-15         51   
1.86 (1.71-2.03) 5.90 x 10-46       0.02†† 53   
3.11 (1.90-5.10) 4.8 x 10-6 3.92 (1.98-7.84) 2.05 (0.85-4.95) 0.21†     139 
rs10994982 ARID5B 
1.61 (1.30-1.90) 5.70 x 10-9         51   
2.29 (1.42-3.69) 6.6 x 10-4 3.79 (1.94-7.45) 1.03 (0.45-2.39) 0.01†     139 
rs7073837 ARID5B 
1.58 (1.35-1.89) 4.66 x 10-16         52   
2.37 (1.45-3.85) 4.8 x 10-4 3.15 (1.60-6.25) 1.52 (0.65-3.35) 0.15     139 
1.64 (1.40-1.92) 1.0 x 10-9         49   
rs10740055 ARID5B 
1.53 (1.41-1.64) 5.35 x 10-14         52   
2.76 (1.68-4.53) 5 x 10-5 4.35 (2.16-8.84) 1.37 (0.58-3.23) 0.03†     139 
1.75 (1.49-2.06) 1.8 x 10-11         49   
rs7089424 ARID5B 
1.65 (1.54-1.76) 6.69 x 10-19         52   
1.83 (1.55-2.15) 6.13 x 10-13         49   
3.11 (1.89-5.12) 6.11 x 10-6 4.11 (2.04-8.35) 1.92 (0.81-4.58) 0.15†     139 
rs4132601 IKZF1 
1.69 (1.58-1.81) 1.20 x 10-19         52   
1.59 (1.34-1.89) 1.2 x 10-7         49   
          0.04†††   140 
**Candidate gene studies, Ref = reference;  †P values denotes the Mantel-Haenszel χ2 test of homogeneity for risk differences between males and 
females;  ††Comparison between age group before 10 y and older than 10 y ;  ††† Recessive model (TT+GT vs GG) yielded significant association (3.83 
year vs 5.58 year) 
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as these controls may have different environmental exposures than childhood ALL cases.  
Re-analysis of GWAS datasets revealed 12 polymorphisms in: coronary artery diseases 
(CAD; rs7865618), Crohn disease (CD; rs3792106 and 6431654), rheumatoid arthritis 
(RA; rs3134926, rs4947244 and rs3132666) and type1 diabetes (T1D; rs2763979, 
rs4148873, rs3131622, rs480092, rs3134926 and rs12660883) that show gender-specific 
associations with increased disease risk in only one gender68. A study on rs3792106 and 
CD successfully replicated gender-specific association (OR heterogeneity P value 0.04; 
OR for females = 1.48, P = 6.9 x 10-13; OR for male = 1.22, P = 0.01) 141. These examples 
emphasize the importance of gender-specific analysis.    
Gender differences play a critical role in drug efficacy and safety profile, and are 
well recognized in drug pharmacokinetics and pharmacodynamics142. Women are at far 
greater risk than men of developing unfavorable outcome to some drugs88, 142-144. Many 
drugs for cardiovascular disorders show significant gender differences in their 
pharmacokinetics profiling142.  For example, CYP (cytochrome P450) genes show 
significant gender-specific activity differences. CYP1A2, CYP2E1 and CYP2D6 genes, all 
have higher activity in males, but CYP3A4 has higher activity in females. These results 
suggest that gender plays a significant role on CYP genes expression levels142.  
Another example of a gender-specific association is glucocorticoid treatment.  
Expression of specific genes is altered in response to glucocorticoid treatment, but in 
opposite directions in males and females145. It has been suggested that anti-inflammatory 
actions of glucocorticoid are more effective in males. These studies suggest that 
physiological phenomenon, such as sex hormones and immune system, that differs 
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between males and females provide the basis for gender-specific genetic associations 
with disease susceptibility86, 88.      
The translation of gender-specific gene expression differences at the protein level 
is imperative26. Studies that compared the proteome of males and females like 
transcriptomic studies, also identified prominent gender differences117. Likewise, a study 
unmasked remarkable gender differences in serum metabolite concentrations. A total of 
102 out of 131 metabolites were statistically different between males and females (P < 
3.8 x 10-4; Bonferroni correction threshold) and were correlated with genetic variants in 
metabolism-related genes146. It suggests sexual dimorphism is also present at the 
metabolomic and proteomic level. To date, no systematic survey has addressed gender-
specific associations in cancer26.  Thus, gender-specific analysis may help to identify 
some of the missing heritability in GWAS56, 68. Sexual dimorphism in gene expression 
may result in such associations (Figure 5), which has been recognized as a common 
occurrence26, 86, 147, 148.   
It has been suggested that "one potential source of genetic variation that may 
contribute to missing heritability is the associations which differ in magnitude and/or 
direction between males and females"57.
30 
 
     
Figure 5. Genetic variants may be either protective or risk markers for childhood ALL depending on the presence or absence of 
environmental risk factors 
Note: Most genetic associations are mediated by gene expression changes due to genetic variation and their effect may be different 
  in males and females. 
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Figure 6. Difference in the direction of a gender-specific association for childhood ALL 
 Note: Males show a risk association and females show a protective association after stratified                  
   analysis by gender. Net effect (odds ratio) is close to one and statistically nonsignificant. OR =      
   odds ratio 
 
 
 
Figure 7. Difference in the magnitude of a gender-specific association for childhood ALL 
Note: Males show a risk association and females do not show any association after stratified     
               analysis by gender. Net effect (odds ratio) shows an average of two odds ratio. OR = odds ratio  
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 In gene expression or genetic association studies, two kinds of gender differences 
are possible26: associations differing in direction (Figure 6) or differing in magnitude 
(Figure 7). The main interest of the present study was to identify the associations that 
differ in direction between males and females. This type of association is called “sexually 
antagonistic interaction”, "cross-over effect" or "qualitative interaction".  The examples 
stated below may arise from known differences in human physiologic functions and gene 
expression levels between males and females26. 
Several examples of associations differing in direction between males and females 
in genetic associations have been reported86. The most remarkable one differing in 
direction concerns the genetic regulation of genetic recombination rates in the human 
genome149. A GWAS designed to examine the genetic basis of recombination rate 
differences has shown an association differing in direction between males and females in 
RNF212 (ring finger protein 212) SNPs149. Two RNF212 SNPs (rs3796619 and 
rs1670533) are associated with higher recombination rate in males. The same two SNPs 
were associated with low recombination rate in females. These associations were 
replicated successfully in an independent sample in the same study149. It was suggested 
that if the frequency of the risk markers changes, the average recombination rate will 
increase for one gender and decrease for the other, but the gender-averaged 
recombination rate of the population can stay relatively constant. The presence of similar 
robust and replicated associations in IFNG (interferon gamma) polymorphism 
(rs2069727) in asthma further confirms the existence of associations differing in direction 
in two genders. The IFNG association in asthma is particularly intriguing in that the 
association is with the heterozygous genotype, but in opposite directions in males and 
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females, heterozygote advantage in females and heterozygote disadvantage in males (Pint 
= 0.008)70. Most importantly, this SNP did not show a significant main effect in overall 
analysis. The same SNP also yielded gender-specific association in childhood ALL 
risk130. 
Since most genetic associations are due to the correlation of associated SNPs with 
gene expression levels, it is of interest to know whether associations differing in 
directions may be due to sexually dimorphic gene expression26. A recent comprehensive 
survey of HapMap population samples for correlation between SNPs and gene expression 
levels by gender revealed that 12% to 15% of autosomal SNPs function in a gender-
biased manner118. It was concluded that such signals are likely to be diluted when both 
genders are analyzed simultaneously. This study highlighted the importance of 
considering each gender separately in genomic studies to uncover new disease and trait 
variants. In another study, the effect of serotonin-related gene polymorphisms on the 
central nervous serotonergic function has showed associations differing in direction 
between two genders: 5HTTLPR (rs479554, SL6A4; solute carrier family 6) short/short 
genotype is associated with higher 5-hydroxyindoleacetic acid (5-HIAA) levels in women 
but with lower levels in men150. A gender-genotype interaction was found (Pinteraction = 
0.04). However, the sample size was small (n = 165). A GWAS meta-analysis identified 
gender differential in associations with sex hormone-binding globulin levels. The loci 
4q13.2-UGT2B15 (rs293428, Pinteraction = 0.003), 17p13.1-SHBG (rs12150660, Pinteraction = 
0.02) and Xq22.3-TDGF3 (rs1573036, Pinteraction = 0.02) were stronger in men whereas 
8q21.12-ZBTB10 (rs440837, Pinteraction = 0.02) was stronger in women. This study 
underscored the gender-differentiated effects in complex trait variance151. Thus, in 
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addition to physiological differences in males and females, there are also differences in 
the correlations between genetic variants and gene expression levels that suggest 
feasibility of gender-specific associations we investigated in the present study. 
There are also examples of gender-specific associations that are only evident in 
one gender (male-specific or female-specific). A GWAS on schizophrenia identified a 
female-specific association with RELN (reelin) gene polymorphism (rs7341475; Pinteraction 
= 1.8 x 10-4)72. This polymorphism was further analyzed in four additional populations in 
the same study, and showed a female-specific association (OR = 1.58, P = 8.8 x 10-7) 
with a significant gender-genotype interaction (Pinteraction = 1.6 x 10-5).  Similarly, 
LYPLAL1 polymorphism (rs2605100) in waist-hip ratio152 also shows a female-specific 
association. These examples provide the proof of principle that heterogeneity in genetic 
associations between two genders exist57. Thus, it is evident that gender could be 
considered as an environmental variable in a gene and environment interaction analysis.  
In this study, we addressed the gender differences, by treating gender as an 
environmental factor, to obtain clues about the etiology of childhood ALL pathogenesis. 
Although the NIH, the Food and Drug Administration (FDA), and the IOM have highly 
recommended the use of gender-specific analysis, to date gender-specificity remains 
underappreciated112, 153. We expected that the proposed study may shed light on the 
influence of genetic factors in gender related differences in disease pathophysiology. In 
the absence of known environmental risk factors, genetic markers have the potential to 
provide etiological clues, and gender-specific analysis is a powerful approach in a disease 
which shows gender effect68.  
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2.5. Age-specific associations 
Like gender, age also plays a significant role in childhood cancer risk22. 
Epidemiological data consistently show a unique age distribution for childhood ALL. 
Childhood ALL incidence shows highest peak between 1 and 5 years of age, with 72 
cases per 1,000,000 per year in the U.S. In contrast, overall incidence rate of childhood 
ALL is around 23 cases per 1,000,000 per year under age 14, excluding the age group of 
1 to 5 years. Overall incidence rate of childhood ALL risk in different age groups are 
shown in Table 8. Tumors of the nervous system also show a higher incidence rate in 
children 0 to 4 years5.  
Table 8. Descriptive epidemiology of childhood acute lymphoblastic leukemia by age-at-
diagnosis 
Age at diagnosis (y) Incidence rate* Number of cases (n) % of cases
<1 20.0 119 2.87 
1-5 72.2 2091 50.41
6-10 30.6 868 20.93
11-14 21.3 514 12.39
15-19 17.8 556 13.40
        *Rate per 1,000,000 per year.  
 
        Source: National Cancer Institute, Surveillance, Epidemiology, and End Results5 
 
There is significant heterogeneity in the age-of-disease-onset of childhood ALL 
(Table 8). Around 50% of childhood ALL occurs between 1 and 5 years. This 
heterogeneity in age groups suggests that certain factors (genetics or environmental) may 
influence the severity and early-onset of ALL risk154.  To understand the relationship 
between age and childhood ALL risk, direct assessment of the age variation at the 
population level is important155. Just like gender-specific associations may be missed in 
the overall analysis, age-specific ones should also be unmasked by stratification. An 
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association with a small effect size in the overall analysis may become stronger in a 
certain age group. Statistical interaction analysis is one way to identify age-specific 
associations or effect modification by age.     
2.6. Genetic basis of age-specific associations 
Cancer in genetically predisposed people occurs at an early age36, 156. Rare 
hereditary cancer syndromes, such as Li-Fraumeni syndrome, accelerate the development 
of several adult cancers134, 157. Just like the effect of the TP53 (tumor protein 53) mutation 
in Li-Fraumeni syndrome on age-of-onset, genetic polymorphisms may also accelerate or 
delay the development of childhood ALL. Any age-specific association, which we aim to 
find would have been missed in previous studies and would contribute to disease biology 
in childhood ALL risk. One of the main purposes of GWAS is to find genetic variants 
that may provide some clues about disease biology related to disease phenotype68. Thus, 
a variant showing a larger effect size for one age group may explain a greater proportion 
of the population attributable risk estimates, which could improve early detection, 
treatment and prevention158, 159.   
Several studies have provided empirical evidence for early- or late- onset of 
diseases, along with severity and their associations with genetic markers. One of the 
classic examples is late-onset Alzheimer disease (AD) and its association with 
apolipoprotein E (APOE) allele75, 76. With increasing number of APOE type 4 alleles, 
mean age-at-onset decreases from 84 to 68 years75. APOE codes for the major carrier 
protein in the brain160, and is an important regulator of lipids161. It is hypothesized that 
the presence of APOE type 4 alleles leads to excess amyloid formation in brain162. A few 
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studies in multiple sclerosis also yielded an association with APOE type 4 alleles and 
disease severity160, 163, 164. A study on African American females has yielded an earlier 
age-of-onset of multiple sclerosis (MS) in people with the APOE risk genotype164. 
However, a few of these studies suffer from low statistical power, as the sample size was 
low163, 165. 
The SNP309 (rs2279744) variant allele, present in the MDM2 (mouse double 
minute 2) oncogene (cancer causing), is more common in early-onset (AA = 85.2 months 
vs AB + BB = 70.5 months) childhood ALL in a multiethnic sample (P = 0.04)154. 
Likewise, the same association with age-at-onset (P = 0.002) is successfully replicated in 
another childhood ALL samples with gender-specificity in a non-Hispanic white 
population126. Results showed a trend toward an earlier age at diagnosis in females (AA = 
59 months vs AB = 44 months vs BB = 32 months) (133). Studies found that MDM2 
expression level is regulated by estrogen signaling in the presence of rs2279744 variant 
allele134, 166, 167. It has been suggested that rs2279744 variant allele may play a significant 
role through negatively regulating TP53. TP53 encoded molecules play an important role 
in genome surveillance (133). MDM2 is a known key negative regulator of TP53 protein, 
and dysregulation of MDM2 may significantly impact the TP53 functions, and increase 
tumorigenesis, including leukemia, via apoptotic pathway. Likewise, recent studies have 
revealed that variant allele of MDM2 rs2279744 can also accelerate tumorigenesis and 
increase the risk of several cancers, through estrogen-signaling pathway, exclusively in 
females167. Estrogen levels in children are negligible, which suggests in utero exposure of 
estrogen in childhood ALL risk (133). 
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A study on colorectal cancer, in two independent groups, showed that women 
who carry the variant allele of rs2279744 have a nine year earlier (at 61 years vs 70 
years) onset than women who carried the wild-type genotype (P = 0.001)168. Results were 
not statistically significant for men. The authors suggest that estrogen influences variant 
allele to accelerate colorectal tumor formation in women at a younger age. Likewise, 
MDM4 polymorphism (rs1563828) had shown an association with an early age-of-onset 
of estrogen-receptor negative breast cancer in two independent cohorts169. Women who 
possess homozygous variant (TT) develop estrogen-receptor negative breast cancer at an 
earlier age than homozygous wild-type (CC) and heterozygote (CT) (first cohort: P = 
0.018 & second cohort: P = 0.006). In both cohorts, age-at-diagnosis is accelerated by 5 
years (43.8 years vs 48.8 years) and 3.8 years (37.2 years vs 41.0 years), respectively.  
An human leukocyte antigen (HLA) study on chronic myeloid leukemia (CML) 
found the age-related effects of HLA-DRB3 and HLA-DRB4 homozygosity170. The 
presence of DRB4 homozygous genotype was associated with risk (OR = 3.36; P = 0.01) 
and homozygosity for DRB3 was protective (OR = 0.51; P= 0.007). DRB4 homozygosity 
rate was high and DRB3 homozygosity rate was low in patients with early-onset CML. 
The age-related changes in their frequencies shown a significant separation (P = 0.02) in 
three age groups (18-32 years, 33-42 years and 43-60 years). The presence of similar 
associations of PTPN2 (protein tyrosine phosphatase, non-receptor 2) polymorphisms 
(rs2542151) in T1D78 and hemochromatosis HFE (hemochromatosis) gene variants in 
colorectal carcinoma171 further confirms the genetic effect on age-at-onset of cancers. It 
is only natural that future association studies should pay attention to these clues.  
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A recent study on IKZF1 (IKORAS family zinc finger one) polymorphisms, 
previously identified as risk markers in childhood ALL52, yielded a significant 
association between rs4132601 with age at diagnosis (P = 0.04)140. The mean age-at-
onset decreases from 5.58 to 3.83 years (TT + TG = 5.58 vs GG = 3.83) with the 
possession of two G alleles. The most recent childhood ALL GWAS53 compared the 
variant allele frequency of rs10821936 between cases that diagnosed ALL before 10 
years of age to those that diagnosed at an older age (> 10 y). Results showed an 
association with non-Hispanic whites (P = 0.02) and Hispanics (P = 0.007). This study 
also yielded a trend for decreasing ORs with increasing age (less than 5 y, 5 to 10 y and 
more than 10 y) for the same polymorphism: 2.0 (1.9-2.2), 1.8 (1.6-2.02) and 1.5 (1.3-
1.7), respectively. Therefore, there are also examples of what we aim to show, namely, 
age-specific genetic associations in childhood ALL.  
Although there are many reports of association with gender and age in cancer 
susceptibility, they are no more than statistical correlations with yet unknown biological 
significance and most have not been replicated. These studies need to be confirmed in a 
much larger population to rule out chance findings. A few of these studies also suffer 
from multiple comparisons. Most of these associations are identified in a case-control 
study design, specifically gender-specific associations. A few studies have used 
convenient samples as a control group, which suggest selection bias. Thus, it is important 
that controls should be representative of the general population. Future studies should 
consider the case-only design to avoid problems related to selection bias and insufficient 
statistical power60. Strong effects play an important role in public health interventions or 
risk profiling158, 159. We proposed to identify the strongest associations that interact with 
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gender and/or age which would have yielded no main effects in the overall analysis in a 
case-control study. In the present study, we used gender and age as effect modifiers.  
Although multiple GWAS have been published in childhood ALL49-54, results are 
consistent but the magnitude of effect is small as in most GWAS. These studies only used 
an overall analysis approach. Prior to the present study, no GWAS in childhood ALL has 
used gender- or age-specific analysis. The presence of gender- and age-specific 
associations underlines the need to conduct a dedicated study on gender- and age-specific 
analysis to identify the previously missed associations in GWAS and candidate gene 
studies. The aim of this study was to fill these gaps in knowledge by performing a 
comprehensive GWAS of genetic susceptibility in childhood ALL to uncover otherwise 
masked gender- and age-specific associations.  
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3. PROJECT AIMS AND HYPOTHESIS  
Despite multiple published GWAS in childhood ALL, identified genetic 
susceptibility represents a small fraction, and leaves a large proportion to be defined. We 
exploited an underutilized design to unravel strong genetic risk markers.   
    We hypothesized that age and gender differences in childhood ALL risk have a 
genetic basis, and the effect modification by gender and age can be exploited to unmask 
yet unknown genetic risk markers.  
To assess the validity of this hypothesis, the proposed study had two specific 
aims:    
Specific Aim 1: To examine gender-specific associations that differs in their directions in 
males and females to gain insight into the pathophysiology of gender differences and 
childhood ALL pathogenesis. 
Specific Aim 2: To examine the relationships of genetic risk markers with age-of-onset 
of ALL to gain insight into the pathophysiology of age peak in childhood ALL. 
The main purpose of this dissertation was to identify gender- and age-specific 
associations. In case of gender-specific associations we are more interested in the 
associations which differ in direction (explained in Chapter 2). No study has explored 
gender-specific associations in childhood ALL GWASs, but all of them only considered 
the overall group. Likewise, age-specific associations may have been missed in the 
analyses of the overall sample. For age-specific associations, the peak age (1-5 years) 
group was compared with the rest of the cases (6-10 years). A time-to-event analysis was 
also performed for the whole case group. These differences in childhood ALL should be 
able to provide some clues on disease pathogenesis. The amalgamation of gender- and 
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age-specific genome-based knowledge related to disease susceptibility into public health 
may contribute to disease prevention, health promotion and risk reduction172. 
Bioinformatic analyses were also performed to examine the functionality of the markers 
that have shown associations. Likewise, empirical data screening was performed to check 
whether these markers regulate expression of any genes or interfere with the genome 
biology in any way. The aim of this effort was to identify causal risk factors and gain 
insight into mechanism of their associations with age-at-onset or gender differential of 
childhood ALL.    
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4. MATERIALS AND METHODS 
This study was based on two specific aims to identify gender- and age-specific 
associations with childhood ALL risk. Genome-wide microarray chips were used for all 
genotyping. Logistic regression, using Plink software, was used to identify gender- and 
age-specific associations. A time-to-event analysis was performed for the whole group to 
explore association with age-at-onset.  
4.1. Ethics statement 
 Institutional review board (IRB) approval was granted by Florida International 
University, Office of Research Integrity (IRB-13-0546). A copy of IRB from Baylor 
College of Medicine (BCM) was also submitted to Office of Research Integrity, Florida 
International University. All samples received from the primary study site were de-
identified, and no one at the FIU site could identify any subject. 
4.2. Research design  
The traditional case-control approach is commonly used in genetic association 
studies for rare diseases such as childhood ALL. In spite of numerous advantages over 
other classical epidemiological study designs, case-control study design has several 
limitations, particularly recruitment of an appropriate control group. The case-only design 
(explained in Chapter 1) is more efficient than other traditional epidemiological studies at 
detecting statistical interactions, which was the main focus of this project58. Recruitment 
of cases in a rare disease like childhood ALL is a challenge59 and hence, preferring a 
statistically powerful research design was more practical and is used in the present study. 
A flow chart explaining whole method section is delineated in Figure 8.
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Figure 8. A flowchart explaining method section 
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4.3. Recruitment of study subjects 
A case-control study design was used to recruit the childhood ALL samples in the 
parent study131. In the present study, only cases were used for GWAS to assess the 
gender- and age-specific analysis. The cases were incident cases of childhood ALL 
consecutively recruited in Texas Children’s Cancer Center (TXCCC), BCM, Pediatric 
Hematology/Oncology Clinic, Houston, Texas from 2007 to 2012. All newly diagnosed 
childhood (age 1-18 years) ALL cases and their parents were approached for informed 
consent and the participation rate was 95%. At the time of enrollment, no case had any 
other disease. The proposed study used 240 cases for case-only analysis. All of these 
cases were non-Hispanic whites aged 1 to 10 years. Demographic characteristics of 
childhood ALL cases collected through questionnaires and are explained in result section 
(Chapter 5).  
4.3.1. Inclusion criteria 
1- All incident cases diagnosed with acute lymphoblastic leukemia confirmed by 
immunophenotyping 
2- Age 1-18 y in the parent study, but only subjects age 1 to 10 years of age were 
included in this study nested within the parent study 
3- All samples were recruited from TXCCC, BCM, Pediatric 
Hematology/Oncology Clinic, Houston, Texas  
4.3.2. Exclusion criteria 
1- The exclusion criteria was refusal to participate or diagnosed with any other 
disease 
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Table 9. Statistical power calculations for the detection of interactions when associations 
differ in direction 
Power 
 
Sample 
size N1 
males 
Sample 
size N2 
females 
Genotype 
frequency 
in male 
cases 
Genotype 
frequency in 
female cases 
OR for 
interaction 
Alpha 
(α) 
0.8147 120 120 0.24 0.10 2.8 0.05 
0.8686 120 120 0.25 0.10 3.0 0.05 
0.7865 120 120 0.30 0.15 2.4 0.05 
0.8596 120 120 0.31 0.15 2.6 0.05 
0.7673 120 120 0.35 0.20 2.2 0.05 
0.8543 120 120 0.38 0.20 2.4 0.05 
0.8139 120 120 0.42 0.25 2.2 0.05 
0.8407 120 120 0.49 0.30 2.2 0.05 
  OR = odds ratio  
 
4.5. Statistical power calculation for statistical interaction when gender-specific 
associations differ in magnitude (quantitative interaction) 
  We also performed a statistical power calculation for various genotype risk 
frequencies and effect size for 240 samples (Table 10). However, to achieve 80% 
statistical power for risk genotype frequency of 10% and minimum OR should be 1.59, 
and sample size should be 686 in each arm; and for risk genotype frequency 30% and OR 
1.55, sample size should be 356 in each arm. Thus, with a sample size of a total of 240 
subjects, we did not have sufficient statistical power to detect quantitative interactions, 
which we did not aim to detect. 
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Table 10. Statistical power calculations for association differing in magnitude 
Power 
 
Sample 
size N1 
male 
Sample 
size N2 
female 
Genotype 
frequency 
in male 
cases 
Genotype 
frequency 
in female 
cases 
OR for 
interaction 
Alpha 
(α) 
0.22 120 120 0.15 0.10 1.59 0.05 
0.58 120 120 0.20 0.10 2.25 0.05 
0.29 120 120 0.22 0.15 1.60 0.05 
0.49 120 120 0.25 0.15 1.89 0.05 
0.43 120 120 0.30 0.20 1.71 0.05 
0.35 120 120 0.35 0.20 2.15 0.05 
0.39 120 120 0.35 0.25 1.62 0.05 
0.37 120 120 0.40 0.30 1.55 0.05 
 OR = odds ratio  
 
4.6. Statistical power calculation for time-to-event analysis 
 
We used STATA v13 for statistical power analysis to compare two survival rates 
(wild-type vs allele positivity). Here we used the dominant genetic risk model (AA as 
referent vs AB + BB as risk genotypes) for statistical power calculation. We calculated 
statistical power for a range of genotype frequencies. Table 11 represents statistical 
power for time-to-event analysis for a sample size of 240 based on a range of risk 
genotype frequencies. The study had 80% statistical power for the statistical significance 
threshold of 0.05, for hazard ratios (HR) ranging between 1.43 and 1.90 for a range of 
risk genotype frequencies. 
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Table 11. Statistical power calculation for time-to-event analysis 
Power  Alpha    (α) 
Risk genotype 
frequency 
Hazard 
Ratio 
0.80 0.05 0.05 1.90 
0.80 0.05 0.10 1.65 
0.80 0.05 0.15 1.55 
0.80 0.05 0.20 1.50 
0.80 0.05 0.25 1.47 
0.80 0.05 0.30 1.45 
0.80 0.05 0.35 1.44 
0.80 0.05 0.40 1.43 
 
 
4.7. DNA extraction 
Genomic DNA was extracted from blood samples using the Qiagen Blood Mini 
Kit (Qiagen, Valencia, California) according to manufacturer's protocol at TXCCC, 
BCM. Only DNA samples with study IDs without any personal identifiers were received 
from TXCCC, BCM, Pediatric Hematology/Oncology Clinic, Houston, Texas. 
Established childhood ALL risk associations identified in GWAS51, 52 have been 
replicated to validate the parent case-control study sample using TaqMan allelic 
discrimination assays at FIU131.  
4.8. DNA quantification 
 
 DNA samples were quantified via the ND-8000 spectrophotometer and DNA 
quality was evaluated via gel electrophoresis on a 0.8% agarose gel at the Hussman 
Institute for Human Genomics (HIHG), University of Miami.  The concentration for all 
qualified samples was normalized to 50ng/ul and samples were arrayed in Matrix 0.5ml 
2D barcoded tubes in racks of 96. 
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4.9. Genotyping methods 
Genotypings for 240 childhood ALL cases were achieved by Illumina Infinium 
HumanCoreExome Chip (Illumina, San Diego, CA, USA). Genotyping was performed at 
the HIHG, University of Miami on the Illumina iScan array scanner system.  
Samples that passed the above exclusion criteria (DNA quantification) were 
genotyped using Illumina Infinium HumanCoreExome Chip, that interrogates 
approximately 500,000 markers.  The samples were processed according to Illumina 
Procedures for processing of the Infinium HD assay.  In brief, on day one of the 
procedure 200ng of DNA were denatured and neutralized in preparation for isothermal 
amplification in an overnight step.  On day two, the amplified products were fragmented, 
precipitated and re-suspended in hybridization buffer.  It was then applied to the Infinium 
HumanCoreExome Chip and the chips were incubated overnight in the Illumina 
hybridization oven. During this incubation the DNA sample was allowed to anneal to 
locus-specific 50mers which were covalently attached to beads assembled into micro-
wells on the ExomeChips substrate. On day 3, unhybridized DNA was washed away.  
Then during a single-base extension of the oligos on the ExomeChips, using the captured 
DNA as a template, fluorescent labels were incorporated on the ExomeChips and the 
genotypes were determined.  The ExomeChips were then scanned on the Illumina iScan.  
The above protocol was automated using the Tecan EVO-1 to further enhance the 
efficiency and consistency of the assay.  Samples were processed in batches of 96.  In 
order to ensure reproducibility of results one quality control DNA sample (CEPH DNA) 
was repeated in each 96 well plate.  Genotype concordance was checked for replicate 
samples following each genotyping run.  Data were extracted by the Illumina ® Genome 
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Studio software from data files created by the Illumina iscan. No additional pre-Plink QC 
steps was performed on either the SNPs or the samples.  
All post Plink QC steps and association analysis of the genotype data were 
conducted with the dedicated GWAS analysis software Plink173. Plink 
(http://pngu.mgh.harvard.edu/~purcell/plink) is a free toolset for whole genome 
association analysis. Most analyses were performed on a Linux-based computer. 
4.10. Quality control 
Genotyping errors have the potential to introduce bias in a genetic association 
study. QCs are required to remove subjects and genetic markers that do not yield 
satisfactory results as they may generate false-positive results. 240 samples were 
genotyped at the UM. All standard GWAS QC steps 82, 173-177 were applied before the 
analysis. A flowchart of all performed QC steps is given in Figure 10. Results of all QC 
steps are provided in Chapter 5. 
4.10.1. Per-individual quality control 
Per-individual QC step screens genotypes to identify subjects that may introduce 
bias if not removed. Poorly genotyped (low call rate) individuals will increase error in the 
study and may significantly affect the results. All steps performed in this study are 
explained below. 
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Quality control steps using 
Plink  
Per individual QC 
Discordant sex information   
Individuals with excessive missing 
rate or outlying heterozygosity rates    
Identification of duplicate and related 
individuals 
Per marker QC 
Markers with excessive 
missing genotype rate
Makers with significantly different 
missing genotype rates between 
males and females 
SNPs with significantly different 
missing genotype rates between cases 
(1-5 years) and controls (6 -10 years) 
Minor allele frequency
Statistical analysis 
Figure 10. A flow chart of quality control steps used before the gender- and age-specific analysis
53 
 
4.10.1.1. Identification of individuals with discordant gender information 
This was the first step of QC, performed to identify subjects that have 
inconclusive/contradictory gender information82, 173, as it can lead to spurious 
associations. In a case-control study, samples that show the wrong gender information are 
suggested to be excluded from further QC and statistical analysis. Subjects were 
appropriately recoded or removed, if information was inconclusive, for further analyses.   
4.10.1.2. Identification of individuals with excessive missing rate or outlying 
heterozygosity rates 
This QC step was used to identify and exclude individuals with too much missing 
genotype data and outlying heterozygosity rate. Genotype accuracy and genotype call rate 
can be significantly affected by variations in DNA quality82. A high genotype failure rate 
and heterozygosity rate suggest poor DNA sample quality. A high heterozygosity rate 
also suggests DNA contamination. We examined the distribution of missing genotypes in 
entire data set, and set a threshold of 1%. It means that individuals with more than 1% 
missing genotypes would be removed from further QC steps.  
4.10.1.3. Identification of duplicated or related individuals 
In a population based study, it is important that all samples should be unrelated. 
Presence of duplicate, first- or second-degree relatives will introduce bias in the study as 
their genotypes will be overrepresented. This step was used to identify all related and 
duplicate individuals for removal. A metric (identity by state, IBS) for each pair of 
individuals was calculated to identify duplicate samples. IBS is defined as, at a locus, two 
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individuals who have an identical nucleotide sequence or the same allele. An IBS score 1 
suggests relatedness between two samples.  
4.10.2. Per-marker quality control 
Like low quality individual samples, low quality markers can also threaten 
internal validity of the results. Exclusion of these markers is necessary to avoid spurious 
associations. The QCs used for marker exclusions are explained below.  
4.10.2.1. Identification of SNPs with an excessive missing genotyping rate 
 
Like individuals with a high rate of poor genotypes, we also removed the markers 
that had high genotyping failure rate. It is important to remove only poorly characterized 
markers because every removed marker is a potentially missed disease variant82. We used 
a 99% threshold to remove markers after carefully scrutinizing the data set. It means to 
include only those SNPs for further analysis which have at least 99% genotyping call 
rate. Acceptable genotyping call rates in GWAS are 1 to 5%.  
4.10.2.2. Removal of markers with a very low minor allele frequency  
In this step of QC, we excluded polymorphisms that had a low minor allele 
frequency (MAF). These SNPs are mostly non-informative as they show little variation in 
the sample set being analyzed. Even power to detect an association will also be low. We 
used a stringent threshold for MAF. SNPs with MAF ≤ 0.03 in the data set were 
removed.   
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4.10.2.3. Identification of SNPs with significantly different missing genotype rates 
between comparison groups 
Substantial differences in genotyping rates between males and females may 
confound the result if the difference is caused by DNA sample quality. To reduce 
confounding, the exclusion of markers with substantially different genotyping rates 
between these groups is crucial. Likewise, for age-specific association, we also checked 
differential missing rates between two age groups (1-5 years and 6-10 years). All markers 
that showed significant difference between two groups were removed from further QC, 
and gender-and age-specific analyses. We used a threshold of < 0.05 after scrutinizing the 
data set.  
4.10.2.4. Identification of SNPs showing a significant deviation from Hardy-
Weinberg equilibrium  
 
Hardy-Weinberg equilibrium (HWE) refers to genotype frequencies being close 
to their expected frequencies estimated from allele frequencies. Goodness-of-fit test is 
used to test the agreement between observed and expected frequencies. In a case-control 
study, markers which significantly deviate from HWE in controls are usually excluded 
from analysis since this finding is an indication of genotyping error. Since this is a case-
only study, HWE test has not been used as a QC step to detect genotyping error before 
the analysis, but markers that have shown associations, were retrospectively assessed for 
their conformity to HWE in the whole group of subjects and in males and females, or in 
age groups separately for gross violations that would indicate genotyping errors rather 
than valid associations.   
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4.11. Genomic control  
The genomic control (GC) is a method to control for population stratification in a 
genetic association study to reduce type I error176, 178, 179. Population stratification may 
confound results, if not adjusted. A population in a genetic association study may arise 
from two distinct sub-populations which may differ in their genetic ancestry. The 
presence of systematic differences in allele frequencies between these two sub-
populations may confound the result. There are thousands of neutral loci, known as 
genomic controls used to correct for population stratification in GWASs. The GC first 
estimates an inflation factor (λ), then adjust all of the test statistics downward by λ. 
Inflation factor λ > 1 indicates population substructure and/or genotyping error. Plink was 
used to adjust results for genomic control. In this study, only non-Hispanic whites were 
used for gender- and age-specific associations. We still adjusted results for GC to avoid 
any confounding by population stratification. 
4.12. Permutation test 
Permutation testing, also known as randomization testing, is a type of statistical 
significance test that is not influenced by multiple comparisons180. Rearrangement of the 
phenotype status, such as case-control status, of each sample is the first step of this test. 
The second step is to compute association analysis after each rearrangement of the case-
control status. This whole procedure is performed by predefined number of times, 10,000 
times in the present study. Test statistics is calculated for actual data set, and each  
permuted data set for predefined number of times. The procedure keeps the P value after 
each permutation. At the end, it compares the distribution of permuted P values with the 
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P value yielded by the original data set. This comparison estimates the proportion of 
chance findings if the study was repeated predefined number of times under the null 
hypothesis. These results are free from multiple comparison issues, as each permutation 
on each SNP assesses the role of chance, and can be performed on thousand of SNPs 
independently. In this study, for gender-specific association analysis, the rearrangement 
of phenotype status involved males and females. Likewise, for age-specific analysis, the 
shuffle was performed between age group 1-5 years (coded as one) and 6-10 years (coded 
as two).  
4.13. Data analysis 
All data analyses were performed using Plink and Stata v13 (StataCorp, College 
Station, TX). For the comparison of continuous variables, results were expressed as 
means and standard deviations (SD) and student t-test (for means) was performed. 
Dichotomous or categorical variables were summarized as a table with counts and 
percentages for comparison, and Pearson’s chi-squared and fisher exact test were 
performed. 
 Unconditional logistic regression was used to calculate OR and 95% CI for 
gender- and age-specific analyses. The main interest was detecting the genotype 
frequency differences between males and females cases. We used logistic regression after 
coding males and females as “2” and “1” as if they were cases and controls, respectively. 
Similarly, in age-specific analysis, we compared different genotype frequencies between 
two age groups (1-5 years vs 6-10 years). Logistic regression was also used for age-
specific analysis after coding age group 1-5 years as “2” and 6-10 years as “1”.  
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Definition of variables for gender-specific and age-specific are summarized in respective 
tables (Tables 12 and 13). We used GC to adjust for population heterogeneity178, 179, 
however, all of these samples were non-Hispanic whites. 
 
Table 12. Summary of variables for gender-specific association 
Variables  Classification  Measurement  
Outcome variable 
Gender Dichotomous  2 (male) or 1 (Female)  
Explanatory variable 
Genotype Categorical AA, AB, BB  
Confounding variable 
Age Continuous years 
 
 
Table 13. Summary of variables for age-specific association 
Variables  Classification  Measurement  
Outcome variable 
Age Dichotomous 2 (1 to 5 y) or 1 (6 to 10 y) 
Explanatory variable 
Genotype Categorical AA, AB, BB 
Confounding variable 
Gender Categorical 1 (Females) or 2 (Male) 
 
4.14. Genetic models for different association tests 
There are several genetic models (Figure 11) used in the analysis of a genetic 
association study181. These genetic models have similarities to the models used in  
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Figure 11. Common genetic risk models use in a genetic association study 
    Here, A and B are two alleles of a SNP. AA is a wild-type, AB is a heterozygote and BB is a variant genotype.  
  Adapted from: Lewis CM, Knight J. Introduction to genetic association studies. Cold Spring Harb Protoc 2012; 2012(3): 297-306  
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environmental epidemiological studies. An additive genetic model was used gender- and 
age-specific association analyses. X-chromosome analysis was based on multiplicative 
genetic model. Time-to-event analysis genetic models were based on Kaplan-Meier plot. 
The counts for three genotypes of a SNP can be analyzed by a 2 x 3 contingency table. 
For a SNP with allele A and B, genotypes will be AA (wild-type), AB (heterozygote) and 
BB (variant).   
4.14.1. Additive model 
The most common genetic model used in the analysis of an association study is 
known as an additive model (Figure 11). This model is tested by Cochran-Armitage trend 
test which assesses gene-dosage effect. This model assumes that having two copies of 
minor allele (BB) will have double the effect of having a single copy of minor allele 
(AB). This genetic model is very similar to a basic epidemiological model (no smoking 
vs 5 cigarettes/day vs 10 cigarettes/day). This test has one degree of freedom. These data 
can be analyzed by logistic regression in which the genotypes are represented as 0 (AA), 
1 (AB) and 2 (BB). 
4.14.2. Dominant model 
This model (Figure 11) suggests that even a single copy of the variant allele has 
an effect on phenotype. We categorized individuals into two groups (AA vs AB + BB) 
based on whether they have at least one minor allele B (either AB or BB) or no copies of 
minor allele (AA). It is a 2x2 table test with one degree of freedom. This model  
is also very similar to basic epidemiological model, for example presence or absence of 
exposure.  
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4.14.3. Recessive model 
In the recessive genetic risk model, two copies of variant allele (BB) is associated 
with risk (Figure 11). In other words, heterozygosity (AB) is not associated with risk. 
Here, we categorized individuals in two groups (AA + AB vs BB). It is tested in a 2x2 
table test with 1 degree of freedom.  
4.14.4. Multiplicative model 
In case of X-chromosome analysis, genotype-based models are not practical for 
statistical analysis. Females have two copies of X chromosomes and males have one copy 
of X chromosome. The most appropriate test is allelic association test. In allelic 
association test (Figure 11) the unit of test is the allele (A and B) rather than individual, 
as each individual contributes two alleles for autosomal chromosomes. Allele counts for 
X-chromosome are obtained in a different way for X chromosome polymorphisms, and 
are given below.  
In case of X chromosome analysis  
Females have a pair of X chromosome means two copies of alleles (AA or AB or BB). 
AA = two A alleles 
AB = one A and one B allele 
BB = two B alleles 
Males have one X chromosome, means one copy of allele (A or B). 
A = 1 allele  
B = 1 allele 
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4.15. Time-to-event analysis 
Time-to-event analysis (survival analysis) was performed on each SNP that has 
shown an association in gender- and age-specific analysis. The top 100 results based on 
the P value and the effect size were used for time-to-event analysis. Kaplan-Meier plots 
were used to generate the survival curves between two or three groups, cases possessing 
different genotypes (wild-type vs heterozygote vs homozygous variant). It also provided 
clues for appropriate genetic model (additive, dominant or recessive) to test the statistical 
significance between three or two curves (depending on the genetic risk model).  
Log-rank test was used to test the statistical difference between survival times 
(time to having leukemia) between two (dominant or recessive model) or three (additive 
model) groups. Cox-proportion hazard model were used to calculate the HR182, 183. 
Definition of variables for survival analysis is summarized in Table 14. 
 
Table 14. Summary of variables for survival analysis 
Variables Classification Measurement 
Outcome variable 
Time-to-event Continuous years 
Explanatory variable 
Genotype Categorical AA, AB, BB 
Confounding variable 
Gender Categorical 1 (Female) or 2 (Male) 
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All statistical tests were two-tailed and threshold for statistical significance was 
0.05. We performed a permutation test for gender- and age-specific associations which is 
not influenced by multiple comparisons. 
4.16. Bioinformatic and empirical screening of data for functional annotation of 
associated markers  
 To assess the functionality of identified gender- and age-specific associated SNPs, 
several bioinformatic tools were used. The main purpose was to examine whether 
identified variants are causative or proxy markers. RegulomeDB184  
(http://regulomedb.org/) and Functional Single Nucleotide Polymorphism (F-SNP)185 
(http://compbio.cs.queensu.ca/F-SNP/) were the two main databases used for this 
purpose. RegulomeDB predicts a score for a variant from 1 to 7. A score of 1 signifies 
the highest functionality of the variant, and 7 the least functional variant. To assess 
functionality, RegulomeDB uses high throughput, computational predictions and other 
sources such as experimental results. F-SNP database generates a score between 0 and 1. 
A score of 1 suggests a high functional score and 0 suggests least functional score. This 
database incorporates information obtained from 16 other bioinformatic tools and the 
functional effects of SNPs. These databases identify and focus on SNPs with potential 
harmful effect on human health.  
Two SNPs, close to each other, on the same chromosome may be statistically 
correlated. These highly correlated SNPs will not provide any additional information for 
statistical analysis. It means that SNP1 and SNP2 will give the same information, such as 
effect size (OR) and P value. These highly correlated SNPs, included in the GWAS chip, 
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were identified through Plink analysis, to avoid redundancy. All top SNPs that show 
correlations are reported in the appendix.  
Most of the time, genetic association studies yield associations with nearby 
correlated SNPs, known as indirect associations. The second step of correlation analysis 
was to identify primary causal SNP, which was not included in the GWAS chip.  We 
generated a list of SNPs, using HaploReg 
(http://www.broadinstitute.org/mammals/haploreg/haploreg.php), for all gender- and age-
specific risk variants, which were correlated. Bioinformatic and empirical analyses were 
performed to identify potentially causal SNPs.  
We also used empirical analysis using SNP and Copy Number Annotation 
(SCAN) database186 (http://www.scandb.org/newinterface/index.html). For each SNP, 
SCAN database provides information from experimental data on gene expression 
regulation. Gene expression is a quantitative trait and an important intermediate 
phenotype that link the genetic polymorphisms and phenotype (here, ALL). Any genetic 
variant that regulates gene expression levels of mRNA and protein is known as an 
expression quantitative trait locus (eQTL). The correlations between SNPs and gene 
expressions ultimately modify disease susceptibility. Thus, eQTL analysis was used to 
evaluate whether the identified gender- and age-specific variants influence expression 
levels of genes. We searched SCAN database and only explored the eQTL effects of 
identified variants in lymphoblastoid cell lines (LCLs) in the Caucasian population. The 
P value was ≤ 1 x 10-5. 
Phenotype-Genotype Integrator (PheGenI) database 
(http://www.ncbi.nlm.nih.gov/gap/phegeni) was used to increase chances of findings of 
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susceptible candidate genes187. The PheGenI, merges National Human Genome Research 
Institute (NHGRI) GWAS catalog data with several other databases housed at the 
National Center for Biotechnology Information. SNPnexus database (http://www.snp-
nexus.org/) was used to retrieve additional information, such as genomic mapping (using 
dbSNP), gene/protein consequences, effect on protein function, regulatory elements, and 
phenotype and disease association188.      
Gene enrichment analysis, also known as pathway-based analysis, is a powerful 
approach to identify disease causal genes from genomic, proteomic and bioinformatics 
dataset. It looks an identified gene list, here gender- and age-specific genes, and finds out 
whether any group of genes belonging to the same pathway are overrepresented in the 
list. We used the Gene Ontoloy Consortium (http://geneontology.org/) for gene 
enrichment analysis189. Bonferroni correction was used for multiple comparisons. The 
Comparative Toxicogenomics Database (CTD) was used to identify chemical-gene-
disease relationships190. The CTD also provides insight into chemical-gene, gene-disease 
and chemical-disease interactions. It nearly contains 15 million toxicogenomic 
relationships. 
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5. RESULTS 
The project, which investigated gender- and age-specific genetic associations with 
childhood ALL risk using a GWAS design has yielded positive results as presented in 
this chapter.  
5.1. Quality control results  
The main aim of QC was to minimize potential bias and error by excluding 
samples and markers, which failed at QC steps. These excluded samples were also 
compared with samples analyzed in this study to check whether their exclusion 
introduced any bias. All steps of QC, explained in Chapter 4, and their results, are 
explained below. Four samples were excluded after agarose gel DNA quantification 
based on lower DNA concentration.  
5.1.1. Results from discordant gender information 
 The first step of QC was used to check the self-reported gender information of 
each individual using genetic data. Plink uses X chromosome data to determine gender 
empirically. This calculation is based on the difference between X chromosome numbers 
in males (one X chromosome) and females (a pair of X chromosomes)82. Males cannot be 
heterozygous (AB) for any marker. Genotype-calling algorithm for this QC step counts 
heterozygote as a missing genotype. A female marked as a male in the data set will show 
a large amount of missing data. This step of QC gives a score between 0 and 1. In an 
ideal situation, we expect homozygosity rate one for males and < 0.2 for a female subject. 
However, a score of ≤ 0.2 suggests a female, and a score of ≥ 0.8 suggests a male. Scores 
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between 0.2 and 0.8 suggest ambiguity in gender information. In the case of discrepancy 
between self-reported sex and genetically determined sex, the genetically determined sex 
was used in the analysis. Seven males (≥ 0.8) and six females (≤ 0.2) were re-coded on 
re-examination of their gender in the original dataset. Four samples scored between 0.2 
and 0.8, and were removed from further QC steps due to ambiguous gender information 
which could not be verified. However, most of these gender discordant samples also 
failed further QC steps suggesting that the ambiguity was due to poor DNA sample 
quality. Inclusion of individuals, with discordant gender information, could have yielded 
spurious associations, and could have hampered the first aim of the study. The idea with 
gender QC is not just to get the genders right, but also to rule out any sample 
handling/labeling problems. 
5.1.2. Results from individuals genotype and heterozygosity rates 
The aim of this QC step was to identify individuals who had low genotype call 
(genotyping) rates and higher heterozygosity rates. Low genotype call rates and higher 
heterozygosity rates are indicative of poor DNA quality. Aberrant genotype calling would 
increase errors in the study, and those samples should be excluded. We excluded twenty 
samples that had the genotype failure rate ≥ 1% and /or the heterozygosity rate outside of 
± 3 standard deviations from the mean. A graph showing how the heterozygosity rate and 
genotype call rate correlate is presented in the appendix (Figure 1). These excluded 
samples were further analyzed to check if there is any substantial difference between 
them and the rest of the samples (explained in 5.2).  
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5.1.3. Results from duplicates and related samples 
 This step of QC was used to identify duplicates and samples from closely related 
individuals to avoid overrepresentation of their genotypes which would introduce bias in 
the study. Plink calculates a metric for each pair of individuals and generates a score 
between 0 and 1. A score of one suggests the presence of a duplicate sample in the data 
set. A total of five samples were excluded from further analysis as they scored more than 
98% (> 0.98) with another sample. All other samples had very low scores (< 0.14). 
Among these five samples, one DNA sample was repeated in each 96 well plate (total 
three), and one sample was used a duplicate. Our results yielded one more sample as a 
duplicate.    
5.1.4. Results from genotyping efficiency 
 This step of QC was used to examine the markers genotyping efficiency. Marker 
genotype efficiency (genotyping rate per marker) indicates marker quality. This QC step 
was used to identify and exclude poorly genotyped markers. These markers are likely to 
increase false associations, if not excluded. We used a ≥ 99% threshold to remove 
markers after carefully scrutinizing the data set. This suggests that markers with 1% or 
more missing data were excluded. A total of 4,710 out of 538,449 markers failed this QC 
step, and were removed from further analysis.  
5.1.5. Results from minor allele frequency filter 
 Removal of markers based on a low allele frequency rate was the next step of the 
QC. Although this step is a part of QC, it does not mean that quality of markers was low. 
These SNPs are mostly non-informative as they show little variation in the sample set 
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being analyzed. The statistical power to detect an association will also be low. The main 
aim of this step was not to hamper the quality of the subsequent analysis. A stringent 
threshold (≤ 0.03) was used to filter rare alleles. A total of 259,565 markers had minor 
allele frequency ≤ 0.03 and were excluded from further analysis.  
5.1.6. Results from genotyping rates between two groups 
 The next step of QC was to identify markers that show significant differences in 
genotyping rates between two groups (males vs females and age groups 1-5 y vs 6-10 y). 
To minimize confounding, markers that showed significant difference in their genotyping 
rates between two groups were excluded from further analysis. We used a threshold of > 
0.05 after critically scrutinizing the data set. A total of 569 SNPs had significantly 
different (> 0.05) genotyping rates between two genders and were removed. Likewise, 
217 SNPs showed a significant difference between the two age groups and were excluded 
from analysis. 
5.1.7. Results from Hardy-Weinberg equilibrium 
 In this study, HWE was used retrospectively to assess their conformity in the 
whole group of subjects in gender- and age-specific analyses. A significant deviation 
from HWE in healthy controls suggests genotyping error, and must be excluded from 
analysis. After critically examining the data set we used a threshold of P < 10-3.  None of 
the top one hundred polymorphisms in gender- and age-specific associations showed a 
significant deviation from HWE in gender- and age-specific analyses.  
Genotype call rates were greater than 99.9% for all childhood ALL cases after all 
QC steps were implemented for gender- and age-specific association analyses. This 
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translates into < 0.01 missing data points. Figure 12 explains a brief summary of all QC 
steps and results. Differences between samples that were excluded from final analysis 
and samples that were retained are reported in the next section.  
  
 
 
Figure 12. Quality control steps, and samples and markers exclusion 
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5.2. Characteristics of childhood ALL study subjects        
All of these samples identified themselves as non-Hispanic white. The final 
sample included 117 males (55.5%) and 94 females (45.5%) (Table 17). This study was 
restricted to age group 1-10 years. There was no statistically significant difference (P = 
0.10) between two genders in their age distribution (Table 18). The mean ages in males 
(4.44 years) and females (4.70 years) were not different (P = 0.45). For age-specific 
analysis, 143 samples (67.8%) were age 1-5 years and 68 samples (32.2%) were age 6-10 
years. Male-to-female ratios were not different (P = 0.42) between the two age groups. 
Individuals excluded after QC were compared with individuals retained for final analysis 
to check any substantial difference between the two groups. A total of 37 individuals 
were excluded from final analysis, including individuals who were excluded before 
genotyping. There were no significant differences between the mean ages (P = 0.67; 
samples excluded: 4.35 years vs samples included: 4.56 years) or male-to-female ratios 
between the two groups (P = 0.45). Thus, there appeared to be no substantial difference 
between the subgroup of excluded samples and the rest of the sample to implicate any 
selection bias.    
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Table 15. Characteristics of childhood ALL cases 
Gender   
Male 117 (55.5%) 
Female 94 (45.5%) 
Age (year) 
Mean (SD) 4.56 (2.46) 
Median (IQR) 4 (3-6) 
Age (year) 
1 17 (8.10%) 
2 28 (13.30%) 
3 45 (21.30%) 
4 29 (13.70%) 
5 24 (11.40%) 
6 17 (8.10%) 
7 17 (8.10%) 
8 15 (7.10%) 
9 13 (6.20%) 
10 6 (2.80%) 
Age groups 
1-5 year 143 (67.8%) 
6-10 year 68 (32.2%) 
Ethnicity Non-Hispanic white 
SD: standard deviation, IQR: Inter quartile range, ALL:  
acute lymphoblastic leukemia 
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Table 16. Characteristics of male and female childhood acute lymphoblastic leukemia cases 
Age/Gender Male Female P value 
1 13 (11.1%) 4 (4.3%) 
2 12 (10.3%) 16 (17.0%) 
3 31 (26.5%) 14 (14.9%) 
4 15 (12.8%) 14 (14.9%) 
5 11 (9.4%) 13 (13.8%) 
6 6 (5.1%) 11 (11.7%) 
7 10 (8.5%) 7 (7.4%) 
8 6 (5.1%) 9 (9.6%) 
9 9 (7.7%) 4 (4.3%) 
10 4 (3.4%) 2 (2.1%) 
117 (100%) 94 (100%) 0.10 
Age (year) 
Mean (SD) 4.44 (2.56) 4.70 (2.33) 0.45 
Median (IQR) 4 (3-6) 4 (3-6) 0.31 
SD: standard deviation, IQR: Inter quartile range 
 
5.3. Results of gender- and age-specific associations             
As routinely done in GWAS, the additive genetic risk model was used for gender- 
and age-specific analyses using logistic regression. In addition, permutation testing 
(10,000 permutations; P ≤ 0.05 for statistical significance) was performed for top one 
hundred results, using Plink, to eliminate false-positives due to chance. These results are, 
therefore, free from multiple comparison issues as the permutation test assesses the role 
of chance on each SNP. Thus, no other statistical approach was used to correct these 
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results for multiple comparisons. Permutation P values alongside the logistic regression 
results are reported in all tables.  
5.3.1. Results of gender-specific associations             
 
 
               
 
 
 
   
 
Figure 13. Q-Q plot for gender-specific association analysis for childhood ALL risk 
The x-axis represents expected P value on logarithmic scale (genomic control), and the y-axis represents 
observed P value on logarithmic scale (GC);. A: Q-Q plot is unadjusted for GC. B: Q-Q plot is adjusted for 
genomic control. 
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The additive genetic risk model was used for analysis of genotype distribution 
differences between male and female cases for each SNP, and results were adjusted for 
potential population stratification using the genomic control (GC) method. A quantile-
quantile (Q-Q) plot (Figure 13) was used to explore systematic errors, and to generate a 
visual representation of observed P values of GWAS results against expected P values. 
The genomic inflation factor for gender-specific analysis was one. A score of one 
indicates no confounding by population stratification. Manhattan plot was generated 
using the results for the additive model (Figure 14).  
 
Figure 14. Manhattan plot for gender-specific association analysis for childhood acute lymphoblastic 
leukemia risk 
The x-axis represents position on each chromosome and the y-axis shows the P value on logarithm scale 
from the additive genetic model. 
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The Manhattan plot visualizes the distribution of association results across the 
genome and with their statistical significance. Here, the X-axis represents SNPs position 
on each chromosome and the Y-axis shows P values on a log scale.  
When results were ranked by their P values, the smallest P value was 1.9 x 10-6 
(RASSF2, rs4813720, ORinteraction = 0.29) (Table 17). Appendix Table 2 shows results for 
the top one hundred gender-specific associations based on the lowest P value. Altogether 
18 SNPs showed associations with a P value of ˂ 1 x 10-4 (Figure 15). Of the top 100 
ranking associations, the maximum number of gender-specific associations was found on 
chromosome 17 (n=15). Several genomic loci, such as 17q12 (ACACA) and 2p22.1, 
yielded multiple associations. However, some of these associations (rs7583193 and 
rs17027254; rs1899286, rs6732320 and rs11687208; rs8081866, rs2542653, rs2542660 
and rs12948120) were due to correlated SNPs (Appendix Table 3).  
77 
 
Table 17. SNPs showed gender-specific associations in childhood ALL risk at the significance level < 1 x 10-4 
 
Minor allele 
frequency  
SNP Gene/region Chr† Minor 
allele 
Feature Males Females ORallele (95% CI)* P value** P value 
(permutation)†† 
rs4813720 RASSF2 20 A 5upstream 0.23 0.47 0.29 (0.17 - 0.48) 1.90 x 10-06 1.0 x 10-4 
rs231237 HSPB6 19 A 5upstream 0.42 0.21 3.00 (1.86 - 4.85) 7.15 x 10-06 1.0 x 10-4 
rs7323018 13q14.1 13 G intergenic 0.17 0.36 0.31 (0.18 - 0.52) 8.40 x 10-06 1.0 x 10-4 
rs17027254 2p22 2 T intergenic 0.19 0.39 0.37 (0.23 - 0.58) 1.86 x 10-05 1.0 x 10-4 
rs7912381 10q26.3 10 G intergenic 0.39 0.21 2.78 (1.71 - 4.51) 3.68 x 10-05 1.0 x 10-4 
rs11687208 2p22 2 C intergenic 0.21 0.40 0.40 (0.26 - 0.62) 4.81 x 10-05 1.0 x 10-4 
rs798292 MAGI2 7 G intronic 0.16 0.35 0.38 (0.24 - 0.61) 4.88 x 10-05 1.5 x 10-4 
rs13107783 4p15.3 4 C intergenic 0.32 0.52 0.40 (0.26 - 0.62) 5.16 x 10-05 2.0 x 10-4 
rs4470624 4p15.3 4 T intergenic 0.32 0.52 0.40 (0.25 - 0.62) 5.16 x 10-05 2.0 x 10-4 
rs1849374 12p11.2 12 A intergenic 0.44 0.25 2.48 (1.58 - 3.88) 7.35 x 10-05 2.0 x 10-4 
rs12948120 ACACA 17 C intronic 0.29 0.49 0.44 (0.29 - 0.66) 7.46 x 10-05 3.0 x 10-4 
rs6904762 6q23 6 G intergenic 0.27 0.46 0.41 (0.26 - 0.64) 1.00 x 10-05 1.0 x 10-4 
rs506389 8q22.3 8 A intergenic 0.28 0.11 2.99 (1.74 - 5.15) 7.98 x 10-05 2.0 x 10-4 
rs6732320 2p22 2 T intergenic 0.2 0.38 0.41 (0.26 - 0.64) 8.08 x 10-05 3.0 x 10-4 
rs8081866 ACACA 17 T intronic 0.28 0.48 0.45 (0.30 - 0.67) 8.64 x 10-05 3.0 x 10-4 
rs349714 3p25 3 G intergenic 0.44 0.26 2.43 (1.56 - 3.80) 8.76 x 10-05 2.0 x 10-4 
rs7583193 2p22 2 G intergenic 0.19 0.38 0.41 (0.26 - 0.64) 9.09 x 10-05 1.0 x 10-4 
*ORinteraction per allele (ORallele) for the additive model; **P value adjusted for genomic control; †Chr = Chromosome, SNP = single nucleotide 
polymorphism;  ††P value permutation = point wise P value from maxT permutation analysis after 10,000 permutation 
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Figure 15. Genome view of single nucleotide polymorphisms or associated genes in gender-specific 
associations based on P values 
 
 
Figure 16. Genome view of single nucleotide polymorphisms or associated genes in gender-specific 
associations based on effect size 
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When we ranked the results by their effect size, the largest effect size (OR) was 
15.7 (HLA-DQA1; rs12722042) (Table 18). Strength of the association was remarkably 
high (ORinteraction ≥ 10.0) for nine SNPs. The top two associations were from the HLA-
DQA1 gene with SNPs (rs12722042 and 12722039), which were correlated. 
Chromosome 2 and chromosome 6 yielded the maximum number of associations, 15 and 
13, respectively (Figure 16). There were sets of SNPs from these regions that were 
correlated with one another (Appendix Table 4). ADAM28, at chromosome 8, showed the 
maximum number of associations (rs11992342, rs7829965, rs36041430), however, 
correlated. Around 50% of identified variants were from intergenic regions (regions 
between genes). Appendix Table 5 shows results for the top one hundred gender-specific 
associations based on the highest effect size. 
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Table 18. SNPs showed gender-specific associations in childhood ALL risk with the highest effect sizes (OR > 10; P value < 0.05) 
 
Minor allele 
frequency  
SNP Gene/region Chr† Minor 
allele 
Feature Males Females ORallele (95% CI)* P value** P value 
(permutation)†† 
rs12722042 HLA-DQA1 6 G coding 0.07 0.005 15.68 (2.03 - 121.2) 0.008 0.001 
rs12722039 HLA-DQA1 6 A coding 0.07 0.005 14.87 (1.94 - 114.0) 0.009 0.002 
rs11992342 ADAM28 8 T intron 0.07 0.005 14.73 (1.92 - 113.9) 0.01 0.001 
rs80040922 UMODL1 21 A coding 0.06 0.005 13.68 (1.77 - 105.6) 0.01 0.004 
rs61753605 LOC100996481 6 C coding 0.06 0.005 13.38 (1.73 - 103.3) 0.01 0.004 
rs35665085 CECR5 22 A coding 0.06 0.005 12.64 (1.63 - 98.00) 0.02 0.006 
rs143021649 CNTN3 3 T coding 0.06 0.005 11.62 (1.49 - 90.58) 0.02 0.009 
rs6795524 PROS1 3 G intron 0.05 0.005 10.63 (1.36 - 83.31) 0.02 0.006 
rs10003468 4q28.1 4 C intergenic 0.05 0.005 10.63 (1.36 - 83.31) 0.02 0.005 
*ORinteraction per allele (ORallele) for the additive model;  **P value adjusted for genomic control;  †Chr = Chromosome; SNP = single nucleotide 
polymorphism;  ††P value permutation = point wise P value from maxT permutation analysis after 10,000 permutation 
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Top ranking results based on the effect size showed associations with more 
missense (resulting in amino acid changes) variations than the results based on the P 
values (29 vs 2) (Appendix Table 6 and Table7). Thus, OR-based top ranking results 
were enriched for missense and/or highly functional SNPs. These missense SNP 
associations with high effect sizes and obvious functional effects on protein structure 
suggest that most of these variants may be causative rather than indirect associations. We 
performed bioinformatic analyses to examine functionality of all gender-specific markers. 
The aim was to check whether these markers were direct or indirect associations with 
childhood ALL risk. Two main databases (RegulomeDB and F-SNP, explained in 
Chapter 4) were used to obtain functional score of markers. Bioinformatic analyses of 
these SNPs yielded high levels of functionality by at least one algorithm for 13 SNPs 
based on the P value, and for 25 SNPs based on the effect size (Appendix Table 6 and 
Table7). Two SNPs, rs8106959 and rs739924, scored 1f for results based on the P value. 
The SNP rs739924 also scored one for F-SNP. Likewise, one SNP (rs6929434) scored 1b 
and four SNPs (rs12722042, rs3847262, rs11751765 and rs130069) scored ≥ 0.75 by F-
SNP database. We also performed bioinformatic analysis of SNPs which were not 
included in the GWAS chip but were highly correlated with gender-specific markers 
(Appendix Table 6 and Table7). Results are only provided if a correlated SNP showed a 
much higher score, by bioinformatic analysis, than associated SNP. Several associated 
SNPs showed correlation with multiple functional variants. The SNP rs9913430 scored 
1a, as the most credible 
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functional variants for results based on the P value. Moreover, two SNPs scored 1d 
(rs9314355 and rs7224979) and two SNPs (rs10413852 and rs1275051) scored 1f for 
results based on the P values. For results based on the effect size one SNP (rs12349952) 
scored 1f. We also performed empirical data screening to complement bioinformatics 
assessment (Appendix Table 8). When we screened existing experimental data, using 
SCAN, only eleven SNPs (results based on the P value) and one SNP (results based on 
the effect size) showed substantial effects on regulation of several genes in the non-
Hispanic population.  
The SNPnexus database provided information from the GWAS catalogue and the 
Catalogue of Somatic Mutations in Cancer (COSMIC). A total of five SNPs (rs552976, 
rs563694, rs560887, rs12940887 and rs9305777) previously showed associations with 
other diseases and traits (Appendix Table 9). Interestingly three SNPs (rs552976, 
rs563694 and rs560887) were located in the same gene (G6PC2). All of these three 
associated SNPs were associated with glucose-related traits. The SNP rs12940887 
showed an association with blood pressure level and rs9305777 was associated with 
platelet aggregation. The COSMIC database showed three SNPs (rs61753605, 
rs35693261 and rs4645656), which may cause functional changes that are advantageous 
for cancer occurrence and/or progression. The SNP rs61753605 showed associations with 
two cancer sites (breast cancer and prostate cancer). However, the SNP, rs35693261, may 
increase the risk of intestinal cancer and rs4645656 may increase the chance of stomach 
cancer. These are somatic mutations. Somatic mutations in cancer cells may be drivers 
(causing or helping progression of cancer) or passengers (just the results of random 
events). All somatic mutations were associations from the highest effect sizes from 
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gender-specific associations. A total of seven SNPs were located in the transcription 
factor binding sites. The transcription factor binding sites are mostly located within the 
promoter region of genes, and may initiate gene function. Thus, SNPs located in these 
regions may have more regulatory functional effects.   
The CTD was used to examine associated genes for their interactions with 
environmental exposures, such as carcinogens. A list of gender-specific genes 
accompanied by their interacting chemicals and appropriate references can be found in 
the appendix (Table 10 & Table 11). Nearly all genes have shown substantial potential 
with chemical interactions in humans and animal models. The most common 
environmental interactions were with vehicle emissions (benzene, 2,6-dinitrotoluene, 
ozone), drugs (acetaminophen), tobacco smoke (benzo(a)pyrene, benzo(a)pyrene diol 
epoxide, nicotine), poly aromatic hydrocarbons (PAH) (benzo(a)pyrene), food cooked on 
the barbecue (benzo(a)pyrene, benzo(a)pyrene diol epoxide), pesticides (fonofos, 
parathion, terbufos, methoxychlor, chlorpyrifos), polychlorinated biphenyls, bisphenol A, 
formaldehyde and hormones (estrogen, progesterone and testosterone). Most of these 
environmental chemicals are ubiquitous and classified as class 1 (benzene, 
benzo(a)pyrene, benzo(a)pyrene diol epoxide tetrachlorodibenzodioxin, aflatoxin B1, 
formaldehyde, asbestos, arsenic, nicotine and estradiol) and class 2 (progesterone, 
polychlorinated biphenyls, ethanol) carcinogens by International Agency for Research on 
Cancer (IARC)191. Some of these chemicals also act as teratogens, such as alcohol, 
tobacco smoke, lead, mercury, benzene, benzo(a)pyrene, estradiol, progesterone, arsenic, 
pesticides and formaldehyde, and may affect disease susceptibility in utero. There are 
few examples of gene-environment interaction and childhood ALL risk. Most of these 
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environmental exposures have not yet been properly evaluated in childhood ALL risk. 
Several studies have found that exposure to these environmental pollutants, such as 
pesticides, benzene, tobacco smoke, formaldehyde and polychlorinated biphenyls, 
specifically during pregnancy, can increase risk of hematopoietic cancers including 
childhood ALL192-196, however, these results are not robust and confirmed ones. Gene-
environment interaction with gender-specificity may unravel some environmental risk 
factors and increased childhood ALL risk.  Studies have also unraveled gender-specificity 
in chemical exposures and metabolisms197-200.  
5.3.2. Results of age-specific associations         
As in gender-specific associations, the additive genetic model was used to 
compare genotype distributions between two age groups, and results were adjusted for 
population stratification using the genomic control method. A Q-Q plot (Figure 17) was 
used to explore systematic errors in the age-specific associations. The adjusted results 
again yielded a genomic inflation factor one for age-specific association. Again, inflation 
factor one ruling out confounding by cryptic population stratification.  
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Figure 17. Q-Q plot for age-specific association analysis for childhood ALL risk 
The x-axis represents expected P value on logarithm scale (genomic control), and the y-axis represents 
observed P value on logarithm scale (GC); A: Q-Q plot unadjusted for GC and observed before QC B: Q-Q 
plot adjusted for genomic control and observed after QC. 
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                B: Q-Q plot for age-specific analysis adjusted for GC and after QC 
A: Q-Q plot for age-specific analysis unadjusted and before QC 
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A total of ten SNPs showed statistically highly significant age-specific 
associations (P value ≤ 1 x 10-4), and the lowest P value was 9.84 x 10-6 (SOX5; 
rs10505918) (Table 19). Among the top one hundred associations (Appendix Table 12), 
chromosome 14 yielded the maximum number of results (Figure 18), some SNPs being in 
correlation with one another (Appendix Table 13). All three polymorphisms (rs8021355, 
rs7144565 and rs2274068) at RALGAPA1 (chromosome 11) were perfectly correlated. 
Several other genomic loci, such as 2p24.3, 5q14.2, 16q22.2 and 21q21.3, also showed 
multiple associations, but few variants (rs377621 and rs16979806; rs6739633 and 
rs1521244) at these loci were correlated.  
When results were ranked by their effect size, the largest effect size was 12.5 
(DIO1, rs17109582) (Table 20 and Appendix Table 14). A total of 4 SNPs have shown 
high effect sizes (ORinteraction > 10, all with P < 0.05). The maximum number of age-
specific association (12 associations) was observed at chromosome 2 and chromosome 6 
(Figure 19). Some of these associations were correlated (Appendix Table 15).  
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Table 19. SNPs showed age-specific associations in childhood ALL risk at the significance level < 1 x 10-4 
 
Minor allele 
frequency  
SNP Gene/region Chr† Minor allele Feature 1-5 y 6-10 y ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs10505918 SOX5 12 A intron 0.42 0.19 3.15 (1.90 - 5.24) 9.84 x 10-06 1 x 10-4 
rs11997355 8q21.11 8 T intergenic 0.05 0.19 0.22 (0.11 - 0.44) 2.74 x 10-05 1 x 10-4 
rs2388773 16q12.2 16 C intergenic 0.14 0.35 0.35 (0.21 -0.57) 3.78 x 10-05 1 x 10-4 
rs665159 CHRM3 1 T intron 0.55 0.33 2.46 (1.58 - 3.84) 7.42 x 10-05 2 x 10-4 
rs3954950 9p24.2 9 T intergenic 0.24 0.43 0.38 (0.24 - 0.62) 7.77 x 10-05 1 x 10-4 
rs7818844 8p12 8 T intergenic 0.40 0.60 0.38 (0.23 - 0.61) 7.86 x 10-05 1 x 10-4 
rs6972158 NPSR1 7 G intron 0.34 0.14 3.03 (1.74 - 5.25) 8.30 x 10-05 1 x 10-4 
rs7320982 8p12 13 C intergenic 0.19 0.38 0.39 (0.24 - 0.62) 8.33 x 10-05 1 x 10-4 
rs7583258 2q22.3 2 G intergenic 0.09 0.24 0.29 (0.16 - 0.54) 8.79 x 10-05 2 x 10-4 
rs1882591 16q12.2 16 G intergenic 0.22 0.42 0.42 (0.27 - 0.64) 9.60 x 10-05 2 x 10-4 
*ORinteraction per allele (ORallele) for the additive model; **P value adjusted for genomic control;  †Chr = Chromosome, SNP = single nucleotide 
polymorphism;  ††P value permutation = point wise P value from maxT permutation analysis after 10,000 permutation 
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Figure 18. Genome view of single nucleotide polymorphisms or associated genes in age-specific 
associations based on P values 
 
 
Figure 19. Genome view of single nucleotide polymorphisms or associated genes in age-specific 
associations based on effect size 
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Table 20. SNPs showed age-specific associations in childhood ALL risk with the highest effect sizes (OR > 9; P value <   
0.05) 
 
Minor allele 
frequency  
SNP Gene/region Chr† Minor 
allele 
Feature 1-5 y 6-10 y ORallele (95% CI)* P value** P value 
(permutation)†† 
rs17109582 DIO1 1 C intron 0.09 0.007 12.46 (1.67 - 93.01) 0.01 0.006 
rs7304215 TMEM132D 12 G intron 0.07 0.007 11.25 (1.47 - 85.90) 0.02 0.01 
rs10999147 AIFM2 10 G coding 0.07 0.007 10.89 (1.43 - 83.02) 0.02 0.01 
rs7330286 13q33.2 13 T intergenic 0.07 0.007 10.01 (1.33 - 75.63) 0.03 0.01 
rs41309927 SEC23B 20 A coding 0.07 0.007 9.70 (1.28 - 73.39) 0.03 0.02 
rs36086854 CFAP99 4 A coding 0.06 0.007 9.42 (1.23 - 72.26) 0.03 0.02 
rs17409162 ANO10 3 A coding 0.06 0.007 9.24 (1.20 - 71.06) 0.03 0.02 
rs13129052 4p16.3 4 G intron 0.06 0.007 9.24 (1.20 - 71.06) 0.03 0.02 
*ORinteraction per allele (ORallele) for the additive model; **P value adjusted for genomic control;  †Chr = Chromosome, SNP = single nucleotide     
polymorphism;  ††P value permutation = point wise P value from maxT permutation analysis after 10,000 permutation 
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The Manhattan plot (Figure 20) was generated to visualize the data. Like gender-
specific associations, this study yielded several risk markers which may increase the risk 
of ALL in a specific age group. 
 
 
Figure 20. Manhattan plot for age-specific association analysis for childhood acute lymphoblastic 
leukemia risk 
The x-axis represents position on each chromosome and the y-axis shows the P value on logarithm scale 
from the additive genetic model 
 
 
Like gender-specific associations, results based on the effect size again showed 
associations with more missense (resulting in amino acid change) variations than results 
based on the P value (24 vs 6), including correlated variants (Appendix Table 16 and 
Table 17). One SNP, rs75411676, results based on effect size, also showed a nonsense 
variation. Nonsense variation is the most severe change, as it prematurely stops protein 
formation. RegulomeDB and F-SNP (explained in Chapter 4) were assessed the 
functionality of all age-specific markers. All six missense variations, results based on P 
value, showed benign/tolerable effect in resulting protein formation. Four SNPs 
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(rs2101919, rs237318, rs6883 and rs6972158) were located in transcription factor 
binding sites, and may affect gene regulation, as they have more chance of regulatory 
effect (Appendix Table 16 and Table 17). A total of 24 SNPs (RegulomeDB ≤ 3a and F-
SNP ≥ 0.2), results based on the P value, yielded much higher functional score by at least 
one algorithm. Two SNPs (rs139886 and rs9897794), scored “1f” (RegulomeDB), were 
suggested most credible functional variants. Nine SNPs scored a much higher functional 
score (≥ 0.5) for F-SNP. Results suggest these associated SNPs may be the main causal 
SNPs rather than proxy associations. Correlated SNPs with age-specific association 
markers, when complemented with RegulomeDB, yielded 34 highly functional variants. 
One SNP (rs4821717) scored “1b”. Moreover, one SNP (rs9897794) scored “1d”, and 
another seven SNPs scored “1f”. Several age-specific risk markers also yielded multiple 
functional variants, including missense variations. These correlated functional variants 
might be the main causal SNPs for which these age-specific risk markers may be proxies. 
Eleven SNPs (results based on the P values) had potential eQTL effects (explained in 
chapter4) on thirteen genes (Appendix Table 18). Six highly functional correlated SNPs 
(results based on the P values) showed eQTL effects on 3 unique genes.   
Ten SNPs were located in TFBSs (Appendix Table 16 and Table 17), and may 
influence disease risk by change in binding site. Results based on effect size showed 28 
SNPs with higher functional score by at least one algorithm. It again suggests that these 
SNPs might be causal variants rather than indirect associations. The SNP rs3204798 
showed a much higher functional score (0.91) by F-SNP. Functional analysis of 
correlated SNPs also showed 36 unique risk variants with much higher functional scores 
or missense variations. One SNP (rs12632793) scored “1d” and two SNPs (rs16909527 
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and rs373690) scored “1f”. The eQTL analysis yielded 3 SNPs with potential effect on 14 
genes (Appendix Table 18). Additional bioinformatic analysis of correlated SNPs 
suggested that several of these associated risk markers might be proxy for highly 
functional correlated SNPs. Results based on effect size were enriched with more 
missense variations with deleterious effect, and also showed more functional variants. 
Overall, our bioinformatic analyses yielded highly functional variants with potential 
regulation effect.       
As for the gender-specific associations, the SNPnexus provided valuable 
information from the GWAS catalogue and the COSMIC database. A total of six SNPs 
were previously associated with some types of traits or diseases (Appendix Table 9), 
including chronic lymphocytic leukemia (CLL) (rs7169431) and nasopharyngeal 
carcinoma (rs28421666). The COSMIC database yielded three SNPs, rs34099167, 
rs762562 and rs1800141, which may increase the risk of stomach cancer, pancreas cancer 
and large intestinal cancer, respectively.  
Like gender-specific associations, the Comparative Toxicogenomics Database 
(CTD) was also used to examine associated genes for their interaction with 
environmental pollutants (Appendix: Table 19 & 20). A detailed list with appropriate 
references can be found in the appendix. Most of the identified genes or nearest genes 
physically located at two sides of SNPs, in case of intergenic variants, have shown 
potential effect of several chemicals, such as poly aromatic hydrocarbons 
(benzo(a)pyrene), tobacco smoke (benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
nicotine), pesticides (insecticides, fungicides, herbicides), vehicle emissions, 
occupational exposures (formaldehyde), polychlorinated biphenyls, bisphenol A, and 
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hormones (estrogen, progesterone and testosterone). However, several of these chemicals 
have previously showed association with childhood ALL, but evidence is limited.  
 We also predicted the deleterious effect of missense variations, including 
statistically correlated SNPs, associated with gender- and age-specificity using SNPnexus 
database (Appendix Table 21 and Table 22). A total of eighteen SNPs from gender-
specific associations and seven SNPs from age-specific associations yielded deleterious 
effects. All of these deleterious missense variations were associated with results based on 
the highest effect sizes. 
5.3.3. Time-to-event analysis
 
 
Figure 21. A flow chart explaining marker selection for time-to-event analysis 
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  Table 21. Time-to-event analysis of identified gender- and age-specific childhood ALL risk markers at the significance level  
< 1 x 10-4 
Overall Male Female 
SNP Log rank 
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs10505918(D)* < 1 x 10-4 1.69 (1.27 - 2.24) < 1 x 10-3 1.55 (1.06 - 2.25) 0.02 1.93 (1.25 - 2.96) 3 x 10-3 
rs2949827(D)* < 1 x 10-4 0.54 (0.38 - 0.77) 1 x 10-3 0.72 (0.46 - 1.12) 0.15 0.39 (0.23 - 0.66) < 1 x 10-3 
rs2212824(D)* < 1 x 10-4 1.76 (1.30 -2.38) < 1 x 10-3 1.76 (1.20 - 2.59) 4 x 10-3 1.76 (1.09 - 2.83) 0.02 
rs1209145(D)*  < 1 x 10-4 1.80 (1.31 - 2.48) < 1 x 10-3 1.62 (1.05 - 2.51) 0.03 2.05 (1.28 - 3.27) 3 x 10-3 
rs1209145(D)* < 1 x 10-4 1.76 (1.28 - 2.41) < 1 x 10-3 1.62 (1.05 - 2.51) 0.03 2.05 (1.28 - 3.27) 3 x 10-3 
rs738027(D)* < 1 x 10-4 1.62 (1.22 -2.15) 1 x 10-3 1.62 (1.10 - 2.38) 0.01 1.62 (1.06 - 2.47) 0.03 
rs2101919(D)* < 1 x 10-4 0.61 (0.46 - 0.80) 1 x 10-3 0.64 (0.44 - 0.94) 0.02 0.56 (0.37 - 0.86) 8 x 10-3 
rs9809647(D)* < 1 x 10-4 0.60 (0.45 - 0.78) 1 x 10-3 0.57 (0.39 - 0.84) 4 x 10-3 0.64 (0.42 - 0.98) 0.04 
rs10133677(D)* < 1 x 10-4 1.78 (1.28 - 2.46) 1 x 10-3 1.65 (1.05 - 2.61) 0.03 1.92 (1.21 - 3.06) 6 x 10-3 
rs10999147(D)** < 1 x 10-4 2.55 (1.59 - 4.08) < 1 x 10-3 2.01 (1.09 - 3.71) 0.03 3.90 (1.85 - 8.22) < 1 x 10-3 
   (D): Dominant genetic model;*Age P; **Age OR; HR = hazard ratio; CI = confidence interval 
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Time-to-event analysis was performed on the top one hundred SNPs for gender- 
and age-specific associations (Figure 21). The log rank test was used for different genetic 
models (additive, dominant and recessive), to compare the differences between time to 
having leukemia between two (dominant or recessive genetic model) or three genotypes 
(additive genetic model). SNPs, which showed statistically significant associations (P ≤ 
0.05) with age-at-onset, are listed in Appendix Table 23. KM plots, only for the SNPs 
with the lowest P values (by log rank), are illustrated in the result section. The Cox 
proportion hazard modeling was also performed for all statistically significant 
associations (log rank P value ≤ 0.05) with age-at-onset to calculate effect size (hazard 
ratio).  
 
 
Figure 22. Genome view of single nucleotide polymorphisms or associated genes with age-at-onset 
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A total of 196 SNPs, based on the log rank test, yielded statistically significant 
associations (P ≤ 0.05) with age-at-onset (Table 21 and Figure 22). The maximum 
number of associations (n = 13) with age-at-onset were observed on chromosomes 1, 8, 
12 and 14. Among the top one hundred markers based on effect size for age-specific 
association results, 91 markers showed associations with age-at-onset. Gender-specific 
association (effect size results) yielded the lowest number of associations (n = 11) with 
age-at-onset. Most of these associations best fitted in the dominant genetic model. Few of 
these SNPs were also correlated. A total of ten SNPs yielded P values < 1 x 10-4 with 
age-at-onset (Table 23).  
 
Figure 23. Kaplan-Meier plot estimates for age-at-diagnosis in childhood ALL with rs10505918 
genotypes 
AA = wild-type; AB = heterozygote; BB = homozygote variant. Note: X-axis represents age-of-onset in 
years, and Y-axis represents survival function. Plot compares genotypes and age-of-onset. Dominant 
genetic model. 
 
The SOX5 rs10505918, which was the top hit for age-specific results (Table 23), 
also yielded the most statistically significant association with age-at-onset (Figure 23).  
Childhood ALL cases who possessed heterozygote (AB) and homozygote variants (BB) 
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developed ALL on average 2 year earlier than participants who were AA genotype (wild-
type) for rs10505918 (median age, 3 years vs 5 years).  The HR was 1.69 that suggests 
1.69 times increased risk of early-onset ALL for children possessing heterozygote (AB) 
and homozygote (BB) genotype.  
 
Figure 24. Kaplan-Meier plot estimates for age-at-diagnosis in childhood ALL with rs2949827 
genotypes 
AA = wild-type; AB = heterozygote; BB = homozygote variant. Note: X-axis represents age-of-onset in 
years, and Y-axis represents survival function. Plot compares genotypes and age-of-onset. Dominant 
genetic model 
 
 
Likewise, SNP rs2949827 also showed a low P value (< 1 x 10-4), however, HR 
was in opposite direction (HR = 0.54) (Figure 24). The HR 0.54 suggests nearly two 
times increased risk for early-onset of childhood ALL for children possessing wild-type 
genotype (AA). Children homozygote for wild-type (AA) developed ALL on average 2 
years earlier than children who were heterozygote (AB) and variant genotype (BB) 
(median age 4 years vs 6 years). Several of these associations were only statistically 
significant (P ≤ 0.05) in one gender. Two associations (rs17170286 and rs1800141) with 
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age-at-onset were gender-specific (Pinteraction ≤ 0.05). Both associations were in the same 
direction but differed in magnitude. For example, overall HR for rs17170286 was 1.60 (P 
= 0.03), however, when results were stratified by gender, males showed a much higher 
increased risk 2.36 (P = 0.003). HR for female was 1.12 (P = 0.72).  
5.3.4. Gene enrichment analysis 
Gene enrichment analysis was performed to examine the pathways associated 
with male or the age group 1-5 year. The main purpose was to assign biological meanings 
to some group of genes. Our results did not yield any statistically significant association 
with any pathways. 
5.3.5. Previously identified gender- and age-specific associations 
We also analyzed previously identified gender-specific associations in childhood 
ALL. To avoid any discrepancy from previous associations, we performed same genetic 
models for association analysis. Our results did not replicate all previous gender-specific 
associations (Appendix Table 24). Two SNPs, rs419788 and rs224589, showed the 
lowest P value, 0.06 and 0.08, respectively. Like gender-specific associations, previously 
identified age-specific childhood ALL SNPs did not show the same association in the 
present study (not reported). Most of the previous associations were either with age-at-
onset or different age groups.  
Previous studies did not counteract the problem of multiple comparisons. Even, 
few studies used adults and convenient samples as a control group. Environmental factors 
play a major role in disease association, and different geographical regions (USA vs UK) 
can also increase the chance of replication failure, as few of these studies were done at 
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the United Kingdom. Many non-cancer gender-specific associations were also analyzed, 
and two of the previously identified associations, rs3131622 (type 1 diabetes) and 
rs10195252 (waist-height ratio) were statistically significant (P value < 0.05).  
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6. DISCUSSION 
To our knowledge, this is the first GWAS, which used a gender- and age-specific 
approach to unravel childhood ALL risk variants. We reported the statistically most 
significant top one hundred results. Permutation testing was performed to eliminate 
chance findings (explained in Chapter 4). These results are free from multiple 
comparison issues, as each permutation on each SNP assesses the role of chance. The 
rs4813720 (RASSF2), rs231237 (HSPB6) and rs7323018 (13q14.1) SNPs showed the 
most statistically significant gender-specific associations. Likewise, the SNP rs10505918 
(SOX5) showed the lowest P value for age-specific associations, and also yielded the 
most statistically significant association with age-at-onset.  
Unlike previous GWASs, as a second approach, we also analyzed results based on 
the effect size, as effect size helps to explore clinically meaningful results, which may not 
have reached statistical significance due to insufficient power201, 202. Again, we applied 
permutation testing for the highest ranking results (top 100 associations), based on the 
effect size, to eliminate chance findings. Two HLA-DQA1 missense SNPs (rs12722042 
and rs12722039) showed the highest effect sizes for gender-specific associations. Several 
other SNPs, such as rs11992342 (ADAM28) and rs80040922 (UMODL1) also yielded the 
highest effect sizes for gender-specific associations. The SNPs rs17109582 (DIO), 
rs7304215 (TMEM132D), rs10999147 (AIFM2) and rs7330286 (13q33.2) yielded the 
highest effect sizes for age-specific associations.   
Among 400 gender- or age-specific variants, only14 variants were previously 
observed associations with other diseases/traits, including CLL (rs7169431)203 and 
nasopharyngeal carcinoma (rs28421666)204. The CLL association (rs7169431) was a risk 
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association (OR = 1.36, P = 4.74 x 10-7) in a previous GWAS. This SNP is located at 
chromosome 15, between the NEDD4 and RFX7 genes. Our results provide further 
evidence for genetic susceptibility of this SNP in childhood ALL with an increased risk 
to the age-group 1-5 years. Bioinformatic analysis did not suggest any functional 
mechanism for increased risk in this age group. Experimental studies are needed to 
understand the mechanism of this SNP on the age effect.   
In this study, we also unmasked several associations located within the HLA 
region at rs28421666, located between the HLA-DRB1 and HLA-DQA1 loci, rs3130161, 
located between HLA-DPB1 and COL11A2, and two missense SNPs (rs12722042 and 
rs12722039) located in the HLA-DQA1 gene. Among all of these previous associations, 
the rs28421666 SNP has shown a protective association with nasopharyngeal 
carcinoma204. Another SNP, rs3130161, has yielded an association with type 1 diabetes 
(T1D)205. Both of these results were linked with age-specific associations in childhood 
ALL risk. These results suggest a role for HLA in childhood ALL risk with age 
specificity. The HLA region is the most polymorphic region in the human genome, which 
plays an important role in the regulation of the immune system. Although the role of 
HLA in ALL etiology is not known, several previous studies suggest the role of HLA in 
childhood ALL risk with gender differential123-125, 206-208. Most of the previously 
identified HLA associations in childhood ALL are in the HLA class II region. All HLA 
associated SNPs are also located in the same region. All of these associations yielded 
significant associations only for males (rs12722042 and rs12722039) or the age group 1-5 
years (rs28421666 and rs3130161), when we ranked results based on the highest effect 
sizes for gender- and age-specific associations. The rs3130161 SNP is statistically 
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correlated with a much higher functional SNP, rs3129203. It suggests the statistically 
correlated SNP might be the main causal SNP, which can affect the gene regulation 
through transcription factor binding site. Extensive bioinformatic screening of these 
SNPs, excluding rs3129203, did not implicate a mechanism behind gender- and age-
specificity in childhood ALL risk, except for rs3130161. Further functional studies are 
warranted to understand the mechanism of these SNPs in sub groups (male gender and 
age group 1-5 year) of children with ALL.  
Among previously identified associations, several of these variants were 
associated with autoimmune disorders, such as T1D (rs3130161 and rs4948088)205, 209 
MS (rs2116078)210, psoriatic arthritis (rs12188300)211 and Crohn disease (CD) 
(rs798292)212. The MS association (rs2116078) was with age-at-onset (mean age = 34 
y)210. Our results also yielded an age-specific association (rs2116078) in childhood ALL 
risk with an increased risk to age-group 1-5 years. Previous epidemiological studies have 
shown an increased risk of hematological malignancies with autoimmune disorders213-218. 
This observation has been commonly noted in MS and risk of leukemia/lymphoma in 
adults213. Epidemiological studies have also shown four times increased risk of ALL in 
children of women with MS214. Thus, the MS risk variant rs2116078 might be commonly 
shared between MS and childhood ALL in age-specific manner, as previously also 
observed130.  
The MAGI2 (membrane associated guanylate kinase, WW and PDZ domain 
containing 2) rs798292 has been previously associated (OR = 1.30, P = 1.01 – 1.69) with 
CD in the Caucasian population212. A previous GWAS on childhood ALL relapse also 
suggests the role of the MAGI2 (rs1496766) gene in childhood ALL risk219. The two 
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polymorphisms (rs798292 and rs1496766) were also not statistically correlated, which 
suggests independent associations. Bioinformatic analyses of gene expression profiles of 
B-cell precursor childhood ALL also suggests that the MAGI2 gene may increase the risk 
of childhood ALL220. Alternatively, MAGI2 inhibits cell migration and proliferation 
through PTEN (phosphatase and tensin homolog), a tumour suppressor gene. PTEN is a 
key regulator in apoptosis, and defects in apoptosis can increase leukemia risk221, 222. 
Moreover, a study on adult B-ALL patients has shown decreased PTEN activity223. 
Empirical analysis also suggested regulatory effect of rs798292 on three genes (MYST2, 
ATAD2B and EIF1AX). It means that the SNP, rs798292, is a putative regulation site and 
it has allele-specific effects on gene expression. Thus, rs798292 may play a significant 
role in childhood ALL risk through regulatory effects or through PTEN interaction.        
A cohort of 24,052 patients of T1D in Sweden showed a co-morbidity between 
early-onset leukemia and T1D (standardized incidence ratio = 8.30; P = 4.91-13.14)218. 
The two polymorphisms (rs3130161 and rs4948088) previously identified as risk variants 
for T1D205, 209 also yielded age-specific associations in childhood ALL. The SNP, 
rs3130161, showed an association with the age-group 1-5 years and the rs4948088 SNP 
yielded an association with the age-group 6-10 years. Autoimmune diseases are the most 
common group that have shown associations with our results presumably due to them 
being more common in one sex. This epidemiological evidence suggests biological 
plausibility between few autoimmune disorders and hematological malignancies, 
including childhood ALL with gender-specificity213-218. Interestingly, autoimmune 
disorders are the most common group that have shown associations with our results due 
to them being more common in one gender110.   
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Childhood ALL shows a consistent association with recurrent miscarriages, 
specifically in males224. The PRLR (prolactin receptor) polymorphism rs37389 is 
involved in recurrent miscarriages225. The role of the PRLR gene is not established in 
leukemogenesis, but a higher expression of this gene in cancer etiology cannot be 
neglected226. Several other previous associations are with HBA1c level (rs552976) and 
fasting glucose level (rs563694). One SNP, rs560887, yielded multiple associations with 
glycemic traits.    
In this study, we have also observed a statistically significant difference for the 
frequency of the ERCC1 (excision repair cross-complementation group 1) rs762562 
polymorphism between two age groups. The functional role of ERCC1 is not clear in 
leukemia. Similar results, however, with different polymorphisms (rs3212986 and 
rs11615), have previously shown associations with childhood ALL risk in a Chinese 
population227. Moreover, the rs3212986 SNP has yielded a much higher risk (OR = 1.87; 
P = 0.04) in the age group < 8 years compare to age group > 8 years (OR = 1.44; P = 
0.24). Both SNPs (rs3212986 and rs11615), in the previous study, have shown an 
increased risk in males (OR = 1.94; P = 0.02 and OR = 2.36; P = 0.04, respectively) in 
comparison to females (OR = 1.19; P = 0.57 and OR = 0.46; P = 0.05). Furthermore, 
rs11615 also yielded a gender-specific association in the present study (P = 0.03), with an 
increased risk in males. Thus, results suggest that ERCC1 gene may be a potential target 
to examine gender- and age-specificity in childhood ALL risk. The SNP rs762562 is 
located in an overlapping region of ERCC1 and CD3EAP. The rs762562 SNP shows a 
missense variation in the CD3EAP gene, which suggests an obvious change in protein 
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function. The SNP rs762562 also showed a somatic mutation by bioinformatic analysis 
(explained later). Thus, it increases the validity of our results.  
The SNP, rs9282777, is present in the coding region of the LMO2 (LIM only 
protein 2) gene and yielded a much higher risk in males. The LMO2 gene plays a crucial 
role in hematopoietic stem cell development, angiogenesis and embryogenesis228, 229. 
Higher expression of the LMO2 gene during immature stages of lymphocyte formation 
has been observed230. The LMO2 gene is considered as a cancer causing gene, and it 
increases the risk of T-cell ALL228, 231-233. Studies also report the higher expression of the 
LMO2 gene in B-cell ALL and other lymphomas229, 234. Our result suggests that rs928277 
may play a significant role in B-cell etiology. Bioinformatic screening did not suggest 
any mechanism in childhood ALL risk with male susceptibility. More functional study is 
needed to understand the mechanism of rs9282777 in gender differential in leukemia risk.   
The rs10505918 SNP showed the most statistically significant age-specific 
association. This SNP is located in the SOX5 (SRY (sex determining region Y)-box 5) 
gene, which is involved in the regulation of embryonic development, however, its role in 
childhood ALL etiology is not clear. Studies suggest that the SOX5 gene expresses in B-
cells and has a functional role in late B-cell development and B-cell differentiation235. 
This gene is also highly expressed in B-cell lymphomas236. The SNP rs10505918 also 
yielded the most statistically significant association with age-at-onset (P < 10-4). 
Interestingly, the SOX5 gene, however, a different polymorphism (rs7294845), also 
showed a gender-specific association based on the P value in this study. This evidence 
altogether suggests a role of SOX5 in childhood ALL risk with gender- and age-
specificity. 
106 
 
The SNP rs11992342 yielded a higher effect size for gender-specific associations. 
This SNP is located in the ADAM28 gene. Recent evidence suggests that ADAM28 is 
expressed on the surface of human lymphocytes237. The role of ADAM28 in 
leukemogenesis is not established, but our results suggest that ADAM28 polymorphism 
(rs11992342) was associated with the gender differential in childhood ALL risk with the 
highest effect sizes. A total of three ADAM28 SNPs (rs11992342, rs7829965 and 
rs36041430) showed gender-specific associations, however, all three SNPs were 
statistically correlated. The rs7829965 is a missense variation, and also yielded a higher 
score for gene expression regulation, which suggests regulatory effects on binding site.   
The ACACA (acetyl-CoA carboxylase alpha) gene is located at chromosome 7, 
which yielded multiple gender-specific associations (rs12948120, rs8081866, rs2542660, 
rs2542653, rs725038) with an increased risk in females. ACACA plays an important role 
in fatty acid synthesis and is regulated by the thyroid hormone238. BRCA1 affects fatty 
acid synthesis through its interaction with ACACA, and this interaction may exert a tumor 
suppressor function239-241. ACACA has also shown associations with breast cancer risk242. 
Childhood leukemia patients have been found to carry MLL fusion to ACACA243. A 
statistically correlated SNP, rs9330250, yielded a higher functional score, which suggests 
gene regulatory function the SNP rs9330250. The SNP rs9330250 was annotated as a 
credible functional variant and may play a mechanistic role in pathogenesis of childhood 
ALL. Thus, ACACA seems to have an additional biological feature, and it may increase 
the risk of leukemogenesis244.  
 The N4BP2 (NEDD4 binding protein 2) gene yielded two missense variations 
(rs61748746 and rs61748749). The encoded protein by this gene binds to B-cell 
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CLL/lymphoma 3 (BCL-3) protein245. The BCL3 translocation with IGH is found in some 
patients with childhood ALL246, and subsequent overexpression of BCL3247 in childhood 
ALL. The gender-specific association we found in this study might be the results of 
obvious change in protein function and its effect on BCL3 expression. However, more 
functional studies need to prove this hypothesis, as bioinformatic analysis did not unravel 
any functional mechanism for male-specific childhood ALL.         
A recent study has shown fusion of HIP1 to PDGFRB in chronic myelomonocytic 
leukemia248. Furthermore, HIP1 is localized in 7q11.3 region, and the possibility of 7q 
deletions is associated with some acute non-lymphocytic leukemia cases249. However, its 
role in lymphoblastic leukemia is not yet established, but our result (rs6962352) suggests 
an additional role of HIP1 in the pathogenesis of leukemia. Down syndrome is a known 
risk factor for childhood ALL. The KIF21A gene shows much higher expression in Down 
syndrome patients in leukocytes250, 251. Unfortunately, unavailability of cytogenetic data 
is a limitation of this study to reach any conclusion. Additional functional studies need to 
confirm the role of rs11172024 (KIF21A) in childhood ALL etiology.  
The rs6151599 SNP yielded an age-specific association result based on the effect 
size.  This SNP is located in a common region shared between the MSH3 (mutS homolog 
3) and DHFR (dihydrofolate reductase) gene. Bioinformatic analysis yielded a 
statistically correlated SNP (rs11749051) with a higher functional score located in the 
DHFR gene. It suggests that the rs11749051 SNP may be the main causal SNP. Studies 
suggest the low DHFR expression may be an important prognostic factor in childhood 
ALL252, 253.  
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In this functional analysis of gender- and age-specific risk variants, our results 
yielded nine highly functional SNPs (six for gender-specific associations and three for 
age-specific associations). Among these SNPs, one SNP (rs6929434) scored 1b and four 
other SNPs (rs8106959, rs739924, rs139886 and rs9897794) scored 1f. Likewise, 
rs739924 and rs130069 scored 1 for F-SNP analysis, and rs11751765 and rs3204798 
scored 0.9. These SNPs are highly functional and likely to be the causal SNPs. However, 
in the results we reported all SNPs which showed RegulomeDB score ≤ 3a.  
In a genetic association study, functional variants are most likely to be located at 
nearby genes around associated risk markers254. These functional variants are mostly in 
strong correlation with associated variants and may be the main causal SNPs. Correlation 
analysis was complemented with functional analysis to identify the causal SNPs. Some 
gender- and age-specific associated risk variants also yielded several statistically 
correlated functional variants. A total of 20 statistically correlated risk variants yielded a 
much higher functional score (≤ 1f). rs9913430 (correlated with rs739924) scored 1a, and 
rs139852 (correlated with rs4821717) scored 1b. These highly functional correlated SNPs 
might be the main causal SNPs for which associated results may be proxies.  
RegulomeDB is a database that explains SNPs with known or predicted functions184. 
Lower scores suggest evidence for a variant to be located in a functional region. It has 
strong power to separate truly functional variants and provide putative regulation site. A 
score ≤ 1f suggests that functional variants are likely to affect the binding site and/or be 
linked to the expression of a gene target.       
Genetic variants play a major role in disease susceptibility by altering gene 
expressions. The eQTL analysis is a well recognized method in evaluating the effect of 
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SNPs in mRNA or protein levels (explained in Chapter 4). eQTL refers explicitly to the 
genomic locus, which influences the variable mRNA or protein level. We found 15 
gender- and age-specific associations with eQTL SNPs. Among all highly functional 
statistically correlated SNPs, nine SNPs showed significant eQTL expressions in LCLs. 
These 24 eQTL SNPs yielded 52 eQTL target genes (n = 22 gender-specific results; n = 
30 age-specific results). Multiple eQTL SNPs identified several common eQTL target 
genes, such as SPATA20, FGD6, LMF1, ZNF420, MRPL14 and SLC13A2, which suggest 
these genes may contribute to the risk of childhood ALL. The eQTL database was 
explored to find whether these SNPs are putative regulations sites and can affect gene 
expressions. For example, the eQTL SNP rs9493135 (gender-specific results based on 
effect size) located in the 6q23.2 region, regulates several eQTL genes, including 
PTPN11. This gene is a member of the protein tyrosine phosphatase family and is highly 
expressed in hematopoietic cells255. This gene plays a very important role in Ras and Jak-
Stat pathways. Both pathways are significantly associated with leukemogenesis221, 255.  
A total of 21 SNPs (seven gender-specific results and 14 age-specific results) 
were located in transcription factor binding sites. These binding sites are mostly 
concentrated within the promoter regions of genes. A promoter is a region of a gene that 
initiates gene function. These 21 SNPs may therefore have greater functional effects on 
gene expression. Genetic variants can also alter protein structure and modify disease risk. 
Fifty-five of gender- and age-specific associations were with missense (31 gender-
specific results and 24 age-specific results) SNPs. However, most of these missense SNPs 
(n = 48) were in the top 100 list based on the effect sizes. These missense variations 
substitute amino acids, which alter the final protein function. Our result also yielded a 
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nonsense variation (rs75411676). Nonsense variation is the most severe change, as it 
prematurely stops the protein formation. These missense or nonsense variations have 
deleterious effect and can increase the risk of childhood ALL. However, we performed 
bioinformatic analysis to identify the significance of these variations. PolyPhen and SIFT 
predicted the damaging effect of 25 missense variations. It suggests that amino acid 
substitutions will have deleterious effect in protein function. We also explored functional 
similarity of identified genes for gender- and age-specific associations, by using stringent 
criteria. We only used eQTL target genes, missense and nonsense variations (only for 
damaging effect) associated genes, and only if a SNP showed a very high functional 
score. However, our results did not show any statistically significant pathway 
associations. Overall, bioinformatic and empirical analyses of gender- and age-specific 
results, including correlation analysis, yielded several functional variants. These 
functional variants may be associated with gender and age differential in childhood ALL 
risk and should be pursued in future studies.   
 Although gene enrichment analysis did not yield any statistically significant 
pathway, some genes are associated with several pathways associated with leukemia. As 
mentioned, most of these gender- and age-specific associated childhood ALL SNPs are 
novel risk variants, as expected. The role of these SNPs is still not clear in childhood 
ALL etiology, however, some of these associated genes play a major role in several 
leukemia associated pathways. For example, Notch1 signaling plays an important role in 
childhood leukemia256. Recent studies have shown the role of MAML1 (mastermind-
like1) in the regulation of Notch oncogenic activities in leukemic cells257-259. The 
MAML1 rs41285557 showed a male-specific association in this study.   
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The RASSF2 (Ras association (RalGDS/AF-6) domain family member 2) SNP, 
rs4813720, yielded the lowest P value for gender-specific associations. RASSF2 is a 
novel tumor suppressor gene and a member of the Ras family that regulates a wide range 
of biological process, including Ras signalling and apoptosis259-261. Studies suggest that 
genes affecting the Ras pathway is the most common occurrence in human cancer, 
including childhood ALL262, 263. Likewise, several other genes, RAB28 (rs10003958), 
ADAMTS12 (rs7700370) and RSU1 (rs4748309) may play a significant role on 
leukemogenesis through the Ras pathway264. The role of gender- and age-specific 
associated risk variants in the Ras pathway may be important to increase the risk of 
leukemia.  
The HSPB6 (rs231237) gene encodes a heat shock protein and is constitutively 
expressed in various tissues265. A study on hepatocellular carcinoma showed its 
interaction with P13K, which ultimately results in suppression of the AKT pathway. 
P13K/AKT pathways also play an important role in childhood leukemogenesis, 
specifically T-cell ALL221, 222. Likewise, the CYFIP2 (rs1030270), OSGIN1 
(rs62640905), ZNF420 (rs4254428 and rs6510588), AIFM2 (rs10999147) and RASSF3 
(rs11175471) genes show TP53 dependent apoptosis and may increase childhood ALL 
susceptibility266-271. Studies suggest that leukemia may be more sensitive to change in 
TP53 dependent apoptosis126. The present findings suggest that the associated variants 
may alter the pathway mediated by TP53 and increase leukemia risk. Some of these SNPs 
were missense variations or yielded a much higher functional prediction score.   
  These pathways may play a significant role in childhood ALL etiology with 
gender- and age-specificity. However, these results should be interpreted cautiously, as 
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none of the age- or gender-specific SNPs or associated genes are directly associated with 
leukemogenesis. How these SNPs affect on gender- and age-specificity in childhood ALL 
risk is still not clear. Some studies suggest that genetic variants in the TP53 pathway 
could interact with gender to affect cancers134, 272.  
Previous GWASs have missed these gender- and age-specific variants as they did 
not stratify their results by gender and age. Association differing in direction, usually 
results in an OR close to the unity (OR = 1.0) with no statistical significance in the 
overall analysis. These SNPs were dismissed by previous studies for further 
considerations. Stratified analysis reduces statistical power. However, it is not true in the 
case of gender- and age-specific associations. In gender- or age-specificity, an overall 
analysis approach does not have sufficient statistical power to detect the association. If 
there is a gender- or age-specificity, stratified analysis will yield much higher effect size 
for a particular group, such as males or the age-group 1-5 years. The statistical power will 
be greater in this case than combined analysis. Other problems with previous studies were 
adjusting the results for gender and declaring there is no gender-specific association. 
Statistical adjustment only rules out confounding by gender, which is not equivalent to 
gender-specificity26. Thus, our approach unraveled novel risk variants, which are 
associated with a particular gender or age group in childhood ALL risk.      
 SNPnexus database used COSMIC database to identify SNPs associated with 
somatic mutations. Somatic mutation is only present in somatic cells. It means that they 
are not present in all body cells or germ cells. Unlike germline mutations, these mutations 
are acquired. Somatic mutations either randomly occur or generate by environmental 
chemicals. Our results yielded several SNPs associated with several cancers through 
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somatic mutations. It has been suggested that somatic mutations in cancer cells may be 
drivers (causing progression of cancer) or passengers (just the results of random 
mutations). A total of six SNPs, rs61753605 (PRIM2B), rs35693261 (MTG2), rs180041 
(LRP1/MIR1228), rs4645656 (ZNF782), rs34099167 (NEK1) and rs762562 
(ERCC1/CD3EAP), detected as somatic mutations by COSMIC database. It suggests that 
these SNPs may cause functional changes that are advantageous for cancer occurrence 
and/or progression. These somatic mutations were associated with prostate, breast, large 
intestine, stomach and pancreatic cancers. The LRP1 gene promotes cancer cell invasion 
by supporting ERK and inhibiting and JNK signaling pathway273. ERK signaling pathway 
is associated with leukemogenesis. Studies suggest that mutation in the NEK1 gene may 
lead to chromosomal instability, and thus increase the risk of cancer. The ERCC1 gene 
has previously showed an increase risk of childhood ALL with male- and age-
specificity227.   
In this study, we found a number of associations with gender- and age-specificity. 
Bioinformatic and empirical analyses suggested that several of associated SNPs may play 
a functional role in gender and age differential in childhood ALL risk, through change in 
protein function (missense variations), regulatory effects on gene expression (eQTL) or 
through alterations of transcription factor binding sites. Although gene enrichment 
analysis did not yield any pathway to explore gender- and age-specificity, several 
genomic locations of associated risk variants are associated with leukemogenesis.  
 In the past few years, GWASs have yielded hundreds of associations for around 
hundred traits and diseases. However, the effect sizes are modest (OR < 1.5)274, 275. The 
median OR for binary traits is 1.28 (interquartile range (IQR) 1.17 to 1.55). Most of the 
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previous GWASs used genome-wide significance (P < 10-8) level to show an association. 
Our results did not reach this significance level for gender- and age-specific associations. 
In comparison to previous GWASs, our gender- and age-specific analyses, which are 
based on statistical significance, yielded a much higher median OR (2.44; IQR = 2.22 - 
2.78). Interpretation of an OR, in a case-only analysis, is important, as a statistically 
significant association with OR > 1 only suggests a positive interaction (risk to males or 
age group 1-5 y). A higher effect size, however, suggests a higher risk to a particular 
gender or age group. An OR < 1 in the present study suggests risk to females or to the 
age group 6-10 years. Even, an inverse relationship has been observed between sample 
sizes and effect sizes. Studies with larger sample sizes mostly yielded lower effect size 
associations. Of course, larger sample sizes provide more statistical power to detect even 
a minute effect size such as OR = 1.1, but the clinical or public health utility of these 
associations is questionable.  
 Most of the previously identified variants, in general, around 88%, were located 
in non-coding regions (43% in intergenic region and 45% in intron). In the present study, 
around 94% of associations were in non coding regions (57% intergenic regions and 38% 
in intron). In comparison to 9% nonsynonymous variations (missense or nonsense) in 
previous GWASs, our results only showed 3% of nonsynonymous variations. In case of 
SNPs location at 3’ or 5’ untranslated region, results were similar (2%). Although we 
used a different GWAS chip, enriched with coding SNPs, gender- and age-specific 
results, based on SNPs location, differ from the previous GWASs. Results based on the 
highest effect sizes for gender- and age-specific associations yielded more meaningful 
SNP locations. Around 67% of identified associations were located in non-coding region 
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of genes (39% in intergenic region and 28% in intron). A total of 25% SNPs were 
missense variations, and 5% of SNPs were located in the 3’ or 5’ untranslated region. 
Results based on the effect sizes yielded more meaningful results in comparison to results 
based on the lowest P values, such as more SNPs in coding region and missense 
variations.  
Genetic variants usually modify disease susceptibility in the presence of 
environmental exposures276. Genetic factors play a predominant role in diseases due to 
rare and highly penetrant mutations. However, common genetic polymorphisms modify 
disease susceptibility in the presence of environmental exposure. Unfortunately, in the 
case of childhood ALL, the only known environmental risk factor is ionizing radiations. 
In this study, the CTD was used to explore the gender- and age-specific associated genes 
and their interactions with environmental chemicals277. The most common environmental 
pollutants interacting with the target genes of the SNPs that have shown in the present 
study were PAH, vehicle emissions, cigarette smoke, pesticides, drugs such as 
acetaminophen, alcohol and formaldehyde. A detailed list of gene-chemical interactions 
and appropriate references are provided in the appendix (Table 10, 11, 19 and 20). These 
environmental chemicals are ubiquitous and show associations with an increased risk for 
childhood ALL192-196, 278. Most of these chemicals are classified as class 1 and class 2 
carcinogens191 or teratogens. Studies suggest that age plays an important role in the 
susceptibility to environmental toxicants279. Because of differential exposure, children are 
more susceptible to a number of different environmental pollutants, including PAH, air 
pollution, cigarette smoke and pesticides. Children consume more foods and water per 
pound of body weight when compared to adults. They breathe air at a faster rate than 
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adults. Thus, children are more vulnerable to environmental toxicants. There is also 
evidence of prenatal exposures and childhood ALL risk, such parental occupational 
exposure, pesticide exposure, tobacco smoke and air pollutants280.  
Like age-specificity, studies also suggest gender-specificity in chemical 
exposures197-200. Benzene and ethanol toxicity is much higher in males, regardless of 
whether exposures occur in utero or adulthood197, 198. These results suggest the 
importance of gender-difference in benzene induced toxicity. Likewise, females have an 
increased risk for acute pesticide-related illness. Exposures during pregnancy may 
increase the susceptibility of childhood ALL.  Thus, age and gender differences in the 
toxicity of environmental chemicals may play a significant role in ALL biology. 
However, interaction between environmental pollutants and gender- and age-specific risk 
markers are not yet known. 
Rarity of childhood ALL makes it difficult to study the cause of the disease. Most 
epidemiological studies of childhood ALL and environmental exposures are case-control 
studies. Case-control studies mostly rely on parents' recall for environmental exposure. 
Parents of childhood cancers may recall their memories more thoroughly than healthy 
controls. Thus, recall bias may inflate the results and introduce systematic error. That is 
one of the potential reasons for the limited evidence for the involvement of 
environmental exposures in the development of childhood ALL.  
There are very few examples of gender- and age-specific associations in disease 
risk. A recent genome-wide meta-analysis of asthma reported gender-specific candidate 
risk markers in IRF1 (rs2549003) and RAP1GAP2 (rs9895098) with regulatory effects in 
gene regulation as eQTL281. Asthma prevalence also shows intriguing gender-specific 
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architecture that differs by age. Males are more susceptible during early childhood and 
females develop asthma during puberty. That study also confirmed the advantage of 
gender-specific approach in a genetic association study to understand disease etiology.       
Likewise, another study in 5,254 participants (2,833 females and 2,421 males) 
from Framingham Heart Study has shown 14 eQTL SNPs (13 autosomal and one X 
chromosome) with gender-genotype interactions and ten eQTL SNPs with age-genotype 
interactions after multiple comparisons282. These eQTL SNPs are associated with several 
complex traits/diseases.  Overall they found 5,866 genes differently expressed between 
males and females. Interestingly, they have also shown different gender-specific models, 
such as associations differing in direction and associations differing in magnitude, in 
gender-genotype interactions, which we also aimed in this study. For example, the 
C5orf35 rs686798, association with plasma triglyceride levels, has shown opposite 
effects on the expression of the IL6ST gene, increased expressions in females (P = 
0.0006) and decreased expressions in males (P = 0.05). Another SNP, rs8047080, 
associated with high-density lipoprotein, has shown higher expression only in males 
(7.03 x 10-5). Thus, these recent studies support the rationale of this dissertation. 
These examples are very recent examples of a gender- and age-specific approach, 
which we had also proposed in this study. Age related eQTL SNPs have also confirmed 
the effects of genetic variants on gene expression throughout the age span. We examined 
these associations in our study, however, none of these showed any age- or gender-
specific associations in childhood ALL risk. These gender- and age-specific variants 
might only be associated with particular diseases/traits.  
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Most of the previous gender-specific associations in childhood ALL are within 
the HLA region. Our results further confirm the role of HLA in childhood ALL risk with 
male-specificity. Early-onset of childhood ALL and HLA associations are new findings 
and may shed some light on childhood ALL risk. Van Der Meulen et al, recently, have 
demonstrated the loss-of-function mutation in the X-linked UTX (KDM6A) gene in 
childhood T-ALL283. This UTX mutation was exclusively present in males, which suggest 
the role of X chromosomes in ALL etiology. Our results did not show any gender-
specific or age-specific associations with X chromosome in the top one hundred 
associations.  
Our results did not replicate the same gender-specific associations for previously 
identified childhood ALL risk markers, even after applying the same genetic models as 
used in previous childhood ALL studies. The closest association was the SKIV2L 
rs419788 (Pinteraction = 0.06). Some of these studies may have suffered from multiple 
comparison issues. Due to rarity of childhood ALL, case-control study design was used 
to identify gender-specific associations. Thus, controls should be representative of the 
general population. One study used adults as a control group125, and another study used 
convenience samples as controls139 to identify gender-specific associations. Thus, gender-
specific associations might be affected by selection bias, as controls may have different 
environmental exposures than childhood ALL. Genetic variants modify disease 
susceptibility in the presence of environmental risk factors, so geographical differences 
may also apply in some replication failure, as few of these gender-specific associations 
were studied in the United Kingdom125, 128, 130. 
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Even after clear heterogeneity in age differences (age peak 1-5 y) in childhood 
ALL, there is not much effort to unravel genetic risk markers in this age group. More 
than 50% of childhood ALL cases belong to the age group 1-5 years. Only four SNPs 
(rs3212986, rs2279744, rs4132601 and rs10821936) have shown age-specificity in 
childhood ALL risk51, 52, 126, 227, and two of them are known childhood ALL risk markers 
(rs4132601 and rs10821936)51, 52. The SNP rs10821936 was compared between age 
group 1-10 years and 11-18 years. Another association (rs4132601) was with age-at-onset 
in childhood ALL risk140. rs2279744 and rs10821936 also failed to replicate previous 
age-specific associations.   
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7. STRENGTHS AND LIMITATIONS 
Due to the rarity of childhood ALL, the sample size of the present study was 
small. Twenty nine samples were excluded after strict QC steps, further reducing 
statistical power. Another limitation was external validity of these results, as all of these 
samples were Non-Hispanic whites. Thus, these results cannot be generalized in any 
other ethnic population. Our study was also restricted to age group 1-10 years, which also 
lessened the statistical power. Self-reported gender, age and ethnicity data may be of 
concern, as misclassification biases. Population-based studies mostly rely on self-
reported data, and residual confounding is possible. In terms of gender, we verified 
discordant gender information by the usage of sex-chromosome genotyping results and 
excluded the samples in case of ambiguity in gender information. Thus, it resulted as a 
strength of this study. Self-reported ethnicity may be reliable284. To avoid false positive 
associations due to population stratification, we adjusted our results using genomic 
controls, which is also a strength of the present study.  In the case of age, we depended on 
self-reported data. Lack of cytogenetic data is another limitation of this study. 
Chromosomal aberrations, such as chromosomal trisomies (such as Down syndrome) or 
chromosomal translocations (fusion of two genes from different chromosomes) are 
associated with childhood ALL risk. Still these chromosomal aberrations represent only a 
fraction of cases, leaving a large proportion with undefined etiology.         
We followed strict safeguards to control genotyping errors. We used a GWAS 
chip developed by Illumina, the industry leader. Our genotyping call rate was 99.9%. A 
limitation of this study was that we were not able to assess the associations between 
genetic risk markers and childhood ALL risk in males and the age group 1-5 years. 
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However, our interest in this study differed from the traditional approach, and we were 
more interested in identifying gender- and age-specific associations. We used gender and 
age as effect modifiers to identify gender- and age-specific associations. The case-only 
design is based on the independence of exposure and genotype, which means there should 
not be any difference in allele frequencies in two groups. Departures from this 
independence may affect the results. In the case of gender and age, it seems impossible to 
have different allele frequencies between males and females and between two age groups 
(1-5 years vs 6-10 years) in a healthy population. A genome-wide meta-analysis across 
51 studies including overall 114,863 samples (61,094 women and 53,769) of European 
ancestry did not find any allele frequency difference at common loci between men and 
women62. However, another study in four different GWAS datasets (n < 165), identified 
allele frequency differences between healthy males and females in European samples285. 
However, none of the confounding SNPs in the second study285 showed statistical 
significant associations in gender-specific analysis in the present study. Such an 
association would be invalid due to the violation of the major assumption of case-only 
approach. 
Issues related with case-control design do not necessarily apply to a case-only 
design. All of these cases were incident cases of childhood ALL and have a well-defined 
phenotype, with molecular ALL sub-types. However, we did not have complete data to 
examine associations in childhood ALL sub-types. One more strength of the present 
study is the validation of previously known leukemia risk markers in the parent case-
control group. Thus, it increases the validity of our results.   
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8. CONCLUSION  
This research was conducted to explore the effect modification by gender and age 
of the risk for childhood ALL. A case-only study was used to examine the gender- and 
age-specific associations. The parent study was a case-control study, and replication of 
GWAS childhood ALL risk markers validated our parent data set and increased the 
credibility of our study. Our study identified novel risk variants for childhood ALL. 
These risk variants are gender- and age-specific, which means they are associated with a 
particular gender (males or females) or age groups (1-5 years or 6-10 years). A total of 
fourteen risk markers were previously yielded associations with other diseases, such as 
autoimmune disorders, CLL (rs7169431) and nasopharyngeal carcinoma (rs28421666).   
The aim to unmask hidden gender- and age-specific risk variants was based on 
clear heterogeneity between two genders and age groups. There are, however, very few 
examples of gender- and age-specific associations in the risk of childhood ALL, but a 
dedicated GWAS was needed to unravel these hidden risk variants. Our results were 
based on two approaches: a conventional statistical analysis based on the most 
statistically significant associations and the results based on the highest effect sizes. The 
SNPs, rs4813720, rs231237 and rs7323018, yielded the statistically most significant 
gender-specific associations. Likewise, rs10505918 yielded the lowest P value for age-
specific associations, and also yielded the most statistically significant association with 
age-at-onset. Two SNPs, rs12722042 and 12722039, from the HLA-DQA1 region 
yielded the highest effect sizes for gender-specific results, and the SNP, rs17109582 and 
rs7304215, yielded the highest effect sizes for age-specific results.  
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The statistical gender- or age-specific associations were complemented with 
bioinformatics and empirical analyses for causality assessment, and yielded some 
functional variants among the set of SNPs. A total of 29 SNPs showed a very high 
functional score for gender- and age-specific results, which suggests they may be very 
important for regulatory effects. Our results also identified a total of 56 nonsynonymous 
variations (55 missense and one nonsense) for gender- and age-specific associations; 
however, most of these nonsynonymous variations were associated with the results based 
on the effect size. These nonsynonymous variations clearly suggest an obvious change in 
protein function. Likewise, 21 SNPs were located in TFBS and may affect the regulatory 
function.    
Gene enrichment analysis did not yield any specific pathways for childhood ALL 
risk in gender and age-specific manner. We still explored the functions of associated 
genes. Several of these genes are associated with RAS, PTEN, JAK/STAT and P13/AKT 
signaling pathways221, 255. These pathways play a significant role in leukemogenesis. 
Overall our results yielded novel gender- and age- specific risk variants in this study. 
Further studies are warranted to replicate the gender- and age-specific associations and to 
examine mechanisms of those that are confirmed.  
Markers, which showed associations differing in directions, will be very useful 
once confirmed risk to males and protection to females. It is important to know that 
because any future intervention to protect males may do harm to females if this difference 
is not recognized. Thus, there is potential for targeted intervention (and maybe treatment 
approaches) of one gender while the same intervention would not be useful to the other. 
These results, once confirmed, may also help to devise more personalized treatment for 
124 
 
males. Just now, they get the same treatment but at a higher dose (with more side effects 
and late effects etc).     
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Appendix Table 1: Genetic risk markers for childhood acute lymphoblastic leukemia in 
previous genome-wide association studies 
 
SNP Gene Gene function OR (95% CI) P value Ref  
rs10821936 ARID5B differentiation of B 
lymphocyte progenitor 
1.91 (1.60-2.20) 1.4 x 10-15 51 
1.86 (1.71-2.03) 5.90 x 10-46 53 
rs10994982 ARID5B differentiation of B 
lymphocyte progenitor 
1.61 (1.30-1.90) 5.70 x 10-9 51 
rs7073837 ARID5B differentiation of B 
lymphocyte progenitor 
1.58 (1.35-1.89) 4.66 x 10-16 52 
1.64 (1.40-1.92) 1.0 x 10-9 49 
rs10740055 ARID5B differentiation of B 
lymphocyte progenitor 
1.53 (1.41-1.64) 5.35 x 10-14 52 
1.75 (1.49-2.06) 1.8 x 10-11 49 
rs7089424 ARID5B differentiation of B 
lymphocyte progenitor 
1.65 (1.54-1.76) 6.69 x 10-19 52 
1.83 (1.55-2.15) 6.13 x 10-13 49 
rs11978267 IKZF1 regulator of lymphocyte 
differentiation 
1.69 (1.40-1.90) 8.8 x 10-11 51 
rs4132601 IKZF1 
regulator of lymphocyte 
differentiation 
1.69 (1.58-1.81) 1.20 x 10-19 52 
1.59 (1.34-1.89) 1.2 x 10-7 49 
rs6964969 IKZF1 regulator of lymphocyte 
differentiation 
1.59 (1.45-1.74) 1.59 x 10-29 53 
rs2239633 CEBPE 
functional maturation of 
granulocyte progenitor 
cells 
1.34 (1.22-1.45) 2.88 x 10-7 52 
rs4982731 CEBPE 
functional maturation of 
granulocyte progenitor 
cells 
1.36 (1.24-1.48) 8.97 x 10-12 53 
rs2089222 KRT85 hair and nail formation 2.26 (1.60-3.00) 8.40 x 10-8 51 
rs11155133 6q24 NA 3.62 (2.10-6.00) 3.0 x 10-7 51 
rs2191566 ZNF230 NA 1.52 (1.20-1.70) 3.5 x 10-7 51 
rs6509133 ZNF230 NA 1.48 (1.20-1.70) 1.4 x 10-6 51 
rs7554607 RYR2 calcium channel 1.49 (1.20-1.70) 1.6 x 10-6 51 
rs12621643 KCNE4 
voltage-gated 
potassium channel 
activity 
1.48 (1.20-1.70) 2.8 x 10-6 51 
rs10873876 ST6GALNAC3 NA 1.55 (1.20-1.80) 4 x 10-6 51 
rs9290663 KCNMB2 
voltage-gated 
potassium channel 
activity 
1.58 (1.20-1.90) 6 x 10-6 51 
rs6428370 1q31 NA 1.43 (1.20-1.60) 7 x 10-6 51 
rs1881797 OR2C3 G protein coupled 
receptor activity 
1.52 (1.20-1.80) 7 x 10-6 51 
    
152 
 
  Appendix Table 1 continued…. 
SNP Gene Gene function OR (95% CI) P value Ref  
rs10849033 C12orf5 
TP53-induced 
glycolysis and 
apoptosis 
2.55 (1.60-3.80) 9 x 10-6 51 
rs1879352 18p11.32 NA 1.53 (1.20-1.80) 9 x 10-6 51 
rs563507 PARD3 protein phosphatase 
binding 
2.00 (1.40-2.70) 9 x 10-6 51 
rs3779084 DDC 
amino acid binding and 
protein domain specific 
binding 
1.44 (1.32-1.56) 8.81 x 10-9 52 
rs880028 DDC 
amino acid binding and 
protein domain specific 
binding 
1.43 (1.30-1.56) 1.26 x 10-7 52 
rs7809758 DDC 
amino acid binding and 
protein domain specific 
binding 
1.44 (1.32-1.54) 2.41 x 10-10 52 
rs2242041 DDC 
amino acid binding and 
protein domain specific 
binding 
1.72 (1.30-2.10) 9.9 x 10-7 51 
rs2167364 DDC 
amino acid binding and 
protein domain specific 
binding 
1.46 (1.20-1.70) 2.8 x 10-6 51 
rs930372 ANKRD44 
recognition of 
phosphoprotein 
substrate 
2.37 (1.65-3.41) 3.1 x 10-6 49 
rs1945213 OR8U8 G protein coupled 
receptor activity 
1.30 (1.19-1.43) 3 x 10-8 54 
rs17505102 TP63 
sequence specific DNA 
binding transcriptional 
activator or repressor 
1.47 (1.28-1.67) 2 x 10-8 54 
rs7156960 GPATCH2L NA 1.22 (1.12-1.33) 3 x 10-6 54 
rs7738636 6q14 NA 1.27 (1.15-1.41) 6 x 10-6 54 
rs282708 4q13.1 NA 1.23 (1.12-1.35) 8 x 10-6 54 
rs4748793 COMMD3 
may down-regulate 
activation of NF-kappa-
B 
1.40 (1.26-1.57) 8.40 x 10-9 53 
rs3776932 MAN2A1 biosynthesis of 
complex N-glycans 
0.23 (0.10-0.50) 0.0006 50 
rs6140264 HAO1 has 2-hydroxyacid 
oxidase activity 
4.33 (1.8-10.20) 0.0008 50 
rs12105972 GCFC2 
factor that represses 
transcription, bind to 
GC-rich sequences 
0.30 (0.10-0.60) 0.0015 50 
rs17837497 TBXAS1 electron carrier activity 
and heme binding 
2.34 (1.65-3.31) 1.89 x 10-6 219 
rs1496766 MAGI2 
enhances the ability of 
PTEN to suppress 
AKT1 activation 
2.84 (1.81-4.44) 5.45 x 10-6 219 
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SNP Gene Gene function OR (95% CI) P value Ref  
rs17079534 MYRIP melanosome transport 4.07 (2.04-6.87) 1.65 x 10-7 219 
rs10170236 LOC642340 NA 1.45 (1.24-1.69) 3.92 x 10-6 219 
rs7578361 2q23 NA 1.40 (1.21-1.63) 8.40 x 10-6 219 
rs7142143 PYGL 
pyridoxal phosphate 
binding and protein 
homodimerization 
activity 
3.61 (2.34-5.57) 6.72 x 10-9 219 
rs6683977 PDE4B ion channel binding 1.41 (1.22-1.64) 5.13 x 10-6 219 
rs546784 PDE4B ion channel binding 1.40 (1.20-1.62) 1.17 x 10-5 219 
  SNP = single nucleotide polymorphism; OR = odds ratio; CI = confidence interval; Ref = reference
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Appendix Table 2: Top one hundred SNPs associated with childhood ALL risk with gender-specificity, results based on the 
lowest P values 
Minor allele 
frequency 
SNP Gene/region Chr† Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs4813720 RASSF2 20 A 5upstream 0.23 0.47 0.29 (0.17 - 0.48) 1.90 x 10-06 1.0 x 10-4 
rs231237 HSPB6 19 A 5upstream 0.42 0.21 3.00 (1.86 - 4.85) 7.15 x 10-06 1.0 x 10-4 
rs7323018 13q14.1 13 G intergenic 0.17 0.36 0.31 (0.18 - 0.52) 8.40 x 10-06 1.0 x 10-4 
rs17027254 2p22 2 T intergenic 0.19 0.39 0.37 (0.23 - 0.58) 1.86 x 10-05 1.0 x 10-4 
rs7912381 10q26.3 10 G intergenic 0.39 0.21 2.78 (1.71 - 4.51) 3.68 x 10-05 1.0 x 10-4 
rs11687208 2p22 2 C intergenic 0.21 0.4 0.40 (0.26 - 0.62) 4.81 x 10-05 1.0 x 10-4 
rs798292 MAGI2 7 G intronic 0.16 0.35 0.38 (0.24 - 0.61) 4.88 x 10-05 1.5 x 10-4 
rs13107783 4p15.3 4 C intergenic 0.32 0.52 0.40 (0.26 - 0.62) 5.16 x 10-05 2.0 x 10-4 
rs4470624 4p15.3 4 T intergenic 0.32 0.52 0.40 (0.25 - 0.62) 5.16 x 10-05 2.0 x 10-4 
rs1849374 12p11.2 12 A intergenic 0.44 0.25 2.48 (1.58 - 3.88) 7.35 x 10-05 2.0 x 10-4 
rs12948120 ACACA 17 C intronic 0.29 0.49 0.44 (0.29 - 0.66) 7.46 x 10-05 3.0 x 10-4 
rs6904762 6q23 6 G intergenic 0.27 0.46 0.41 (0.26 - 0.64) 1.00 x 10-05 1.0 x 10-4 
rs506389 8q22.3 8 A intergenic 0.28 0.11 2.99 (1.74 - 5.15) 7.98 x 10-05 2.0 x 10-4 
rs6732320 2p22 2 T intergenic 0.2 0.38 0.41 (0.26 - 0.64) 8.08 x 10-05 3.0 x 10-4 
rs8081866 ACACA 17 T intronic 0.28 0.48 0.45 (0.30 - 0.67) 8.64 x 10-05 3.0 x 10-4 
rs349714 3p25 3 G intergenic 0.44 0.26 2.43 (1.56 - 3.80) 8.76 x 10-05 2.0 x 10-4 
rs7583193 2p22 2 G intergenic 0.19 0.38 0.41 (0.26 - 0.64) 9.09 x 10-05 1.0 x 10-4 
rs206457 18p11.2 18 A intergenic 0.59 0.38 2.24 (1.49 - 3.35) 9.32 x 10-04 1.0 x 10-4 
rs7723568 5p15.3 5 A intergenic 0.35 0.18 2.66 (1.62 - 4.36) 1.10 x 10-04 2.0 x 10-4 
rs2542660 ACACA 17 C intronic 0.26 0.46 0.45 (0.30 - 0.68) 1.16 x 10-04 3.0 x 10-4 
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       Appendix Table 2 continued…. 
Minor allele 
frequency
SNP Gene/region Chr† Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs1899286 2p22 2 A intergenic 0.21 0.39 0.42 (0.27 - 0.66) 1.19 x 10-04 2.0 x 10-4 
rs9563035 13q14 13 G intergenic 0.5 0.31 2.30 (1.50 - 3.52) 1.24 x 10-04 1.0 x 10-4 
rs2542653 ACACA 17 C intronic 0.26 0.46 0.46 (0.31 - 0.68) 1.32 x 10-04 2.0 x 10-4 
rs6490437 13q12 13 G intergenic 0.41 0.6 0.44 (0.29 - 0.67) 1.34 x 10-04 2.0 x 10-4 
rs4794031 17q21 17 C intergenic 0.43 0.24 2.32 (1.50 - 3.58) 1.42 x 10-04 3.0 x 10-4 
rs2544371 2q31 2 G intergenic 0.37 0.57 0.45 (0.30 - 0.68) 1.52 x 10-04 1.0 x 10-4 
rs1372166 2p22 2 C intergenic 0.13 0.28 0.36 (0.21 - 0.61) 1.83 x 10-04 2.0 x 10-4 
rs7294845 SOX5 12 T intronic 0.20 0.37 0.41 (0.26 - 0.65) 1.59 x 10-04 1.0 x 10-4 
rs12219278 10q26 10 T intergenic 0.29 0.14 2.74 (1.62 - 4.64) 1.79 x 10-04 2.0 x 10-4 
rs4942264 13q13 13 T intergenic 0.12 0.26 0.36 (0.21 - 0.62) 2.04 x 10-04 2.5 x 10-4 
rs11708505 3p13 3 A intergenic 0.41 0.6 0.47 (0.31 - 0.70) 2.11 x 10-04 2.0 x 10-4 
rs6540610 HHAT 1 A intronic 0.18 0.39 0.39 (0.24 - 0.65) 2.18 x 10-04 4.0 x 10-4 
rs2764928 1p32 1 A intergenic 0.12 0.26 0.36 (0.21 - 0.62) 2.43 x 10-04 2.0 x 10-4 
rs1550017 4q32 4 A intergenic 0.17 0.05 4.23 (1.96 - 9.14) 2.45 x 10-04 1.0 x 10-4 
rs12054636 4q32 4 A intergenic 0.17 0.05 4.23 (1.96 - 9.14) 2.45 x 10-04 1.0 x 10-4 
rs2764933 1p32 1 A intergenic 0.32 0.51 0.45 (0.30 - 0.69) 2.48 x 10-04 2.0 x 10-4 
rs468771 GRIK1 21 T intronic 0.33 0.17 2.48 (1.52 - 4.02) 2.54 x 10-04 3.0 x 10-4 
rs864674 5p13 5 C intergenic 0.55 0.38 2.27 (1.46 - 3.53) 2.65 x 10-04 1.0 x 10-4 
rs8106959 KMT2B 19 G intronic 0.25 0.11 2.87 (1.63 - 5.07) 2.66 x 10-04 3.0 x 10-4 
rs9561489 GPC6 13 A intronic 0.40 0.57 0.45 (0.29 - 0.70) 2.86 x 10-04 4.0 x 10-4 
rs4934956 10p11.2 10 T intergenic 0.56 0.38 2.20 (1.44 - 3.37) 2.91 x 10-04 3.0 x 10-4 
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     Appendix Table 2 continued…. 
Minor allele 
frequency
SNP Gene/region Chr† Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs9897342 17q11.1 17 A intergenic 0.43 0.26 2.21 (1.44 - 3.40) 3.03 x 10-04 5.0 x 10-4 
rs756134 1p13 1 A intergenic 0.53 0.35 2.10 (1.40 - 3.15) 3.11 x 10-04 4.0 x 10-4 
rs4926465 KIF28P 1 G 5upstream 0.49 0.44 0.43 (0.27 - 0.68) 3.14 x 10-04 3.0 x 10-4 
rs552976 ABCB11 2 T intronic 0.17 0.53 0.40 (0.24 - 0.66) 3.15 x 10-04 1.0 x 10-4 
rs563694 2q31 2 G intergenic 0.16 0.54 0.38 (0.23 - 0.65) 3.20 x 10-04 3.0 x 10-4 
rs1529186 3q13.1 3 A intergenic 0.14 0.29 0.40 (0.24 - 0.66) 3.47 x 10-04 2.0 x 10-4 
rs11049786 12p11.2 12 G intergenic 0.44 0.27 2.24 (1.44 - 3.50) 3.50 x 10-04 4.0 x 10-4 
rs9510793 TNFRSF19 13 C intronic 0.35 0.20 2.40 (1.49 - 3.88) 3.51 x 10-04 3.0 x 10-4 
rs61748746 N4BP2 4 A coding 0.02 0.10 0.10 (0.02 - 0.36) 3.64 x 10-04 1.5 x 10-4 
rs2874641 SHISA6 17 G intronic 0.19 0.35 0.43 (0.27 - 0.69) 3.64 x 10-04 2.0 x 10-4 
rs560887 G6PC2 2 A intronic 0.14 0.59 0.37 (0.21 - 0.64) 3.72 x 10-04 4.5 x 10-4 
rs7025331 9p24 9 C intergenic 0.40 0.57 0.46 (0.30 - 0.71) 3.72 x 10-04 4.5 x 10-4 
rs7917910 10q26 10 A intronic 0.24 0.33 0.43 (0.27 - 0.69) 3.74 x 10-04 6.0 x 10-4 
rs349707 3p25 3 G intergenic 0.43 0.57 0.51 (0.35 - 0.74) 3.76 x 10-04 2.0 x 10-4 
rs61748749 N4BP2 4 G coding 0.16 0.10 0.10 (0.03 - 0.36) 3.93 x 10-04 1.5 x 10-4 
rs9873177 PDIA5 3 C intronic 0.06 0.18 0.30 (0.16 - 0.59) 4.03 x 10-04 2.0 x 10-4 
rs739924 SPATA20 17 C intronic 0.25 0.43 0.45 (0.29 - 0.70) 4.04 x 10-04 4.0 x 10-4 
rs12505859 4q35 4 G intergenic 0.39 0.30 2.07 (1.38 - 3.11) 4.10 x 10-04 4.0 x 10-4 
rs7322477 LINC00284 13 C intronic 0.14 0.27 0.39 (0.23 - 0.66) 4.15 x 10-04 6.0 x 10-4 
rs1978759 MGMT 10 A intronic 0.36 0.36 0.44 (0.27 - 0.69) 4.17 x 10-04 6.0 x 10-4 
rs725038 ACACA 17 C intronic 0.32 0.55 0.51 (0.35 - 0.74) 4.18 x 10-04 5.0 x 10-4 
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      Appendix Table 2 continued…. 
Minor allele 
frequency
SNP Gene/region Chr† Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs729867 CSRNP3 2 T intronic 0.18 0.09 2.92 (1.61 - 5.31) 4.33 x 10-04 3.0 x 10-4 
rs4875742 CSMD1 8 C intronic 0.30 0.23 0.36 (0.20 - 0.64) 4.63 x 10-04 2.0 x 10-4 
rs1720326 11q24 11 G intergenic 0.49 0.25 2.18 (1.41 - 3.39) 5.06 x 10-04 2.0 x 10-4 
rs1713676 11q23 11 T intergenic 0.43 0.39 2.21 (1.41 - 3.45) 5.10 x 10-04 6.0 x 10-4 
rs3857193 SORCS2 4 C intronic 0.25 0.36 0.46 (0.29 - 0.71) 5.18 x 10-04 8.0 x 10-4 
rs6987111 CCDC25 8 A intronic 0.15 0.05 3.91 (1.81 - 8.46) 5.21 x 10-04 4.0 x 10-4 
rs4801931 ZNF611 19 C intronic 0.28 0.54 0.49 (0.32 - 0.73) 5.24 x 10-04 6.0 x 10-4 
rs12940887 ZNF652 17 T intronic 0.30 0.19 2.27 (1.43 - 3.61) 5.28 x 10-04 2.0 x 10-4 
rs7225787 ZNF652 17 C intronic 0.34 0.27 2.09 (1.38 - 3.16) 5.28 x 10-04 3.0 x 10-4 
rs11079867 17q21 17 C intergenic 0.44 0.28 2.07 (1.37 - 3.12) 5.32 x 10-04 7.0 x 10-4 
rs4680582 SMC4 3 A intronic 0.16 0.06 3.33 (1.69 - 6.58) 5.33 x 10-04 5.0 x 10-4 
rs1429143 6p12 6 G intergenic 0.37 0.34 0.43 (0.27 - 0.69) 5.39 x 10-04 3.0 x 10-4 
rs10506041 12p11.2 12 A intergenic 0.46 0.38 2.16 (1.40 - 3.34) 5.47 x 10-04 4.0 x 10-4 
rs1915337 3q13.1 3 A intergenic 0.10 0.24 0.39 (0.22 - 0.66) 5.50 x 10-04 7.0 x 10-4 
rs6962352 HIP1 7 G intronic 0.21 0.45 0.49 (0.33 - 0.74) 5.52 x 10-04 5.0 x 10-4 
rs634413 LINC00544 13 A intronic 0.30 0.59 0.50 (0.34 - 0.74) 5.56 x 10-04 4.0 x 10-4 
rs4074605 SYNRG 17 C intronic 0.21 0.1 2.84 (1.57 - 5.14) 5.66 x 10-04 5.0 x 10-4 
rs7407281 18p21 18 A intergenic 0.23 0.1 2.69 (1.53 - 4.74) 6.04 x 10-04 7.0 x 10-4 
rs10778311 TXNRD1 12 G intronic 0.26 0.24 2.09 (1.37 - 3.20) 6.06 x 10-04 4.0 x 10-4 
rs7492685 14q21 14 C intergenic 0.16 0.11 0.10 (0.03 - 0.39) 6.08 x 10-04 3.0 x 10-4 
rs4246284 15q26 15 C intergenic 0.16 0.26 0.40 (0.24 - 0.67) 6.12 x 10-04 2.0 x 10-4 
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      Appendix Table 2 continued…. 
Minor allele 
frequency
SNP Gene/region Chr† Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs10128580 ZBTB16 11 G intronic 0.21 0.09 3.04 (1.61 - 5.74) 6.13 x 10-04 7.0 x 10-4 
rs7243843 DLGAP1 18 T intronic 0.28 0.55 0.51 (0.34 - 0.75) 6.20 x 10-04 8.0 x 10-4 
rs1602491 4q34 4 G intergenic 0.36 0.21 2.24 (1.41 – 3.55) 6.23 x 10-04 7.0 x 10-4 
rs17439813 12p11.2 12 C intergenic 0.44 0.27 2.17 (1.39 - 3.37) 6.23 x 10-04 7.0 x 10-4 
rs9373051 EYA4 6 T intronic 0.25 0.07 3.18 (1.64 - 6.16) 6.26 x 10-04 6.0 x 10-4 
rs309026 12p11.2 12 T intergenic 0.46 0.29 2.07 (1.36 – 3.15) 6.30 x 10-4 1.0 x 10-4 
rs11011225 10p11.2 10 T intergenic 0.07 0.18 0.32 (0.17 - 0.62) 6.62 x 10-4 2.0 x 10-4 
rs12904345 15q26.2 15 C intergenic 0.02 0.24 0.39 (0.23 – 0.67) 6.64 x 10-4 3.0 x 10-4 
rs7700370 ADAMTS12 5 C intronic 0.37 0.21 2.18 (1.39 – 3.40) 6.69 x 10-4 4.0 x 10-4 
rs910850 DOK5 20 G intronic 0.42 0.26 2.08 (1.36 – 3.16) 6.73 x 10-4 4.0 x 10-4 
rs12822012 12q13.1 12 C intergenic 0.09 0.20 0.34 (0.18 – 0.63) 6.81 x 10-4 9.0 x 10-4 
rs7237664 18q11.2 18 T intergenic 0.25 0.54 0.51 (0.34 - 0.75) 6.86 x 10-4 4.0 x 10-4 
rs1821567 C8orf34 8 C intronic 0.31 0.29 2.13 (1.38 - 3.31) 7.07 x 10-4 5.0 x 10-4 
rs1477656 5q21 5 T intergenic 0.23 0.10 2.75 (1.53 – 4.95) 7.09 x 10-4 3.0 x 10-4 
rs7163190 15q14 15 G intergenic 0.20 0.36 0.47 (0.30 – 0.72) 7.12 x 10-4 7.0 x 10-4 
rs11648233 HSD17B2 16 C intronic 0.26 0.44 0.49 (0.32 – 0.74) 7.15 x 10-4 5.0 x 10-4 
      *ORinteraction per allele (ORallele) for the additive model; **P value adjusted for genomic control; ††P value permutation = point wise P value from 
      maxT permutation analysis after   10,000 permutation 
 
         †Chr = Chromosome, SNP = single nucleotide polymorphism
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Appendix Table 3: List of single nucleotide polymorphisms that showed gender-
specific associations based on the P value and were statistically correlated   
Chr A SNP 1 Chr B SNP 2 
2 rs7583193 2 rs17027254 
2 rs6732320 2 rs1899286 
2 rs6732320 2 rs11687208 
2 rs1899286 2 rs11687208 
2 rs563694 2 rs552976 
2 rs17027254 2 rs6732320 
2 rs7583193 2 rs6732320 
2 rs7583193 2 rs1899286 
2 rs17027254 2 rs11687208 
2 rs17027254 2 rs1899286 
2 rs560887 2 rs563694 
2 rs7583193 2 rs11687208 
4 rs13107783 4 rs4470624 
4 rs61748746 4 rs61748749 
4 rs1550017 4 rs12054636 
12 rs17439813 12 rs11049786 
12 rs17439813 12 rs1849374 
12 rs11049786 12 rs1849374 
13 rs4942264 13 rs7322477 
13 rs634413 13 rs6490437 
15 rs4246284 15 rs12904345 
17 rs8081866 17 rs2542653 
17 rs8081866 17 rs2542660 
17 rs8081866 17 rs12948120 
17 rs2542653 17 rs2542660 
17 rs2542653 17 rs12948120 
17 rs2542660 17 rs12948120 
17 rs4794031 17 rs7225787 
17 rs11079867 17 rs7225787 
17 rs4794031 17 rs11079867 
17 rs12940887 17 rs7225787 
17 rs725038 17 rs2542653 
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                         Appendix Table 3 continued…. 
Chr A SNP 1 Chr B SNP 2 
17 rs725038 17 rs2542660 
17 rs4794031 17 rs12940887 
            Chr = chromosome; SNP = single nucleotide polymorphism 
            Note: Chromosome A and Chromosome B are same chromosome. SNP1 and 
                          SNP2 and statistically correlated SNPs  
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Appendix Table 4: List of single nucleotide polymorphisms that showed gender-
specific associations based on effect size and were statistically correlated  
Chr A SNP 1 Chr B SNP 2 
2 rs1049894 2 rs11904365 
4 rs10003958 4 rs9993832 
6 rs130069 6 rs6929434 
6 rs12722039 6 rs12722042 
6 rs17080410 6 rs61742396 
7 rs4496864 7 rs35912436 
7 rs4496864 7 rs2160271 
7 rs35912436 7 rs2160271 
8 rs34265667 8 rs34664882 
8 rs11992342 8 rs36041430 
8 rs36041430 8 rs7829965 
8 rs11992342 8 rs7829965 
9 rs3847262 9 rs2890707 
9 rs4645656 9 rs7848710 
9 rs4645656 9 rs7037100 
9 rs4645656 9 rs6477733 
9 rs7848710 9 rs7037100 
9 rs7848710 9 rs6477733 
9 rs7037100 9 rs6477733 
19 rs16973890 19 rs117923468 
19 rs16973890 19 rs182319278 
19 rs117923468 19 rs182319278 
   Chr = chromosome; SNP = single nucleotide polymorphism 
    Note: Chromosome A and Chromosome B are same chromosome.  
                  SNP1 and SNP2 and statistically correlated SNPs  
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Appendix Table 5: Top one hundred SNPs associated with childhood ALL risk with gender-specificity, results based on the 
highest effect sizes (P <  0.05) 
 
 
Minor allele 
frequency  
SNP Gene/region Chr Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs12722042 HLA-DQA1 6 G coding 0.07 0.005 15.68 (2.03 - 121.2) 0.008 0.001 
rs12722039 HLA-DQA1 6 A coding 0.07 0.005 14.87 (1.94 - 114.0) 0.009 0.002 
rs11992342 ADAM28 8 T intron 0.07 0.005 14.73 (1.92 - 113.9) 0.01 0.001 
rs80040922 UMODL1 21 A coding 0.06 0.005 13.68 (1.77 - 105.6) 0.01 0.004 
rs61753605 LOC100996481 6 C coding 0.06 0.005 13.38 (1.73 - 103.3) 0.01 0.004 
rs35665085 CECR5 22 A coding 0.06 0.005 12.64 (1.63 - 98.00) 0.02 0.006 
rs143021649 CNTN3 3 T coding 0.06 0.005 11.62 (1.49 - 90.58) 0.02 0.009 
rs6795524 PROS1 3 G intron 0.05 0.005 10.63 (1.36 - 83.31) 0.02 0.006 
rs10003468 4q28.1 4 C intergenic 0.05 0.005 10.63 (1.36 - 83.31) 0.02 0.005 
rs10131142 14q11.2 14 A intergenic 0.07 0.01 7.82 (1.76 - 34.78) 0.007 0.002 
rs3732042 CNRIP1 2 A 3utr 0.08 0.01 7.50 (1.71 - 32.96) 0.008 0.002 
rs34022679 GRK4 4 C coding 0.07 0.01 6.98 (1.58 - 30.76) 0.01 0.003 
rs7829965 ADAM28 8 A coding 0.06 0.01 6.77 (1.51 – 30.38) 0.01 0.007 
rs7097067 10q22.1 10 T intergenic 0.06 0.01 6.77 (1.51 – 30.38) 0.01 0.01 
rs35912436 7p21.3 7 C intergenic 0.08 0.01 6.69 (1.54 – 29.00) 0.01 0.003 
rs2160271 7p21.3 7 C intergenic 0.08 0.01 6.69 (1.54 – 29.00) 0.01 0.003 
rs17588454 13q12.3 13 G intergenic 0.07 0.01 6.47 (1.46 - 28.61) 0.01 0.006 
rs368390 C18orf42 18 T intron 0.09 0.02 6.25 (1.80 – 21.76) 0.004 0.001 
rs17080410 PLEKHG1 6 C coding 0.06 0.01 6.25 (1.38 - 28.25) 0.02 0.01 
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Appendix Table 5 continued…. 
 
Minor allele 
frequency  
SNP Gene/region Chr Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs61742396 PLEKHG1 6 A coding 0.06 0.01 6.25 (1.38 - 28.25) 0.02 0.01 
rs35672330 EXO5 1 C coding 0.06 0.01 5.98 (1.35 - 26.50) 0.02 0.01 
rs1503292 TLL1 4 C intron 0.06 0.01 5.97 (1.35 - 26.47) 0.02 0.01 
rs1978526 2q24.3 2 G intergenic 0.06 0.01 5.91 (1.33 - 26.19) 0.02 0.01 
rs6887604 5q12.3 5 T intergenic 0.06 0.01 5.75 (1.26 - 26.16) 0.02 0.01 
rs10063286 5q35.2 5 G intergenic 0.06 0.01 5.75 (1.26 - 26.16) 0.02 0.01 
rs16879126 NT5C3A 7 C intron 0.06 0.01 5.75 (1.26 - 26.16) 0.02 0.009 
rs34265667 ANK1 8 A coding 0.06 0.01 5.75 (1.26 - 26.16) 0.02 0.009 
rs34664882 ANK1 8 A coding 0.06 0.01 5.75 (1.26 - 26.16) 0.02 0.009 
rs61731389 PCDH15 10 C coding 0.06 0.01 5.75 (1.26 - 26.16) 0.02 0.01 
rs4764332 12p13.2 12 T intergenic 0.06 0.01 5.75 (1.26 - 26.16) 0.02 0.01 
rs4496864 7p21.3 7 T intergenic 0.07 0.01 5.72 (1.32 - 24.80) 0.02 0.01 
rs6936494 6q15 6 T intergenic 0.11 0.02 5.67 (1.91 - 16.83) 0.002 7.5 x 10-4 
rs3847262 TPD52L3 9 T coding 0.06 0.01 5.49 (1.24 - 24.43) 0.03 0.009 
rs2890707 TPD52L3 9 A 3utr 0.06 0.01 5.49 (1.24 - 24.43) 0.03 0.009 
rs7626907 3p24.3 3 A intergenic 0.10 0.02 5.37 (1.81 - 15.99) 0.003 0.001 
rs2229528 ACAA1 3 G coding 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.02 
rs9842465 SCHIP1 3 T intron 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs6796558 3q28 3 A intergenic 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.02 
rs55882716 MAST4 5 T coding 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs1030270 CYFIP2 5 A intron 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
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Appendix Table 5 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs205944 SLC35F1 6 A intron 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.02 
rs381783 IL20RA 6 T intron 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs11980237 KDELR2 7 A intron 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs720872 7p21.2 7 C intergenic 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs147596194 RGS3 9 T intron 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs61745456 MAMDC4 9 T coding 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs117923468 WDR87 19 A coding 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs182319278 WDR87 19 C coding 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs9305777 21q21.1 21 T intergenic 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.02 
rs8129749 21q21.2 21 T intergenic 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs985456 21q21.3 21 C intergenic 0.05 0.01 5.26 (1.15 - 24.11) 0.03 0.01 
rs16863233 LPP 3 C intron 0.07 0.02 5.16 (1.46 - 18.18) 0.01 0.008 
rs7037100 ZNF782 9 C intron 0.07 0.02 5.16 (1.46 - 18.18) 0.01 0.008 
rs7630157 EGFEM1P 3 C intron 0.06 0.01 5.07 (1.14 - 22.62) 0.03 0.01 
rs62640905 OSGIN1 16 C coding 0.06 0.01 5.02 (1.13 - 22.40) 0.03 0.01 
rs16973890 ZNF571/ZNF540 19 C intron 0.06 0.01 5.02 (1.13 - 22.40) 0.03 0.01 
rs35693261 MTG2 20 T coding 0.06 0.01 5.02 (1.13 - 22.40) 0.03 0.01 
rs7539097 TNR 1 G intron 0.08 0.02 5.00 (1.44 - 17.32) 0.01 0.005 
rs9493135 6q23.2 6 A intergenic 0.08 0.01 4.94 (1.43 - 17.14) 0.01 0.005 
rs6722598 MFF 2 A 5upstream 0.09 0.02 4.92 (1.63 - 14.89) 0.005 0.002 
rs1049894 PSME4 2 T coding 0.07 0.02 4.81 (1.36 - 17.03) 0.02 0.01 
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Appendix Table 5 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs11904365 2p16.2 2 C intergenic 0.07 0.02 4.81 (1.36 - 17.03) 0.02 0.009 
rs10003958 RAB28 4 C intron 0.07 0.02 4.81 (1.36 - 17.03) 0.02 0.01 
rs9993832 RAB28 4 T intron 0.07 0.02 4.81 (1.36 - 17.03) 0.02 0.01 
rs36041430 ADAM28 8 A coding 0.07 0.02 4.81 (1.36 - 17.03) 0.02 0.01 
rs78888579 CROCC 1 A coding 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.01 
rs10218650 1q31.3 1 T intergenic 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.04 
rs13405142 2p22.1 2 T intergenic 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.03 
rs10194197 2p12 2 T intergenic 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.04 
rs61741435 CCDC173 2 T coding 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.02 
rs4856270 CADM2 3 T intron 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.02 
rs2165084 4q31.3 4 G intergenic 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.02 
rs7703414 5p13.1 5 A intergenic 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.03 
rs11751765 TRERF1 6 T coding 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.04 
rs7797334 7p21.2 7 C intergenic 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.02 
rs4278110 7p12.2 7 A intergenic 0.05 0.02 4.77 (1.03 - 22.10) 0.05 0.03 
rs11987106 COLEC10 8 A intron 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.03 
rs61735202 CCIN 9 A coding 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.04 
rs943811 10q26.2 10 A intergenic 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.03 
rs10430621 10q26.3 10 C intergenic 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.04 
rs11182332 TMEM117 12 A intron 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.04 
rs2293624 C12orf73 12 A coding 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.04 
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Appendix Table 5 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature Males Females ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs4770684 PARP4 13 A coding 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.03 
rs7182827 UBE3A 15 C intron 0.05 0.01 4.77 (1.03 - 22.10) 0.05 0.04 
rs12621721 MAP3K19 2 A intron 0.05 0.01 4.72 (1.02 - 21.86) 0.05 0.03 
rs7275217 21q22.1 21 G intergenic 0.05 0.01 4.72 (1.02 - 21.86) 0.05 0.03 
rs41299607 RGSL1 1 A coding 0.05 0.01 4.56 (1.02 - 20.41) 0.05 0.03 
rs9282777 LMO2 11 A coding 0.05 0.01 4.56 (1.02 - 20.41) 0.05 0.02 
rs10520291 2p12 2 A intergenic 0.08 0.02 4.52 (1.33 - 15.39) 0.02 0.009 
rs12037891 PDE4B 1 A intron 0.06 0.02 4.46 (1.25 – 15.91) 0.02 0.02 
rs73022563 PLEKHG4B 5 T coding 0.06 0.02 4.46 (1.25 – 15.91) 0.02 0.02 
rs130069 CCHCR1 6 T coding 0.06 0.02 4.46 (1.25 – 15.91) 0.02 0.02 
rs6929434 TCF19 6 A 5upstream 0.06 0.02 4.46 (1.25 – 15.91) 0.02 0.02 
rs10975823 KDM4C 9 C intron 0.06 0.02 4.46 (1.25 – 15.91) 0.02 0.02 
rs4645656 ZNF782 9 T coding 0.06 0.02 4.46 (1.25 – 15.91) 0.02 0.02 
rs7848710 ZNF782 9 T intron 0.06 0.02 4.46 (1.25 – 15.91) 0.02 0.02 
rs6477733 ZNF782 9 G intron 0.06 0.02 4.46 (1.25 – 15.91) 0.02 0.02 
rs17000817 21q21.2 21 C intergenic 0.08 0.02 4.45 (1.46 - 13.59) 0.009 0.004 
rs2633820 SUMF1 3 A intron 0.08 0.02 4.39 (1.32 - 14.63) 0.02 0.007 
rs9469223 6p24 6 G intergenic 0.08 0.02 4.39 (1.32 - 14.63) 0.02 0.007 
*ORinteraction per allele (ORallele) for the additive model; **P value adjusted for genomic control; ††P value permutation = point wise P value from maxT 
permutation analysis after 10,000 permutation 
 
 Chr = Chromosome, SNP = single nucleotide polymorphism  
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Appendix Table 6: Bioinformatic analysis of genetic risk markers for the top one hundred gender-specific associations, results 
based on the lowest P values  
 
SNP Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNPs) 
rs4813720 20 NS 0.18 RASSF2  rs3215695 2b RASSF2 
rs231237 19 2b 0.12 HSPB6 . . . 
rs7323018 13 5 NS  LACC1-SMIM2 . . . 
rs17027254 2 6 NS HNRNPA1P57-LDHAL3 . . . 
rs7912381 2 NS 0.1   TCERG1L-PPP2R2D . . . 
rs11687208 2 NS 0.1 HNRNPA1P57-LDHAL3 rs1899286 3a HNRNPA1P57-LDHAL3 
rs798292 7 6 NS MAGI2 . . . 
rs13107783 4 6 0.1 RPL21P46-SLIT2 rs1905844 2b RPL21P46-SLIT2 
rs4470624 6 6 0.1 RPL21P46-SLIT2 rs1905844 2b RPL21P46-SLIT2 
rs1849374 12 6 NS CCDC91- FAR2 . . . 
rs12948120 17 6 0.21 ACACA rs9330250 2b ACACA 
rs6904762 6 5 NS  TMEM244-L3MBTL3 . . . 
rs506389 8 NS NS   ZNF706-DUXAP2 . . . 
rs6732320 2 6 NS HNRNPA1P57-LDHAL3 rs1899286 3a HNRNPA1P57-LDHAL3 
rs8081866 17 4 0.21 ACACA rs9330250 2b ACACA 
rs349714 3 5 0.1  SLC6A1-HRH1 rs13317174 2b  SLC6A1-HRH1 
rs7583193 2 NS NS HNRNPA1P57-LDHAL3 . . . 
rs206457 18 6 NS   VAPA-APCDD1 . . . 
rs7723568 5 5 NS  IRX1-LOC101929153 . . . 
rs2542660 17 5 0.18 ACACA rs9330250 2b ACACA 
rs37389 5 NS 0.27 PRLR . . . 
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     Appendix Table 6 continued…. 
SNP Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNPs) 
rs1899286 2 3a 0.1 HNRNPA1P57-LDHAL3 . . . 
rs9563035 13 NS NS    LINC00371-FAM124A . . . 
rs2542653 17 NS 0 ACACA rs4299194  2b            ACACA 
rs2542653 17 NS 0 ACACA rs9330250 2b ACACA 
rs6490437 13 6 NS  LINC00544-LINC00384 rs7334559 2b  LINC00544-LINC00384 
rs4794031 17 5 0.5  PHOSPHO1-ZNF652 . . . 
rs2544371 2 6 NS LRP2-BBS5 . . . 
rs1372166 2 NS 0.1 HNRNPA1P57-LDHAL3 . . . 
rs7294845 12 5 NS SOX5 rs11047322  3a            SOX5 
rs7294845 12 5 NS SOX5 rs11047322  3a            SOX5 
rs12219278 10 5 NS   TCERG1L-BNIP3 . . . 
rs4942264 13 NS NS    DGKZP1-LINC00284 rs4418956 2b LINC00284 
rs11708505 3 5 0.1 RYBP-SHQ1 rs11708482 2b RYBP-SHQ1 
rs6540610 1 NS 0.1 HHAT . . . 
rs2764928 1 NS 0.1   LINC01135-PHBP3 rs7555848 3a   LINC01135-PHBP3 
rs1550017 4 6 NS GRIA2-LOC340017 rs7694905 3a GRIA2-LOC340017 
rs12054636 4 NS NS GRIA2-LOC340017 rs7694905 3a GRIA2-LOC340017 
rs2764933 1 5 NS   LINC01135-PHBP3 . . . 
rs468771 21 NS NS GRIK1 . . . 
rs864674 5 5 0.1 SUB1-NPR3 . . . 
rs8106959 19 1f NS KMT2B  rs10413852   1f UPK1A 
rs8106959 19 1f NS KMT2B rs12461333    1f            UPK1A-ZBTB32         
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     Appendix Table 6 continued…. 
SNP Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNPs) 
rs8106959 19 1f NS KMT2B   rs12461285    1f            UPK1A-ZBTB32         
rs8106959 19 1f NS KMT2B rs3848662 1f            KMT2B 
rs9561489 13 NS NS GPC6 rs9556347 3a GPC6 
rs4934956 10 5 NS   CICP9-ABCD1P2 . . . 
rs9897342 17 2b 0.5   MYO18A-TWF1P1 rs7225149 2a MYO18A 
rs756134 1 4 NS ALX3-UBL4B . . . 
rs4926465 1 6 NS KIF28P rs7520180 3a KIF28P 
rs552976 2 3a 0.27 ABCB11 . . . 
rs563694 2 NS 0.1 G6PC2-ABCB11 rs566879 3a ABCB11 
rs1529186 3 4 0.1 LOC100422385-
LOC440973 
rs62281690 3a LOC100422385-
LOC440973 
rs11049786 12 6 NS   CCDC91-FAR2 . . . 
rs9510793 13 6 NS TNFRSF19 . . . 
rs61748746* 4 6 NS N4BP2 . . . 
rs2874641 17 5 NS SHISA6 . . . 
rs560887 2 NS NS G6PC2 . . . 
rs7025331 9 4 NS SMARCA2-  
LOC102723835 
. . . 
rs7917910 10 NS NS C10orf90-DOCK1 . . . 
rs349707 3 6 NS  SLC6A1-HRH1 . . . 
rs61748749* 4 2b NS N4BP2 . . . 
rs9873177 3 5 0.1 PDIA5 . . . 
rs739924 17 1f 1 SPATA20 rs9913430 1a SPATA20 
rs12505859 4 NS 0.5 ICE2P1-LINC01060 . . . 
170 
 
      Appendix Table 6 continued…. 
SNP Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNPs) 
rs7322477 13 NS 0 LINC00284 rs4418956 2b LINC00284 
rs1978759 10 4 NS MGMT rs1978756 2b MGMT 
rs725038 17 6 0.21 ACACA . . . 
rs729867 2 6 0.1 CSRNP3 . . . 
rs4875742 8 6 NS CSMD1 . . . 
rs1720326 11 4 NS SCN3B-ZNF202 rs1275051 1f SCN3B-ZNF202 
rs1713676 11 5 NS   LOC390251-USP28 rs11214739 3a  USP28 
rs3857193 4 3a NS SORCS2 . . . 
rs6987111 8 6 NS CCDC25 rs9314355 1d            LOC100130612-
SCARA5     
rs6987111 8 6 NS CCDC25 rs17057911 1f             PBK                  
rs6987111 8 6 NS CCDC25 rs17057863 1f ESCO2  
rs4801931 19 5 NS ZNF611 . . . 
rs12940887 17 NS NS ZNF652 rs16948048 3a  ZNF652 
rs7225787 17 NS NS ZNF652 . . . 
rs11079867 17 NS NS FLJ40194-ZNF652 rs2011767 2a FLJ40194-ZNF652 
rs4680582 3 6 0.1 SMC4 rs73155903 2b TRIM59 
rs1429143 6 NS NS ELOVL5-NANOGP3 . . . 
rs10506041 12 NS NS LOC101928705-FAR2 . . . 
rs1915337 3 NS NS   LOC100422385-
LOC440973 
. . . 
rs6962352 7 5 0.18 HIP1 . . . 
rs634413 13 5 NS LINC00544 rs4769779 3a  LINC00544 
rs4074605 17 4 NS SYNRG   rs7224979  1d            SYNRG                 
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      Appendix Table 6 continued…. 
SNP Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNPs) 
rs4074605 17 4 NS SYNRG   rs3110626  1f            SYNRG                 
rs4074605 17 4 NS SYNRG   rs6607279    1f            SYNRG                 
rs4074605 17 4 NS SYNRG    rs8080313 1f SYNRG 
rs7407281 18 NS NS  LOC100128022- 
NFE2L3P1 
. . . 
rs10778311 12 5 NS TXNRD1 rs7138523  3a            TXNRD1               
rs10778311 12 5 NS TXNRD1 rs4329742  3a            TXNRD1               
rs10778311 12 5 NS TXNRD1  rs4569072  3a            TXNRD1               
rs7492685 14 6 NS  RPL18P1-ATP5GP2 . . . 
rs4246284 15 6 NS RPL31P55-FAM149B1P1 rs12898262 3a 
RPL31P55-
FAM149B1P1 
rs10128580 11 5 0 ZBTB16 . . . 
rs7243843 18 5 0.55 DLGAP1 rs7228679 2b DLGAP1 
rs1602491 4 5 0.1  ADAM29-LOC100129957 
. . . 
rs17439813 12 NS NS  LOC101928705- FAR2 . . . 
rs9373051 6 6 NS EYA4 . . . 
rs309026 12 5 NS  LOC101928705- FAR2 . . . 
rs11011225 10 5 NS TMEM161BP1-TACC1P1 
. . . 
rs12904345 15 NS NS RPL31P55-FAM149B1P1 rs12898262 3a 
RPL31P55-
FAM149B1P1 
rs7700370 5 6 0.1 ADAMTS12 . . . 
rs910850 20 5 NS DOK5 . . . 
rs12822012 12 NS NS  RPL13AP21- SLC38A1 . . . 
rs7237664 18 5 NS CDH2-ARIH2P . . . 
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     Appendix Table 6 continued…. 
SNP Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNPs) 
rs1821567 8 NS NS C8orf34 . . . 
rs1477656 5 6 0.24  LOC285706-EEF1A1P20 . . . 
rs7163190 15 NS NS GOLGA8B-GJD2 . . . 
rs11648233 16 6 0.5 HSD17B2 . . . 
 Note: Some associated SNPs showed multiple statistically correlated functional variants   
 Chr = Chromosome; NS = No score; SNP = single nucleotide polymorphism; *Missense; ††SNPs change or create a binding site for transcription 
factors 
 
 †RegulomDb predicts score from 1 to 7.  A score of one suggests SNPs have higher functionality and may play an important role in gene regulation A 
score of 7 predicts least functionality 
 
     **F-SNP predicts score from 0 to 1. A score of one suggest higher functionality and a score zero suggests no functional role of a SNP
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Appendix Table 7: Bioinformatic analysis of genetic risk markers for the top one hundred gender-specific associations with 
childhood ALL with the highest effect sizes (P < 0.05) 
 
SNP Chr Feature RegulomeDB Score† F-SNP
** Gene/region Correlated SNP 
RegulomeDB 
score† 
Gene               
(Correlated SNPs) 
rs12722042* 6 coding 4 0.75 HLA-DQA1 rs28619112 3a HLA-DQA1 
rs12722039* 6 coding 4 0.41 HLA-DQA1 rs28619112 3a HLA-DQA1 
rs11992342 8 intron 6 0.5 ADAM28 . . . 
rs80040922* 21 coding NS NS UMODL . . . 
rs61753605 6 coding 5 NS LOC100996481 . . . 
rs35665085* 22 coding 6 0 CECR5 . . . 
rs143021649* 3 coding NS NS CNTN3 . . . 
rs6795524 3 intron 5 0.26 PROS1 rs76514818 3a ARL13B 
rs10003468 4 intergenic NS 0.1 FAT4-NUPL1P1 . . . 
rs10131142 14 intergenic NS 0.5 EDDM3A-EDDM3B . . . 
rs3732042 2 3utr 6 0.24 CNRIP1 rs73935338 2b PPP3R1- CNRIP1 
rs34022679* 4 coding 5 0.1 GRK4 . . . 
rs7829965* 8 coding 2b 0.5 ADAM28 . . . 
rs7097067 10 intergenic 6 0.5 PPA1-NPFFR1 rs60660561 2b PPA1 
rs7097067 10 intergenic 6 0.5 PPA1-NPFFR1 rs56938544 2b NPFFR1 
rs35912436 7 intergenic 6 NS TMEM106B-VWDE rs2192840 2b TMEM106B-VWDE 
rs2160271 7 intergenic NS NS TMEM106B-VWDE rs2192840 2b TMEM106B-VWDE 
rs17588454 13 intergenic 5 NS LINC00544- LINC00384 rs4534683 2b 
LINC00544-
LINC00384 
rs368390 18 intron 6 0.5 C18orf42 . . . 
rs17080410* 6 coding 5 0 PLEKHG1 . . . 
rs61742396* 6 coding 5 NS PLEKHG1 rs57264696 2a PLEKHG1- MTHFD1L 
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Appendix Table 7 continued…. 
SNP Chr Feature RegulomeDB Score† F-SNP
** Gene/region Correlated SNP 
RegulomeDB 
score† 
Gene               
(Correlated SNPs) 
rs35672330* 1 coding 5 0 EXO5 . . . 
rs1503292 4 intron 6 NS TLL1 . . . 
rs1978526 2 intergenic 6 NS KCNH7-  RPL7P61 rs72623141 3a KCNH7-RPL7P61 
rs6887604 5 intergenic 6 NS CD180- LOC101928819 rs78308574 3a 
CD180- 
LOC101928819 
rs10063286 5 intergenic NS 0.1 DRD1-SFXN1 rs201488474 3a DRD1-SFXN1 
rs16879126 4 intron 4 NS NT5C3 rs72555715 2c NT5C3A 
rs34265667 8 coding 5 0.14 ANK1 . . . 
rs34664882* 8 coding 5 0 ANK1 . . . 
rs61731389* 10 coding 6 NS PCDH15 rs72797047 3a PCDH15 
rs4764332 12 intergenic NS NS GABARAPL1- KLRD1 rs73060081 2b 
GABARAPL1- 
KLRD1 
rs4496864 7 intergenic NS NS TMEM106B-VWDE rs2192840 2b TMEM106B-VWDE 
rs6936494 6 intergenic NS NS ACTBP8-  LOC101928936 . . . 
rs3847262 9 coding NS 0.87 TPD52L3 rs10758768 2a TPD52L3-UHRF2 
rs2890707 9 3utr 2b NS TPD52L3 rs10758768 2a TPD52L3-UHRF2 
rs7626907 3 intergenic NS NS KCNH8-EFHB . . . 
rs2229528 3 coding 2b NS ACAA1 . . . 
rs9842465 3 intron NS 0.24 SCHIP1 rs13434009 3a SCHIP1 
rs6796558 3 intergenic 6 0.1 PYDC2-FGF12 . . . 
rs55882716* 5 coding 5 NS MAST4 . . . 
rs1030270 5 intron NS NS CYFIP2 rs61088678 3a CYFIP2 
rs205944 6 intron NS NS SLC35F1 . . . 
rs381783 6 intron NS NS IL20RA rs276497 2b IL20RA 
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Appendix Table 7 continued…. 
SNP Chr Feature RegulomeDB Score† F-SNP
** Gene/region Correlated SNP 
RegulomeDB 
score† 
Gene               
(Correlated SNPs) 
rs381783 6 intron NS NS IL20RA rs276498 2b IL20RA 
rs381783 6 intron NS NS IL20RA rs276499 2b IL20RA 
rs11980237 7 intron NS 0 KDELR2 . . . 
rs720872 7 intergenic NS NS DGKB-AGMO rs218078 3a DGKB-AGMO 
rs147596194* 9 intron 4 NS RGS3 rs118167986 2b RGS3 
rs147596194* 9 intron 4 NS RGS3 rs76385691 2b RGS3 
rs147596194* 9 intron 4 NS RGS3 rs117507747 2b RGS3 
rs147596194* 9 intron 4 NS RGS3 rs113069800 2b RGS3 
rs147596194* 9 intron 4 NS RGS3 rs150767530 2b RGS3-LOC100288542 
rs61745456* 9 coding 5 NS MAMDC4 . . . 
rs117923468* 19 coding NS NS WDR87 . . . 
rs182319278* 19 coding NS NS WDR87 . . . 
rs9305777 5 intergenic 5 NS MIR99AHG-NEK4P1 . . . 
rs8129749 21 intergenic NS NS LOC339622-RNA5SP489 rs11909912 3a 
LOC339622-
RNA5SP489 
rs985456 21 intergenic 5 NS MARCKSP1-  LOC100996571 rs79015379 3a 
LOC102724317-
CYYR1-AS1 
rs16863233 3 intron NS 0.24 LPP . . . 
rs7037100 9 intron 5 NS ZNF782 rs12349952 1f ZNF510 
rs7630157 3 intron NS 0.1 EGFEM1P . . . 
rs62640905* 16 coding 5 NS OSGIN1 . . . 
rs16973890* 19 intron 4 0.62 ZNF571 . . . 
rs35693261* 20 coding 5 0.1 MTG2 . . . 
rs7539097 1 intron 5 NS TNR rs80216135 3a TNR 
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Appendix Table 7 continued…. 
SNP Chr Feature RegulomeDB Score† F-SNP
** Gene/region Correlated SNP 
RegulomeDB 
score† 
Gene               
(Correlated SNPs) 
rs9493135 6 intergenic 4 NS ENPP1-CTGF rs73779142 3a ENPP1-CTGF 
rs9493135 6 intergenic 4 NS ENPP1-CTGF rs9493137 3a ENPP1-CTGF 
rs9493135 6 intergenic 4 NS ENPP1-CTGF rs57896928 3a ENPP1-CTGF 
rs6722598 2 5upstream 5 0.24 MFF rs138676164 3a LOC654841 
rs6722598 2 5upstream 5 0.24 MFF rs201829089 3a LOC654841 
rs1049894 2 coding NS 0.37 PSME4 rs10180492 3a GPR75-ASB3 
rs1049894 2 coding NS 0.37 PSME4 rs78542544 3a PSME4 
rs11904365 2 intergenic 6 0.1 PSME4-RPL21P30 . . . 
rs10003958 4 intron 5 0.1 RAB28 rs7673680 3b RAB28 
rs9993832 4 intron 5 NS RAB28 rs7673680 3b RAB28 
rs36041430 8 coding NS 0 ADAM28 . . . 
rs78888579* 1 coding 5 NS CROCC rs116314250 2b CROCC 
rs78888579* 1 coding 5 NS CROCC rs140067167 2b CROCC 
rs10218650 1 intergenic NS 0.1 CDC73-KCNT2 . . . 
rs13405142 2 intergenic NS 0.1 HNRNPA1P57-LDHAP3 . . . 
rs10194197 2 intergenic 6 0.1 GCFC2- SUCLA2P2 . . . 
rs61741435* 2 coding 6 NS CCDC173 rs79306213 2b PPIG 
rs4856270 3 intron 5 0.1 CADM2 rs6809486 3a CADM2 
rs2165084 4 intergenic 3a 0.27 KIAA0922-WDR45P rs2118864 2a KIAA0922-WDR45P 
rs7703414 5 intergenic 6 0.1 INTS6P1-LINC00603 . . . 
rs11751765* 6 coding 5 0.9 TRERF1 . . . 
rs7797334 7 intergenic 5 NS LOC101927558-
ISPD 
. . . 
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Appendix Table 7 continued…. 
SNP Chr Feature RegulomeDB Score† F-SNP
** Gene/region Correlated SNP 
RegulomeDB 
score† 
Gene               
(Correlated SNPs) 
rs4278110 7 intergenic 5 NS LOC101927558-ISPD rs6583519 3a 
CDC14C-  
LOC100533714 
rs11987106 8 intron 6 NS COLEC10 . . . 
rs61735202 9 coding 6 NS CCIN . . . 
rs943811 10 intergenic 5 NS LINC01163-MGMT . . . 
rs10430621 10 intergenic 6 NS TCERG1L-PPP2R2D . . . 
rs11182332 12 intron 6 NS TMEM117 . . . 
rs2293624* 12 coding NS 0.37 C12orf73 . . . 
rs4770684* 13 coding NS 0.32 PARP4 . . . 
rs7182827 15 intron 6 NS UBE3A rs74946267 2b UBE3A 
rs12621721 2 intron 6 0.1 MAP3K19/YSK4 rs78265845 2b MAP3K19 
rs7275217 21 intergenic 6 NS KRTAP21-1-KRTAP8 . . . 
rs41299607* 1 coding 6 0.1 RGSL1 . . . 
rs9282777 11 coding 5 0.37 LMO2 . . . 
rs10520291 2 intergenic NS 0.1 CTNNA2-SUCLG1 . . . 
rs12037891 1 intron 6 0.1 PDE4B . . . 
rs73022563* 5 coding 5 NS PLEKHG4B . . . 
rs130069* 6 coding 5 1 CCHCR1 . . . 
rs6929434 6 5upstream 1b 0.5 TCF19 . . . 
rs10975823 9 intron NS 0 KDM4C rs10118219 2a KDM4C 
rs4645656* 9 coding 5 0.5 ZNF782 rs12349952 1f ZNF510 
rs7848710 9 intron NS NS ZNF782 rs12349952 1f ZNF510 
rs6477733 9 intron 5 0.5 ZNF782 rs12349952 1f ZNF510 
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Appendix Table 7 continued…. 
SNP Chr Feature RegulomeDB Score† F-SNP
** Gene/region Correlated SNP 
RegulomeDB 
score† 
Gene               
(Correlated SNPs) 
rs17000817 9 intergenic 5 0.5 RNA5SP489-  
RPL13AP7 
. . . 
rs2633820 3 intron NS 0.1 SUMF1 . . . 
rs9469223 6 intergenic NS NS NEDD9-HIVEP1 rs17608111 3a NEDD9-HIVEP1 
 Note: Some associated SNPs showed multiple statistically correlated functional variants 
Chr = Chromosome; NS = No score; SNP = single nucleotide polymorphisms; *Missense; ††SNPs change or create a binding site for transcription 
factors 
 
†RegulomDb predicts score from 1 to 7.  A score of one suggests SNPs have higher functionality and may play an important role in gene regulation. A 
score of 7 predicts least functionality 
 
 **F-SNP predicts score from 0 to 1. A score of one suggest higher functionality and a score zero suggests no functional role of a SNP
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Appendix Table 8: Expression quantitative trait locus analysis of gender-specific 
associated genetic risk variants 
SNP Chr Feature Gene eQTL 
rs7912381* 2 intergenic   TCERG1L-PPP2R2D FGD6 
rs798292* 7 intronic MAGI2 MYST2, ATAD2B,  EIF1AX 
rs1550017* 4 intergenic GRIA2-LOC340017  FGD6 
rs12054636* 4 intergenic GRIA2-LOC340017  FGD6 
rs560887* 2 intronic G6PC2 P4HA2  
rs739924* 17 intronic SPATA20 SPATA20 
rs725038* 17 intronic ACACA COL9A3 
rs12904345* 15 intergenic RPL31P55-FAM149B1P1 ROPN1, ROPN1B  
rs4299194*  17 intronic ACACA  LOC100131190, MX2, PLSCR1   
rs12461333*   19 intergenic UPK1A-ZBTB32      CANT1, CLPTM1,   
rs9913430* 17 intronic SPATA20 SPATA20 
rs9493135** 6 intergenic  ENPP1-CTGF 
NPAL2, ENOSF1, SMG1, 
PTPN11, ACACA, GALK2, 
LOC440354, LOC595101, 
LOC641298              
        eQTL = expression quantitative trait loci; Chr = chromosome 
 
       *Gender-specific results based on the P value; **Gender-specific results based on the effect sizes 
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Appendix Table 9: Gender- and age-specific single nucleotides polymorphisms and their previous GWAS associations 
SNP Gene Disease/trait Results  PUBMED ID 
rs552976 G6PC2 Glycated hemoglobin levels Gender P value 20858683 
rs563694 G6PC2 Fasting plasma glucose Gender P value 18521185 
rs560887 G6PC2 Glycemic traits (pregnancy) Gender P value 23903356 
rs560887 G6PC2 Metabolite levels Gender P value 22916037 
rs560887 G6PC2 Fasting glucose-related traits (interaction with BMI) Gender P value 22581228 
rs560887 G6PC2 Fasting plasma glucose Gender P value 22508271 
rs560887 G6PC2 Metabolic syndrome Gender P value 22399527 
rs560887 G6PC2 Metabolite levels Gender P value 22286219 
rs560887 G6PC2 Fasting glucose-related traits Gender P value 20081858 
rs560887 G6PC2 Fasting glucose-related traits Gender P value 20081858 
rs560887 G6PC2 Metabolic traits Gender P value 19060910 
rs560887 G6PC2 Fasting plasma glucose Gender P value 19060907 
rs560887 G6PC2 Fasting plasma glucose Gender P value 18451265 
rs12940887 ZNF652 Blood pressure Gender P value 21909110 
rs9305777 intergenic Platelet aggregation Gender OR 17903294 
rs5028798 EHF Volumetric brain MRI Age P value 17903297 
rs4948088 COBL Type 1 diabetes Age P value 19430480 
rs2116078 KCNB2 Multiple sclerosis (age of onset) Age P value 19010793 
rs12188300 IL12B Psoriatic arthritis Age OR 20953186 
rs28421666 intergenic Nasopharyngeal carcinoma Age OR 20512145 
rs7169431 intergenic Chronic lymphocytic leukemia Age OR 23770605 
rs7169431 intergenic Chronic lymphocytic leukemia Age OR 20062064 
 SNP = single nucleotide polymorphism; OR: odds ratio 
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Appendix Table 10: Genes showing gender-specific associations (ranked by their P values) and their interactions 
with chemicals in studies curated in the Comparative Toxicological Database 
Gene/region SNP Chemical interaction PubMed IDs 
RASSF2 rs4813720 
aflatoxin B1, arsenite, benzene, bisphenol A , 
copper sulfate, dust, ethinyl estradiol, 
tetrachlorodibenzodioxin, 4-hydroxy-2-nonenal, 
acetaminophen                                
22100608, 18929588, 19162166, 
12075121,  12075121, 20080153, 
20436886 , 17562736, 19549813, 
17805423  
TCERG1L rs7912381* rs12219278 
arsenite, fonofos, parathion, terbufos,  
pentachlorophenol 
23974009, 22847954, 22847954, 
23724009,   23892564 
PPP2R2D rs7912381* 
benzo(a)pyrene diol epoxide, PCBs, 
acetaminophen, bisphenol A, 
tetrachlorodibenzodioxin, 2,6-dinitrotoluene, 
sodium selenite 
20971185, 19114083, 17562736, 
24534842, 21570461, 21346803, 
18175754 
MAGI2 rs798292 
acetaminophen, aflatoxin B1, arsenite, 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
bisphenol A, PCB, methoxychlor, 
tetrachlorodibenzodioxin, tungsten carbide, 
ammonium chloride, bisphenol A, dibutyl phthalate, 
diethylhexyl phthalate, ammonium chloride 
22230336, 21632981, 22100608, 
23974009, 20106945, 20382639, 
21632981, 21871943,  23359474, 
23303685, 21177773, 24935251, 
20105288, 23829299, 19114083, 
23829299, 16483693, 23359474, 
16483693 
SLIT2 rs13107783* rs4470624* 
aflatoxin B1, asbestos, atrazine, benzo(a)pyrene, 
benzo(a)pyrene diol epoxide, estradiol, bisphenol 
A, estrogens, N-acetyl-4-benzoquinoneimine, 
tetrachlorodibenzodioxin, chlorpyrifos, dibutyl 
phthalate, flusilazole, hexaconazole, nitrofen, 
thiram, 2,6-dinitrotoluene, acetaldehyde, 
ammonium chloride, cyproconazole 
20106945, 17331233, 22378314, 
21871943, 19150397, 19484750, 
22576693, 21233418, 21177773, 
21296121, 17361019, 22634333, 
20406850, 22634333, 16483693, 
22045034 
FAR2 
rs1849374* 
rs17439813 
rs10506041 
arsenite, benzo(a)pyrene, formaldehyde, 
methylmercuric chloride, potassium chromate(VI), 
testosterone, tetrachlorodibenzodioxin, aluminum 
23974009, 20064835, 23649840, 
23179753, 22079256, 21592394, 
21998131,21298039 
TMEM244 rs6904762 air pollutants 21757418 
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ACACA 
rs12948120 
rs8081866 
rs2542660 
rs2542653 
aflatoxin B1, dihydrotestosterone, arsenite, 
benzo(a)pyrene, estradiol, formaldehyde, hydrogen 
peroxide, niclosamide, tetrachlorodibenzodioxin,  
1,4-bis(2-(3,5-dichloropyridyloxy))benzene, 2,4-
dinitrotoluene, 2,6-dinitrotoluene, acetaminophen, 
ammonium chloride, aristolochic acids, atrazine, 
benzene, bisphenol A, bis(tri-n-butyltin)oxide, 
chlorpyrifos, decamethrin, ethanol, ethinyl 
estradiol, flusilazole, insecticides,  
lipopolysaccharides, 2,6-dinitrotoluene, ammonium 
chloride, ethanol, nicotine  
20106945, 18801408, 23974009, 
20106945, 23019147, 23649840, 
21179406, 22576131, 21632981, 
24878338, 21346803, 20406850, 
17562736, 16483693, 21167265, 
24440342, 19483382, 21932408, 
22174045, 21356183, 23401056, 
23692951, 24440342, 22382673, 
23401056, 22025971, 20406850, 
16483693, 23692951, 17635921  
L3MBTL3 rs6904762 potassium chromate(VI), acetaminophen, estradiol, copper sulfate, tetrachlorodibenzodioxin 
22079256, 17562736, 20068009, 
19789285, 21570461 
ZNF706 rs506389* atrazine, benzo(a)pyrene, copper sulfate, bisphenol A 
22378314, 20064835, 19549813, 
24534842 
SLC6A1 rs349714* rs349707* 
aflatoxin B1, estradiol, agrochemicals, herbicides, 
lipopolysaccharides, progesterone, toluene 
20106945, 20106945, 22467014, 
22467014, 21219332, 20631399, 
21827849 
HRH1 rs349714* rs349707* 
PCB, aflatoxin B1, asbestos, benzo(a)pyrene, 
benzo(a)pyrene diol epoxide, lipopolysaccharides, 
particulate matter, vehicle emissions, endosulfan, 
tetrachlorodibenzodioxin 
11238657, 22100608, 22398240, 
20064835, 20382639, 21255012, 
10051702, 10051702, 16263506, 
21570461 
VAPA rs206457 
benzene, acetaminophen, benzo(a)pyrene, bisphenol 
A, dibutyl phthalate, particulate matter, 
tetrachlorodibenzodioxin, vehicle emissions 
19162166, 17562736, 21569818, 
21786754, 17379624, 17295261, 
21570461, 17295261 
APCDD1 rs206457 
benzo(a)pyrene diol epoxide, copper sulfate, 
progesterone, tetrachlorodibenzodioxin, trichostatin 
A, acetaminophen, estradiol, carbon tetrachloride, 
toluene 
20382639, 19549813, 20864642, 
22298810, 24935251, 17562736, 
14664709, 17484886, 22967744  
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PRLR rs37389 
arsenite, azaspiracid, benzo(a)pyrene, estradiol, 
hydrogen peroxide, potassium chromate(VI), 
progesterone, methoxychlor, 2,4-dinitrotoluene, 
PCBs, acetaminophen, aflatoxin B1, benzene, 
bisphenol A, cadmium,  carbon tetrachloride, 
clofibric acid, , cyproconazole, dibutyl phthalate, 
diethylhexyl phthalate, diethylnitrosamine, 
diethylstilbestrol, epoxiconazole, ethinyl estradiol, 
fumonisin B1, lead acetate, 2-methoxyethanol, 
methylmercury II, progesterone, propiconazole, 
sodium arsenite, sulpiride, sumatriptan, 
testosterone, tetrachlorodibenzodioxin, 
trichloroethylene 
23974009, 20547569, 22316170, 
20660070, 18951874, 22079256, 
20660070, 19414516, 21346803, 
19467301, 20959002, 17562736, 
19770486, 17905399, 22349186, 
24067728, 12734012, 17602206, 
19770486, 22334560, 21266533, 
19850644, 22129741, 22349186, 
12655037, 21864555, 23303685, 
21061450, 17905399, 16251485, 
22937105, 18467677, 16107292, 
18162529, 20844152, 21570461, 
17905399 
FAM124A rs9563035 atrazine, benzo(a)pyrene, copper sulfate, bisphenol A, tetrachlorodibenzodioxin 
22378314, 22316170, 19549813, 
19770486 
LRP2 rs2544371 
bisphenol A, ethinyl estradiol, hydrogen peroxide, 
tetrachlorodibenzodioxin, PCB, cycloheximide, 
particulate matter, progesterone, pseudocumene 
20170705, 20170705, 20044591, 
22298810, 23994337, 20576581, 
19176365, 17251523 
BBS5 rs2544371 
copper sulfate, estrogens, acetaminophen, dibutyl 
phthalate, dioxins, furan, progesterone, 
tetrachlorodibenzodioxin 
19549813, 21233418, 17562736, 
21266533, 20463971, 22079235, 
19690047, 21570461 
SOX5 rs7294845 
benzo(a)pyrene,  arsenite, benzo(a)pyrene diol 
epoxide, bisphenol A, copper sulfate, vomitoxin, 
acetaminophen, carbon tetrachloride, bis(2-
ethylhexyl) phthalate, ethinyl estradiol, 
methylmercury, mustard gas, polychlorinated 
biphenyls, potassium dichromate, propiconazole, 
tetrachlorodibenzodioxin, tobacco smoke pollution 
22316170, 23974009, 20382639, 
20170705, 19549813, 23792671, 
17562736, 17484886, 19850644, 
17555576, 20020106, 15674844, 
20020106, 23608068, 21278054, 
21570461, 20133372 
RYBP rs11708505 
acetaminophen, copper sulfate, formaldehyde, 
hydrogen peroxide, benzo(a)pyrene, dibutyl 
phthalate 
21420995, 19549813, 23649840, 
20044591, 20504355, 21266533 
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SHQ1 rs11708505 atrazine, bisphenol A, tetrachlorodibenzodioxin 22378314, 21786754, 21570461 
HHAT rs6540610 
aflatoxin B1, benzo(a)pyrene, copper sulfate,  
formaldehyde, hydrogen peroxide, 
tetrachlorodibenzodioxin  
20106945, 20106945, 21632981, 
20106945, 23649840, 23649840, 
20106945, 21632981 
GRIA2 rs1550017 rs12054636 
arsenite, aflatoxin B1, estradiol, bisphenol A, 
chlorpyrifos, dieldrin, ethanol, lead, progesterone, 
tetrachlorodibenzodioxin, toluene 
23974009, 23630614, 22154832, 
22504913, 11772933, 23719929, 
22154832, 16922920, 21827849 
GRIK1 rs468771 benzo(a)pyrene, tetrachlorodibenzodioxin, ammonium chloride, progesterone  
21802500, 21802500, 16483693, 
19690047 
SUB1 rs864674 
arsenic trioxide, atrazine, formaldehyde, mercury, 
tetrachlorodibenzodioxin, benzo(a)pyrene, 
bisphenol A, dioxins, ethinyl estradiol, fipronil, 
nicotine 
20458559, 22378314, 23649840, 
19937285, 22574217, 22228805, 
21786754, 20463971, 17555576, 
23962444, 17456735 
NPR3 rs864674 
aflatoxin B1, benzo(a)pyrene diol, estradiol, copper 
sulfate, fonofos, parathion, progesterone, smoke, 
terbufos, PCB, acetaminophen, arsenic, 
benzo(a)pyrene, bisphenol A, carbon tetrachloride, 
lipopolysaccharides, nitrofen, ozone, 
tetrachlorodibenzodioxin, tobacco smoke pollution 
22100608, 20382639, 23019147, 
19549813, 22847954, 20864642, 
21095227, 22847954, 24935251, 
17562736, 19654921, 15034205, 
19228888, 17484886, 22128259, 
10898224, 19555225, 15034205, 
20133372 
KMT2B rs8106959 
asbestos, benzene, mercury, 
tetrachlorodibenzodioxin, uranium compounds, 
aflatoxin B1, methylcholanthrene   
17331233, 19162166, 16823088, 
21296121, 19654044, 19770486, 
18804290 
GPC6 rs9561489 
acetaminophen, aflatoxin B1, arsenite, 
benzo(a)pyrene,  benzo(a)pyrene diol, testosterone, 
carbon tetrachloride 
21420995, 20106945, 23974009, 
20106945, 21632981, 20382639, 
20106945, 23300844,  23179753, 
24383497, 24935251, 17484886 
MYO18A rs9897342 
estradiol, bisphenol A, copper sulfate, 
acetaminophen, aflatoxin B1, benzo(a)pyrene, 
carbon tetrachloride, tetrachlorodibenzodioxin 
23019147, 19549813, 17562736, 
19770486, 22228805, 17484886, 
21570461 
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ALX3 rs756134 fonofos, parathion, terbufos 22847954, 22847954, 22847954 
ABCB11 rs552976 rs563694 
acetaminophen, aflatoxin B1, diethylstilbestrol, 
ethinyl estradiol, lipopolysaccharides, progesterone, 
tetrachlorodibenzodioxin, benzo(a)pyrene, carbon 
tetrachloride, potassium dichromate 
21420995,  22100608, 20829430, 
15205115, 24014644, 16837569, 
19770486, 17522070, 23608068 
TNFRSF19 rs9510793 
arsenic, benzo(a)pyrene,  benzo(a)pyrene diol 
epoxide, estradiol,  potassium chromate(VI), 
progesterone, tetrachlorodibenzodioxin, PCB, 
acetaminophen, cyproconazole, epoxiconazole, 
methoxychlor, methylmercuric chloride, DDT, 
propiconazole  
24675094, 20106945, 21632981, 
20382639, 23649840, 22079256, 
20660070, 21632981, 24383497, 
21851831, 17562736, 22334560, 
23970803, 20829426, 20864626, 
18925944, 21278054, 22334560, 
23970803,  
N4BP2 rs61748746 
acetaminophen, aflatoxin B1, benzo(a)pyrene, 
formaldehyde, PCB, bisphenol A, 
tetrachlorodibenzodioxin 
21420995, 20106945, 20106945, 
23649840,  21786754, 21570461 
G6PC2   rs563694 rs560887 cyclophosphamide 15331540 
SMARCA2 rs7025331 
acetaminophen, arsenic trioxide, benzo(a)pyrene, 
copper sulfate, potassium chromate(VI), PCB, 
bisphenol A, dibutyl phthalate, ethinyl estradiol, 
pentachlorophenol, tetrachlorodibenzodioxin 
21420995, 20458559, 20106945, 
19549813, 22079256, 19114083, 
23359474, 23359474, 17942748, 
24642059, 17942748 
DOCK1 rs7917910 
acetaminophen, aflatoxin B1, atrazine, 
benzo(a)pyrene, copper sulfate, dibutyl phthalate, 
lead acetate, methylmercuric chloride, progesterone, 
sodium arsenite, tetrachlorodibenzodioxin  
17562736, 21641981, 22378314, 
22316170, 19549813, 21266533, 
20542052, 23103053, 19690047, 
21297353, 21570461 
PDIA5 rs9873177 
acetaminophen, atrazine, diazinon, benzo(a)pyrene, 
bisphenol A, clofibric acid, diethylhexyl phthalate, 
pentachlorophenol, propiconazole, 
tetrachlorodibenzodioxin 
21420995, 22378314, 22964155, 
23179753, 24383497, 19770486, 
21786754, 21318169, 21278054, 
18495758 
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SPATA20 rs739924 
arsenic trioxide, benzo(a)pyrene, benzo(a)pyrene 
diol epoxide,  cadmium, copper sulfate, 
tetrachlorodibenzodioxin, bisphenol A, 
chlorpyrifos, progesterone 
20707922, 21632981, 19150397, 
24376830, 19549813, 20106945, 
21632981, 24586524, 21356183, 
23012394 
MGMT rs1978759 
aflatoxin B1, benzo(a)pyrene, ethylene dibromide, 
dust, fonofos, parathion, polycyclic aromatic 
hydrocarbon, acetaminophen, ammonium chloride, 
arsenite, estradiol, bisphenol A, carbon 
tetrachloride, diethylstilbestrol, furan, 
methylnitrosourea, ozone, praziquantel, sodium 
arsenite, tetrachlorodibenzodioxin    
20106945, 20064835, 12151404, 
17805423, 8823159, 23543013, 
12883083, 16483693, 18929588, 
20965277, 20965277, 17484886, 
15890375, 22507866, 20965277, 
23358140, 18636392, 15890375, 
21813463, 11241755, 21215274 
CSRNP3 rs729867 PCB, dibutyl phthalate 19114083, 21266533 
CSMD1 rs4875742 aflatoxin B1, tetrachlorodibenzodioxin 23630614, 21570461  
SCN3B rs1720326 
aflatoxin B1, methylcholanthrene, PCB, arsenic, 
benzo(a)pyrene, estradiol, bisphenol A, carbon 
tetrachloride, cyfluthrin, cypermethrin, dibutyl 
phthalate, fenvalerate, nitrofen, Ozone 
20106945, 20348232, 19114083, 
19654921, 21569818, 23557687, 
23359474, 12629582, 18538810, 
18538810, 23359474, 18538810, 
20638522, 17095637 
ZNF202 rs1720326 estradiol, formaldehyde 20106945, 20655997 
SORCS2 rs3857193 
aflatoxin B1, benzo(a)pyrene,  formaldehyde, 
hydrogen peroxide, tetrachlorodibenzodioxin, 
tobacco smoke pollution 
22100608, 21871943, 23649840, 
20044591,   24383497, 19933214, 
20133372 
CCDC25 rs6987111 
copper sulfate, acetaminophen, benzo(a)pyrene, 
bisphenol A, dibutyl phthalate, testosterone, 
tetrachlorodibenzodioxin 
19549813, 17562736, 22228805, 
21786754, 21266533, 20844152, 
21570461 
ZNF611 rs4801931 formaldehyde, smoke 23649840, 21095227 
ZNF652 
rs12940887 
rs7225787 
rs4794031 
rs11079867 
acetaminophen, aflatoxin B1, benzo(a)pyrene, 
benzo(a)pyrene diol epoxide, estradiol, copper 
sulfate, formaldehyde, hydrogen peroxide, 
progesterone, tetrachlorodibenzodioxin, dibutyl 
phthalate 
21420995, 22100608, 22316170, 
20018196, 17404688, 19549813, 
20655997, 23649840,  23649840, 
17404688, 20106945, 21632981, 
23179753, 21266533 
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SMC4 rs4680582 
acetaminophen, aflatoxin B1, arsenic trioxide, 
benzene, benzo(a)pyrene diol epoxide, estradiol, 
bisphenol A, hydrogen peroxide, mercury, 
polychlorinated biphenyls, progesterone, 
testosterone, tetrachlorodibenzodioxin 
22230336, 20106945, 17547211, 
19162166, 19150397, 20018196, 
20382639, 16474171, 19167446, 
23410634, 17547211, 23649840, 
16474171, 21795739, 18691609 
HIP1 rs6962352 
acetaminophen, benzo(a)pyrene, copper sulfate, 
potassium chromate(VI), tetrachlorodibenzodioxin,  
dibutyl phthalate, ethinyl estradiol,  
21420995, 20106945, 19549813, 
22079256,  21934132, 21266533, 
20227414 
SYNRG rs4074605 formaldehyde, acetaminophen, chlorpyrifos, tetrachlorodibenzodioxin 
20655997, 17562736, 18668222, 
21570461 
TXNRD1 rs10778311 
acetaminophen,  arsenic trioxide, arsenite, asbestos, 
benzo(a)pyrene,  benzo(a)pyrene diol epoxide, 
estradiol, caffeine, chlorobenzene, chloropicrin, 
copper sulfate, cupric chloride, cycloheximide, 
cylindrospermopsin, diquat, epichlorohydrin, 
glycidamide, hydrogen peroxide, hydroquinone, 
mercuric chloride, mercury, methylmercuric 
chloride, tetrachlorodibenzodioxin, tobacco smoke 
pollution 
21420995, 17640917, 18550526, 
18687144, 20106945, 21632981, 
22316170, 19150397, 23665804, 
18444173, 19800902, 19549813, 
21172416, 24211530, 17822822, 
18951874, 15452088, 24816296, 
17547211, 24816296, 22298810 
ZBTB16 rs10128580 
acetaminophen, estradiol, mercury, progesterone, 
arsenic, chlorpyrifos, cyproconazole, flusilazole, 
hexaconazole, mercuric chloride, ozone, 
progesterone, propiconazole, sodium arsenite, 
tetrachlorodibenzodioxin, tobacco smoke pollution 
22230336, 17404688, 19937285, 
17404688,  19654921, 20350560, 
22045034, 20353558, 17460151, 
17251523, 21278054, 17682005, 
20055451, 20133372 
DLGAP1 rs7243843 
aflatoxin B1, formaldehyde, 
tetrachlorodibenzodioxin,  bisphenol A, dibutyl 
phthalate, environmental pollutants, progesterone 
22100608, 23649840, 21296121, 
24820113, 21266533, 20064776, 
22238285 
EYA4 rs9373051 
benzo(a)pyrene diol epoxide, estradiol, bisphenol 
A, lead acetate, tetrachlorodibenzodioxin, tobacco 
smoke pollution 
19150397, 23179753, 24383497, 
23557687, 21786754, 22641619, 
19933214, 20133372 
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ADAMTS12 rs7700370 acetaminophen, smoke, benzo(a)pyrene, carbon tetrachloride 
22230336, 21095227, 24935251, 
20713471, 17484886 
DOK5 rs910850 arsenic trioxide, arsenite, PCB, benzo(a)pyrene, dibutyl phthalate, potassium chromate(VI) 
20458559, 23974009, 24383497, 
24935251, 23829299, 14625279, 
21266533, 14625279 
SLC38A1 rs12822012 
acetaminophen, atrazine, benzo(a)pyrene, 
benzo(a)pyrene diol epoxide, copper sulfate, DDT,  
chlorpyrifos, heptachlor, lipopolysaccharides, 
progesterone, tetrachlorodibenzodioxin 
21420995, 22378314, 20064835, 
20382639, 19549813, 18204070, 
18668222, 23153324, 21645290, 
20726854, 19770486,  
CDH2 rs7237664 
arsenite, benzo(a)pyrene, benzo(a)pyrene diol 
epoxide, DDT, estrogens, hydrogen peroxide, 
acetaminophen, aflatoxin B1, agrochemicals, 
bisphenol A, dibutyl phthalate, herbicides, mercuric 
chloride, methylcholanthrene, pentachlorophenol, 
progesterone, tetrachlorodibenzodioxin, tobacco 
smoke pollution 
23974009, 17690111, 19150397, 
24820114, 15473135, 12419474, 
17562736, 19770486, 22467014, 
21786754, 21266533, 22467014, 
21126564, 21163286, 17556502, 
24680724, 20133372 
GOLGA8B rs7163190 DDT, hydrogen peroxide 25014179, 21179406 
GJD2 rs7163190 tetrachlorodibenzodioxin 20055451 
HSD17B2 rs11648233 
acetaminophen, aflatoxin B1, arsenic trioxide, 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
estradiol, copper sulfate, hydrogen peroxide, 
progesterone, testosterone, 
tetrachlorodibenzodioxin, atrazine, bisphenol A, 
carbon tetrachloride, hexachlorobenzene, mercuric 
chloride, methoxychlor 
21420995, 20106945, 17547211, 
20106945, 20382639, 21972996, 
19549813, 20044591, 20660070, 
16054388, 22298810, 16249480, 
22285353, 22285353, 16239168, 
15159207, 16507785, 22285353 
SNP = single nucleotide polymorphism  
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HLA-DQA1 rs12722042 rs12722039  
PCB, arsenic, benzene, lipopolysaccharides, 
mercury, progesterone, aluminum 
20638727, 18414638, 16188091, 
22235868, 19690047, 21298039 
ADAM28 
rs11992342 
rs7829965 
rs36041430 
benzo(a)pyrene, estradiol, progesterone, 
tetrachlorodibenzodioxin, bisphenol A 
22316170, 20660070, 20660070, 
22298810, 24935251, 24586524 
UMODL1 rs80040922 tetrachlorodibenzodioxin, vehicle emissions 21570461, 23940539 
CECR5 rs35665085 acetaminophen,  2,4-dinitrotoluene 21420995, 21346803 
CNTN3 rs143021649 
acetaminophen, aflatoxin B1,  benzo(a)pyrene diol 
epoxide, progesterone, trichostatin A, PCB, 
ammonium chloride, ethinyl estradiol 
21420995, 22100608, 20382639, 
21795739, 24935251, 23179753, 
19114083, 16483693, 17557909 
PROS1 rs6795524 
acetaminophen, benzo(a)pyrene diol, estradiol, 
copper sulfate, particulate matter, PCBs, 
tetrachlorodibenzodioxin, vehicle emissions, 
asbestos, benzo(a)pyrene, bisphenol A, carbon 
tetrachloride, diuron, fipronil, 2,4-dinitrotoluene, 
2,6-dinitrotoluene, ammonium chloride, ethinyl 
estradiol, silicon dioxide 
22230336, 20382639, 19619570, 
19549813, 17987463, 21334430, 
20436886, 19619570, 21934132, 
24935251, 23179753, 17987463, 
22352330, 22228805, 21786754, 
17484886, 23962444, 21346803, 
21346803, 16483693, 15288212, 
19073995 
FAT4 rs10003468 potassium chromate(VI), benzo(a)pyrene, dibutyl phthalate, tetrachlorodibenzodioxin, toluene 
22079256, 21569818, 21266533, 
19933214, 22967744 
CNRIP1 rs3732042 PCB, Acetaminophen, Aflatoxin B1, trichostatin A, Valproic Acid, Tetrachlorodibenzodioxin, Tretinoin 
23146750, 21420995, 22100608, 
24935251, 23179753, 19654925, 
20488242 
GRK4 rs34022679 arsenic trioxide, PCBs, benzo(a)pyrene, ethinyl estradiol, tetrachlorodibenzodioxin 
15761015, 19114083, 19654925, 
17942748, 17942748 
PPA1 rs7097067 
acetaminophen, copper sulfate, dust, 
benzo(a)pyrene, estradiol, bisphenol A, furan, 
pentachlorophenol, progesterone, 
tetrachlorodibenzodioxin 
22230336, 19549813, 17805423, 
22228805, 19484750, 21786754, 
22240984, 23018184, 21570461 
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TMEM106B rs35912436* rs2160271* 
benzo(a)pyrene diol epoxide, hydrogen peroxide, 
testosterone, PCB, acetaminophen, aflatoxin B1, 
carbon tetrachloride, copper sulfate, 
tetrachlorodibenzodioxin 
20018196, 18951874, 21592394, 
22298810,  19467301, 17562736, 
19770486, 17484886, 18579281, 
22298810 
VWDE rs35912436* rs2160271* benzo(a)pyrene, tetrachlorodibenzodioxin 22316170, 21570461 
KATNAL1 rs17588454 
acetaminophen, copper sulfate, potassium 
chromate(VI),  bisphenol A, fipronil, 
tetrachlorodibenzodioxin 
22230336, 19549813, 22079256, 
21786754, 21570461  
PLEKHG1 rs17080410 rs61742396 
arsenic trioxide, formaldehyde, methylmercuric 
chloride, nicotine, acetaminophen 
20458559, 23649840, 23179753, 
18438686, 17562736 
EXO5 rs35672330 acetaminophen, atrazine, copper sulfate, tetrachlorodibenzodioxin 
22230336, 22378314, 19549813, 
22574217,  
TLL1 rs1503292 lipopolysaccharides, tetrachlorodibenzodioxin, thiram 12057914, 19933214, 20530235 
KCNH7 rs1978526 
uranium compounds, PCB, aflatoxin B1, carbon 
tetrachloride, paraquat, perfluorooctane sulfonic 
acid 
19654044, 19114083, 23630614, 
12734012, 22563483, 19162173 
CD180 rs6887604 acetaminophen, benzo(a)pyrene, estradiol, progesterone, testosterone, biological toxins 
17562736, 22228805, 19693291, 
19693291, 19693291, 19682533 
DRD1 rs10063286 
fonofos, parathion, terbufos, 
tetrachlorodibenzodioxin, formaldehyde, 
methoxychlor 
22847954, 22847954, 19901195, 
17434604 
SFXN1 rs10063286 
acetaminophen, arsenite, benzo(a)pyrene diol 
epoxide, bisphenol A, copper sulfate, formaldehyde, 
PCB, estradiol, tetrachlorodibenzodioxin 
21420995, 23974009, 19150397, 
22576693, 19549813, 23649840, 
20959002, 16684588, 21570461 
NT5C3 rs16879126 acetaminophen, ethinyl estradiol, fipronil, lead, tetrachlorodibenzodioxin  
17562736, 17942748, 23962444, 
16672222, 21570461 
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ANK1 rs34265667 rs34664882 
 mercury, testosterone, benzo(a)pyrene, estradiol, 
dieldrin, tetrachlorodibenzodioxin 
19937285, 21592394, 22228805, 
20068009, 17942748 
GABARAPL1 rs4764332 
aflatoxin B1, air pollutants, atrazine, 
benzo(a)pyrene, copper sulfate, hydrogen peroxide, 
tetrachlorodibenzodioxin, tobacco smoke pollution, 
acetaminophen, benzene, dibutyl phthalate, 
progesterone 
21641981, 21757418, 22378314, 
22316170, 19549813, 20044591, 
21632981, 19101580, 17562736, 
15120971, 21266533 
KLRD1 rs4764332 
acetaminophen, arsenite, benzo(a)pyrene, 
methotrexate, estradiol, tetrachlorodibenzodioxin, 
tobacco smoke pollution 
17093179, 23974009, 22316170,  
17400583, 19484750, 21041162, 
20133372 
KCNH8 rs7626907 arsenite, lead 23974009, 19921347 
EFHB rs7626907 atrazine, copper sulfate, estradiol, chlorpyrifos 22378314, 19549813, 19484750, 21356183 
ACAA1 rs2229528 
acetaminophen, aflatoxin B1, copper sulfate, 
hydrogen peroxide, bisphenol A, cadmium, dibutyl 
phthalate, furan, phthalic acids, 
tetrachlorodibenzodioxin 
22230336, 20106945, 19549813, 
18951874, 19287073, 17327699, 
21266533, 15120968, 15728792, 
16960034 
SCHIP1 rs9842465 
acetaminophen, atrazine, benzo(a)pyrene, 
benzo(a)pyrene diol, copper sulfate, estrogens, 
aflatoxin B1, carbon tetrachloride, dibutyl 
phthalate, tetrachlorodibenzodioxin 
21420995, 22378314, 20106945, 
19150397, 19549813, 21233418, 
23724009, 19770486, 17484886, 
21266533, 21570461 
FGF12 rs6796558 
aflatoxin B1, arsenic, arsenic trioxide, arsenite, 
fonofos, methotrexate, parathion, potassium 
chromate(VI), terbufos, uranium compounds, PCB, 
benzo(a)pyrene, carbon tetrachloride 
22100608, 24675094, 22521957, 
23974009, 22847954, 17400583, 
22847954, 22079256, 22847954, 
17045167, 19654044, 23179753, 
19114083, 22228805, 17484886  
MAST4 rs55882716 
acetaminophen, aflatoxin B1, cadmium chloride, 
copper sulfate, dibutyl phthalate, formaldehyde, 
smoke, testosterone, tetrachlorodibenzodioxin 
17562736, 21641981, 12160620, 
19549813, 21266533, 20655997, 
21095227, 21592394, 22298810 
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CYFIP2 rs1030270 
acetaminophen, aflatoxin B1, air pollutants, arsenic 
trioxide, atrazine, benzo(a)pyrene, benzo(a)pyrene 
diol, estradiol, cupric chloride, formaldehyde, 
progesterone, bisphenol A, methylmercury 
compounds, tetrachlorodibenzodioxin 
22230336, 20106945, 21757418, 
15894607, 22378314, 22316170, 
20382639, 20660070, 17211630, 
23649840, 23649840, 23649840, 
20660070, 15894607, 17183730, 
21786754, 21664453, 19759094, 
15901671 
SLC35F1 rs205944  dibutyl phthalate, tetrachlorodibenzodioxin  21266533, 21570461 
IL20RA rs381783 
estradiol, progesterone, tetrachlorodibenzodioxin, 
acetaminophen, benzo(a)pyrene, bisphenol A, 
mercuric chloride, tetrachlorodibenzodioxin 
20660070, 23152189, 23724009, 
17562736, 22228805, 21786754, 
18496552, 21570461 
KDELR2 rs11980237 
asbestos, atrazine, copper sulfate, formaldehyde, 
acetaminophen, bisphenol A, cadmium sulfate, 
ethinyl estradiol, propiconazole, sodium arsenate, 
tetrachlorodibenzodioxin  
18687144, 22378314, 19549813, 
23649840,  21786754, 16221973, 
17942748, 21278054, 16882884, 
18495758 
DGKB rs720872 progesterone, occupational air pollutants,  21795739, 19936710 
AGMO rs720872 
aflatoxin B1, benzo(a)pyrene, copper sulfate, 
acetaminophen,  agrochemicals, diuron, herbicides, 
mercuric Chloride, tetrachlorodibenzodioxin 
22100608, 21871943, 19549813, 
17562736, 22467014, 21551480, 
22467014, 20353558, 19770486 
RGS3 rs147596194 
acetaminophen, asbestos, benzo(a)pyrene, estradiol, 
diazinon, hydrogen peroxide, progesterone, 
arsenite, benzene, carbon tetrachloride, dibutyl 
phthalate, methylmercury II, 
tetrachlorodibenzodioxin 
21420995, 17331233, 21714911, 
20660070, 23410634, 21592394, 
24935251, 18929588, 17905399, 
17484886, 21266533, 17905399, 
21570461 
MAMDC4 rs61745456 benzo(a)pyrene, tetrachlorodibenzodioxin 22228805, 22298810 
WDR87 rs117923468 rs182319278 tobacco smoke pollution 18087596 
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APP rs985456 
benzene, benzo(a)pyrene, cadmium, estradiol, 
fonofos, hydrogen peroxide, ibuprofen, iron, lead, 
mercury, methotrexate, nicotine, ozone, parathion, 
particulate matter, terbufos, uranium, aluminum 
chloride, cadmium chloride, carbon tetrachloride, 
dichlorvos, diuron, fipronil, lead acetate, 
lipopolysaccharides, nickel, nicotine, DDT, 
progesterone, propiconazole, sodium arsenite, 
tetrachlorodibenzodioxin, toluene 
15707952, 22316170, 16266835, 
12963085, 22847954, 21179406, 
12777371, 16308480, 22313790, 
10617124, 12182891, 17400583, 
16627626, 15513908, 22847954, 
15513908, 18482095, 19840844, 
17484886, 21551480, 23962444, 
17277887, 11080519, 16230335, 
22764079, 15919760, 21952557, 
17135361, 17984292, 19162173, 
22484513, 17988898, 21440049 
CYYR1 rs985456 
arsenite, methylmercuric chloride, silicon dioxide, 
dibutyl phthalate, fipronil, 
tetrachlorodibenzodioxin, toluene 
23974009, 23179753, 23806026, 
21266533, 23962444, 24680724 
LPP rs16863233 
acetaminophen, aflatoxin B1, benzo(a)pyrene, 
estradiol, copper sulfate, methylmercuric chloride, 
PCBs, tetrachlorodibenzodioxin, dibutyl phthalate 
21420995, 20106945, 20064835, 
19549813, 23179753, 21334430, 
21632981, 21266533 
ZNF782 rs7037100 arsenic, methylmercuric chloride 21291286, 23103053 
OSGIN1 rs62640905 
acetaminophen, benzo(a)pyrene, bisphenol A, 
copper sulfate, hydrogen peroxide, methylmercury 
compounds, particulate matter, testosterone, 
tetrachlorodibenzodioxin, vehicle emissions, 
aflatoxin B1, cadmium chloride, carbon 
tetrachloride, diethylhexyl phthalate, furan, 
mercuric chloride, propiconazole 
21420995, 22316170, 20170705, 
19549813, 23410634,22129749, 
20307321, 21592394, 21632981, 
20307321, 19770486, 20061341, 
17484886, 19850644, 24183702, 
16507785, 21278054, 17963808 
MTG2 rs35693261 arsenic, hydrogen peroxide, PCBs, dibutyl phthalate, tetrachlorodibenzodioxin 
18414638, 18951874, 19114083, 
21266533,21570461 
TNR rs7539097 copper sulfate, lead, PCBs, arsenic, chlorpyrifos 19549813, 19921347, 19114083, 24019935, 18668222 
 
 
 
194 
 
           Appendix Table 11 continued…. 
Gene/region SNP Chemical interaction PubMed IDs 
 ENPP1 rs9493135 
aflatoxin B1, benzo(a)pyrene diol epoxide, 
mercury, potassium dichromate, progesterone, 
tetrachlorodibenzodioxin, PCB, bisphenol A, 
carbon tetrachloride, chlorpyrifos, dibutyl phthalate, 
lipopolysaccharide, progesterone 
22100608, 20382639, 17547211, 
17547211, 20864642, 21632981, 
24935251, 24383497, 23196670, 
20739668, 17484886, 21356183, 
21266533, 17573159, 23018184 
CTGF rs9493135 
1-nitropyrene, acetaminophen, arsenic, asbestos, 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
estradiol, bisphenol A, cadmium, copper sulfate, 
cycloheximide, diuron, dust, ethinyl estradiol, 
fonofos, formaldehyde, hydrogen peroxide, 
lipopolysaccharides, methylmercuric chloride, 
parathion, piroxicam, smoke, sodium arsenite, 
terbufos, tetrachlorodibenzodioxin, trichostatin A, 
aflatoxin B1, aspirin, carbon tetrachloride, 
chlorpyrifos, dibutyl phthalate, diuron, ethanol, 
nitrofen, particulate matter, progesterone, 
testosterone, tobacco smoke pollution, vehicle 
emissions 
19041380, 22230336, 24675094, 
22076105, 21632981, 20018196, 
14699072, 20170705, 19369054, 
19549813, 19684285, 24172598, 
15735009, 20170705, 22847954, 
23416264, 17965732, 23179753, 
22847954, 23155386, 12377979, 
22847954, 22298810, 19606018, 
24935251, 19770486, 14586741, 
19484750, 24586524, 15240111, 
20371981, 14724832, 21356183, 
21266533, 21551480, 19280452, 
21258935, 23358140, 21708214, 
23018184, 15788153, 22761892, 
21258935, 19165385 
ZNF540 rs16973890 acetaminophen 22230336 
ZNF571 rs16973890 formaldehyde 20655997 
MFF rs6722598 acetaminophen, copper sulfate, hydrogen peroxide 21420995, 19549813, 20044591 
PSME4 rs1049894 
arsenic trioxide, benzene, benzo(a)pyrene, estradiol, 
copper sulfate, decamethrin, formaldehyde, 
cadmium chloride, dibutyl phthalate, lead nitrate, 
tetrachlorodibenzodioxin 
22521957, 19162166, 23892563, 
23019147, 19549813, 23892563, 
19187980, 21266533, 19187980, 
21570461 
ACYP2 rs11904365 
atrazine, benzo(a)pyrene, estradiol, ethinyl 
estradiol, copper sulfate, aflatoxin B1, arsenite, 
bisphenol A, lead acetate, progesterone, 
tetrachlorodibenzodioxin  
22378314, 22316170, 23019147, 
19549813, 17942748, 24935251, 
19770486, 18929588, 21932408, 
20542052, 23012394, 21570461 
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RAB28 rs10003958 rs9993832 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
copper sulfate, potassium chromate(VI), dibutyl 
phthalate, ethinyl estradiol, methylmercuric 
chloride, tetrachlorodibenzodioxin 
22316170, 19150397, 19549813, 
22079256, 23179753, 21266533, 
17942748, 23458150, 21570461, 
15901671 
CROCC rs78888579 PCBs, benzo(a)pyrene, dibutyl phthalate, mercuric chloride, tetrachlorodibenzodioxin 
21334430, 22228805, 21266533, 
16507785, 21570461 
KCNT2 rs10218650 acetaminophen, air pollutants, arsenite, progesterone,  benzo(a)pyrene, ethinyl estradiol 
21420995, 21757418, 23974009, 
21795739,  19770486, 17557909 
GCFC2 rs10194197 manganese, fipronil, potassium dichromate 17175027, 23962444, 23608068 
CCDC173 rs61741435 tetrachlorodibenzodioxin 22298810 
CADM2 rs4856270 aflatoxin B1, methylmercuric chloride, tetrachlorodibenzodioxin 20106945, 23179753, 20055451 
KIAA0922 rs2165084 air pollutants, atrazine, benzo(a)pyrene diol epoxide, PCB, potassium chromate(VI) 
21757418, 22378314, 20382639, 
21334430, 22079256 
TRERF1 rs11751765 
aflatoxin B1, arsenic trioxide, asbestos, estradiol, 
potassium chromate(VI), Progesterone, ethinyl 
estradiol, furan, tetrachlorodibenzodioxin, vehicle 
emissions 
22100608, 20458559, 17331233, 
20660070, 22079256, 20660070, 
24935251, 24935251, 17942748, 
22079235, 17942748, 23940539 
MEOX2 rs7797334 
acetaminophen, environmental pollutants, mercury, 
tetrachlorodibenzodioxin, PCB, chlorine, dibutyl 
phthalate, diethylstilbestrol, nickel, ozone 
22230336, 12655031, 16823088, 
22298810, 21934132, 20959002, 
18636392, 21266533, 15591538, 
23153324, 12540486, 18636392,  
ISPD rs7797334 PCB, aflatoxin B1, benzo(a)pyrene, copper sulfate, diquat, potassium dichromate 
19114083, 19770486, 19770486, 
19789285, 22814884, 23608068 
CDC14C rs4278110 estradiol 22574217 
COLEC10 rs11987106 arsenic trioxide, acetaminophen, benzo(a)pyrene 15761015, 17562736, 21569818 
CCIN rs61735202 acetaminophen, cadmium chloride, tetrachlorodibenzodioxin 17562736, 22457795, 21354282 
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MGMT rs943811 
aflatoxin B1, benzo(a)pyrene, ethylene dibromide, 
dust, fonofos, parathion, polycyclic aromatic 
hydrocarbon, acetaminophen, ammonium chloride, 
arsenite, estradiol, bisphenol A, carbon 
tetrachloride, diethylstilbestrol, furan, 
methylnitrosourea, ozone, piperonyl butoxide, 
praziquantel, sodium arsenite, 
tetrachlorodibenzodioxin 
20106945, 20064835, 12151404, 
17805423, 8823159, 22847954, 
23543013, 12883083, 16483693, 
18929588, 20965277, 20965277, 
17484886, 15890375, 22507866, 
20965277, 23358140, 18636392, 
15890375, 21813463, 11241755, 
21215274, 17292431 
TMEM117 rs11182332 
aflatoxin B1, benzo(a)pyrene, benzo(a)pyrene diol 
epoxide, copper sulfate, diuron, potassium 
chromate(VI), PCB 
20106945, 21714911, 19150397, 
19549813, 24172598, 22079256, 
23724009, 24935251, 23179753, 
19114083 
PARP4 rs4770684 
acetaminophen, arsenite, estradiol, copper sulfate, 
hydrogen peroxide, nicotine, potassium 
chromate(VI), aflatoxin B1, arsenic, benzo(a)pyrene 
21420995, 23974009, 22574217, 
19549813, 21179406, 23825647, 
22079256, 19770486, 19654921, 
21839799 
UBE3A rs7182827 
arsenic trioxide, atrazine, benzo(a)pyrene diol, 
estradiol, nicotine, acetaminophen, benzo(a)pyrene, 
bisphenol A, cadmium sulfate, 
tetrachlorodibenzodioxin, tobacco smoke pollution  
20458559, 22378314, 19150397, 
23665804, 12588870, 16140955, 
17562736, 22228805, 23593014, 
16221973, 21570461, 18087596 
KRTAP21-1 rs7275217 aluminum 21298039 
RGSL1 rs41299607 cadmium 24376830 
LMO2 rs9282777 
arsenic trioxide, Benzo(a)pyrene, Estradiol, 
Isotretinoin, Testosterone, 
Tetrachlorodibenzodioxin, Tretinoin, trichostatin A, 
Valproic Acid, bisphenol A, Cadmium Chloride, 
Carbon Tetrachloride, Dibutyl Phthalate, Ozone 
19128835, 22316170, 22574217, 
20436886, 21592394, 22903824, 
21934132, 24935251, 24935251, 
21786754, 22457795, 17484886, 
21266533, 17095637 
CTNNA2 rs10520291 
acetaminophen, estradiol, progesterone, 
testosterone, 2,6-dinitrotoluene, bisphenol A, 
dibutyl phthalate, dioxins, ethinyl estradiol, ozone, 
tetrachlorodibenzodioxin  
22230336, 20660070, 20660070, 
21592394, 23179753, 20406850, 
21786754, 21266533, 20463971, 
17942748, 12763052, 21570461, 
16211290 
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PDE4B rs12037891 
arsenic, arsenic trioxide, benzo(a)pyrene, estradiol, 
formaldehyde, lipopolysaccharides, progesterone, 
smoke, testosterone, atrazine, bisphenol A, carbon 
tetrachloride, dibutyl phthalate, fipronil, furan, 
testosterone, tetrachlorodibenzodioxin 
16835338, 15761015, 22316170, 
14699072, 23649840, 20655997, 
21854221, 21795739, 21095227, 
18535249, 19541795, 21932408, 
17484886, 21266533, 22079235, 
18535249, 22298810 
CCHCR1 rs130069 acetaminophen, potassium chromate(VI), benzo(a)pyrene, tetrachlorodibenzodioxin 22230336, 22228805, 21570461 
TCF19 rs6929434 acetaminophen, aflatoxin B1, benzo(a)pyrene diol, estradiol, copper sulfate, formaldehyde, testosterone 
22230336, 20106945, 20382639, 
19167446, 19549813, 23649840, 
23649840, 21592394 
KDM4C rs10975823 acetaminophen, aflatoxin B1, atrazine, benzo(a)pyrene, potassium chromate(VI) 
22230336, 22378314, 22378314, 
22316170, 22079256 
ZNF782 
rs4645656        
rs7848710    
rs6477733 
arsenic, methylmercuric chloride 21291286,  23103053 
SUMF1 rs2633820 
copper sulfate, formaldehyde, hydrogen peroxide, 
tetrachlorodibenzodioxin, bisphenol A, dibutyl 
phthalate, tetrachlorodibenzodioxin 
19549813, 23649840, 18951874, 
22574217, 24935251, 21786754, 
21266533, 21570461 
NEDD9 rs9469223 
benzene, benzo(a)pyrene, benzo(a)pyrene diol, 
estradiol, bisphenol A, copper sulfate, diuron, 
ethylbenzene, formaldehyde, methylmercuric 
chloride, particulate matter, PCB, smoke, 
tetrachlorodibenzodioxin, tobacco tar, toluene,  2,6-
dinitrotoluene, acetaminophen, carbon tetrachloride, 
dibutyl phthalate, diethylstilbestrol, diuron, ethinyl 
estradiol, lipopolysaccharide, nicotine, 
propiconazole, sodium arsenite  
20359517, 20064835, 20382639, 
22574217, 20170705, 19549813, 
24172598, 20359517, 23649840, 
23179753, 22178795, 16474171, 
21095227, 19619570, 19559774, 
24383497, 20406850, 18700144, 
17484886, 21266533, 21658437, 
24172598, 20170705, 18930950, 
17456735, 16014739, 19015723 
        SNP = single nucleotide polymorphism
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Minor allele 
frequency  
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs10505918 SOX5 12 A intron 0.42 0.19 3.15 (1.90 - 5.24) 9.84 x 10-06 1 x 10-4 
rs11997355 8q21.11 8 T intergenic 0.05 0.19 0.22 (0.11 - 0.44) 2.74 x 10-05 1 x 10-4 
rs2388773 16q12.2 16 C intergenic 0.14 0.35 0.35 (0.21 -0.57) 3.78 x 10-05 1 x 10-4 
rs665159 CHRM3 1 T intron 0.55 0.33 2.46 (1.58 - 3.84) 7.42 x 10-05 2 x 10-4 
rs3954950 9p24.2 9 T intergenic 0.24 0.43 0.38 (0.24 - 0.62) 7.77 x 10-05 1 x 10-4 
rs7818844 8p12 8 T intergenic 0.4 0.6 0.38 (0.23 - 0.61) 7.86 x 10-05 1 x 10-4 
rs6972158 NPSR1 7 G intron 0.34 0.14 3.03 (1.74 - 5.25) 8.30 x 10-05 1 x 10-4 
rs7320982 8p12 13 C intergenic 0.19 0.38 0.39 (0.24 - 0.62) 8.33 x 10-05 1 x 10-4 
rs7583258 2q22.3 2 G intergenic 0.09 0.24 0.29 (0.16 - 0.54) 8.79 x 10-05 2 x 10-4 
rs1882591 16q12.2 16 G intergenic 0.22 0.42 0.42 (0.27 - 0.64) 9.60 x 10-05 2 x 10-4 
rs7318021 13q31.3 13 T intergenic 0.23 0.43 0.42 (0.27 - 0.66) 1.16 x 10-04 1 x 10-4 
rs7016929 8q31.3 8 A intergenic 0.2 0.39 0.40 (0.25 - 0.64) 1.18 x 10-04 1 x 10-4 
rs10079494 5q14.1 5 A intergenic 0.28 0.1 3.39 (1.82 - 6.32) 1.22 x 10-04 2 x 10-4 
rs10250709 NPSR1 7 A intron 0.33 0.14 3.03 (1.72 - 5.32) 1.22 x 10-04 1 x 10-4 
rs7720650 5q31.2 5 A intergenic 0.12 0.27 0.32 (0.18 - 0.57) 1.33 x 10-04 1 x 10-4 
rs2949827 7q31.1 7 A intergenic 0.08 0.21 0.29 (0.16 - 0.55) 1.44 x 10-04 2 x 10-4 
rs2396653 7q31.1 7 A intergenic 0.14 0.29 0.34 (0.19 - 0.59) 1.57 x 10-04 2 x 10-4 
rs202050948 CD97 19 T intron 0.04 0.15 0.22 (0.10 - 0.48) 1.72 x 10-04 1 x 10-4 
rs1191818 2p24.1 2 C intergenic 0.38 0.59 0.43 (0.28 - 0.67) 1.76 x 10-04 6 x 10-4 
rs3800292 GNMT 6 G intron 0.02 0.11 0.13 (0.04 - 0.38) 1.87 x 10-04 1 x 10-4 
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Minor allele 
frequency  
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs1881116 C7orf50 7 A intron 0.38 0.21 2.70 (1.60 - 4.57) 2.04 x 10-04 2 x 10-4 
rs4821717 22q13.1 22 A intergenic 0.45 0.26 2.46 (1.53 - 3.97) 2.06 x 10-04 5 x 10-4 
rs2212824 21q21.3 21 G intergenic 0.44 0.26 2.52 (1.55 - 4.11) 2.15 x 10-04 2 x 10-4 
rs7157104 14q13.2 14 G intergenic 0.15 0.3 0.36 (0.21 - 0.62) 2.28 x 10-04 1 x 10-4 
rs2051713 12q21.33 12 G intergenic 0.52 0.32 2.40 (1.51 - 3.82) 2.30 x 10-04 2 x 10-4 
rs2125649 8p21.3 8 G intergenic 0.07 0.19 0.28 (0.14 - 0.55) 2.32 x 10-04 1 x 10-4 
rs6739633 2p24.3 2 T intergenic 0.48 0.28 2.36 (1.50 - 3.74) 2.33 x 10-04 2 x 10-4 
rs738027 PYROXD1 12 A intron 0.43 0.24 2.45 (1.52 - 3.96) 2.55 x 10-04 3 x 10-4 
rs237320 17p12 17 T intergenic 0.11 0.26 0.35 (0.20 - 0.62) 2.65 x 10-04 1 x 10-4 
rs139886 SOX10 22 C intron 0.47 0.28 2.41 (1.50 - 3.87) 2.67 x 10-04 2 x 10-4 
rs13116233 4q34.3 4 C intergenic 0.36 0.17 2.56 (1.54 - 4.25) 2.69 x 10-04 3 x 10-4 
rs6519091 MICALL1 22 C intron 0.51 0.32 2.33 (1.48 - 3.69) 2.87 x 10-04 5 x 10-4 
rs6109487 20p12.1 20 A intergenic 0.24 0.09 3.55 (1.79 - 7.03) 2.90 x 10-04 3 x 10-4 
rs1151277 16q12.2 16 T intergenic 0.13 0.29 0.38 (0.23 - 0.64) 2.93 x 10-04 1 x 10-4 
rs6052937 SLC23A2 20 A 3'UTR 0.12 0.27 0.38 (0.22 - 0.64) 2.99 x 10-04 1 x 10-4 
rs34099167 NEK1 4 C coding 0.04 0.15 0.24 (0.11 - 0.52) 3.07 x 10-04 1 x 10-4 
rs7722067 5q14.2 5 C intergenic 0.16 0.31 0.38 (0.22 - 0.64) 3.08 x 10-04 1 x 10-4 
rs1004327 CLNK 4 C intron 0.41 0.24 2.54 (1.53 - 4.22) 3.11 x 10-04 3 x 10-4 
rs3993401 12q21.31 12 C intergenic 0.24 0.41 0.41 (0.25 - 0.67) 3.16 x 10-04 3 x 10-4 
rs6492498 13q31.3 13 A intergenic 0.29 0.49 0.45 (0.30 - 0.70) 3.22 x 10-04 5.9 x 10-4 
rs2806907 13q14.13 13 T intergenic 0.32 0.51 0.44 (0.28 - 0.69) 3.29 x 10-04 4 x 10-4 
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Appendix Table 12 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs2101919 NID2 14 G coding 0.28 0.46 0.44 (0.28 - 0.69) 3.31 x 10-04 4 x 10-4 
rs2899293 ANKRD54 22 G intron 0.51 0.32 2.32 (1.47 - 3.68) 3.32 x 10-04 5.9 x 10-4 
rs1028695 SPATA13 13 T intron 0.14 0.29 0.38 (0.23 - 0.65) 3.38 x 10-04 2 x 10-4 
rs2185230 PCSK5 9 A intron 0.34 0.17 2.76 (1.58 - 4.81) 3.39 x 10-04 3 x 10-4 
rs4254428 ZNF420 19 C intron 0.43 0.63 0.45 (0.29 - 0.70) 3.41 x 10-04 4 x 10-4 
rs139866 POLR2F 22 C intron 0.45 0.27 2.40 (1.49 - 3.88) 3.46 x 10-04 3 x 10-4 
rs5028798 11p13 11 T intergenic 0.28 0.46 0.44 (0.28 - 0.69) 3.48 x 10-04 5 x 10-4 
rs2065212 13q31.3 13 A intergenic 0.31 0.51 0.46 (0.30 - 0.71) 3.51 x 10-04 5 x 10-4 
rs222314 7p21.3 7 G intergenic 0.2 0.05 4.52 (1.98 - 10.35) 3.52 x 10-04 2 x 10-4 
rs1894381 TMC5 16 G intron 0.16 0.32 0.41 (0.25 - 0.67) 3.52 x 10-04 5 x 10-4 
rs9809647 3q28 3 T intergenic 0.34 0.54 0.48 (0.32 - 0.72) 3.53 x 10-04 2 x 10-4 
rs898982 1p34.3 1 C intergenic 0.04 0.14 0.24 (0.11 - 0.52) 3.65 x 10-04 3 x 10-4 
rs1868368 8q24.23 8 C intergenic 0.19 0.35 0.41 (0.25 - 0.67) 3.74 x 10-04 1 x 10-4 
rs9392857 6p25.3 6 A intergenic 0.3 0.48 0.44 (0.28 - 0.69) 3.77 x 10-04 1 x 10-4 
rs8014810 BRMS1L 14 T intron 0.13 0.26 0.36 (0.20 - 0.63) 3.88 x 10-04 2 x 10-4 
rs8021355 RALGAPA1 14 A intron 0.15 0.29 0.38 (0.22 - 0.65) 4.10 x 10-04 3 x 10-4 
rs7144565 RALGAPA1 14 A intron 0.15 0.29 0.38 (0.22 - 0.65) 4.10 x 10-04 3 x 10-4 
rs2274068 RALGAPA1 14 C coding 0.15 0.29 0.38 (0.22 - 0.65) 4.10 x 10-04 3 x 10-4 
rs762562 ERCC1/ CD3EAP 19 G 3'UTR 0.19 0.36 0.43 (0.26 - 0.68) 4.22 x 10
-04 2 x 10-4 
rs4948088 7p12.1 7 A intergenic 0.05 0.15 0.26 (0.12 - 0.55) 4.23 x 10-04 2 x 10-4 
rs3850942 MARK2 11 C intron 0.03 0.12 0.20 (0.09 - 0.49) 4.35 x 10-04 1 x 10-4 
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Appendix Table 12 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs2899469 15q21.2 15 G intergenic 0.48 0.29 2.24 (1.43 - 3.52) 4.45 x 10-04 4 x 10-4 
rs8011343 MDGA2 14 C intron 0.19 0.06 4.21 (1.89 - 9.41) 4.51 x 10-04 5 x 10-4 
rs2031293 13q34 13 A intergenic 0.43 0.63 0.47 (0.30- 0.71) 4.61 x 10-04 3 x 10-4 
rs11171543 12q12 12 A intergenic 0.09 0.24 0.37 (0.21 - 0.64) 4.75 x 10-04 5.9 x 10-4 
rs11172024 KIF21A 12 C intron 0.06 0.18 0.30 (0.15 - 0.59) 4.76 x 10-04 3 x 10-4 
rs1510136 4q31.21 4 G intergenic 0.19 0.35 0.44 (0.28 - 0.70) 4.80 x 10-04 4 x 10-4 
rs16979806 21q21.3 21 T intergenic 0.21 0.38 0.45 (0.29 - 0.71) 4.86 x 10-04 6.9 x 10-4 
rs17017488 CCSER1 4 C intron 0.36 0.54 0.47 (0.31 - 0.72) 5.04 x 10-04 5.9 x 10-4 
rs10511980 MAMDC2 9 A intron 0.27 0.45 0.46 (0.30 - 0.71) 5.04 x 10-04 5 x 10-4 
rs2620870 12q14.1 12 G intergenic 0.55 0.36 2.06 (1.37 - 3.10) 5.08 x 10-04 4 x 10-4 
rs377621 21q21.3 21 G intergenic 0.23 0.41 0.46 (0.30 - 0.72) 5.15 x 10-04 7.9 x 10-4 
rs6510588 ZNF420 19 A intron 0.43 0.62 0.46 (0.30 - 0.72) 5.17 x 10-04 5 x 10-4 
rs10739501 9q33.1 9 C intergenic 0.34 0.52 0.46 (0.29 - 0.71) 5.18 x 10-04 5.9 x 10-4 
rs6834625 4q31.21 4 G intergenic 0.17 0.33 0.44 (0.28 - 0.70) 5.22 x 10-04 3 x 10-4 
rs1209145 14q22.3 14 G intergenic 0.17 0.05 4.48 (1.91 - 10.5) 5.51 x 10-04 2 x 10-4 
rs1481046 8q13.3 8 G intergenic 0.3 0.15 2.71 (1.54 - 4.77) 5.57 x 10-04 4 x 10-4 
rs924615 5q14.2 5 T intergenic 0.26 0.43 0.47 (0.31 - 0.72) 5.70 x 10-04 1 x 10-4 
rs26784 MSH3 5 C intron 0.43 0.26 2.28 (1.43 - 3.65) 5.71 x 10-04 5.9 x 10-4 
rs11120342 PTPN14 1 C intron 0.2 0.36 0.45 (0.28 - 0.71) 5.76 x 10-04 8.9 x 10-4 
rs2830698 21q21.3 21 T intergenic 0.2 0.37 0.44 (0.27 - 0.70) 5.77 x 10-04 2 x 10-4 
rs6037033 20p11.21 20 A intergenic 0.32 0.49 0.45 (0.29 - 0.71) 5.80 x 10-04 5.9 x 10-4 
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Appendix Table 12 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)†† 
rs12073211 1p32.1 1 C intergenic 0.35 0.53 0.46 (0.30 - 0.72) 5.82 x 10-04 4 x 10-4 
rs3825594 NID2 14 T intron 0.26 0.43 0.46 (0.29 - 0.72) 5.86 x 10-04 5 x 10-4 
rs742390 1p36.11 1 T intron 0.38 0.21 2.43 (1.46 - 4.02) 5.87 x 10-04 5.9 x 10-4 
rs973358 SHISA6 17 A intron 0.46 0.29 2.32 (1.44 - 3.75) 5.92 x 10-04 5.9 x 10-4 
rs10133677 MDGA2 14 G intron 0.16 0.05 4.92 (1.98 - 12.23) 5.97 x 10-04 3 x 10-4 
rs1493897 16q12.2 16 A intergenic 0.17 0.33 0.44 (0.27 - 0.70) 5.99 x 10-04 6.9 x 10-4 
rs9694342 AGO2 8 T intron 0.24 0.41 0.46 (0.30 - 0.72) 6.17 x 10-04 5.9 x 10-4 
rs7952853 OR6C2 12 T intron 0.28 0.46 0.45 (0.29 - 0.71) 6.20 x 10-04 3 x 10-4 
rs6943934 7p22.3 7 C intergenic 0.04 0.14 0.25 (0.11 - 0.56) 6.21 x 10-04 1 x 10-4 
rs1610315 6q27 6 C intergenic 0.21 0.38 0.43 (0.27 - 0.70) 6.24 x 10-04 4 x 10-4 
rs1521244 2p24.3 2 C intergenic 0.43 0.26 2.26 (1.42 - 3.61) 6.26 x 10-04 4 x 10-4 
rs9897794 EFCAB5 17 T coding 0.36 0.46 0.45 (0.28 - 0.71) 6.34 x 10-04 6.9 x 10-4 
rs877111 6p21.1 6 C intergenic 0.4 0.23 2.40 (1.45 - 3.97) 6.36 x 10-04 5.9 x 10-4 
rs753712 10q26.3 10 T intergenic 0.38 0.57 0.48 (0.31 - 0.73) 6.39 x 10-04 5.9 x 10-4 
rs1430838 8q13.3 8 C intergenic 0.52 0.35 2.28 (1.42 - 3.67) 6.48 x 10-04 5.9 x 10-4 
rs2116078 8q13.3 8 G intergenic 0.52 0.35 2.28 (1.42 - 3.67) 6.48 x 10-04 5.9 x 10-4 
rs2615874 ATRNL1 10 G intron 0.4 0.09 3.12 (1.62 - 5.99) 6.51 x 10-04 5 x 10-4 
 *ORinteraction per allele (ORallele) for the additive model; **P value adjusted for genomic control; ††P value permutation = point wise P value from maxT 
permutation analysis after 10,000   permutation 
 
  Chr = Chromosome, SNP = single nucleotide polymorphism   
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Appendix Table 13: List of single nucleotide polymorphisms that showed  
age-specific associations based on the P value and were statistically correlated 
Chr A SNP 1 Chr B SNP 2 
2 rs1521244 2 rs6739633 
4 rs6834625 4 rs1510136 
7 rs10250709 7 rs6972158 
8 rs1430838 8 rs2116078 
13 rs6492498 13 rs2065212 
14 rs7157104 14 rs2274068 
14 rs7157104 14 rs8021355 
14 rs7157104 14 rs7144565 
14 rs2274068 14 rs8021355 
14 rs2274068 14 rs7144565 
14 rs8021355 14 rs7144565 
14 rs3825594 14 rs2101919 
16 rs1151277 16 rs2388773 
19 rs4254428 19 rs6510588 
21 rs16979806 21 rs377621 
22 rs2899293 22 rs6519091 
22 rs6519091 22 rs139886 
22 rs139866 22 rs139886 
          SNP = single nucleotide polymorphism 
             Note: Chromosome A and Chromosome B are same chromosome.  
                           SNP1 and SNP2 and statistically correlated SNPs 
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Appendix Table 14: Top one hundred SNPs associated with childhood ALL risk with age-specificity, results based on the highest 
effect sizes   (P < 0.05) 
 
Minor allele 
frequency  
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)† 
rs17109582 DIO1 1 C intron 0.09 0.007 12.46 (1.67 - 93.01) 0.01 0.006 
rs7304215 TMEM132D 12 G intron 0.07 0.007 11.25 (1.47 - 85.90) 0.02 0.01 
rs10999147 AIFM2 10 G coding 0.07 0.007 10.89 (1.43 - 83.02) 0.02 0.01 
rs7330286 13q33.2 13 T intergenic 0.07 0.007 10.01 (1.33 - 75.63) 0.03 0.01 
rs41309927 SEC23B 20 A coding 0.07 0.007 9.70 (1.28 - 73.39) 0.03 0.02 
rs36086854 CFAP99 4 A coding 0.06 0.007 9.42 (1.23 - 72.26) 0.03 0.02 
rs17409162 ANO10 3 A coding 0.06 0.007 9.24 (1.20 - 71.06) 0.03 0.02 
rs13129052 4p16.3 4 G intron 0.06 0.007 9.24 (1.20 - 71.06) 0.03 0.02 
rs9856456 3p22.1 3 C intergenic 0.06 0.007 8.78 (1.14 - 67.62) 0.04 0.02 
rs6927353 6q26 6 A intergenic 0.06 0.007 8.68 (1.16 - 64.90) 0.04 0.02 
rs11651675 TMC8 17 A coding 0.05 0.007 8.65 (1.11 - 67.50) 0.04 0.03 
rs10109794 TRIM55 8 T intron 0.06 0.007 8.58 (1.13 - 65.16) 0.04 0.02 
rs10099957 TRIM55 8 A intron 0.11 0.007 8.58 (2.00 - 36.93) 0.004 0.001 
rs56291145 ATP12A 13 C coding 0.06 0.007 8.40 (1.09 - 64.78) 0.04 0.02 
rs2909644 18q22 18 G intergenic 0.06 0.007 8.40 (1.09 - 64.78) 0.04 0.03 
rs6093579 PTPRT 20 T intron 0.06 0.007 8.40 (1.09 - 64.78) 0.04 0.02 
rs17039265 1p36.21 1 A intergenic 0.06 0.007 8.29 (1.08 - 63.96) 0.04 0.02 
rs9728577 PRAMEF2 1 A coding 0.06 0.007 8.29 (1.08 - 63.96) 0.04 0.02 
rs75411676 PRAMEF2 1 T coding 0.06 0.007 8.29 (1.08 - 63.96) 0.04 0.02 
rs36068434 CDS1 4 T coding 0.06 0.007 8.29 (1.08 - 63.96) 0.04 0.02 
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   Appendix Table 14 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)† 
rs11916525 CEP70 3 C coding 0.06 0.007 8.29 (1.07 - 64.03) 0.04 0.02 
rs3204798 PRAMEF2 1 G intron 0.06 0.007 8.25 (1.07 - 63.64) 0.04 0.02 
rs35340237 CEP70 3 C coding 0.06 0.007 8.21 (1.06 - 63.41) 0.04 0.02 
rs8176018 KEL 7 T intron 0.06 0.007 8.19 (1.07 - 62.68) 0.04 0.02 
rs1835154 2q24.1 2 G intergenic 0.06 0.007 8.05 (1.06 - 61.21) 0.04 0.03 
rs78323957 SLC10A5 8 G coding 0.05 0.007 8.02 (1.03 - 62.12) 0.05 0.03 
rs16909509 ZFAND1 8 T intron 0.05 0.007 8.02 (1.03 - 62.12) 0.05 0.03 
rs3729598 LIFR 5 G intron 0.05 0.007 7.94 (1.03 - 61.48) 0.05 0.04 
rs568760 HCN4 15 T intron 0.06 0.007 7.78 (1.02 - 59.39) 0.05 0.03 
rs1800141 LRP1 12 A coding 0.05 0.007 7.75 (1.00 - 59.98) 0.05 0.04 
rs35384751 FYB 5 T coding 0.06 0.007 7.68 (1.01 - 58.62) 0.05 0.03 
rs11175471 RASSF3 12 C intron 0.1 0.01 7.56 (1.77 - 32.29) 0.006 0.004 
rs2389891 4q26 4 G intergenic 0.09 0.01 7.21 (1.66 - 31.40) 0.008 0.005 
rs35424709 ATP13A4 3 A coding 0.11 0.02 6.74 (1.95 - 23.25) 0.003 0.009 
rs12188300 5q33.3 5 T intergenic 0.08 0.01 6.58 (1.51 - 28.74) 0.01 0.007 
rs7303641 RASSF3 12 G intron 0.09 0.01 6.57 (1.54 - 28.09) 0.01 0.004 
rs34139105 PRRG4 11 A coding 0.08 0.01 6.36 (1.44 - 28.06) 0.01 0.009 
rs10500248 19q12 19 C intergenic 0.08 0.01 6.34 (1.45 - 27.77) 0.01 0.01 
rs2124906 19q12 19 G intergenic 0.08 0.01 6.34 (1.45 -27.77) 0.01 0.01 
rs7492685 14q21.3 14 C intergenic 0.07 0.01 6.26 (1.38 - 28.46) 0.02 0.009 
rs276725 19q12 19 C intergenic 0.08 0.01 6.05 (1.38 - 26.56) 0.02 0.007 
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   Appendix Table 14 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)† 
rs6851586 4p15.2 4 A intergenic 0.09 0.01 5.87 (1.38 - 24.92) 0.02 0.01 
rs16871434 KCNIP4 4 A intron 0.08 0.01 5.79 (1.34 - 25.04) 0.02 0.01 
rs28421666 6p21.3 6 G intergenic 0.1 0.02 5.58 (1.63 - 19.06) 0.006 0.003 
rs17055478 13q21.1 13 A intergenic 0.07 0.01 5.58 (1.26 - 24.70) 0.02 0.02 
rs1582274 7q31.1 7 A intergenic 0.07 0.01 5.48 (1.24 - 24.24) 0.02 0.02 
rs6572051 LOC644919 14 G intron 0.07 0.01 5.40 (1.22 - 23.85) 0.03 0.02 
rs9407838 SH3GL2 9 T intron 0.11 0.02 5.32 (1.58 - 17.89) 0.007 0.004 
rs72838683 PDZD7 10 T 3'UTR 0.07 0.01 5.31 (1.22 - 23.05) 0.03 0.02 
rs11250832 10p15.3 10 T intergenic 0.1 0.02 5.29 (1.56 - 17.97) 0.008 0.005 
rs16827743 3q13.32 3 T intergenic 0.07 0.01 5.28 (1.20 - 23.32) 0.03 0.03 
rs12705300 7q22.3 7 A intron 0.12 0.02 5.27 (1.61 - 17.30) 0.006 0.003 
rs1915164 15q21.1 15 T intergenic 0.07 0.01 5.24 (1.20 - 22.95) 0.03 0.01 
rs12083795 1p34.3 1 T intergenic 0.07 0.01 5.21 (1.18 - 23.08) 0.03 0.02 
rs9861022 3q13.32 3 C intergenic 0.07 0.01 5.14 (1.18 - 22.38) 0.03 0.02 
rs16964079 C15orf41/ CSNK1A1P1 15 A 3'UTR 0.07 0.01 5.10 (1.17 -22.22) 0.03 0.02 
rs10157510 1q24.3 1 T intergenic 0.08 0.01 5.00 (1.18 - 21.27) 0.03 0.02 
rs10224856 VPS41 7 A intron 0.07 0.01 4.95 (1.12 - 21.93) 0.04 0.03 
rs1728850 15q21.3 15 G intergenic 0.07 0.01 4.95 (1.12 - 21.93) 0.04 0.03 
rs17055548 13q21.1 13 G intergenic 0.06 0.01 4.94 (1.11 - 22.03) 0.04 0.03 
rs10133677 MDGA2 14 G intron 0.16 0.04 4.92 (1.98 -12.23) 0.0006 0.0004 
rs3130161 6p21.3 6 C intergenic 0.07 0.01 4.89 (1.13 - 21.23) 0.03 0.04 
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   Appendix Table 14 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)† 
rs1000521 SLC8A3 14 G intron 0.11 0.02 4.87 (1.46 - 16.18) 0.01 0.005 
rs12257453 ARMC3 10 G intron 0.07 0.01 4.86 (1.12 - 21.19) 0.04 0.03 
rs11833839 EP400 12 T coding 0.06 0.01 4.85 (1.09 - 21.59) 0.04 0.03 
rs3790126 EMP2 16 A 3'UTR 0.08 0.01 4.85 (1.15 - 20.38) 0.03 0.02 
rs16950438 16q12.1 16 C intergenic 0.1 0.02 4.84 (1.44 - 16.25) 0.01 0.005 
rs6151599 MSH3/ DHFR 5 G intron 0.1 0.02 4.82 (1.45 - 16.10) 0.01 0.008 
rs4546429 5p13.1 5 T intergenic 0.07 0.01 4.79 (1.10 - 20.82) 0.04 0.03 
rs11234604 C11orf73 11 A 5'UTR 0.06 0.01 4.78 (1.07 - 21.24) 0.04 0.03 
rs6708453 2q21.1 2 C intergenic 0.17 0.04 4.72 (1.92 - 11.62) 0.0007 0.0007 
rs3805114 ABCC5 3 C 3'UTR 0.06 0.01 4.71 (1.06 - 20.95) 0.04 0.04 
rs9328207 6p25.2 6 T intergenic 0.06 0.01 4.71 (1.06 - 20.95) 0.04 0.04 
rs2864680 FSTL4 5 A intron 0.07 0.01 4.71 (1.10 - 20.10) 0.04 0.02 
rs4741086 9p24.3 9 A intergenic 0.17 0.04 4.67 (1.91 - 11.42) 0.0007 0.0009 
rs10514074 18q22.3 18 C intergenic 0.1 0.02 4.66 (1.37 - 15.88) 0.01 0.01 
rs41285557 MAML1 5 A coding 0.06 0.01 4.65 (1.02 - 21.12) 0.05 0.03 
rs7620914 3p22.3 3 A intron 0.14 0.04 4.64 (1.75 - 12.32) 0.002 0.001 
rs7091901 10p11.22 10 T intergenic 0.09 0.02 4.64 (1.35 - 15.96) 0.02 0.01 
rs8100295 19q13.42 19 T intergenic 0.06 0.01 4.62 (1.04 - 20.60) 0.04 0.04 
rs17407084 AK8 9 C coding 0.06 0.01 4.58 (1.03 - 20.51) 0.05 0.03 
rs222314 7p21.3 7 G intergenic 0.2 0.05 4.52 (1.98 - 10.35) 0.0003 0.0002 
rs7770942 6p25.3 6 T intergenic 0.09 0.02 4.51 (1.31 - 15.54) 0.05 0.01 
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    Appendix Table 14 continued…. 
     
Minor allele 
frequency    
SNP Gene/region Chr Minor allele Feature 1-5 year 6-10 year ORallele (95% CI)* P value** 
P value 
(permutation)† 
rs16916188 RBM12B 8 G coding 0.06 0.01 4.51 (1.01 - 20.12) 0.05 0.03 
rs17140942 RBFOX1 16 G intron 0.06 0.01 4.51 (1.01 - 20.12) 0.05 0.03 
rs7172316 15q24.1 15 G intergenic 0.07 0.02 4.49 (1.03 - 19.51) 0.05 0.03 
rs1209145 14q22.3 14 G intergenic 0.17 0.05 4.48 (1.91 - 10.50) 0.0006 0.0003 
rs10902652 1p36.11 1 C intergenic 0.06 0.01 4.46 (1.02 - 19.61) 0.05 0.04 
rs1457759 5q22.3 5 C intergenic 0.09 0.02 4.44 (1.31 - 15.08) 0.02 0.01 
rs10826912 10p11.22 10 G intergenic 0.08 0.02 4.44 (1.29 - 15.33) 0.02 0.008 
rs61744122 VWA3A 16 A intron 0.06 0.01 4.44 (1.02 - 19.36) 0.05 0.04 
rs4748309 RSU1 10 A intron 0.1 0.02 4.39 (1.33 - 14.52) 0.02 0.008 
rs8013602 14q21.2 14 A intergenic 0.06 0.01 4.39 (1.00 - 19.23) 0.05 0.04 
rs9560160 13q34 13 C intergenic 0.13 0.03 4.38 (1.54 - 12.49) 0.005 0.003 
rs1755588 ACOT11 1 T intron 0.09 0.02 4.36 (1.28 - 14.88) 0.02 0.01 
rs10493958 1p21.2 1 A intergenic 0.07 0.01 4.32 (1.01 - 18.51) 0.05 0.03 
rs7169431 15q21.3 15 A intergenic 0.08 0.02 4.31 (.124 - 14.96) 0.02 0.02 
rs17170286 BBS9 7 C intron 0.09 0.02 4.30 (1.26 - 14.68) 0.02 0.02 
rs11945730 4p15.32 4 G intergenic 0.12 0.03 4.28 (1.47 - 12.40) 0.007 0.006 
rs17149645 11q14.2 11 T intergenic 0.11 0.03 4.25 (1.45 - 12.46) 0.008 0.006 
*ORinteraction per allele (ORallele) for the additive model; **P value adjusted for genomic control;  ††P value permutation = point wise P value from     
maxT permutation analysis after 10,000 permutation 
 
 Chr = Chromosome, SNP = single nucleotide polymorphism 
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Appendix Table 15: List of single nucleotide polymorphisms that showed age-
specific associations based on effect size and were statistically correlated 
Chr A SNP 1 Chr B SNP 2 
1 rs17039265 1 rs9728577 
1 rs17039265 1 rs3204798 
1 rs17039265 1 rs75411676 
1 rs9728577 1 rs3204798 
1 rs9728577 1 rs75411676 
1 rs3204798 1 rs75411676 
3 rs9861022 3 rs16827743 
8 rs78323957 8 rs16909509 
10 rs7091901 10 rs10826912 
12 rs11175471 12 rs7303641 
13 rs17055478 13 rs17055548 
14 rs4502127 14 rs11157201 
19 rs10500248 19 rs2124906 
  SNP = single nucleotide polymorphism 
 Note: Chromosome A and Chromosome B are same chromosome.  
               SNP1 and SNP2 and statistically correlated SNPs 
 
 
 
 
 
 
 
 
 
 
 
 
210 
 
Appendix Table 16: Bioinformatic analysis of genetic risk markers for the top one hundred age-specific associations with 
childhood ALL with the lowest P values 
 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated   SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNP) 
rs10505918 12 NS NS SOX5 . . . 
rs11997355 8 3a NS HNF4G-ZFHX4 . . . 
rs2388773 16 5 NS IRX-CRNDE3 . . . 
rs665159 1 5 0.5 CHRM3 rs112493720 2b CHRM3 
rs3954950 9 5 NS RFX-GLIS33 . . . 
rs7818844 8 5 NS CYCSP3-RPL10AP3 . . . 
rs6972158*†† 7 5 0.41 NPSR1 . . . 
rs7320982 13 5 NS MIRHG1-GPC5 . . . 
rs7583258 2 5 0.1 TEX41-ACVR2A . . . 
rs1882591 16 NS NS IRX-CRNDE3  rs1151271 3a IRX3-CRNDE 
rs7318021 13 NS NS KRT18P27-RNU6-75P  rs7996128 3a KRT18P27-RNU6-75P 
rs7016929 8 5 NS KHDRBS3-LOC101927892 . . . 
rs10079494 5 4 NS MSH3-RASGRF2  rs7708505 2b MSH3-RASGRF2 
rs10250709 7 5 0.18 NPSR1 . . . 
rs7720650 5 5 NS WNT8A-NME5 rs56331448  2b WNT8A-NME5 
rs2949827 7 NS NS GPR85-PPP1R3A . . . 
rs2396653 7 6 NS GPR85-PPP1R3A . . . 
rs202050948 19 5 NS CD97 . . . 
rs1191818 2 2a 0.1 MATN3-LAPTM4A . . . 
rs3800292 6 5 0.21 GNMT  rs3831135  2b            PEX6                  
rs3800292 6 5 0.21 GNMT rs2274518  2b   PEX6       
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     Appendix Table 16 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated   SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNP) 
rs3800292 6 5 0.21 GNMT rs8540 2b KLHDC3  
rs1881116 7 5 NS C7orf50 . . . 
rs4821717 22 5 0.5 GCAT-GALR3 rs139852  1b            EIF3EIP                
rs4821717 22 5 0.5 GCAT-GALR3 rs7290156 1f GALR3  
rs2212824 21 6 NS  ADAMTS5-GPXP2 . . . 
rs7157104 14 6 NS KRT18P6-INSM2 . . . 
rs2051713 12 6 NS MRPL2P1-C12orf37 . . . 
rs2125649 8 NS NS   RP11-24P4.1-GFRA2 . . . 
rs6739633 2 6 0.1 TRIB2-FAM84A . . . 
rs738027 12 6 NS PYROXD1 rs7133853 3a PYROXD1  
rs237320 17 5 NS MAP2K4-MYOCD  rs237318†† 2b MAP2K4-MYOCD 
rs139886 22 1f 0.18 SOX10 rs139892 1f POLR2F  
rs13116233 4 6 0.1  AGA-LINC01098 . . . 
rs6519091 22 2b NS MICALL1 rs4821723 1f MICALL1  
rs6109487 20 5 NS PA2G4P2-SPTLC3 rs73088401 2c PA2G4P2-SPTLC3 
rs1151277 16 6 NS IRX-CRNDE3 . . . 
rs6052937 20 5 NS SLC23A2 . . . 
rs34099167* 4 NS 0 NEK1 rs6818590 2b NEK1 
rs7722067 5 NS 0.1 ATP6AP1L-RPL5P16 . . . 
rs1004327 4 3a 0.24 CLNK . . . 
rs3993401 12 NS NS C12orf26- TMTC2 . . . 
rs6492498 13 4 NS KRT18P27-LINC01049 . . . 
rs2806907 13 6 NS  SIAH3-ZC3H13 rs9522975 3a KRT18P27 - LINC01049 
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     Appendix Table 16 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated   SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNP) 
rs2101919*†† 14 6 0.37 NID2 . . . 
rs2899293 22 6 0.5 ANKRD54 . . . 
rs1028695 13 NS 0.5 SPATA13 rs4821722  1f EIF3L                
rs1028695 13 NS 0.5 SPATA13 rs4821723 1f MICALL1 
rs2185230 9 NS 0.5 PCSK5 . . . 
rs4254428 19 NS NS ZNF420  rs2562599  1f            ZNF568-ZNF420         
rs4254428 19 NS NS ZNF420 rs1402468  1f ZNF420  
rs4254428 19 NS NS ZNF420 rs11666786  1f ZNF420-ZNF585A    
rs4254428 19 NS NS ZNF420 rs7245882 1f ZNF420 
rs139866 22 NS NS POLR2F rs139886  1f SOX10        
rs139866 22 NS NS POLR2F rs139892 1f POLR2F  
rs5028798 11 5 NS  ELF5- EHF rs12793417 2b  ELF5- EHF 
rs2065212 13 NS NS KRT18P27-LINC01049 rs9522975 3a KRT18P27-LINC01049 
rs222314 7 NS NS LOC340268-HSPA8P8 . . . 
rs1894381 16 NS NS TMC5 . . . 
rs9809647 3 6 0.24  PYDC2-FGF12 . . . 
rs898982 1 5 0.1 POU3F1- RRAGC rs77420329 2a POU3F1- RRAGC 
rs1868368 8 5 NS  KHDRBS3-LOC101927892 . . . 
rs9392857 6 5 NS  EXOC2-OC101927691 . . . 
rs8014810 14 NS NS BRMS1L rs7152711    3a  GARNL1               
rs8014810 14 NS NS BRMS1L rs10146494  3a BRMS1L   
rs8014810 14 NS NS BRMS1L rs71124724 3a BRMS1L-LOC644584  
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     Appendix Table 16 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated   SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNP) 
rs8021355 14 6 NS RALGAPA1 . . . 
rs7144565 14 6 NS RALGAPA1 . . . 
rs2274068* 14 4 0.65 RALGAPA1 . . . 
rs762562* 19 NS 0.09 ERCC1/CD3EAP . . . 
rs4948088 7 5 NS GRB10-COBL . . . 
rs3850942 11 4 NS MARK2 rs61886104 2b MARK2 
rs2899469 15 5 NS TNFAIP8L3-CYP19A1 rs4551976 2b TNFAIP8L3-CYP19A1 
rs8011343 14 NS 0.5 MDGA2 rs10133677 3a MDGA2 
rs2031293 13 5 NS C13orf16-SOX1 . . . 
rs11171543 12 NS NS  CPNE8- KIF21A . . . 
rs11172024 12 6 NS KIF21A rs11171955  3a            KIF21A                
rs11172024 12 6 NS KIF21A rs11171957  3a  KIF21A   
rs11172024 12 6 NS KIF21A rs12228664 3a KIF21A-BCD2 
rs1510136 4 5 NS  INPP4B-USP38  rs11306676 2b  INPP4B-USP38 
rs16979806 21 4 NS ADAMTS5-LOC102724355 . . . 
rs17017488 4 5 0.5 CCSER1 . . . 
rs10511980 9 NS NS MAMDC2 rs2209779  2b MAMDC2 
rs2620870 12 NS NS SLC16A7- USP15 . . . 
rs377621 21 NS NS ADAMTS5-LOC102724355  rs368477 2b 
ADAMTS5-
LOC102724355 
rs6510588 19 6 NS ZNF420  rs2562599    1f ZNF568-ZNF420         
rs6510588 19 6 NS ZNF420 rs1402468 1f ZNF420 
rs6510588 19 6 NS ZNF420 rs11666786 1f ZNF420-ZNF585A  
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     Appendix Table 16 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated   SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNP) 
rs6510588 19 6 NS ZNF420 rs7245882 1f ZNF420  
rs10739501 9 NS NS  TLR4-BRINP1 . . . 
rs6834625 4 NS 0.1  INPP4B-USP38  rs11306676 2b  INPP4B-USP38 
rs1209145 14 6 NS C14orf105-SLC35F4 rs373690 1f C14orf105-SLC35F4 
rs1481046 8 6 NS NCOA2-TRAM1 rs10096078 2c NCOA2-TRAM1 
rs924615 5 NS NS FLJ41309-RPL5P16 . . . 
rs26784 5 6 0.27 MSH3 . . . 
rs11120342 1 NS 0.24 PTPN14 . . . 
rs2830698 21 NS NS ADAMTS5-LOC102724355 rs2830715 3a 
ADAMTS5-
LOC102724355 
rs6037033 20 5 NS  VSX1- ENTPD6 rs4815392 2b  ENTPD6  
rs12073211 1 NS 0.1 MYSM1-JUN rs11207297 2b MYSM1  
rs3825594 14 NS NS NID2 . . . 
rs742390 1 4 NS   RUNX3-SYF2 . . . 
rs973358 17 5 NS SHISA6 . . . 
rs10133677 14 3a 0 MDGA2 . . . 
rs1493897 16 6 NS IRX3-CRNDE . . . 
rs9694342 8 2b 0 AGO2 . . . 
rs7952853 12 6 0.4 OR6C2 . . . 
rs6943934 7 5 NS C7orf50-ZFAND2A rs73264941 2b C7orf50-ZFAND2A 
rs1610315 6 6 NS  GNG5P1-PRR18 . . . 
rs1521244 2 5 NS  TRIB2-LOC100506474 . . . 
rs9897794* 17 1f 0.37 EFCAB5  rs9890205 1d EFCAB5 
 
215 
 
      Appendix Table 16 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated   SNP 
RegulomeDB 
score† 
Gene                  
(correlated SNP) 
rs877111 6 6 0.5 C6orf223-MRPL14  rs7770652    1f MRPL14                
rs877111 6 6 0.5 C6orf223-MRPL14 rs4714739   1f   C6orf223-MRPL14  
rs877111 6 6 0.5 C6orf223-MRPL14 rs4714741 1f C6orf223-MRPL14 
rs877111 6 6 0.5 C6orf223-MRPL14 rs1321097 1f C6orf223-MRPL14  
rs877111 6 6 0.5 C6orf223-MRPL14 rs910616  1f C6orf223-MRPL14  
rs877111 6 6 0.5 C6orf223-MRPL14 rs4714745 1f C6orf223-MRPL14  
rs877111 6 6 0.5 C6orf223-MRPL14 rs4714742 1f C6orf223-MRPL14 
rs877111 6 6 0.5 C6orf223-MRPL14 rs6883  1f MRPL14             
rs877111 6 6 0.5 C6orf223-MRPL14 rs4711767   1f  MRPL14 
rs877111 6 6 0.5 C6orf223-MRPL14 rs910616 1f C6orf223-MRPL14  
rs877111 6 6 0.5 C6orf223-MRPL14 rs1935611   1f MRPL14 
rs877111 6 6 0.5 C6orf223-MRPL14 rs9462964 1f TMEM63B    
rs877111 6 6 0.5 C6orf223-MRPL14 rs4714755 1f TMEM63B   
rs753712 10 6 NS   MKI67-MGMT . . . 
rs1430838 8 NS NS  TRPA1-KCNB2 . . . 
rs2116078 8 5 NS  TRPA1-KCNB2 . . . 
rs2615874 10 5 NS ATRNL1 . . . 
     Note: Some associated SNPs showed multiple correlated functional variants 
  Chr = Chromosome; NS = No score; SNP = single nucleotide polymorphism; *Missense; ††SNPs change or create a binding site for transcription             
factors 
 
†RegulomDb predicts score from 1 to 7.  A score of one suggests SNPs have higher functionality and may play an important role in gene regulation. A 
score of 7 predicts least functionality 
 
    **F-SNP predicts score from 0 to 1. A score of one suggest higher functionality and a score zero suggests no functional role of a SNP
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Appendix Table 17: Bioinformatic analysis of genetic risk markers for the top one hundred age-specific associations with 
childhood    ALL with the highest effect sizes (P < 0.05) 
 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                
(correlated SNP) 
rs17109582 1 5 NS DIO1 rs76114672  2b   DIO1-HSPB11    
rs17109582 1 5 NS DIO1 rs77840912 2b HSPB11 
rs7304215 12 NS NS TMEM132D . . . 
rs10999147* 10 4 0.31 AIFM2 . . . 
rs7330286 13 6 NS   LINC00343-RNA5SP38 . . . 
rs41309927*†† 20 7 NS SEC23B . . . 
rs36086854* 4 4 0.07 CFAP99 . . . 
rs17409162* 3 5 0.37 ANO10 rs9856765 2a  ANO10-ABHD5 
rs13129052 4 5 0.1 RGS12 rs994425  2b  C4orf44-RGS12    
rs13129052 4 5 0.1 RGS12 rs61211078 2b C4orf44-RGS12 
rs9856456 3 NS 0.1 LOC101926953-IGSF11 . . . 
rs6927353 6 6 NS TCP10-LOC401286 . . . 
rs11651675* 17 2a 0.5 TMC8 rs117626020 2a TMC8 
rs10109794 8 3a NS TRIM55 rs112477862 2b LOC101060153  
rs10099957 8 4 NS TRIM55 rs7846184  2b            DNAJC5B-TRIM55   
rs10099957 8 4 NS TRIM55 rs7843038 2b TRIM55 
rs56291145* 13 4 NS ATP12A . . . 
rs2909644 18 NS NS RP11-146N18.1-
LOC101927404 
. . . 
rs6093579†† 20 6 0.27 PTPRT rs6093581 3a PTPRT  
rs17039265 1 5 0.27 HNRNPCL1-PRAMEF2 rs138700801 Missense HNRNPCL1 
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   Appendix Table 17 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                
(correlated SNP) 
rs17039265 1 5 0.27  HNRNPCL1-PRAMEF2 rs141872266 Missense  HNRNPCL1   
rs17039265 1 5 0.27  HNRNPCL1-PRAMEF2 rs41279492 Missense  HNRNPCL1   
rs17039265 1 5 0.27  HNRNPCL1-PRAMEF2 rs9728577 Missense  PRAMEF2  
rs9728577* 1 6 0.27 PRAMEF2 . . . 
rs75411676** 1 NS NS PRAMEF2 . . . 
rs36068434* 4 5 0.1 CDS1 rs148100862 2b CDS1 
rs36068434* 4 5 0.1 CDS1 rs113914543 2b CDS1 
rs11916525 3 5 NS CEP70  rs12632793    1d              CEP70 
rs11916525 3 5 NS CEP70 rs12632794 1d CEP70 
rs11916525 3 5 NS CEP70 rs9049   1f   CEP70 
rs11916525 3 5 NS CEP70 rs1563615 1f   CEP70 
rs3204798* 1 6 0.91 PRAMEF2 . . . 
rs35340237* 3 NS NS CEP70 rs35537868†† Missense FAM62C  
rs8176018 7 4 0 KEL rs7810229 2b  KEL  
rs1835154 2 3a NS  GALNT13-KCNJ3  rs16837893 3a GALNT13-KCNJ3 
rs78323957* 8 4 NS SLC10A5 rs16909527 1f CHMP4C  
rs16909509* 8 NS NS ZFAND1 rs16909527 1f CHMP4C  
rs3729598 5 6 0.27 LIFR rs76127780 3a LIFR  
rs568760 15 5 0 HCN4 . . . 
rs1800141†† 12 4 0.27 LRP1/MIR1228 . . . 
rs35384751*†† 5 4 0.64 FYB . . . 
rs11175471 12 NS 0 RASSF3 rs17223244 2b RASSF3  
rs2389891 4 NS NS  PDE5A . . . 
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    Appendix Table 17 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                
(correlated SNP) 
rs35424709* 3 5 0.1 ATP13A4 . . . 
rs12188300 5 4 NS   IL12B-LOC285627 . . . 
rs7303641 12 NS 0 RASSF3 rs7959471 2b RASSF3  
rs34139105* 11 NS 0 PRRG4 . . . 
rs10500248 19 NS NS ZNF536- LOC101927254 . . . 
rs2124906 19 NS NS ZNF536- LOC101927254 . . . 
rs7492685 14 6 NS RPL18P1-ATP5G2P2 . . . 
rs276725 19 NS NS ZNF536- LOC101927254 . . . 
rs6851586 4 5 0.1 ANAPC4-LOC645433 . . . 
rs16871434 4 6 0.1 KCNIP4 . . . 
rs28421666 6 3a NS   HLA-DRB1-HLA-DQA1 rs2395226 3a 
HLA-DRB1- 
HLA-DQA1 
rs17055478 13 NS NS   DNAJA1P1-HMGN2P39 . . . 
rs1582274 7 NS NS IMMP2L- DOCK4 rs75469463 3a   IMMP2L-DOCK4 
rs6572051 14 6 NS LOC644919 . . . 
rs9407838 9 6 0.5 SH3GL2 . . . 
rs72838683* 10 4 NS PDZD7 . . . 
rs11250832 10 6 NS ADARB2- LINC00700 . . . 
rs16827743 3 5 0.1  LOC101926953- LOC101926968 . . . 
rs12705300 7 4 NS SRPK2 . . . 
rs1915164 15 NS NS  SQRDL-LOC729316 . . . 
rs12083795 1 5 0.1   POU3F1- RRAGC rs72663642 2a   POU3F1- RRAGC 
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    Appendix Table 17 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                
(correlated SNP) 
rs9861022 3 4 0.1 LOC101926953-IGSF11 . . . 
rs16964079 15 6 NS C15orf41/CSNK1A1P1 rs28659969   3a C15orf41             
rs16964079 15 6 NS C15orf41/CSNK1A1P1 rs28480404  3a C15orf41 
rs16964079 15 6 NS C15orf41/CSNK1A1P1 rs28629456 3a C15orf41 
rs16964079 15 6 NS C15orf41/CSNK1A1P1 rs12903299  3a C15orf41 
rs16964079 15 6 NS C15orf41/CSNK1A1P1 rs77483951  3a CSNK1A1P1    
rs16964079 15 6 NS C15orf41/CSNK1A1P1 rs8031162  3a C15orf41     
rs16964079 15 6 NS C15orf41/CSNK1A1P1 rs12595212 3a CSNK1A1P1 
rs10157510 1 4 NS VAMP4-METTL13 rs10913576 2b VAMP4  
rs10224856 7 NS NS VPS41 rs2214668 2b VPS41  
rs1728850 15 5 NS UNC13C-RSL24D1 rs183003270  3a                UNC13C-RSL24D1   
rs1728850 15 5 NS UNC13C-RSL24D1 rs139840085 3a UNC13C-RSL24D1 
rs17055548 13 6 NS   DNAJA1P1-HMGN2P39 . . . 
rs10133677 14 3a 0 MDGA2 . . . 
rs3130161 6 5 0.5 HLA-DPB1-COL11A2 rs3129203 2b HLA-DPB1-
COL11A2 
rs1000521 14 NS NS SLC8A3 rs8011824   2b              SLC8A3              
rs1000521 14 NS NS SLC8A3 rs17107699†† 2b SLC8A3  
rs12257453 10 6 NS ARMC3 . . . 
rs11833839 12 6 NS EP400 rs1127023 2b EP400  
rs3790126 16 4 0.18 EMP2 rs12598331 2a  ATF7IP2-EMP2 
rs16950438 16 5 NS LINC01571-C16orf97 . . . 
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   Appendix Table 17 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene                
(correlated SNP) 
rs6151599 5 4 0.27 MSH3/DHFR rs11749051 3a DHFR  
rs4546429 5 5 0.1 LINC00603- PTGER4 . . . 
rs11234604 11 2b NS C11orf73 . . . 
rs6708453 2 5 0.1 TEKT4P3-TRNAE26 rs55872863  3a IMP4  
rs3805114 3 5 0.24 ABCC5 . . . 
rs9328207 6 5 0.5  TDGF1P4-LOC728344 . . . 
rs2864680 5 NS NS FSTL4 . . . 
rs4741086 9 NS NS DMRT2-RPS27AP14 . . . 
rs10514074 18 NS NS   LOC100505817- 
FBXO15 
. . . 
rs41285557* 5 4 NS MAML1 . . . 
rs7620914 3 NS 0.1  LOC101928135 . . . 
rs7091901 10 5 NS   ZNF438-ZEB1 rs10826908  2c ZNF438-LOC100129789 
rs8100295 19 4 NS ZNF331-DPRX . . . 
rs17407084* 9 5 0.56 AK8 rs73550647 2a AK8  
rs222314 7 NS NS   LOC340268-HSPA8P8 . . . 
rs7770942 6 2b NS   EXOC2- LOC101927691 rs6900976 2b EXOC2-LOC285768 
rs16916188* 8 5 0.5 RBM12B . . . 
rs17140942 16 NS 0.5 RBFOX1 . . . 
rs7172316 15 2b NS NPM1P42- NEO1 . . . 
rs1209145 14 5 NS   C14orf105- SLC35F4 rs373690 1f C14orf105-SLC35F4 
rs10902652 1 NS 0.1  SNRPEP7-WDTC1 . . . 
rs1457759 5 NS 0.1 LOC101927041- KCNN2 . . . 
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   Appendix Table 17 continued…. 
SNP  Chr RegulomeDB score† F-SNP
** Gene Correlated SNP 
RegulomeDB 
score† 
Gene               
(correlated SNP) 
rs10826912 10 5 NS   ZNF438-ZEB1 rs10826908 2c   ZNF438-ZEB1 
rs61744122* 16 NS NS VWA3A . . . 
rs4748309†† 10 6 NS RSU1 . . . 
rs8013602 14 6 NS HNRNPUP1-KRT8P2 . . 
rs9560160 13 5 NS  LOC102724489-LOC102724510 . . . 
rs1755588 1 4 0.07 ACOT11 rs1655527   2b ACOT11             
rs1755588 1 4 0.07 ACOT11 rs114205182 2b ACOT11             
rs1755588 1 4 0.07 ACOT11 rs116752923 2b ACOT11 
rs1755588 1 4 0.07 ACOT11 rs41313244  2b ACOT11 
rs1755588 1 4 0.07 ACOT11 rs60613980  2b ACOT11 
rs10493958†† 1 3a NS LOC102723784-OLFM3  rs12724739 3a LOC102723784-OLFM3 
rs7169431 15 5 NS  NEDD4-RFX7 . . . 
rs17170286†† 7 5 0.50 BBS9 . . . 
rs11945730 4 3a 0.27  BST1-CD38 . . . 
rs17149645 11 NS NS  LOC100506368-TMEM135 . . . 
   Note: Some associated SNPs showed multiple correlated functional variants  
Chr = Chromosome; NS = No score; SNP = single nucleotide polymorphism; *Missense; **Nonsense;  ††SNPs change or create a binding site for     
transcription factors 
 
†RegulomDb predicts score from 1 to 7.  A score of one suggests SNPs have higher functionality and may play an important role in gene regulation. A 
score of 7 predicts least functionality 
 
    **F-SNP predicts score from 0 to 1. A score of one suggest higher functionality and a score zero suggests no functional role of a SNP
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Appendix Table 18: Expression quantitative trait locus analysis of age-specific associated 
genetic risk variants 
SNP Chr Feature Gene eQTL 
rs7320982* 13 intergenic MIRHG1-GPC5  ADM, GNB4 
rs2212824* 21 intergenic  ADAMTS5-GPXP2 CRIPAK, MTG1   
rs2051713* 12 intergenic MRPL2P1-C12orf37  H1FX 
rs6519091* 22 intron MICALL1  LMF1, MYD88 
rs2899293* 22 intron ANKRD54 LMF1 
rs139866* 22 intron POLR2F CNPY3 
rs6510588* 19 intron ZNF420 ZNF420 
rs1209145* 14 intergenic C14orf105-SLC35F4 CCR10 
rs973358* 17 intron SHISA6 WDTC1  
rs7952853* 12 intron OR6C2 PAG1 
rs877111* 6 intergenic C6orf223 MRPL14 
rs4821723* 22 5' upstream MICALL1  LMF1  
 rs2562599*  19 intergenic ZNF568-ZNF420  SLC13A2, ZNF420 
 rs735482* 19 3'UTR ERCC1/CD3EAP HDGFL1, ERCC1 
rs4714739* 6 intergenic C6orf223-MRPL14    MRPL14 
rs4714755* 6 intron TMEM63B    MRPL14 
rs1321097* 6 intergenic C6orf223-MRPL14    MRPL14 
rs910616* 6 intergenic C6orf223-MRPL14  MRPL14 
 rs4711767* 6 intron MRPL14  MRPL14 
rs9462964* 6 intron TMEM63B    MRPL14 
rs1935611* 6 intron MRPL14  MRPL14 
rs4714741* 6 intergenic C6orf223-MRPL14    MRPL14 
rs7770652* 6 intron MRPL14  MRPL14 
rs7304215** 12 intron TMEM132D BCR, FLJ42953, LOC728468  
rs10514074** 18 intergenic   LOC100505817- FBXO15 
ZC3H7A, KIF5B, CORO1A, 
LOC606724, APRT, STX10, 
ARHGEF1, AGPAT9, CHTF18, 
C16orf24 
rs1209145** 14 intergenic   C14orf105- SLC35F4  CCR10 
eQTL = expression quantitative trait loci; Chr = chromosome 
*Age-specific results based on P value; **Age-specific results based on effect size 
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Appendix Table 19: Genes showing age-specific associations (ranked by their P values) and their interactions with 
chemicals in studies curated in the Comparative Toxicological Database 
Gene/region SNP Chemical interaction PUBMED ID 
SOX5 rs10505918 
arsenite, benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
bisphenol A, copper sulfate, acetaminophen, carbon 
tetrachloride, diethylhexyl phthalate, ethinyl estradiol, 
methylmercury compounds, PCB, potassium 
dichromate, propiconazole, tetrachlorodibenzodioxin, 
tobacco smoke pollution 
23974009, 22316170, 20382639, 20170705, 
19549813, 17562736, 17484886, 19850644, 
17555576, 20020106, 20020106, 23608068, 
21570461, 17942748, 20133372 
HNF4G rs11997355* 
acetaminophen, aflatoxin B1, air pollutants, 
benzo(a)pyrene, formaldehyde, 
tetrachlorodibenzodioxin, lead acetate, 
diethylnitrosamine, chlordane 
22230336, 20106945, 21632981, 23649840, 
21632981, 22609695, 22129741, 20403969 
ZFHX4 rs11997355* 
atrazine, benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
carbon tetrachloride, diethylnitrosamine, 
propiconazole, tobacco smoke pollution 
22378314, 22316170, 20382639, 17484886, 
22129741, 21278054, 20133372 
IRX3 
rs2388773* 
rs1151277*  
rs1882591* 
rs1493897* 
estradiol, coppoer sulfate, formaldehyde, smoke, 
tetrachlorodibenzodioxin, aflatoxin B1, 
benzo(a)pyrene, caffeine, nicotine, nitrofen 
21185374, 19549813, 20655997, 21095227, 
21632981, 19770486, 22228805, 20230807, 
20230807, 21238641 
CHRM3 rs665159 
lead, silicon dioxide, testosterone, PCB, aflatoxin B1, 
ammonium chloride, carbon tetrachloride, chlorpyrifos, 
diazinon, dibutyl phthalate, dichlorvos, dimethoate, 
disulfoton, environmental pollutants, chlorinated 
hydrocarbons, methyl parathion, potassium dichromate, 
progesterone, trinitrotoluene 
19921347, 23806026, 21592394, 19114083, 
23630614, 16483693, 16644059, 17666426, 
16207942, 15620428, 19100812, 15033006, 
22872703, 22872703, 17666426, 23608068, 
15900516, 21346803 
RFX3 rs3954950* arsenic, atrazine, diazinon, formaldehyde, potassium chromate(VI), PCB, benzo(a)pyrene 
16835338, 22378314, 22964155, 23649840, 
22079256, 19114083, 19770486 
GLIS3 rs3954950* asbestos, benzo(a)pyrene, estradiol, potassium chromate(VI), carbon tetrachloride 
17331233, 20106945, 20106945, 22079256, 
17484886 
RNF122 rs7818844* benzo(a)pyrene, dibutyl phthalate 22228805, 21266533 
NPSR1 rs6972158 rs10250709 
atrazine, cadmium, lead acetate, 
tetrachlorodibenzodioxin 22378314, 24376830, 22641619, 21570461 
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GPC5 rs7320982* PCB, atrazine, benzo(a)pyrene, cocaine, diethylnitrosamine 
23829299, 22378314, 20106945, 18355967, 
22129741 
GPC5 rs7320982* PCB, atrazine, benzo(a)pyrene, cocaine, diethylnitrosamine 
23829299, 22378314, 20106945, 18355967, 
22129741 
KHDRBS3 rs7016929* rs1868368* 
acetaminophen, cobaltous chloride, 
tetrachlorodibenzodioxin, PCB, aflatoxin B1, 
benzo(a)pyrene, carbon tetrachloride 
21420995, 19320972, 22574217, 19114083, 
19770486, 19770486  
MSH3 rs10079494* rs26784 
benzo(a)pyrene, copper sulfate, 
tetrachlorodibenzodioxin, tobacco smoke pollution, 
PCB, aflatoxin B1, cadmium chloride, propiconazole 
21632981, 19549813, 11007951, 22623965, 
19114083, 19770486, 11958953, 21278054 
RASGRF2 rs10079494* 
arsenite, copper sulfate, PCB, acetaminophen, 
benzo(a)pyrene, dibutyl phthalate, tobacco smoke 
pollution 
23974009, 19549813, 19114083, 17585979, 
21839799, 18087596, 21266533 
WNT8A rs7720650* bisphenol A 21786754 
NME5 rs7720650* PCB, tetrachlorodibenzodioxin 21334430, 19933214 
GPR85 rs2949827*  rs2396653* 
carbon tetrachloride, chlorpyrifos, copper sulfate, 
tetrachlorodibenzodioxin 17484886, 18668222, 18579281, 21570461 
PPP1R3A rs2949827*  rs2396653* acetaminophen, bisphenol A, copper sulfate 17562736, 17706920, 18579281 
CD97 rs202050948 
aflatoxin B1, arsenic trioxide, benzo(a)pyrene, 
estradiol, copper sulfate, hydrogen peroxide, lithium 
chloride, PCB, 2,6-dinitrotoluene, acetaminophen, 
tetrachlorodibenzodioxin, toluene 
20106945, 19128835, 20064835, 23019147, 
19549813, 20044591, 23527032, 19114083, 
21346803, 17562736, 24680724, 22967744 
MATN3 rs1191818* 
aflatoxin B1, atrazine, benzo(a)pyrene, copper sulfate, 
diuron, ethanol, fonofos, hydrogen peroxide, parathion, 
terbufos, testosterone, tetrachlorodibenzodioxin 
21632981, 22378314, 21632981, 19549813, 
24172598, 20621659, 22847954, 20044591, 
22847954, 22847954, 21592394, 21632981 
LAPTM4A rs1191818* atrazine, potassium dichromate, lipopolysaccharides, pentachlorophenol, Tetrachlorodibenzodioxin 
22378314, 23718831, 10975854, 23892564, 
21570461 
GNMT rs3800292 
aflatoxin B1, benzo(a)pyrene, estradiol, copper sulfate, 
dioxins, methylcholanthrene, testosterone, 
tetrachlorodibenzodioxin, acetaminophen, carbon 
tetrachloride, lipopolysaccharide, 
tetrachlorodibenzodioxin 
20106945, 22100608, 20106945, 19549813, 
22100608, 22100608, 21592394, 22298810, 
17562736, 18346771, 18346771, 16214954 
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C7orf50 rs1881116 arsenic, benzene, benzo(a)pyrene, cobaltous chloride 18414638, 19162166, 21632981, 19320972 
GCAT rs4821717* 
copper sulfate, diazinon, tetrachlorodibenzodioxin, 2,4-
dinitrotoluene, acetaminophen, aflatoxin B1, 
benzo(a)pyrene, carbon tetrachloride, dibutyl phthalate, 
testosterone, tetrachlorodibenzodioxin 
19549813, 22964155, 21632981, 21346803, 
17562736, 19770486, 23735875, 17484886, 
17361019, 20403060, 19770486 
GALR3 rs4821717* aflatoxin B1, lead, methylmercuric chloride, PCB, acetaminophen 
22100608, 19921347, 21385734, 19114083, 
17562736 
 ADAMTS5 rs2212824* 
acetaminophen, arsenic trioxide, benzo(a)pyrene diol 
epoxide, fonofos, parathion, particulate matter, 
potassium chromate(VI), terbufos, PCB, aflatoxin B1, 
carbon tetrachloride, diuron, tetrachlorodibenzodioxin 
21420995, 25258189, 20382639, 22847954, 
22847954, 23085030, 22079256, 22847954, 
23196670, 23630614, 17484886, 25152437, 
19465110 
INSM2 rs7157104* atrazine, copper sulfate, tetrachlorodibenzodioxin 22378314, 19549813, 21354282 
GFRA2 rs2125649* atrazine, cobaltous chloride, PCB, carbon tetrachloride, chlorpyrifos, cocaine, paraquat, progesterone 
22378314, 17553155, 19114083, 17805973, 
17452286, 12358776, 18198484, 22238285 
TRIB2 rs6739633* 
acetaminophen, arsenic trioxide, asbestos, atrazine, 
benzo(a)pyrene diol epoxide, estradiol, formaldehyde, 
nicotine, progesterone, smoke, 
tetrachlorodibenzodioxin, benzo(a)pyrene, dibutyl 
phthalate, lead acetate, paraquat, potassium dichromate 
21420995, 20458559, 17331233, 22378314, 
20382639, 14699072, 23649840, 16949557, 
20660070, 21095227, 21296121, 22610609, 
21266533, 21829687, 21371552, 23608068 
FAM84A rs6739633* acetaminophen, benzo(a)pyrene, estradiol, dibutyl phthalate, propiconazole 
17562736, 19770486, 19484750, 21266533, 
21278054 
MAP2K4 rs237320* 
arsenic trioxide, benzo(a)pyrene diol epoxide, 
estradiol, cadmium chloride, hydrogen peroxide, 
lipopolysaccharides, acetaminophen, cocaine, 
diethylnitrosamine, lipopolysaccharides, 
methylmercury compounds, tetrachlorodibenzodioxin, 
tobacco smoke pollution 
14701702, 19150397, 23094148, 18703135, 
16707465,  21112663, 17562736, 18355967, 
18691550, 21548916, 19666049, 21570461, 
15289447 
MYOCD rs237320* 
asbestos, benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
fonofos, parathion, progesterone, terbufos, PCB, 
tetrachlorodibenzodioxin, tobacco smoke pollution 
18687144, 22178795, , 20382639, 22847954, 
22847954, 20864642, 22847954, 19114083, 
17942748, 20133372  
SOX10 rs139886 lead, diethylnitrosamine, progesterone 19921347, 20360939, 17478888 
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 AGA rs13116233* 
cobaltous chloride, fonofos, parathion, terbufos, 2,6-
dinitrotoluene, acetaminophen, benzo(a)pyrene, dibutyl 
phthalate, vehicle emissions 
19376846, 22847954, 22847954, 22847954, 
21346803, 17562736, 21715664, 21266533, 
19165385 
MICALL1 rs6519091 
acetaminophen, aflatoxin B1, benzo(a)pyrene, 
estradiol, cobaltous chloride, formaldehyde, 
methylmercuric chloride  
22230336, 20106945, 21632981, 20106945, 
19320972, 23649840, 23179753 
SPTLC3 rs6109487* 
acetaminophen, aflatoxin B1, air pollutants, 
benzo(a)pyrene, copper sulfate, formaldehyde, 
nicotine, PCB, tetrachlorodibenzodioxin 
21420995, 20106945, 21757418, 22316170, 
19549813, 23649840, 23825647, 21334430, 
21632981 
SLC23A2 rs6052937 
acetaminophen, air pollutants, arsenite, 
benzo(a)pyrene, estradiol, cobaltous chloride, 
progesterone, tetrachlorodibenzodioxin, carbon 
tetrachloride, iron, ozone, paraquat, propiconazole, 
toluene 
21420995, 21757418, 23974009, 21632981, 
17092984, 19376846, 17092984, 21632981, 
17484886, 16629162, 20417186, 22558179, 
22334560, 18653662 
NEK1 rs34099167 
acetaminophen, arsenic trioxide, benzo(a)pyrene, 
cobaltous chloride, copper sulfate, hydrogen peroxide, 
potassium chromate(VI) 
22230336, 22521957, 20064835, 19376846, 
19549813, 18951874, 22079256 
ATP6AP1L rs7722067* aflatoxin B1, benzo(a)pyrene 23630614, 21839799 
CLNK rs1004327 potassium dichromate, tetrachlorodibenzodioxin 23608068, 21570461 
TMTC2 rs3993401* 
atrazine, benzo(a)pyrene, formaldehyde, hydrogen 
peroxide, lead, methylcholanthrene, smoke, 
tetrachlorodibenzodioxin, acetaminophen, aflatoxin 
B1, arsenic, dibutyl phthalate, tobacco smoke pollution 
22378314, 22316170, 23649840, 18951874, 
19921347, 20348232, 21095227, 22903824, 
17562736, 19770486, 19654921, 21266533, 
20133372 
ZC3H13 rs2806907* formaldehyde, acetaminophen, diuron, ethanol, tetrachlorodibenzodioxin 
23649840, 17562736, 25152437, 17618662, 
21889950 
NID2 rs2101919 rs3825594 
air pollutants, arsenates, arsenite, atrazine, PCB, 
benzo(a)pyrene, estradiol, carbon tetrachloride, 
diethylnitrosamine, diuron, testosterone, 
tetrachlorodibenzodioxin 
21757418, 18585445, 23974009, 18585445, 
23196670, 22228805, 19484750, 17484886, 
18164116, 20032058, 21570461 
ANKRD54 rs2899293 copper sulfate, aflatoxin B1, dibutyl phthalate, nickel monoxide, tetrachlorodibenzodioxin 
19549813, 19770486, 21266533, 19167457, 
21570461 
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SPATA13 rs1028695 
arsenic trioxide, benzo(a)pyrene diol epoxide, 
estradiol, copper sulfate, aflatoxin B1, ciguatoxins, 
dibutyl phthalate, propiconazole 
20458559, 19150397, 17962382, 19549813, 
19770486, 18353800, 21266533, 21278054 
PCSK5 rs2185230 
PCB, arsenic trioxide, benzene, benzo(a)pyrene, 
estradiol, copper sulfate, progesterone, 
tetrachlorodibenzodioxin, 2,4-dinitrotoluene, 
acetaminophen, aflatoxin B1, carbon tetrachloride, 
dibutyl phthalate, diuron, propiconazole 
19692669, 15761015, 19162166, 22316170, 
20660070, 19549813, 20660070, 22298810, 
21346803, 17585979, 19770486, 17484886, 
21266533, 25152437, 21278054 
ZNF420 rs4254428 arsenite, formaldehyde 23974009, 20655997 
POLR2F rs139866 
cobaltous chloride, copper sulfate, diazinon, hydrogen 
peroxide, PCB, 2,6-dinitrotoluene, dibutyl phthalate, 
tetrachlorodibenzodioxin 
19376846, 19549813, 22964155, 18951874, 
19114083, 21346803, 21266533, 21570461 
 ELF rs5028798* copper sulfate 16973896 
EHF rs5028798* 
arsenite, asbestos, estradiol, formaldehyde, 
progesterone, smoke, tetrachlorodibenzodioxin, 
aflatoxin B1, furan, tobacco smoke pollution 
23974009, 17331233, 20660070, 23649840, 
20660070, 21095227, 23152189, 23630614, 
22079235, 20133372 
TMC5 rs1894381 
air pollutants, arsenic trioxide, benzo(a)pyrene diol 
epoxide, copper sulfate, hydrogen peroxide, smoke, 
tetrachlorodibenzodioxin, tobacco smoke pollution 
21757418, 20707922, 20018196, 19549813, 
18951874, 21095227, 21570461, 20133372 
 FGF12 rs9809647* 
aflatoxin B1, arsenic, arsenic trioxide, arsenite, 
fonofos, parathion, potassium chromate(VI), terbufos, 
uranium compounds 
22100608, 24675094, 22521957, 23974009, 
22847954, 22847954, 22079256, 22847954, 
19654044 
POU3F1 rs898982* 
diazinon, lead, PCB, acetaminophen, arsenite, 
diethylnitrosamine, diuron, potassium dichromate, 
tetrachlorodibenzodioxin 
22964155, 19921347, 24046277, 17562736, 
18929588, 18164116, 25152437, 23608068, 
22298810 
RRAGC rs898982* 
acetaminophen, asbestos, benzene, cobaltous chloride, 
copper sulfate, formaldehyde, benzo(a)pyrene, 
tetrachlorodibenzodioxin 
22230336, 18687144, 19162166, 19376846, 
19549813, 23649840, 20504355, 21570461 
 EXOC2 rs9392857* 
benzo(a)pyrene, potassium chromate(VI), PCB, 2,4-
dinitrotoluene, cadmium chloride, dibutyl phthalate, 
diethylnitrosamine, tetrachlorodibenzodioxin 
22316170, 22079256, 19114083, 21346803, 
22457795, 21266533, 23968726, 21570461 
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BRMS1L rs8014810 
acetaminophen, aflatoxin B1, benzo(a)pyrene, 
benzo(a)pyrene diol epoxide, formaldehyde, dibutyl 
phthalate, particulate matter, pentachlorophenol 
22230336, 21641981, 22316170, 19150397, 
23649840, 21266533, 19176365, 23892564 
RALGAPA1 
rs8021355 
rs7144565 
rs2274068 
arsenic trioxide, benzo(a)pyrene, benzo(a)pyrene diol 
epoxide, copper sulfate, hydrogen peroxide, mercury, 
2,6-dinitrotoluene, acetaminophen, lead acetate, 
sodium arsenate 
20458559, 20064835, 19150397, 19549813, 
21179406, 19937285, 21346803, 17562736, 
20542052, 21795629 
ERCC1 rs762562 
aflatoxin B1, arsenic, asbestos, benzene, 
benzo(a)pyrene diol epoxide, benzo(a)pyrene, 
estradiol, cobaltous chloride, copper sulfate, 
lipopolysaccharides, paraquat, 2,4-dinitrotoluene, 
acetaminophen, benzo(a)pyrene, carbon tetrachloride, 
furan, lead nitrate, particulate matter, 
tetrachlorodibenzodioxin, vehicle emissions 
22100608, 16882524, 20855422, 16188086, 
23203453, 20624995, 22082530, 19376846, 
19549813, 22777745, 23613995, 21346803, 
17562736, 22641617, 15056808, 22079235, 
11891201, 12919963, 21570461, 12919963 
CD3EAP rs762562 aflatoxin B1, cobaltous chloride, formaldehyde, hydrogen peroxide, acetaminophen, benzo(a)pyrene 
22100608, 19320972, 23649840, 20044591, 
17562736, 21715664 
GRB10 rs4948088* 
arsenic trioxide, benzo(a)pyrene, benzo(a)pyrene diol 
epoxide, estradiol, cobaltous chloride, copper sulfate, 
progesterone, PCB, aflatoxin B1, carbon tetrachloride, 
chlorpyrifos, diuron, lead acetate, particulate matter, 
testosterone, vehicle emissions 
20458559, 22316170, 20382639, 14699072, 
19320972, 19549813, 21795739, 19114083, 
19770486, 17484886, 20350560, 25152437, 
25270620, 21222557, 20403060, 21222557 
COBL rs4948088* 
acetaminophen, aflatoxin B1, benzo(a)pyrene, 
benzo(a)pyrene diol epoxide, estradiol, copper sulfate, 
smoke, caffeine, copper sulfate, diuron, 
lipopolysaccharides, propiconazole, 
tetrachlorodibenzodioxin 
22230336, 20106945, 22316170, 20018196, 
23019147, 19549813, 21095227, 20864626, 
18579281, 21551480, 12057914, 21278054, 
19933214 
MARK2 rs3850942 copper sulfate, 2,4-dinitrotoluene, 2,6-dinitrotoluene, acetaminophen, propiconazole 
19549813, 21346803, 21346803, 17562736, 
22228805, 16730040 
TNFAIP8L rs2899469* aflatoxin B1, benzo(a)pyrene, tetrachlorodibenzodioxin 22100608, 20064835, 21889950 
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CYP19A1 rs2899469* 
PCB, aflatoxin B1, atrazine, benzo(a)pyrene, estradiol, 
bisphenol A, cadmium, chlordan, copper sulfate, 
dicofol, endosulfan, estrogens, flusilazole, heptachlor, 
hexaconazole, Ibuprofen, lipopolysaccharides, 
methoxychlor, progesterone, propiconazole, 
testosterone, tetrachlorodibenzodioxin 
16216300, 23402939, 11675267, 24361490, 
12839940, 22120136, 24376830, 16996190, 
19549813, 10806373, 16996190, 16054421, 
15554355, 16996190, 12127262, 15964185, 
10657851, 22120136, 22130322, 16996190, 
12628686, 19147701 
MDGA2 
rs8011343 
rs10133677  
rs10133677 
sodium arsenite, benzo(a)pyrene, 
tetrachlorodibenzodioxin 21925251, 22228805, 21570461 
SOX1 rs2031293* benzo(a)pyrene, hydralazine, dibutyl phthalate, tetrachlorodibenzodioxin 22316170, 17183730, 21266533, 24680724 
 CPNE8 rs11171543* 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
potassium chromate(VI), smoke, 
tetrachlorodibenzodioxin, acetaminophen, cocaine, 
tetrachlorodibenzodioxin 
21632981, 20018196, 22079256, 21095227, 
21632981, 17562736, 17898221, 21570461 
KIF21A rs11171543* rs11172024 
aspirin, benzo(a)pyrene diol epoxide, estradiol, 
cobaltous chloride, hydrogen peroxide, 2,6-
dinitrotoluene, benzo(a)pyrene, 
tetrachlorodibenzodioxin 
11906190, 19150397, 20404318, 19320972, 
21179406, 21346803, 22228805, 21570461 
 INPP4B rs1510136* rs6834625* 
atrazine, benzene, benzo(a)pyrene, benzo(a)pyrene diol 
epoxide, estradiol, progesterone, 
tetrachlorodibenzodioxin, 2,4-dinitrotoluene, 2,6-
dinitrotoluene, paraquat 
22378314, 19162166, 22316170, 20382639, 
23019147, 21795739, 20106945, 21346803, 
21346803, 18198484 
USP38 rs1510136* rs6834625* 
atrazine, benzo(a)pyrene diol epoxide, cobaltous 
chloride, copper sulfate, formaldehyde, 2,6-
dinitrotoluene 
22378314, 20018196, 19320972, 19549813, 
20655997, 21346803 
ADAMTS5 
rs16979806* 
rs377621* 
rs2830698* 
acetaminophen, arsenic trioxide, benzo(a)pyrene diol 
epoxide, fonofos, parathion, particulate matter, 
potassium chromate(VI), terbufos, PCB, aflatoxin B1, 
carbon tetrachloride, diuron, tetrachlorodibenzodioxin 
21420995, 25258189, 20382639, 22847954, 
22847954, 23085030, 22079256, 22847954, 
23196670, 23630614, 17484886, 25152437, 
19465110 
CCSER1 rs17017488 cocaine 18438686 
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MAMDC2 rs10511980 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
progesterone, acetaminophen, carbon tetrachloride, 
diuron, lead acetate, tetrachlorodibenzodioxin 
22316170, 20382639, 21795739, 17562736, 
17484886, 25152437, 22641619, 19654925 
SLC16A7 rs2620870* 
acetaminophen, air pollutants, benzo(a)pyrene diol 
epoxide, estradiol, copper sulfate, progesterone, smoke, 
tetrachlorodibenzodioxin, 2,4-dinitrotoluene, 
acetaminophen, aflatoxin B1, ethanol, heptachlor, 
hydrogen peroxide, tetrachlorodibenzodioxin 
21420995, 21757418, 20018196, 19619570, 
19549813, 21795739, 21095227, 19619570, 
21346803, 17562736, 19770486, 19167417, 
23153324, 16766717, 20702594 
USP15 rs2620870* 
aspirin, cobaltous chloride, formaldehyde, PCB, 2,6-
dinitrotoluene, acetaminophen, benzo(a)pyrene, 
tetrachlorodibenzodioxin 
11906190, 19376846, 23649840, 21334430, 
21346803, 17942131, 15034205, 15034205 
 TLR4 rs10739501* 
PCB, aflatoxin B1, arsenic, lipopolysaccharides, 
progesterone, smoke, tobacco smoke pollution, 
acetaminophen, benzo(a)pyrene, carbon tetrachloride, 
ethanol, ozone, paraquat, particulate matter, 
tetrachlorodibenzodioxin, tobacco smoke pollution, 
vehicle emissions 
21703328, 22100608, 19945496, 22014880, 
22014880, 22516759, 24269501, 17562736, 
22228805, 17484886, 16439473, 17626835, 
23969119, 12832678, 21653731, 24612634, 
20362647 
BRINP1 rs10739501* arsenic trioxide, PCB 15761015, 23196670 
C14orf105 rs1209145* 
acetaminophen, aflatoxin B1, arsenic trioxide, 
benzo(a)pyrene, formaldehyde, 
tetrachlorodibenzodioxin 
21420995, 20106945, 15761015, 20106945, 
23649840, 20106945 
SLC35F4 rs1209145* acetaminophen, potassium dichromate 17562736, 23608068 
NCOA2 rs1481046* 
aflatoxin B1, air pollutants, arsenic trioxide, 
benzo(a)pyrene, estradiol, bisphenol A, 
lipopolysaccharides, potassium chromate(VI), 
tetrachlorodibenzodioxin, furan, lead acetate, 
lipopolysaccharides, progesterone 
20106945, 21757418, 19131511, 21632981, 
17962382, 23583298, 21370964, 22079256, 
18842620, 22079235, 22641619, 16847310, 
17556502 
TRAM1 rs1481046* benzo(a)pyrene diol epoxide, copper sulfate, PCB, estradiol 20018196, 19549813, 19114083, 20068009 
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PTPN14 rs11120342 
cobaltous chloride, copper sulfate, PCB, 
benzo(a)pyrene, dibutyl phthalate, diuron, lead acetate, 
ozone, tetrachlorodibenzodioxin 
19320972, 19549813, 19114083, 21569818, 
21266533, 25152437, 25270620, 17095637, 
21570461 
 VSX1 rs6037033* acetaminophen, arsenite, copper sulfate, hydrogen peroxide, aflatoxin B1 
22230336, 23974009, 19549813, 18951874, 
23630614 
ENTPD6 rs6037033* acetaminophen 21420995 
MYSM1 rs12073211* 
formaldehyde, potassium chromate(VI), 
tetrachlorodibenzodioxin, 2,4-dinitrotoluene, 2,6-
dinitrotoluene, benzo(a)pyrene, propiconazole, 
tetrachlorodibenzodioxin 
20655997, 22079256, 22298810, 21346803, 
21346803, 19770486, 21278054, 21570461 
JUN rs12073211* 
PCB, aflatoxin B1, air pollutants, arsenic trioxide, 
arsenite, asbestos, aspirin, atrazine, benzene, 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
estradiol, cadmium chloride, cocaine, copper sulfate, 
diquat, endosulfan, heptachlor, hydrogen peroxide, 
lipopolysaccharides, nicotine, paraquat, particulate 
matter, potassium dichromate, 
tetrachlorodibenzodioxin 
16611624, 22100608, 21757418, 18633430, 
22260869, 18687144, 16600694, 22378314, 
17119257, 16041517, 20382639, 15930183, 
11341981, 15814102, 19549813, 21172416, 
22146149, 15888667, 8853906, 24149798, 
11592233, 16237197, 22178795, 20493934, 
15019843 
  RUNX3 rs742390* 
arsenite, benzo(a)pyrene, estradiol, diazinon, fonofos, 
parathion, terbufos, tetrachlorodibenzodioxin, tobacco 
smoke pollution, 4-amino-2,6-dinitrotoluene, 
acetaminophen 
23974009, 20064835, 20404318, 22964155, 
22847954, 22847954, 22847954, 22298810, 
23724145, 21346803, 17562736 
SYF2 rs742390* 
atrazine, copper sulfate, formaldehyde, potassium 
chromate(VI), PCB, acetaminophen, benzo(a)pyrene, 
tetrachlorodibenzodioxin 
22378314, 19549813, 23649840, 22079256, 
17562736, 22228805, 24680724 
SHISA6 rs973358 Tretinoin 21934132 
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AGO2 rs9694342 
benzo(a)pyrene diol epoxide, estradiol, copper sulfate, 
diazinon, formaldehyde, 2,4-dinitrotoluene, 
acetaminophen, cocaine, mercuric chloride, 
tetrachlorodibenzodioxin 
20018196, 23019147, 19549813, 22964155, 
20655997, 21346803, 17562736, 20643829, 
16507785, 21570461 
ZFAND2A rs6943934* 
acetaminophen, benzo(a)pyrene, benzo(a)pyrene diol 
epoxide, estradiol, cobaltous chloride, copper sulfate, 
diazinon, formaldehyde, potassium chromate(VI), 
tobacco smoke pollution, aflatoxin B1, arsenite, 
bisphenol A, dibutyl phthalate, 
tetrachlorodibenzodioxin 
21420995, 21632981, 19150397, 20106945, 
19320972, 19549813, 22964155, 23649840, 
22079256, 22363418, 19770486, 16973439, 
21932408, 21266533, 21570461 
 TRIB2 rs1521244* 
acetaminophen, arsenic trioxide, asbestos, atrazine, 
benzo(a)pyrene diol epoxide, estradiol, formaldehyde, 
hydralazine, nicotine, progesterone, smoke, 
tetrachlorodibenzodioxin, benzo(a)pyrene, dibutyl 
phthalate, lead acetate, paraquat 
21420995, 20458559, 17331233, 22378314, 
20382639, 14699072, 23649840, 17183730, 
16949557, 20660070, 21095227, 21296121, 
22610609, 21266533, 21829687, 21371552 
EFCAB5 rs9897794 potassium dichromate, tetrachlorodibenzodioxin 23608068, 21570461 
C6orf223 rs877111 acetaminophen, formaldehyde 22230336, 23649840 
  MKI67 rs753712 
acetaminophen, aflatoxin B1, atrazine, benzene, 
benzo(a)pyrene diol epoxide, estradiol, copper sulfate, 
methylmercuric chloride, PCB, progesterone, 
benzo(a)pyrene, bisphenol A, carbon tetrachloride, 
diazinon, diethylnitrosamine, propiconazole, asbestos 
22230336, 20106945, 18585445, 21843810, 
21776270, 19167446, 19549813, 23179753, 
21334430, 16888808, 21569818, 22875908, 
17484886, 22546817, 24012840, 21278054, 
17200189 
 TRPA1 rs1430838 rs2116078 
benzene, benzo(a)pyrene diol epoxide, coal ash, dibutyl 
phthalate, formaldehyde, ozone, particulate matter, 
smoke 
21591660, 20382639, 22155782, 22935519, 
21591660, 20008466, 23541125, 23541125 
ATRNL1 rs2615874 atrazine, estradiol, fonofos, parathion, terbufos, tetrachlorodibenzodioxin 
22378314, 19619570, 22847954, 22847954, 
22847954, 19619570 
     SNP = single nucleotide polymorphism 
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chemicals in studies curated in the Comparative Toxicological Database 
Gene/region SNP Chemical interaction PUBMED ID 
DIO1 rs17109582 
aflatoxin B1, benzo(a)pyrene, estradiol,copper sulfate, 
tetrachlorodibenzodioxin, PCB, 2,4-dinitrotoluene, 
acetaminophen, arsenic, cobaltous chloride, 
diethylnitrosamine, ethanol, fipronil, furan, 
hexachlorobenzene, lead acetate, methoxychlor, 
pentachlorophenol 
20106945, 21871943, 20106945, 
19549813, 22298810, 15254343, 
20959002, 21346803, 17562736, 
18288313, 21139344, 17602206, 
15353170, 23962444, 22079235, 
15664263, 22609695, 7574712 
TMEM132D rs7304215 fonofos, parathion, terbufos, potassium dichromate 22847954, 22847954, 22847954, 23608068 
AIFM2 rs10999147 benzo(a)pyrene, cobaltous chloride, copper sulfate, tetrachlorodibenzodioxin, cadmium, hydrogen peroxide 
21632981, 19320972, 19549813, 
24067728, 14987999 
SEC23B rs41309927 atrazine, cobaltous chloride, 2,6-dinitrotoluene 22378314, 19376846, 21346803 
ANO10 rs17409162 formaldehyde, testosterone, aflatoxin B1, dibutyl phthalate, tetrachlorodibenzodioxin 
23649840, 21592394, 19770486, 
21266533, 21570461 
RGS12 rs13129052 
acetaminophen, benzo(a)pyrene, copper sulfate, aflatoxin 
B1, benzo(a)pyrene, dibutyl phthalate, diethylnitrosamine,  
ethinyl estradiol, propiconazole, tetrachlorodibenzodioxin 
22230336, 20064835, 19549813, 
19770486, 22228805, 21266533, 
18164116, 17108234, 21278054, 
21570461 
IGSF11 rs9856456* rs9861022* 
estradiol, PCB, acetaminophen, benzo(a)pyrene, 
chlorpyrifos, diethylnitrosamine, tetrachlorodibenzodioxin 
20404318, 19114083, 17562736, 
19770486, 18668222, 17602206, 
21570461 
TMC8 rs11651675 arsenic, copper sulfate, tetrachlorodibenzodioxin 18414638, 19549813, 21570461 
TRIM55 rs10109794 rs10099957 methylcholanthrene, acetaminophen, coal ash,  20348232, 17562736, 19000753 
ATP12A rs56291145 tetrachlorodibenzodioxin, estradiol, lead acetate, smoke 23152189, 19484750, 25270620, 23693141 
PTPRT rs6093579 fonofos, parathion, terbufos, acetaminophen, aflatoxin B1, diethylnitrosamine 
22847954, 22847954, 22847954, 
17562736, 23630614, 22129741 
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PRAMEF2 
rs17039265* 
rs9728577 
rs75411676   
rs3204798 
aflatoxin B1 22100608 
CDS1 rs36068434 
estradiol, nicotine, benzo(a)pyrene, 
tetrachlorodibenzodioxin, PCB, 2,4-dinitrotoluene, 
tetrachlorodibenzodioxin 
19167446, 23825647, 22228805, 
17942748,  19114083, 21346803, 
21215274  
CEP70 rs11916525 rs35340237 
acetaminophen, aflatoxin B1, air pollutants, arsenic trioxide, 
atrazine, Benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
copper sulfate, potassium chromate(VI), 3-dinitrobenzene 
22230336, 22100608, 21757418, 
20458559, 22378314, 21632981, 
20018196, 19549813, 22079256, 
21983209 
KEL rs8176018 formaldehyde, acetaminophen, potassium dichromate, tetrachlorodibenzodioxin 
23649840, 17562736, 23608068, 
19465110 
 GALNT13 rs1835154* copper sulfate, PCB, estradiol 19549813, 19114083, 19484750 
KCNJ3 rs1835154* benzo(a)pyrene, carbon tetrachloride, ethanol 22316170, 16644059, 22164246 
SLC10A5 rs78323957 arsenic 21291286 
ZFAND1 rs16909509 tetrachlorodibenzodioxin, acetaminophen, dibutyl phthalate 21632981, 17562736, 21266533 
LIFR rs3729598 
aflatoxin B1, arsenic, asbestos, benzo(a)pyrene, 
benzo(a)pyrene diol epoxide, estradiol, methylmercuric 
chloride, PCBs, testosterone, tetrachlorodibenzodioxin, 2,6-
dinitrotoluene, acetaminophen, arsenite, carbon 
tetrachloride, furan, lipopolysaccharides, maneb, paraquat, 
progesterone 
22100608, 24675094, 17297452, 
21632981, 20018196, 21185374, 
23179753, 21334430, 21592394, 
20106945, 21346803, 17585979, 
18929588, 17484886, 22079235, 
17321000, 22563483, 22563483, 
21770760 
HCN4 rs568760 aflatoxin B1, diazinon, methoxychlor 22100608, 22964155, 23303685 
LRP1 rs1800141* 
air pollutants, arsenic trioxide, copper sulfate, hydrogen 
peroxide, 2,4-dinitrotoluene, 2,6-dinitrotoluene, 
acetaminophen, aflatoxin B1, benzo(a)pyrene, estradiol, 
dibutyl phthalate, diethylnitrosamine, lipopolysaccharide, 
propiconazole, tetrachlorodibenzodioxin 
21757418, 22521957, 19549813, 
23410634, 21346803, 21346803, 
17585979, 19770486, 22228805, 
16977382, 21266533, 17942915, 
16977382, 21278054, 21570461 
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FYB rs35384751 
arsenic trioxide, benzo(a)pyrene, cobaltous chloride, diuron, 
fonofos, parathion, terbufos, acetaminophen, 
tetrachlorodibenzodioxin 
15761015, 20064835, 19376846, 
24172598, 22847954, 22847954, 
22847954, 17562736, 20702594 
RASSF3 rs11175471 rs7303641 
acetaminophen, benzo(a)pyrene, carbon tetrachloride, 
tetrachlorodibenzodioxin 
17562736, 19770486, 17484886, 
21570461 
 PDE5A rs2389891* 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, estradiol, 
PCB, caffeine, carbon tetrachloride, chlorpyrifos, diazinon, 
methylmercuric chloride, testosterone, 
tetrachlorodibenzodioxin, tobacco smoke pollution 
22316170, 20382639, 22574217, 
23196670, 20864626, 16644059, 
17452286, 17452286, 20864626, 
17138653, 24680724, 20133372 
ATP13A4 rs35424709 hydralazine, aflatoxin B1, diethylnitrosamine, tetrachlorodibenzodioxin, tobacco smoke pollution 
17183730, 19770486, 17942915, 
19770486, 20133372  
  IL12B rs12188300* 
estradiol, lipopolysaccharides, progesterone, PCB, 
acetaminophen, aflatoxin B1, benzene, benzo(a)pyrene, 
bisphenol A, diazinon, diethylnitrosamine, ethanol, 
formaldehyde, hydrogen peroxide, methoxychlor, nicotine, 
ozone, particulate matter, progesterone, 
tetrachlorodibenzodioxin, tobacco smoke pollution, vehicle 
emissions 
20130130, 19211157, 20130130, 
19114083, 22575169, 22445859, 
15894107, 17275222, 18569609, 
17499902, 25051504, 20624996, 
12161283, 15723204, 22842586, 
21237301, 18929643, 19805405, 
21977998, 21097750, 20133372, 
19805405 
PRRG4 rs34139105 
benzo(a)pyrene diol epoxide, formaldehyde, smoke, 
tetrachlorodibenzodioxin, acetaminophen, aflatoxin B1, 
benzo(a)pyrene, diethylnitrosamine 
22101062, 23649840, 21095227, 
22298810, 17562736, 23630614, 
19770486, 22129741 
ANAPC4 rs6851586* 
arsenite, potassium chromate(VI), 2,4-dinitrotoluene, 2,6-
dinitrotoluene, acetaminophen, benzo(a)pyrene, ethanol, 
tetrachlorodibenzodioxin 
23974009, 22079256, 21346803, 
21346803, 17562736, 22228805, 
17618662, 21570461 
KCNIP4 rs16871434 benzo(a)pyrene, copper sulfate, furan, progesterone, testosterone, tobacco smoke pollution 
22316170, 19549813, 22079235, 
22238285, 19693291, 19969065 
  HLA-DRB1 rs28421666* arsenic, aspirin, benzo(a)pyrene, estradiol, lead, progesterone, smoke 
18414638, 20485159, 20106945, 
20660070, 19921347, 20660070, 
21095227 
HLA-DQA1 rs28421666* PCB, Arsenic, Benzene, Lipopolysaccharides, Mercury, Progesterone, Aluminum 
20638727, 18414638, 16188091, 
22235868, 19690047, 21298039 
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IMMP2L rs1582274* aflatoxin B1, benzo(a)pyrene, copper sulfate, formaldehyde, acetaminophen, estradiol, tetrachlorodibenzodioxin 
20106945, 22316170, 19549813, 
23649840, 17562736, 19484750, 
21570461 
DOCK4 rs1582274* 
aflatoxin B1, asbestos, benzo(a)pyrene, benzo(a)pyrene diol 
epoxide, diazinon, hydrogen peroxide, progesterone, 
potassium dichromate, tetrachlorodibenzodioxin 
20106945, 18687144, 21714911, 
19150397, 22964155, 18951874, 
21795739, 23608068, 19465110 
SH3GL2 rs9407838 
aflatoxin B1, arsenic trioxide, benzo(a)pyrene, fonofos, 
parathion, terbufos, tetrachlorodibenzodioxin, PCB, dibutyl 
phthalate, paraquat, potassium dichromate 
20106945, 15761015, 20106945, 
22847954, 22847954, 22847954, 
20106945, 21673325,  21266533, 
21371552, 23608068 
PDZD7 rs72838683 arsenic trioxide, copper sulfate 20458559, 19549813 
ADARB2 rs11250832* acetaminophen, aflatoxin B1, PCB, tetrachlorodibenzodioxin 
22230336, 22100608, 19114083, 
21570461 
SRPK2 rs12705300 
acetaminophen, arsenite, benzo(a)pyrene, benzo(a)pyrene 
diol epoxide, paraquat, potassium chromate(VI), 2,4-
dinitrotoluene, 2,6-dinitrotoluene, aflatoxin B1, carbon 
tetrachloride, chlorpyrifos, lipopolysaccharides, potassium 
dichromate, propiconazole, toluene 
22230336, 23974009, 20106945, 
19150397, 23613995, 22079256, 
21346803, 21346803, 19770486, 
17484886, 18668222, 12057914, 
23608068, 21278054, 22166486 
 SQRDL rs1915164* 
acetaminophen, benzo(a)pyrene, estradiol, copper sulfate, 
hydrogen peroxide, potassium chromate(VI), progesterone, 
tetrachlorodibenzodioxin, propiconazole 
21420995, 22316170, 22574217, 
19549813, 23410634, 22079256, 
21795739, 21632981, 21278054 
  POU3F1 rs12083795* 
diazinon, lead, PCB, acetaminophen, arsenite, 
diethylnitrosamine, diuron, potassium dichromate, 
tetrachlorodibenzodioxin 
22964155, 19921347, 19114083, 
17562736, 18929588, 18164116, 
25152437, 23608068, 24046277 
 RRAGC rs12083795* acetaminophen, asbestos, benzene, copper sulfate, formaldehyde, benzo(a)pyrene, tetrachlorodibenzodioxin 
22230336, 18687144, 19162166, 
19549813, 23649840, 20504355, 
21570461 
C15orf41 rs16964079 potassium chromate(VI) 22079256 
VAMP4 rs10157510* 
arsenic trioxide, cobaltous chloride, copper sulfate, 
formaldehyde, aflatoxin B1, benzo(a)pyrene, nicotine, 
tetrachlorodibenzodioxin 
20458559, 19376846, 19549813, 
23649840, 19770486, 15034205, 
17997037, 15034205 
METTL13 rs10157510* acetaminophen, atrazine, copper sulfate, tetrachlorodibenzodioxin 
21420995, 22378314, 19549813, 
19654925 
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VPS41 rs10224856 
atrazine, benzo(a)pyrene, bisphenol A, copper sulfate, 
hydrogen peroxide, caffeine, dibutyl phthalate, nicotine, 
tetrachlorodibenzodioxin 
22378314, 20064835, 22576693, 
19549813, 21179406, 21266533, 
20230807, 21570461 
UNC13C rs1728850* formaldehyde, benzo(a)pyrene, furan, paraquat, testosterone 23649840, 21839799, 22079235, 22563483, 20403060 
RSL24D1 rs1728850* acetaminophen, benzo(a)pyrene diol epoxide, copper sulfate 22230336, 20018196, 19549813 
MDGA2 rs10133677 sodium arsenite, benzo(a)pyrene, tetrachlorodibenzodioxin 21925251, 22228805, 21570461 
HLA-DPB1 rs3130161* benzene, benzo(a)pyrene, tetrachlorodibenzodioxin 16188091, 15034205, 15034205 
COL11A2 rs3130161* copper sulfate, diuron, tetrachlorodibenzodioxin 19549813, 21551480, 21570461 
SLC8A3 rs1000521 PCB, bisphenol A, fonofos, parathion, terbufos, ethanol 23146750, 23146750, 22847954, 22847954, 22847954, 20655511 
ARMC3 rs12257453 benzo(a)pyrene 22316170 
EP400 rs11833839 
cobaltous chloride, copper sulfate, formaldehyde, 2,6-
dinitrotoluene, acetaminophen, benzo(a)pyrene, 
propiconazole, tetrachlorodibenzodioxin 
19320972, 19549813, 23649840, 
21346803, 17562736, 20504355, 
21278054, 21570461 
EMP2 rs3790126 
acetaminophen, benzo(a)pyrene,  benzo(a)pyrene diol 
epoxide, estradiol, bisphenol A, copper sulfate, 
progesterone, tetrachlorodibenzodioxin, PCB, dibutyl 
phthalate, furan 
22230336, 22316170, 20382639, 
16474171, 16474171, 19549813, 
20864642, 22574217, 19114083, 
21266533, 24183702 
MSH3 rs6151599 
benzo(a)pyrene, copper sulfate, tetrachlorodibenzodioxin, 
tobacco smoke pollution, PCB, aflatoxin B1, cadmium 
chloride, propiconazole 
21632981, 19549813, 11007951, 
22623965, 19114083, 19770486, 
11958953, 21278054 
DHFR rs6151599 
acetaminophen, air pollutants, benzo(a)pyrene, 
benzo(a)pyrene diol epoxide, estradiol, cobaltous chloride, 
copper sulfate, formaldehyde, nicotine, potassium 
chromate(VI), PCB, aflatoxin B1, arsenite, carbon 
tetrachloride, dibutyl phthalate, diethylnitrosamine, 
tetrachlorodibenzodioxin 
22230336, 21757418, 20064835, 
20018196, 19167446, 19376846, 
19549813, 23649840, 12588870, 
22079256, 20005886, 19770486, 
18929588, 17484886, 21266533, 
20360939, 21570461 
PTGER4 rs4546429* 
benzo(a)pyrene, benzo(a)pyrene diol epoxide, estradiol, 
cobaltous chloride, diuron, formaldehyde, particulate matter, 
polychlorinated biphenyls, tetrachlorodibenzodioxin, 
ammonium chloride, bisphenol A, carbon tetrachloride, 
dibutyl phthalate, diuron, hydrazine, progesterone 
22316170, 20382639, 19619570, 
19320972, 24172598, 20655997, 
22178795, 21334430, 19619570, 
16483693, 20096755, 17484886, 
15620428, 21551480, 15282401,  
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C11orf73 rs11234604 copper sulfate, potassium chromate(VI) 19549813, 22079256 
ABCC5 rs3805114 
acetaminophen, arsenic trioxide, aspirin, benzo(a)pyrene, 
estradiol, estrogens, formaldehyde, hydrogen peroxide, 
potassium chromate(VI), tetrachlorodibenzodioxin, PCB, 
dibutyl phthalate, diethylnitrosamine, testosterone 
17627974, 20458559, 21900887, 
21871943, 15072547, 21233418, 
23649840, 21179406, 22079256, 
19619570, 15833929, 21266533, 
17602206, 20403060 
FSTL4 rs2864680 arsenic trioxide, benzo(a)pyrene, potassium dichromate 15894607, 22228805, 23608068 
DMRT2 rs4741086* arsenite, cobalt, cobaltous chloride, fonofos, parathion, terbufos, lead acetate,  
23974009, 20105288,20105288, 
22847954, 22847954, 22847954, 
21829687 
FBXO15 rs10514074* aflatoxin B1, tetrachlorodibenzodioxin 22100608, 22298810 
MAML1 rs41285557 arsenic trioxide, asbestos, acetaminophen, benzo(a)pyrene, propiconazole, tetrachlorodibenzodioxin 
20458559, 17331233, 17562736, 
22228805, 21278054, 21570461 
  ZNF438 rs7091901*  rs10826912* cobaltous chloride, copper sulfate, potassium chromate(VI) 20105288, 19549813, 22079256 
ZEB1 rs7091901*  rs10826912* 
acetaminophen, arsenic trioxide, benzo(a)pyrene diol 
epoxide, estradiol, cobaltous chloride, copper sulfate, 
estrogens, formaldehyde, progesterone, benzo(a)pyrene, 
chlorpyrifos, diuron, mercuric chloride, 
tetrachlorodibenzodioxin 
21420995, 20707922, 19150397, 
12154049, 19376846, 19549813, 
18622689, 23649840, 20864642, 
15034205, 20350560, 25152437, 
16507785, 15034205 
ZNF331 rs8100295* arsenic, atrazine, benzene, lead 16835338, 22378314, 17119257, 19921347 
AK8 rs17407084 benzo(a)pyrene, cadmium chloride 22228805, 22457795 
  EXOC2 rs7770942* benzo(a)pyrene, potassium chromate(VI), PCB, 2,4-dinitrotoluene, dibutyl phthalate, tetrachlorodibenzodioxin 
22316170, 22079256, 19114083, 
21346803, 21266533, 21570461 
RBM12B rs16916188 atrazine, formaldehyde, aflatoxin B1, tetrachlorodibenzodioxin 
22378314, 20655997, 19770486, 
21215274 
RBFOX1 rs17140942 PCB, dibutyl phthalate, tetrachlorodibenzodioxin 19933214, 17361019, 19933214 
NEO1 rs7172316* 
acetaminophen, atrazine, benzo(a)pyrene, estradiol, 
hydrogen peroxide, progesterone, progesterone, 2,4-
dinitrotoluene,  aflatoxin B1, carbon tetrachloride, cocaine, 
dibutyl phthalate, formaldehyde, tetrachlorodibenzodioxin 
22230336, 22378314, 21632981, 
20660070, 20044591, 20660070, 
20660070, 21346803, 19770486, 
17484886, 15056714, 21266533, 
12679049, 21570461 
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  C14orf105 rs1209145* acetaminophen, aflatoxin B1, arsenic trioxide, benzo(a)pyrene, formaldehyde, tetrachlorodibenzodioxin 
21420995, 20106945, 15761015, 
20106945, 23649840, 20106945 
SLC35F4 rs1209145* acetaminophen, potassium dichromate 17562736, 23608068 
WDTC1 rs10902652* acetaminophen, diazinon, tetrachlorodibenzodioxin, 2,4-dinitrotoluene, propiconazole, tetrachlorodibenzodioxin 
22230336, 22964155, 22298810, 
21346803, 21278054, 24680724 
KCNN2 rs1457759* 
arsenite, benzo(a)pyrene, benzo(a)pyrene diol epoxide, 
testosterone, tetrachlorodibenzodioxin, PCB, 
acetaminophen, aflatoxin B1, ammonium chloride, 
bisphenol A, dibutyl phthalate, diethylnitrosamine, 
methoxychlor, tobacco smoke pollution 
23974009, 21802500, 20382639, 
21592394, 22298810, 19114083, 
17562736, 19770486, 16483693, 
23359474, 23359474, 15833021, 
23303685, 18087596 
VWA3A rs61744122 copper sulfate, tetrachlorodibenzodioxin 19549813, 21570461 
RSU1 rs4748309 arsenite, estradiol, PCB, aflatoxin B1, benzo(a)pyrene, tetrachlorodibenzodioxin 
23974009, 19167446, 19114083, 
19770486, 21715664, 21570461 
ACOT11 rs1755588 
aflatoxin B1, atrazine, benzo(a)pyrene, copper sulfate, 
fonofos, hydrogen peroxide, parathion, terbufos, 
testosterone 
21641981, 22378314, 22316170, 
19549813, 22847954, 20044591, 
22847954, 22847954, 21592394 
OLFM3 rs10493958* atrazine, benzo(a)pyrene, acetaminophen 22378314, 22316170, 17562736 
 NEDD4 rs7169431* 
acetaminophen, arsenite, copper sulfate, potassium 
chromate(VI), benzo(a)pyrene, diuron, ethinyl estradiol, 
testosterone, tetrachlorodibenzodioxin 
21420995, 23974009, 19549813, 
22079256, 20127859, 25152437, 
17555576, 21669218, 21570461 
RFX7 rs7169431* atrazine, estradiol, copper sulfate, formaldehyde 22378314, 22574217, 19549813, 20655997 
BBS9 rs17170286 aflatoxin B1, air pollutants, arsenic trioxide, benzo(a)pyrene, cobaltous chloride, formaldehyde, tetrachlorodibenzodioxin 
20106945, 21757418, 20458559, 
21632981, 19320972, 23649840, 
21570461 
 BST1 rs11945730* 
aflatoxin B1, benzo(a)pyrene diol epoxide, cobaltous 
chloride, tetrachlorodibenzodioxin, acetaminophen, arsenic, 
chlorpyrifos, cocaine, diazinon, ethanol, testosterone, 
tobacco smoke pollution 
22100608, 20382639, 19320972, 
17101203, 17562736, 19654921, 
21968025, 20187946, 21968025, 
15353170, 15788153, 20133372 
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      Appendix Table 20 continued…. 
Gene/region SNP Chemical interaction PUBMED ID 
CD38 rs11945730* 
arsenic trioxide, parathion, progesterone, terbufos, arsenic, 
estradiol, paraquat, particulate matter, progesterone, 
testosterone, tetrachlorodibenzodioxin 
18297255, 22847954, 21768398, 
22847954, 19654921, 21840325, 
18198484, 23638009, 21770760, 
21840325, 21570461 
 TMEM135 rs17149645* 
acetaminophen, aflatoxin B1, benzo(a)pyrene, copper 
sulfate, potassium chromate(VI), PCB, 
tetrachlorodibenzodioxin 
22230336, 20106945, 21632981, 
19549813, 22079256, 19114083, 
24680724 
     SNP = single nucleotide polymorphism  
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Appendix Table 21: Deleterious effect of missense variations associated with gender-specificity in 
childhood ALL risk 
SNP                
(missense variations) 
Gender-
specific results 
SIFT 
score 
SIFT 
prediction 
SIFT 
confidence 
PolyPhen 
score 
PolyPhen 
prediction 
rs9913430 Gender P value 0.74 tolerated high 0 benign 
rs61748746 Gender P value 0.25 tolerated high 0.24 possibly damaging 
rs61748749 Gender P value 0.43 tolerated high 0.24 possibly damaging 
rs35693261 Gender OR 0.01 damaging high 0.01 benign 
rs4770684 Gender OR 0.63 tolerated high 0.03 benign 
rs35665085 Gender OR 0.13 tolerated high 0.01 benign 
rs3847262 Gender OR 0.05 damaging high 0.93 probably damaging 
rs17080410 Gender OR 1 tolerated low 0 benign 
rs61742396 Gender OR 1 tolerated low 0 benign 
rs35672330 Gender OR 0 damaging high 1 probably damaging 
rs11751765 Gender OR 0.16 tolerated high 0.91 probably damaging 
rs73022563 Gender OR 0.05 damaging high 0.96 probably damaging 
rs61731389 Gender OR 0.06 tolerated high 0.86 probably damaging 
rs143021649 Gender OR 0.29 tolerated high 0.01 benign 
rs61745456 Gender OR 0.97 tolerated high 0.98 probably damaging 
rs36041430 Gender OR 0.22 tolerated high 0.001 benign 
rs7829965 Gender OR 0.72 tolerated high 0 benign 
rs34022679 Gender OR 0 damaging high 1 probably damaging 
rs2293624 Gender OR 0.11 tolerated low 0.003 benign 
rs62640905 Gender OR 0.36 tolerated high 0.52 possibly damaging 
rs16973890 Gender OR 0.08 tolerated high 0.52 possibly damaging 
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                             Appendix Table 21 continued…. 
SNP                
(missense variations) 
Gender-
specific results 
SIFT 
score 
SIFT 
prediction 
SIFT 
confidence 
PolyPhen 
score 
PolyPhen 
prediction 
rs117923468 Gender OR 0.5 tolerated high 0.21 possibly damaging 
rs182319278 Gender OR 0.97 tolerated low 0 benign 
rs4645656 Gender OR 0.04 tolerated high 0.56 possibly damaging 
rs12722039 Gender OR 0.5 tolerated low 0 benign 
rs12722042 Gender OR 0.66 tolerated low 0.36 possibly damaging 
rs130069 Gender OR 0.47 tolerated high 0.24 possibly damaging 
rs78888579 Gender OR 0.51 tolerated high 0 benign 
rs56278097 Gender OR 0.22 tolerated high 0 benign 
rs2229528 Gender OR 0.05 tolerated high 0.48 possibly damaging 
rs55882716 Gender OR 0.43 tolerated low 0 benign 
rs34664882 Gender OR 0.02 damaging high 0.003 benign 
rs80040922 Gender OR 0.02 damaging high 0.96 probably damaging 
rs61741435 Gender OR 0.71 tolerated high 0.91 probably damaging 
rs147596194 Gender OR 0 damaging low 0 benign 
SNP = single nucleotide polymorphisms; SIFT & PolyPhen: databases for missense SNP prediction 
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                      Appendix Table 22: Deleterious effect of missense variations associated with age-specificity in  
                      childhood ALL risk 
SNP              
(missense variations) 
Age-specific 
results 
SIFT 
score 
SIFT 
prediction 
SIFT 
confidence 
PolyPhe 
score PolyPhen prediction 
rs2274068 Age P value 0.45 Tolerated High 0 Benign 
rs762562 Age P value 1 Tolerated High 0 Benign 
rs735482 Age P value 0.56 Tolerated High 0 Benign 
rs9897794 Age P value 0.34 Tolerated High 0.003 Benign 
rs2101919 Age P value 0.57 Tolerated High 0 Benign 
rs6972158 Age P value 0.43 Tolerated High 0 Benign 
rs56291145 Age OR 0.16 Tolerated Low 0.02 Benign 
rs35384751 Age OR 0 Damaging High 0.63 Possibly damaging 
rs10999147 Age OR 0.4 Tolerated High 0.24 Possibly damaging 
rs17409162 Age OR 0.22 Tolerated High 0.97 Probably damaging 
rs16916188 Age OR 0.09 Tolerated High 0.14 Benign 
rs35537868 Age OR 0.82 Tolerated High 0.08 Benign 
rs35340237 Age OR 0.84 Tolerated High 0 Benign 
rs17407084 Age OR 0 Damaging High 1 Probably damaging 
rs41309927 Age OR 0.34 Tolerated High 0 Benign 
rs36086854 Age OR 0.34 Tolerated High 0.05 Benign 
rs34139105 Age OR 0.29 Tolerated High 0.4 Possibly damaging 
rs36068434 Age OR 0.02 Tolerated Low 0 Benign 
rs11651675 Age OR 0.62 Tolerated High 0.001 Benign 
rs41279492 effect size 0.35 Tolerated High 0 Benign 
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                            Appendix Table 22 continued…. 
SNP              
(missense variations) 
Age-specific 
results 
SIFT 
score 
SIFT 
prediction 
SIFT 
confidence 
PolyPhe 
score PolyPhen prediction 
rs141872266 Age OR 0.01 Damaging High 0.04 Benign 
rs138700801 Age OR 0.19 Tolerated High 0.08 Benign 
rs9728577 Age OR 0.05 Damaging High 0.006 Benign 
rs3204798 Age OR 0.11 Tolerated High 0 Benign 
rs41285557 Age OR 0.68 Tolerated High 0.001 Benign 
rs35424709 Age OR 0.39 Tolerated High 1 Probably damaging 
rs61744122 Age OR 0.33 Tolerated High 0.16 Benign 
rs78323957 Age OR 0.13 Tolerated High 0.001 Benign 
rs35384751 Age OR 0.02 Damaging High 0.63 Possibly damaging 
rs35340237 Age OR 1 Tolerated High 0 Benign 
SNP = single nucleotide polymorphisms; SIFT & PolyPhen: databases for missense SNP prediction 
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     Appendix Table 23: Time-to-event analysis of identified gender- and age-specific childhood ALL risk markers  
 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs10505918(D)* < 1 x 10-4 1.69 (1.27 - 2.24) < 1 x 10-3 1.55 (1.06 - 2.25) 0.02 1.93 (1.25 - 2.96) 3 x 10-3 
rs2949827(D)* < 1 x 10-4 0.54 (0.38 - 0.77) 1 x 10-3 0.72 (0.46 - 1.12) 0.15 0.39 (0.23 - 0.66) < 1 x 10-3 
rs2212824(D)* < 1 x 10-4 1.76 (1.30 -2.38) < 1 x 10-3 1.76 (1.20 - 2.59) 4 x 10-3 1.76 (1.09 - 2.83) 0.02 
rs1209145(D)*  < 1 x 10-4 1.80 (1.31 - 2.48) < 1 x 10-3 1.62 (1.05 - 2.51) 0.03 2.05 (1.28 - 3.27) 3 x 10-3 
rs1209145(D)* < 1 x 10-4 1.76 (1.28 - 2.41) < 1 x 10-3 1.62 (1.05 - 2.51) 0.03 2.05 (1.28 - 3.27) 3 x 10-3 
rs738027(D)* < 1 x 10-4 1.62 (1.22 -2.15) 1 x 10-3 1.62 (1.10 - 2.38) 0.01 1.62 (1.06 - 2.47) 0.03 
rs2101919(D)* < 1 x 10-4 0.61 (0.46 - 0.80) 1 x 10-3 0.64 (0.44 - 0.94) 0.02 0.56 (0.37 - 0.86) 8 x 10-3 
rs9809647(D)* < 1 x 10-4 0.60 (0.45 - 0.78) 1 x 10-3 0.57 (0.39 - 0.84) 4 x 10-3 0.64 (0.42 - 0.98) 0.04 
rs10133677(D)* < 1 x 10-4 1.78 (1.28 - 2.46) 1 x 10-3 1.65 (1.05 - 2.61) 0.03 1.92 (1.21 - 3.06) 6 x 10-3 
rs10999147(D)** < 1 x 10-4 2.55 (1.59 - 4.08) < 1 x 10-3 2.01 (1.09 - 3.71) 0.03 3.90 (1.85 - 8.22) < 1 x 10-3 
rs1882591(D)* 1 x 10-4 0.63 (0.48 - 0.83) 1 x 10-3 0.55 (0.38 - 0.81) 2 x 10-3 0.75 (0.49 - 1.13) 0.17 
rs10099957(D)** 1 x 10-4 2.00 (1.35 - 2.95 < 1 x 10-3 2.32 (1.36 - 3.95) 2 x 10-3 1.70 (0.95 - 3.02) 0.07 
rs4741086(D)** 1 x 10-4 1.75 (1.26 - 2.44) 1 x 10-3 1.48 (0.98 - 2.24) 0.06 2.39 (1.40 - 4.08) 1 x 10-3 
rs7091901(D)** 1 x 10-4 2.00 (1.33 - 3.01) 1 x 10-3 1.76 (1.01 - 3.06) 0.05 2.38 (1.30 - 4.35) 5 x 10-3 
rs1457759(D)** 1 x 10-4 2.05 (1.37 - 3.06) < 1 x 10-3 2.43 (1.43 - 4.16) 1 x 10-3 1.67 (0.90 - 3.09) 0.10 
rs10826912(D)** 1 x 10-4 2.00 (1.32 - 3.02) 1 x 10-3 1.74 (0.98 - 3.06) 0.06 2.38 (1.30 - 4.35) 5 x 10-3 
rs237320(D)* 2 x 10-4 0.62 (0.45 -0.84) 2 x 10-3 0.65 (0.42 - 1.00) 0.05 0.58 (0.38 - 0.91) 0.02 
rs17109582(D)** 2 x 10-4 2.05 (1.33 -3.16) 1 x 10-3 2.13 (1.21 - 3.74) 9 x 10-3 1.96 (1.00 - 3.82) 0.05 
rs9856456(D)** 2 x 10-4 2.27 (1.37 - 3.75) 1 x 10-3 1.89 (1.05 - 3.40) 0.03 4.36 (1.68 - 11.32) 2 x 10-3 
rs1894381(D)* 3 x 10-4 0.63 (0.47 - 0.85) 2 x 10-3 0.54 (0.36 -0.80) 2 x 10-3 0.78 (0.51 - 1.20) 0.26 
rs10079494(D)* 4 x 10-4 1.53 (1.16 - 2.03) 3 x 10-3 1.44 (0.99 - 2.10) 0.06 1.69 (1.11 - 2.59) 0.02 
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     Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs35424709(D)** 4 x 10-4 1.83 (1.24 - 2.68) 2 x 10-3 1.79 (0.98 - 3.28) 0.06 1.85 (1.13 - 3.05) 0.02 
rs2388773(D)* 5 x 10-4 0.65 (0.49 - 0.87) 4 x 10-3 0.58 (0.39 - 0.86) 6 x 10-3 0.77 (0.51 - 1.17) 0.22 
rs9694342(D)* 6 x 10-4 0.66 (0.50 - 0.87) 3 x 10-3 0.63 (0.43 - 0.92) 0.02 0.69 (0.45 - 1.04) 0.08 
rs16827743(D)** 6 x 10-4 2.00 (1.27 - 3.14) 3 x 10-3 1.81 (1.02 - 3.20) 0.04 2.40 (1.14 - 5.06) 0.02 
rs8011343(D)* 7 x 10-4 1.57 (1.16 - 2.13) 4 x 10-3 1.78 (1.16 - 2.74) 9 x 10-3 1.40 (0.90 - 2.17) 0.13 
rs1493897(D)* 7 x 10-4 0.67 (0.50 - 0.88) 5 x 10-3 0.59 (0.40 - 0.86) 6 x 10-3 0.79 (0.52 - 1.21) 0.27 
rs1915164(D)** 7 x 10-4 2.00 (1.26 - 3.19) 3 x 10-3 1.75 (0.84 - 3.66) 0.13 2.21 (1.21 - 4.03) 0.01 
rs11014598(D)†† 8 x 10-4 0.45 (0.25 -0.81) 8 x 10-3 0.47 (0.24 - 0.90) 0.02 0.38 (0.09 - 1.54) 0.18 
rs6972158(D)* 8 x 10-4 1.50 (1.14 - 1.98) 4 x 10-3 1.59 (1.09 - 2.31) 0.02 1.39 (0.92 - 2.10) 0.12 
rs7320982(D)* 8 x 10-4 0.66 (0.50 - 0.88) 5 x 10-3 0.85 (0.59 -1.23) 0.39 0.48 (0.31 - 0.74) 1 x 10-3 
rs6492498(D)* 8 x 10-4 0.66 (0.50 - 0.88) 4 x 10-3 0.61 (0.42 - 0.89) 0.01 0.74 (0.49 - 1.13) 0.16 
rs10250709(D)* 8 x 10-4 1.50 (1.14 - 1.98) 4 x 10-3 1.59 (1.09 - 2.31) 0.02 1.39 (0.92 - 2.10) 0.12 
rs1191818(D)* 8 x 10-4 0.65 (0.48 - 0.87) 4 x 10-3 0.65 (0.44 - 0.96) 0.03 0.66 (0.41 - 1.05) 0.08 
rs2909644(D)** 8 x 10-4 2.10 (1.26 - 3.48) 4 x 10-3 1.70 (0.89 - 3.27) 0.11 3.14 (1.39 - 7.11) 6 x 10-3 
rs6708453(D)** 8 x 10-4 1.61 (1.17 - 2.22) 4 x 10-3 1.86 (1.23 - 2.83) 4 x 10-3 1.31 (0.78 - 2.20) 0.31 
rs222314(D)* 8 x 10-4 1.56 (1.15 - 2.13) 4 x 10-3 1.47 (0.98 - 2.20) 0.06 1.72 (1.06 - 2.78) 0.03 
rs139886(D)* 8 x 10-4 1.51 (1.13 - 2.02) 5 x 10-3 1.32 (0.90 -1.93) 0.16 1.84 (1.16 - 2.81) 9 x 10-3 
rs17409162(D)** 8 x 10-4 2.09 (1.27 - 3.44) 4 x 10-3 2.06 (1.03 - 4.11) 0.04 2.13 (1.04 - 4.33) 0.04 
rs9560160(D)** 8 x 10-4 1.73 (1.19 -2.52) 4 x 10-3 1.35 (0.81 - 2.23) 0.25 2.50 (1.43 - 4.36) 1 x 10-3 
rs7791037(R)†  1 x 10-3 1.66 (1.17 - 2.37) 4 x 10-3 1.78 (1.04 - 3.06) 0.04 1.59 (1.00 - 2.51) 0.05 
rs1881116(D)* 1 x 10-3 1.48 (1.12 - 1.95) 6 x 10-3 1.17 (0.81 - 1.68) 0.41 2.29 (1.46 - 3.60) < 1 x 10-3 
 
247 
 
     Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs11997355(D)* 1 x 10-3 0.61 (0.43 - 0.87) 7 x 10-3 0.62 (0.38 - 0.98) 0.04 0.61 (0.36 - 1.04) 0.07 
rs7720650(D)* 1 x 10-3 0.65 (0.48 - 0.88) 6 x 10-3 0.76 (0.50 - 1.16) 0.20 0.55 (0.35 - 0.85) 7 x 10-3 
rs2396653(D)* 1 x 10-3 0.66 (0.50 - 0.89) 6 x 10-3 0.82 (0.55 - 1.20) 0.31 0.52 (0.33 - 0.80) 3 x 10-3 
rs1151277(D)* 1 x 10-3 0.66 (0.49 - 0.89) 7 x 10-3 0.55 (0.37 - 0.82) 4 x 10-3 0.84 (0.54 - 1.31) 0.44 
rs12073211(D)* 1 x 10-3 0.67 (0.50 -0.90) 7 x 10-3 0.75 (0.51 - 1.10) 0.14 0.58 (0.37 - 0.89) 0.01 
rs3825594(D)* 1 x 10-3 0.67 (0.51 - 0.89) 5 x 10-3 0.75 (0.51 - 1.08) 0.12 0.59 (0.39 - 0.89) 0.01 
rs1610315(D)* 1 x 10-3 0.68 (0.51 - 0.89) 6 x 10-3 0.57 (0.39 -0.84) 4 x 10-3 0.83 (0.55 - 1.24) 0.36 
rs9897794(D)* 1 x 10-3 0.66 (0.49 - 0.89) 6 x 10-3 0.76 (0.52 - 1.12) 0.17 0.49 (0.31 - 0.80) 4 x 10-3 
rs8014810(D)* 1 x 10-3 0.67 (0.50 - 0.90) 7 x 10-3 0.69 (0.46 -1.02) 0.06 0.64 (0.41 - 0.98) 0.04 
rs3954950(D)* 1 x 10-3 0.68 (0.51 - 0.89) 6 x 10-3 0.67 (0.46 - 0.98) 0.04 0.67 (0.44 - 1.02) 0.06 
rs56291145(D)** 1 x 10-3 2.06 (1.24 -3.43) 5 x 10-3 1.90 (0.98 - 3.68) 0.06 2.34 (1.06 - 5.20) 0.04 
rs9861022(D)** 1 x 10-3 1.94 (1.23 -3.05) 4 x 10-3 1.73 (0.98 - 3.07) 0.06 2.40 (1.14 - 5.06) 0.02 
rs10493958(D)** 1 x 10-3 1.99 (1.23 -3.21) 5 x 10-3 1.95 (0.98 - 3.87) 0.06 2.03 (1.04 - 3.97) 0.04 
rs9392857(D)* 2 x 10-3 0.68 (0.51 - 0.90) 8 x 10-3 0.77 (0.52 - 1.13) 0.18 0.55 (0.36 - 0.85) 8 x 10-3 
rs4948088(D)* 2 x 10-3 0.61 (0.42 - 0.90) 8 x 10-3 0.72 (0.43 - 1.21) 0.21 0.49 (0.28 - 0.86) 0.01 
rs7583258(D)* 2 x 10-3 0.66 (0.48 - 0.91) 0.01 0.55 (0.36 - 0.84) 5 x 10-3 0.85 (0.53 - 1.35) 0.49 
rs7722067(D)* 2 x 10-3 0.68 (0.51 - 0.91) 9 x 10-3 0.74 (0.51 - 1.08) 0.12 0.61 (0.40 - 0.94) 0.03 
rs2065212(D)* 2 x 10-3 0.68 (0.52 - 0.91) 8 x 10-3 0.64 (0.44 - 0.93) 0.02 0.74 (0.49 - 1.13) 0.17 
rs2830698(R)*  2 x 10-3 0.51 (0.30 - 0.87) 0.01 0.53 (0.25 - 1.11) 0.09 0.49 (0.22 - 1.07) 0.08 
rs4748309(D)** 2 x 10-3 1.78 (1.18 - 2.65) 6 x 10-3 1.51 (0.87 - 2.62) 0.14 2.18 (1.20 -3.98) 0.01 
rs11945730(D)** 2 x 10-3 1.66 (1.15 - 2.41) 7 x 10-3 1.42 (0.88 - 2.31) 0.16 2.13 (1.20 - 3.81) 0.01 
rs7294845(D)†  3 x 10-3 1.43 (1.08 - 1.89) 0.01 1.32 (0.90 - 1.93) 0.15 1.57 (1.04 - 2.38) 0.03 
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      Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs6739633(D)* 3 x 10-3 1.44 (1.08 - 1.91) 0.01 1.23 (0.83 - 1.81) 0.30 1.85 (1.18 - 2.88) 7 x 10-3 
rs139866(D)* 3 x 10-3 1.44 (1.08 - 1.92) 0.01 1.27 (0.87 - 1.86) 0.22 1.73 (1.11 - 2.69) 0.02 
rs3800292(D)* 3 x 10-3 0.55 (0.34 - 0.88) 0.02 0.58 (0.25 - 1.32) 0.19 0.54 (0.30 - 0.96) 0.04 
rs36068434(D)** 3 x 10-3 1.93 (1.17 - 3.20) 0.01 1.96 (1.05 - 3.69) 0.04 1.88 (0.81 - 4.38) 0.14 
rs16909509(D)** 3 x 10-3 1.86 (1.10 - 3.13) 0.02 2.17 (1.03 - 4.55) 0.04 1.62 (0.78 - 3.37) 0.20 
rs12705300(D)** 3 x 10-3 1.64 (1.12 -2.40) 0.01 1.83 (1.10 - 3.07) 0.02 1.44 (0.81 - 2.56) 0.21 
rs4821717(D)* 4 x 10-3 1.42 (1.07 - 1.88) 0.02 1.35 (0.92 - 1.96) 0.12 1.51 (0.98 - 2.33) 0.06 
rs7157104(D)* 4 x 10-3 0.71 (0.53 - 0.94) 0.02 0.76 (0.52 - 1.12) 0.12 0.64 (0.42 - 0.98) 0.04 
rs973358(D)* 4 x 10-3 1.44 (1.07 - 1.92) 0.02 1.66 (1.12 - 2.46) 0.01 1.18 (0.76 - 1.83) 0.46 
rs41309927(D)** 4 x 10-3 1.85 (1.15 - 2.99) 0.01 1.52 (0.84 - 2.74) 0.17 2.93 (1.32 - 6.52) 8 x 10-3 
rs276725(D)** 4 x 10-3 1.75 (1.14 -2.71) 0.01 2.28 (1.26 - 4.15) 7 x 10-3 1.37 (0.72 - 2.58) 0.33 
rs11250832(D)** 4 x 10-3 1.64 (1.11 -2.42) 0.01 1.54 (0.97 - 2.46) 0.07 1.89 (0.94 - 3.80) 0.08 
rs2899293(D)* 5 x 10-3 1.43 (1.06 - 1.93) 0.02 1.26 (0.86 - 1.86) 0.24 1.76 (1.10 - 2.83) 0.02 
rs7318021(D)* 5 x 10-3 0.72 (0.55 - 0.94) 0.02 0.61 (0.42 - 0.89) 0.01 0.86 (0.57 - 1.29) 0.46 
rs8021355(D)* 5 x 10-3 0.71 (0.53 - 0.94) 0.02 0.77 (0.53 -1.13) 0.19 0.63 (0.41 - 0.96) 0.02 
rs7144565(D)* 5 x 10-3 0.71 (0.53 - 0.94) 0.02 0.77 (0.53 -1.13) 0.19 0.63 (0.41 - 0.96) 0.02 
rs2274068(D)* 5 x 10-3 0.71 (0.53 - 0.94) 0.02 0.77 (0.53 -1.13) 0.19 0.63 (0.41 - 0.96) 0.02 
rs17017488(D)* 5 x 10-3 0.71 (0.53 - 0.94) 0.02 0.75 (0.50 - 1.11) 0.15 0.66 (0.44 - 1.01) 0.06 
rs10511980(D)* 5 x 10-3 0.69 (0.52 - 0.90) 8 x 10-3 0.66 (0.46 - 0.96) 0.03 0.72 (0.47 - 1.09) 0.12 
rs11172024(D)* 5 x 10-3 0.66 (0.46 - 0.93) 0.02 0.61 (0.37 - 1.00) 0.05 0.71 (0.42 - 1.17) 0.18 
rs6052937(D)* 5 x 10-3 0.70 (0.52 - 0.94) 0.02 0.73 (0.48 - 1.13) 0.16 0.65 (0.42 - 1.01) 0.054 
rs10500248(D)** 5 x 10-3 1.70 (1.11 - 2.61) 0.01 1.81 (1.02 - 3.21) 0.04 1.59 (0.84 - 3.00) 0.16 
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     Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs2124906(D)** 5 x 10-3 1.70 (1.11 - 2.61) 0.01 1.81 (1.02 - 3.21) 0.04 1.59 (0.84 - 3.00) 0.16 
rs6572051(D)** 5 x 10-3 1.75 (1.12 -2.73) 0.02 1.55 (0.85 - 2.84) 0.15 2.05 (1.05 - 4.02) 0.04 
rs17149645(D)** 5 x 10-3 1.79 (1.22 - 2.62) 3 x 10-3 2.03 (1.13 - 3.66) 0.02 1.68 (1.01 - 2.77) 0.05 
rs6037033(D)* 6 x 10-3 0.71 (0.53 - 0.94) 0.02 0.63 (0.43 - 0.93) 0.02 0.81 (0.53 - 1.23) 0.33 
rs1521244(D)* 6 x 10-3 1.41 (1.06 - 1.88) 0.02 1.18 (0.81 - 1.72) 0.4 1.75 (1.14 - 2.70) 0.01 
rs1430838(R)*  6 x 10-3 1.56 (1.09 -2.25) 0.02 1.25 (0.79 - 1.97) 0.34 2.44 (1.36 - 4.39) 0.19 
rs2116078 (R)*  6 x 10-3 1.56 (1.09 -2.25) 0.02 1.25 (0.79 - 1.97) 0.34 2.44 (1.36 - 4.39) 0.19 
rs10157510 (D)** 6 x 10-3 1.72 (1.10 - 2.71) 0.02 1.61 (0.90 - 2.88) 0.11 1.93 (0.95 - 3.92) 0.07 
rs13116233(D)* 7 x 10-3 1.37 (1.04 - 1.81) 0.02 1.41 (0.98 - 2.05) 0.07 1.32 (0.87 - 1.99) 0.19 
rs6519091(D)* 7 x 10-3 1.51 (1.12 - 2.04) 7 x 10-3 1.35 (0.91 - 2.00) 0.13 1.76 (1.10 - 2.83) 0.02 
rs2185230(A)* 7 x 10-3 1.33 (1.05 - 1.68) 0.02 1.09 (0.81 - 1.47) 0.58 1.93 (1.30 - 2.88) 1 x 10-3 
rs7620914(D)** 7 x 10-3 1.50 (1.06 - 2.11) 0.02 1.84 (1.16 - 2.90) 9 x 10-3 1.18 (0.70 - 1.99) 0.53 
rs3850942(D)* 8 x 10-3 0.62 (0.40 - 0.95) 0.03 0.65 (0.35 - 1.22) 0.18 0.59 (0.33 - 1.07) 0.08 
rs3993401(D)* 8 x 10-3 0.73 (0.56 - 0.96) 0.03 0.69 (0.48 - 0.99) 0.05 0.79 (0.52 - 1.20) 0.28 
rs13129052(D)** 8 x 10-3 1.78 (1.08 - 2.91) 0.02 1.87 (0.93 - 3.76) 0.08 1.69 (0.84 - 3.41) 0.14 
rs6093579(D)** 8 x 10-3 1.80 (1.08 - 2.98) 0.02 2.38 (1.21 - 4.68) 0.01 1.34 (0.62 - 2.91) 0.62 
rs78323957(D)** 8 x 10-3 1.86 (1.10 - 3.13) 0.02 2.17 (1.03 - 4.55) 0.04 1.62 (0.78 - 3.37) 0.2 
rs16950438(D)** 8 x 10-3 1.59 (1.07 -2.37) 0.02 1.78 (1.03 -3.03) 0.04 1.42 (0.78 - 2.57) 0.25 
rs2125649(D)* 9 x 10-3 0.69 (0.50 - 0.96) 0.03 0.70 (0.44 - 1.10) 0.12 0.69 (0.43 - 1.10) 0.12 
rs5028798(D)* 9 x 10-3 0.73 (0.55 - 0.96) 0.03 0.62 (0.43 - 0.90) 0.01 0.90 (0.59 -1.36) 0.6 
rs6151599(D)** 9 x 10-3 1.57 (1.06 -2.32) 0.03 1.65 (0.96 - 2.84) 0.07 1.49 (0.84 - 2.63) 0.17 
rs7492685(D)†  0.01 1.72 (1.07 - 2.77) 0.03 1.54 (0.49 - 4.89) 0.46 1.76 (1.04 - 2.99) 0.04 
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     Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs13387046(D)†† 0.01 0.58 (0.34 - 0.97) 0.04 0.57 (0.32 - 1.01) 0.05 0.62 (0.20 - 1.98) 0.42 
rs4254428(D)* 0.01 0.71 (0.53 - 0.97) 0.03 0.73 (0.50 - 1.08) 0.12 0.69 (0.42 - 1.16) 0.16 
rs6510588(D)* 0.01 0.71 (0.53 - 0.97) 0.03 0.73 (0.50 - 1.08) 0.12 0.69 (0.42 - 1.16) 0.16 
rs2051713(D)* 0.01 1.42 (1.04 - 1.98) 0.03 1.15 (0.75 - 1.77) 0.52 1.74 (1.12 - 2.73) 0.02 
rs6109487(D)* 0.01 1.38 (1.03 - 1.84) 0.03 1.39 (0.94 -2.06) 0.1 1.36 (0.89 - 2.08) 0.16 
rs16979806(R)* 0.01 0.61 (0.38 - 0.99) 0.04 0.64 (0.34 - 1.21) 0.14 0.57 (0.27 - 1.19) 0.14 
rs11120342(D)* 0.01 0.73 (0.56 - 0.97) 0.03 0.69 (0.48 - 1.01) 0.06 0.79 (0.52 - 1.20) 0.27 
rs1481046(D)* 0.01 1.36 (1.03 - 1.79) 0.03 1.31 (0.91 - 1.90) 0.15 1.43 (0.94 - 2.17) 0.09 
rs753712(D)* 0.01 0.72 (0.54 -0.97) 0.03 0.70 (0.47 - 1.04) 0.07 0.75 (0.48 - 1.18) 0.17 
rs6927353(D)** 0.01 1.68 (1.04 -2.73) 0.04 1.41 (0.79 - 2.53) 0.25 2.70 (1.15 - 6.35) 0.02 
rs1800141(D)** 0.01 1.76 (1.04 - 2.98) 0.04 1.26 (0.65 - 2.43) 0.49 4.65 (1.91 - 11.32) 1 x 10-3 
rs2389891(D)** 0.01 1.57 (1.05 - 2.37) 0.03 1.92 (1.14 - 3.26) 0.02 1.20 (0.62 - 2.33) 0.59 
rs12188300(D)** 0.01 1.57 (1.03 - 2.39) 0.04 1.85 (1.08 - 3.19) 0.03 1.25 (0.64 - 2.46) 0.52 
rs7303641(D)** 0.01 1.60 (1.06 - 2.42) 0.03 1.84 (1.06 - 3.19) 0.03 1.35 (0.72 - 2.55) 0.35 
rs34139105(D)** 0.01 1.64 (1.06 - 2.55) 0.03 2.16 (1.11 - 4.21) 0.02 1.38 (0.78 - 2.46) 0.27 
rs9328207(D)** 0.01 1.70 (1.06 - 2.73) 0.03 1.57 (0.86 - 2.88) 0.15 1.94 (0.91 - 4.15) 0.09 
rs10514074(D)** 0.01 1.60 (1.07 - 2.38) 0.02 1.66 (1.01 - 2.71) 0.05 1.49 (0.75 - 2.98) 0.26 
rs61744122(D)** 0.01 1.68 (1.05 - 2.69) 0.03 1.63 (0.82 - 3.27) 0.17 1.72 (0.90 - 3.28) 0.10 
rs17170286(D)** 0.01 1.60 (1.06 - 2.42) 0.03 2.36 (1.34 - 4.16) 3 x 10-3 1.12 (0.61 - 2.06) 0.72 
rs7776264(D)†  0.02 1.33 (1.01 - 1.76) 0.04 1.23 (0.84 -1.79) 0.28 1.47 (0.97 - 2.24) 0.07 
rs468771(R)†  0.02 1.77 (1.03 - 3.05) 0.04 1.64 (0.91 - 2.94) 0.10 3.32 (0.79 - 13.88) 0.10 
rs1713676(D)†  0.02 1.56 (1.03 - 2.37) 0.04 1.68 (1.03 - 2.74) 0.04 1.29 (0.56 - 2.96) 0.55 
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     Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs349714(R)†  0.02 0.70 (0.50 - 0.98) 0.04 0.68 (0.40 -1.14) 0.15 0.72 (0.47 - 1.11) 0.14 
rs2229528(D)†† 0.02 1.78 (1.02 - 3.12) 0.04 1.64 (0.90 - 3.00) 0.11 3.32 (0.79 - 13.88) 0.10 
rs35693261(D)†† 0.02 1.76 (1.00 - 3.08) 0.05 1.53 (0.84 - 2.80) 0.17 8.41 (1.94 - 36.47) 4 x 10-3 
rs368390(D)†† 0.02 0.63 (0.40 - 1.01) 0.053 0.59 (0.36 - 0.97) 0.04 1.06 (0.33 - 3.38) 0.92 
rs6936494(D)†† 0.02 0.66 (0.44 - 1.00) 0.053 0.66 (0.42 - 1.04) 0.07 0.69 (0.24 - 1.95) 0.48 
rs9842465(D)†† 0.02 1.75 (1.00 - 3.06) 0.05 1.75 (0.95 -3.21) 0.07 1.77 (0.43 - 7.26) 0.43 
rs665159(D)* 0.02 1.35 (1.00 -1.82) 0.05 1.19 (0.80 - 1.78) 0.38 1.65 (1.04 - 2.63) 0.03 
rs924615(D)* 0.02 0.75 (0.57 - 0.99) 0.04 0.73 (0.50 - 1.06) 0.10 0.78 (0.52 - 1.19) 0.25 
rs877111(D)* 0.02 1.31 (1.00 - 1.73) 0.052 1.30 (0.90 - 1.89) 0.17 1.30 (0.86 - 1.96) 0.21 
rs742390(D)* 0.02 1.33 (1.01 - 1.75) 0.04 1.36 (0.94 - 1.96) 0.10 1.31 (0.87 - 1.98) 0.20 
rs2620870(D)* 0.02 1.35 (1.01 - 1.82) 0.05 1.40 (0.94 - 2.08) 0.10 1.28 (0.82 - 2.01) 0.28 
rs1868368(D)* 0.02 0.76 (0.58 -1.01) 0.054 0.67 (0.46 -0.97) 0.04 0.89 (0.59 - 1.34) 0.58 
rs762562(D)* 0.02 0.76 (0.58 -1.00) 0.05 0.78 (0.54 - 1.14) 0.20 0.71 (0.47 - 1.07) 0.10 
rs11171543(D)* 0.02 0.73 (0.53 - 1.00) 0.051 0.65 (0.42 - 0.99) 0.05 0.85 (0.53 - 1.36) 0.50 
rs36086854(D)** 0.02 1.65 (1.02 - 2.68) 0.04 1.54 (0.86 - 2.78) 0.15 1.92 (0.82 - 4.48) 0.13 
rs1835154(D)** 0.02 1.71 (1.03 - 2.84) 0.04 2.00 (1.03 -3.88) 0.04 1.42 (0.65 - 3.11) 0.37 
rs11175471 (D)** 0.02 1.50 (1.01 - 2.22) 0.04 1.44 (0.86 - 2.41) 0.16 1.59 (0.86 - 2.94) 0.14 
rs28421666 (D)** 0.02 1.47 (1.00 -2.15) 0.05 1.46 (0.87-2.46) 0.15 1.48 (0.84 -2.59) 0.18 
rs17055478 (D)** 0.02 1.58 (1.01 -2.48) 0.05 1.97 (1.01 - 3.84) 0.05 1.35 (0.73 - 2.48) 0.34 
rs3805114(D)** 0.02 1.62 (1.01 - 2.58) 0.04 1.84 (0.99 - 3.40) 0.05 1.37 (0.66 -2.85) 0.39 
rs17140942(D)** 0.02 1.65 (1.02 - 2.66) 0.04 1.46 (0.76 -2.82) 0.26 1.92 (0.95 -3.85) 0.07 
rs6696657(D)†  0.03 1.31 (0.99 - 1.74) 0.06 1.32 (0.99 - 1.76) 0.06 0.61 (0.05 - 6.73) 0.69 
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     Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs3857193(D)†   0.03 0.76 (0.56 - 1.01) 0.06 0.82 (0.56 - 1.20) 0.30 0.68 (0.44 - 1.06) 0.09 
rs117923468(D)†† 0.03 1.71 (0.98 -3.00) 0.06 1.58 (0.86 - 2.90) 0.14 3.01 (0.73 - 12.40) 0.13 
rs16973890(D)†† 0.03 1.71 (0.98 - 3.00) 0.06 1.58 (0.86 - 2.90) 0.14 3.01 (0.73 - 12.40) 0.13 
rs182319278(D)†† 0.03 1.71 (0.98 -3.00) 0.06 1.58 (0.86 - 2.90) 0.14 3.01 (0.73 - 12.40) 0.13 
rs7818844(D)* 0.03 0.74 (0.54 - 1.01) 0.06 0.76 (0.49 - 1.16) 0.20 0.72 (0.45 - 1.14) 0.16 
rs2899469(D)* 0.03 1.30 (0.98 - 1.73) 0.07 1.08 (0.74 - 1.60) 0.68 1.71 (1.12 - 2.62) 0.01 
rs202050948(D)* 0.03 0.70 (0.49 - 1.02) 0.06 0.67 (0.40 - 1.11) 0.12 0.74 (0.42 - 1.31) 0.30 
rs7330286(D)** 0.03 1.55 (0.97 - 2.48) 0.07 1.18 (0.61 - 2.28) 0.61 1.66 (0.98 - 2.82) 0.06 
rs11651675(D)** 0.03 1.69 (1.00 - 2.87) 0.05 1.41 (0.57 - 3.46) 0.46 1.89 (0.98 - 3.65) 0.06 
rs10109794(D)** 0.03 1.60 (0.98 -2.61) 0.06 1.83 (0.97 - 3.46) 0.06 1.34 (0.62 - 2.90) 0.46 
rs568760(D)** 0.03 1.65 (0.99 -2.74) 0.06 1.58 (0.90 - 2.78) 0.11 1.98 (0.62 - 6.33) 0.25 
rs6851586(D)** 0.03 1.49 (0.97 - 2.29) 0.07 1.06 (0.60 - 1.86) 0.85 2.93 (1.51 - 5.71) 2 x 10-3 
rs3790126(D)** 0.03 1.59 (1.00 - 2.53) 0.05 2.15 (1.07 - 4.31) 0.03 1.30 (0.71 - 2.41) 0.40 
rs41285557(D)** 0.03 1.63 (0.99 -2.69) 0.05 1.66 (0.67 -4.10) 0.28 1.63 (0.90 - 2.94) 0.11 
rs17407084(D)** 0.03 1.58 (0.98 -2.56) 0.06 1.43 (0.72 - 2.83) 0.31 1.77 (0.90 - 3.47) 0.10 
rs7172316(D)** 0.03 1.57 (0.98 - 2.51) 0.06 1.40 (0.75 - 2.64) 0.29 1.82 (0.90 - 3.69) 0.10 
rs10902652(D)** 0.03 1.58 (0.98 - 2.56) 0.06 1.27 (0.64 - 2.51) 0.50 2.07 (1.04 - 4.13) 0.04 
rs8013602(D)** 0.03 1.57 (0.97 - 2.52) 0.06 1.29 (0.67 - 2.47) 0.45 2.06 (1.03 - 4.13) 0.04 
rs4680582(D)†  0.04 1.30 (0.97 - 1.75) 0.08 1.34 (0.88 - 2.04) 0.17 1.26 (0.83 - 1.91) 0.28 
rs4792149(D)†  0.04 1.33 (0.96 - 1.84) 0.09 1.35 (0.92 - 1.99) 0.13 1.27 (0.69 - 2.34) 0.44 
rs2874641(D)†  0.04 1.30 (0.98 - 1.72) 0.07 1.24 (0.84 - 1.83) 0.11 1.36 (0.90 - 2.08) 0.15 
rs1550017(A)† 0.04 1.36 (0.99 – 1.88) 0.06 1.36 (0.95 – 1.95) 0.10 1.38 (0.69 – 2.77) 0.36 
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     Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs34022679(D)†† 0.04 1.58 (0.96 – 2.59) 0.07 1.77 (1.03 – 3.03) 0.04 0.90 (0.22 – 3.66) 0.88 
rs2031293(D)* 0.04 0.76 (0.56 – 1.03) 0.08 0.99 (0.65 – 1.53) 0.99 0.48 (0.30 – 0.76) 2 x 10-3 
rs7016929(D)* 0.04 0.78 (0.59 – 1.03) 0.08 0.84 (0.63 – 1.13) 0.25 0.81 (0.56 – 1.17) 0.27 
rs1004327(A)* 0.04 1.25 (1.01 -1.26) 0.04 1.19 (0.88 – 1.60) 0.25 1.34 (0.97 – 1.85) 0.08 
rs377621®* 0.04 0.68 (0.44 – 1.05) 0.08 0.76 (0.44 – 1.31) 0.32 0.57 (0.27 – 1.19) 0.14 
rs7304215(D)** 0.04 1.53 (0.97 – 2.44) 0.07 2.00 (1.03 – 3.88) 0.04 1.25 (0.66 – 2.36) 0.50 
rs17039265(D)** 0.04 1.58 (0.95 – 2.63) 0.08 1.39 (0.74 – 2.62) 0.31 2.08 (0.89 – 4.84) 0.09 
rs9728577(D)** 0.04 1.58 (0.95 – 2.63) 0.08 1.39 (0.74 – 2.62) 0.31 2.08 (0.89 – 4.84) 0.09 
rs75411676(D)** 0.04 1.58 (0.95 – 2.63) 0.08 1.39 (0.74 – 2.62) 0.31 2.08 (0.89 – 4.84) 0.09 
rs8176018(D)** 0.04 1.62 (0.96 – 2.72) 0.07 0.94 (0.38 – 2.30) 0.89 2.51 (1.29 – 4.86) 7 x 10-3 
rs9407838(D)** 0.04 1.41 (0.96 -2.08) 0.08 1.35 (0.81 – 2.24) 0.25 1.51 (0.84 – 2.73) 0.17 
rs16964079(D)** 0.04 1.48 (0.94 -2.32) 0.09 1.50 (0.87 – 2.60) 0.15 1.44 (0.66 -3.14) 0.36 
rs3130161(D)** 0.04 1.52 (0.86 -2.41) 0.07 2.06 (1.11 – 3.82) 0.02 1.13 (0.56 – 2.25) 0.73 
rs12257453(D)** 0.04 1.53 (0.97 – 2.43) 0.07 1.55 (0.86 – 2.81) 0.15 1.51 (0.73 – 3.14) 0.27 
rs11833839(D)** 0.04 1.51 (0.94 -2.42) 0.09 1.71 (0.89 -3.30) 0.11 1.34 (0.68 – 2.64) 0.40 
rs6904762®†  0.05 0.70 (0.46 – 1.07) 0.10 0.54 (0.26 – 1.11) 0.10 0.83 (0.49 – 1.41) 0.48 
rs26784(A)* 0.05 1.23 (1.00 – 1.50) 0.05 1.26 (0.93 – 1.70) 0.14 1.20 (0.91- 1.59) 0.19 
rs3204798(D)** 0.05 1.57 (0.94 – 2.62) 0.08 1.39 (0.74 – 2.62) 0.31 2.03 (0.87 – 4.74) 0.10 
rs3729598(D)** 0.05 1.58 (0.94 – 2.66) 0.08 1.26 (0.64 – 2.51) 0.51 2.31 (1.05 – 5.13) 0.04 
rs35384751(D)** 0.05 1.58 (0.94 -2.65) 0.08 1.99 (0.96 – 4.13) 0.07 1.31 (0.63 – 2.71) 0.47 
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     Appendix Table 23 continued…. 
Overall Male Female 
SNP Log rank  
P value 
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
rs11234604(D)** 0.05 1.51 (0.94 – 2.40) 0.09 1.39 (0.74 – 2.60) 0.31 1.68 (0.84 – 3.36) 0.15 
rs2864680(D)** 0.05 1.53 (1.03 – 2.28) 0.03 1.42 (0.84 – 2.40) 0.19 1.71 (0.95 -3.09) 0.08 
     (D): Dominant genetic model; (A): Additive genetic model; (R): Recessive genetic model 
      *SNPs yielded age-specific associations results based on the P values; ** SNPs yielded age-specific associations results based on the effect sizes 
        †SNPs yielded gender-specific associations results based on the P values; ††SNPs yielded gender-specific associations results based on the effect 
     sizes            
 
      SNP = single nucleotide polymorphism; HR = hazard ratio; CI = confidence interval 
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Appendix Table 24. Previously identified gender-specific genetic risk markers in childhood ALL and their evidence in 
the present study 
 
SNP Gene Previous association      (P interaction) Gender-specificity/risk 
P value*        
(present study) 
rs10994982 ARID5B 0.01 Male-specific 0.91 
rs10740055 ARID5B 0.03 Male-specific 0.91 
rs2395185 HLA-DRB9 0.001 association differs in direction 0.58 
rs7192 HLA-DRA 0.03 association differs in direction 0.85 
rs419788 SKIV2L 0.04 association differs in direction 0.06 
rs224589 SLC11A2 0.02 association differs in direction 0.08 
rs3130342 TNXB 0.04 association differs in direction 0.47 
rs422982 NRAMP2 0.007 association differs in direction 0.92 
rs807212 HFE 0.05 association differs in direction 0.46 
  ALL = acute lymphoblastic leukemia; SNP = single nucleotide polymorphism 
*P value represents statistical interaction 
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Appendix Figure 1. Genotype failure rate versus heterozygosity rate across all individuals 
in the study. Shading indicates sample density and dashed line denote quality control 
threshold. X-axis represents proportion of missing genotypes on log scale and Y-axis represents 
heterozygosity rates. 
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